"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's First Quarter Earnings Conference Call and Webcast. Hosting the call today from Ireland is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eas",77,"Welcome to Mylan's First Quarter Earnings Conference Call and Webcast. Hosting the call today from Ireland is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern standard time. The dial in number is (800)585-8367, or (404)537-3406 for international callers. With pin number 70819215. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King, you may begin."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Beverly. Good morning, everyone. Welcome to Mylan's First Quarter 2012 Earnings Call. Joining me to for today's call are Mylan's CEO, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and",347,"Thank you, Beverly. Good morning, everyone. Welcome to Mylan's First Quarter 2012 Earnings Call. Joining me to for today's call are Mylan's CEO, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During the During today's call, including the Q&A, we will be making forward-looking statements including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties, and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our report on Form 10-Q for the period ended December 31, 2012, and in our other SEC filings. You can access our Form 10-Q and other SEC filings through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures such as adjusted revenues, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings press release, which is available on our website, as it contains detailed GAAP to non-GAAP reconciliations of our actual first quarter results.
Before I turn the floor over to Heather, let me also remind you that the material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'd like to turn the call over to Heather."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us today. Before we get started, like to welcome and recognize all of our fellow employees around the world for their passion and hard work. We delivered very strong growth this quarte",1151,"Thank you, Kris, and good morning, everyone, and thank you for joining us today. Before we get started, like to welcome and recognize all of our fellow employees around the world for their passion and hard work. We delivered very strong growth this quarter. On behalf of the Board of Directors and our entire management team, I would like to thank each and every one of them. 
Our diverse global platform had once again delivered strong results, representing a great start to 2012. Double-digit growth on our North American Asia/Pacific and Specialty businesses allowed us to deliver robust financial results despite persistent macroeconomic headwinds and certain regions, specifically Europe and Australia. We are reaffirming our 2012 guidance of $2.30 to $2.50 per share and we see opportunities for upside during the year. Further, the strength of our platform, first-in-class science and robust product portfolio give us continued confidence in our long-term growth target for 2013 and beyond. 
During the first quarter, we generated total adjusted revenues of $1.58 billion, an increase of 11% on a constant currency basis as compared to last year's first quarter revenues of $1.45 billion. On the bottom line, we delivered adjusted diluted earnings per share of $0.52, an 18% increase over the $0.44 per share we delivered during the first quarter of '11.
In our North American generics business, third-party net revenues for the quarter were $777 million, up more than 15% from the comparable year ago period. This strong growth was driven in part by a launches as of 11 products and the U.S., including ibandronate and escitalopram, a first equivalent product which generate the highest and fastest conversion rate in any generic launch we seen in history. We also enjoyed strong sales in the U.S. in many of our existing products. 
Further, consistent with the strength of our R&D capability to of the 8 first quarter products submissions we made in the U.S. or first-to-file opportunities, currently we have 171 ANDAs pending FDA approval, 40 of which are potential first to file. With regard to our neurology franchise which is our strategic growth drivers we're awaiting or 2 and the impact infringement case to trial concluded in September of '11. We remain convinced that we have an AB-rated product and look forward to is secure approval in the second half of this year. While we eagerly anticipate the court's ruling in regulatory approval, I'd like to remind them everybody that we are not relying on this product to achieve our 2013 target of $275 million. We also are pleased with our performance in Canada, and it's another example of the robust of our global pipeline. 
In Canada, we launched 9 products during the quarter, which is more than we launched during all of 2011. Our expanded portfolio is feeling sales and growth in our customer base, along with a cost of goods efficiency. At it will help us weather price cuts and remain competitive and ensure consistent supply in every product. 
In EMEA, as anticipated, we delivered third-party net revenues of $336 million during the quarter, a decline of approximately 14% compared to last year's first quarter results. On a constant currency basis, revenues saw 10%. New products launched throughout the region served to offset volume pressure on sales of existing products and mitigate some of the effects of unfavorable pricing. 
During the quarter, we also enjoyed constant currency revenue growth of 8% in Italy, one of Europe's fastest growing market, and in Spain, our sales volume grew along with this rapidly expanding market. Results in both cases were driven by increased generic utilization. Moreover, we remain on track to launch nearly 300 new products in Europe this year. By now, it should be very evident that our powerful global platform has and will continue to demonstrate its ability to absorb headwinds such as those occurring in Europe. Despite such headwinds, we have maintained our leadership position in several markets such as France, Italy, Spain, U.K., Belgium and Portugal. 
Moving now to our Asia-Pacific region. We generated third-party net-net revenues of nearly $299 million during the first quarter, an increase of more than 8% over last year's results and 12% higher on a constant currency basis. Our double-digit growth was driven largely by the strong performance of our business in India. We continue to see growth in our third-party business and accelerated growth in our ARV franchise, both in finished dosage form and API. We currently supply to more than 90 countries. We keep expanding our ARV business by adding products and geographies in expanding market access. Further, we remain on track to launch our commercial business in India later this year. 
Finally, our Mylan Specialty business reported a 67% year-over-year increase in third-party net revenues, which totaled more than $162 million during the first quarter. This exceptional performance resulted from higher sales of the EpiPen Auto-Injector, another strategic growth driver. Increased volumes and favorable pricing drove the growth in sales, and we continue to see double-digit accelerated quarter-over-quarter sales growth. The settlement announced this morning with Teva only further enhances our confidence in the anticipated continued strong performance of this product and our entire Specialty franchise. 
As we've stated before, we see tremendous opportunity ahead for EpiPen as only 7% or 2 million of the 28 million people estimated to be at risk for anaphylaxis actually carries one. Continually increasing public awareness is essential to ensuring access to this product for people who need it, and generating sustained market expansion. Now let me turn to some of our other important strategic growth drivers.
Our global Institutional business continues to deliver double-digit growth. We anticipate that this business can become a $1 billion franchise by 2016. We remain focused on supply chain integrity and optimization of our cost of goods, we benefited and we will continue to benefit from being vertically integrated and we now have successfully internalize the manufacture of 80% of our products globally, giving us even greater control of our cost and quality at each point in the supply chain. We also expect significant growth in our product portfolio and are on track to launch approximately 650 products and file more than 750 regulatory submissions globally this year. We also are pursuing external opportunities to expand our portfolio such as our acquisition of 2 limited competition dermatological products from Valiant earlier this year. 
Looking at our respiratory platform, we have made good progress on the integration of the Pfizer business we acquired in November of 2011, and we believe we are on track to launch the first AV-rated generic version of 
Finally, with respect to buy generics, we have had productive discussions with the FDA regarding our portfolio and remain confident that we will be in the U.S. market starting in 2016. With that, I look forward to responding to your questions and will now turn the call over to John."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to bring referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures and I remind you of Kris's comments at the beginning of the",1537,"Thank you, Heather, and good morning, everyone. This morning, I'm going to bring referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures and I remind you of Kris's comments at the beginning of the call today regarding our use of adjusted measure. 
I am extremely pleased with our financial results for the first quarter of 2012, a great start to what we firmly believe will be the most successful year in our company's history. Our Q1 results were achieved and our full year results will be achieved amid the macroeconomic headwinds that continue to plague Europe and in the wake of a 10% price cut in Japan and the most significant price cuts in Australian industry, both of which occurred this quarter. This is a testament to the strength of our diverse global business, our first-in-class science, and our robust product portfolio. 
The difficult pricing environment in several of our locations was certainly not expected -- unexpected, nor were the positive development which served to offset, and in some cases, fully mitigate the unfavorable impact. In fact, our first quarter results came in line with what we -- with that which we have forecasted in our Investor Day on February 21. Also, our current quarter results were in line with those of the fourth quarter -- of 2011 on a pre-tax basis. Adjusted pre-tax income in the current quarter was $304 million compared to $294 million sequentially. Getting in the details, let me walk you through our financial results for the first quarter of 2012.
I will also provide an update on our capital structure and liquidity position.
Starting at the top of our income statement, total revenues for the quarter were $1.59 billion, an increase of 10% over last year's first quarter revenues of $1.45 billion. Year-over-year, first quarter third-party net revenue growth on a constant currency basis was approximately 11%. The relatively small unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar comparison to certain other function currencies of our major operations, mainly in Europe and in India. 
Included in total revenues for the current quarter is approximately $9 million of other revenue related to a clean energy investment subsidiary, which we invested in near the end of 2011 and whose activities qualify for tax credit under Section 45 of the U.S. Internal Revenue Code. Our adjusted metrics, which I'll discuss momentarily, exclude all activity related to this investment with the exception of the net tax effect related to its operation, which is included in our adjusted effective tax rate. As a reminder, our guidance range for total revenue for the full year 2012 is between $6.8 billion and $7.2 billion.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 first quarter was a very strong 48%, up approximately 1 percentage point from the same prior year period. Our strong current quarter margin are primarily the result of favorable pricing on EpiPen in our Specialty segment. Within generics, gross margins remain stable as new product launches in North America served to offset the normal pricing trend in the generic pharmaceutical industry. 
Our operations, particularly in Europe, continue to employ cost-saving initiatives, especially from the perspective of cost of goods sold. These efforts have proven successful, and adjusted gross margins in Europe, on a sequential quarter-over-quarter basis and excluding the effect of foreign exchange, and as we anticipated, increased nearly 300 basis points despite lower sales. And while I'm certainly not going to predict when the economic situation in Europe will improve, these initiatives are expected to continue to have an incremental positive impact on our adjusted gross margin throughout 2012. 
Adjusted operating income was $368 million for the first quarter of 2012, an 8% increase from Q1 2011. This is primarily the result of the favorable gross profit that I previously discussed, partially offset by increased levels of spending on R&D and SG&A. 
R&D expense on an adjusted basis was $80 million, or approximately 5% of total revenues and up approximately 7% from the prior year. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues. The timing of certain R&D spending amounts related to our biologic and respiratory platforms has shifted into later periods of the current year with no impact on the timing of the programs themselves, and we continue to expect that the full year spend will be within our guidance range. 
At the same time, SG&A also on an adjusted basis, was $312 million or approximately 19.7% of total revenues, closer to the high end of our full year guidance range of 18% to 20%. The increase in SG&A in the current quarter is due in large part to our investment in our Specialty franchise, which has resulted in higher volumes and increased market share.
Adjusted EBITDA for the 3 months ended March 31, 2012, was $411 million and remains forecasted to be between $1.75 billion and $1.95 billion for the full year. 
Moving onto our consolidated nonoperating financial metrics. Adjusted interest expense for the first quarter of 2012 was $61 million. We continue to benefit from low, short-term interest rates. As of March 31, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70 / 30, fixed to floating debt portfolio, which we believe is an optimal ratio. 
As I mentioned before, our adjusted pre-tax earnings in the current quarter was slightly favorable as compared to that of the fourth quarter of the prior year. However, the effective tax rate in the current quarter was 26% as compared to 23% in the sequential quarter. The net result was adjusted diluted EPS in the current quarter in line with that of the fourth quarter of the prior year. Our full year 2012 tax rate range is unchanged at 26% to 27%, and we continue believe that this rate will be sustainable at this level going forward.
First quarter adjusted net income was $224 million, or $0.52 per share, an 18% increase from our Q1 2011 adjusted diluted EPS of $0.44 per share and in line with that of the fourth quarter 2011 after their adjusting for and fully consistent with, our expectations for from our -- and adjusting for the higher tax rate in Q1 2012.
Our guidance range for adjusted diluted EPS for 2012 remains at $2.30 to $2.50 per share. And as I previously mentioned, and fully consistent with our expectations from our Investor Day, we expect earnings in the second quarter to be in line with the first before accelerating into the third quarter, which will be by far our strongest of the year and finishing with the fourth quarter that will propel us to our midpoint of $2.40 per share.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis was approximately $67 million. This takes into account certain  account -- certain special area items principally the exclusion of payments of approximately $90 million related to previously settled and accrued litigation primarily related to AWP and the inclusion of approximately $62 million related to amounts due in 2012, which were received in late summer 2011 but excluded for adjusted cash flow purposes from that quarter.
Our GAAP cash flow from operations for the current quarter was a cash outflow of $109 million, leaving us with unrestricted cash and marketable securities totaling approximately $267 million. The first quarter is historically the heaviest in terms of the usage of cash and as a result of the timing of certain payments including taxes, interest and incentive optimization. But we are still forecasting our full year 2012 adjusted operating cash flow to be within our guidance range of $900 million to $1 billion. 
First quarter capital spending was $36 million and we expect full year capital expenditures to be within our guidance range of $300 million to $400 million. In addition to capital expenditures, approximately $70 million was spent during the quarter to acquire product rights and licenses, the majority of which relates to the purchase of 2 limited competition dermatological products from Valiant Pharmaceuticals. 
During the current quarter, we repaid us $600 million due under our convertible notes and made a scheduled payment on our term loans. Both of these payments were made during a combination of cash on hand, borrowings our under our revolver and the cash received from our accounts receivable securitization facility, which we established in February. During the first quarter, we borrowed $285 million under this facility.
At the end of the quarter, following the debt repayment and additional borrowings under the revolver and the AR facility, our leverage ratio remains at 2.9x and we continue to have more than ample borrowing capacity.
To summarize, our first quarter was strong and was in line with what we had anticipated. This is an indication of things to come throughout what we believe will be our strongest year yet and another chapter in the exciting story that is Mylan.
That concludes my remarks. And I'll turn the call over to the operator for Q&A. Operator?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from the line of Douglas Tsao with Barclays.",14,"[Operator Instructions] Our first question comes from the line of Douglas Tsao with Barclays."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Just a couple of questions. First, I was just hoping you could speak a little bit to what your current greatly seeing in terms of market conditions in Europe? Just given some concerns regarding economic stability or softness, obviously, you expected, you",63,"Just a couple of questions. First, I was just hoping you could speak a little bit to what your current greatly seeing in terms of market conditions in Europe? Just given some concerns regarding economic stability or softness, obviously, you expected, you saw good results from Spain and Italy. In particular, I was curious if you could something seeing in Spain right now?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","I think Europe overall, what I'd say is, we're seeing what we've been seeing and saying that we're not trying to predict the future of when that's going to turnaround. And obviously, why we continue to say we did not predict or forecast growth for you're",153,"I think Europe overall, what I'd say is, we're seeing what we've been seeing and saying that we're not trying to predict the future of when that's going to turnaround. And obviously, why we continue to say we did not predict or forecast growth for you're European region. I think with that being said, we do see increased generic utilization beginning to increase, especially in the southern European market. We saw growth and maintain leadership position obviously in Italy. We see this same with Spain. We see that volume through increased utilization offsetting some of the price cuts. So I definitely would say that governments are beginning to realize that for sustainable cost-containment, utilization increase is a more proven and has a better track record than just got a cost. So I would say there are some optimism that, that trend certainly will continue but again, we certainly didn't predict growth this year."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And that I would just like to add although we're not seeing growth, we are focused on maintaining the profitability of the region through cost savings and vertical integration initiatives, and we saw a very nice growth in margins in Europe in the first qu",46,"And that I would just like to add although we're not seeing growth, we are focused on maintaining the profitability of the region through cost savings and vertical integration initiatives, and we saw a very nice growth in margins in Europe in the first quarter."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","And in terms of the product introductions that you referred to in the prepared remarks, is that broadly across the entire region and applicable across all countries?",27,"And in terms of the product introductions that you referred to in the prepared remarks, is that broadly across the entire region and applicable across all countries?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Yes, absolutely.",2,"Yes, absolutely."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","And also just a point of clarity on the settlement with Teva that was announced this morning, and if they do make changes to their be ANDA and there are meaningful, perhaps, design changes to their product, do you still have the opportunity to reinitiate",46,"And also just a point of clarity on the settlement with Teva that was announced this morning, and if they do make changes to their be ANDA and there are meaningful, perhaps, design changes to their product, do you still have the opportunity to reinitiate litigation?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Well look, I think as far as our current settlement, it's very clear that we have through June of 2015. And as we made reference in there, they still have to receive regulatory approval, which we continue to believe that hurdle remains very high. So I wou",112,"Well look, I think as far as our current settlement, it's very clear that we have through June of 2015. And as we made reference in there, they still have to receive regulatory approval, which we continue to believe that hurdle remains very high. So I would look at it as kind of regardless of product or changes, obviously, we would look at any of those things that happen in the future, but I would say we're excited and I think that this settlement just further enhances and underscores truly the value of the franchise in our ability to now have some great runway just with continue to show accelerated growth quarter-over-quarter."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Chris Schott with JP Morgan.",11,"Our next question is coming from Chris Schott with JP Morgan."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First question, just would be interested in your views of the implications of further consolidation of the U.S. market with the Watson transaction yesterday, just really feel for the health of the U.S. generic market and Mylan's business specifically?",39,"First question, just would be interested in your views of the implications of further consolidation of the U.S. market with the Watson transaction yesterday, just really feel for the health of the U.S. generic market and Mylan's business specifically?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. I think it's a fantastic deal. I think as we said for quite a while and Robert has been very vocal about the consolidation, is needed, taking capacity out of the market is especially a large player, like Activists is certainly benefits the global ma",90,"Sure. I think it's a fantastic deal. I think as we said for quite a while and Robert has been very vocal about the consolidation, is needed, taking capacity out of the market is especially a large player, like Activists is certainly benefits the global marketplace. I think it further underscores the need to be globally competitive, which underscores the platform that we've pulled together over the last 5 years. So look, I think congratulations to them, it's good and I think there's more to come, more consolidation to come."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","A great. And then second question, just changing gears a little bit. Asia increasingly appears to be a more driver to your numbers than Europe, is that kind of low teens organic growth we saw this quarter was a decent proxy for that growth you can see for",68,"A great. And then second question, just changing gears a little bit. Asia increasingly appears to be a more driver to your numbers than Europe, is that kind of low teens organic growth we saw this quarter was a decent proxy for that growth you can see for the rest of the year given the Australian and Japanese price activity you just kind of referenced on the call?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. First of all, as I said in my remarks, our business in India is just hitting on all cylinders from third-party basis. The ARV franchise continues to grow, we continue to add diversity of our product line. And so we see, as we said, we anticipate con",168,"Sure. First of all, as I said in my remarks, our business in India is just hitting on all cylinders from third-party basis. The ARV franchise continues to grow, we continue to add diversity of our product line. And so we see, as we said, we anticipate continued double-digit growth. As far as Japan, again, we see a nice steady increase, increased utilization continue to go up. We could due to build our product portfolio most likely, we continue to internalize these product, giving us much more flexibility, controlling the supply in the quality of that supply chain. So as Australia obviously usually continues to be a market that is undergoing significant pressure, I think since '08, we've shown our ability to manage through those headwind and we're going to continue to do that. So I think all in all, Japan, and certainly, India offsetting any of that pressure that we're feeling in Australia and why we continue to be very confident in our growth in that region."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Elliot Wilbur of Needham & Company.",11,"Our next question is coming from Elliot Wilbur of Needham & Company."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Just an additional follow-up question, Heather, the settlement. At your Analyst Day, you talked about the company's view that the financial community sort of over estimated the potential negative impact and Milos numbers, if and when the generic was intro",176,"Just an additional follow-up question, Heather, the settlement. At your Analyst Day, you talked about the company's view that the financial community sort of over estimated the potential negative impact and Milos numbers, if and when the generic was introduced of EpiPen. Is there anything in the agreement itself enabling in June 2015 that changes your expectations that a competitive generic entry will get roughly 40% of the market that will result in roughly an 8% to 12% negative impact on Mylan's bottom line? Then follow-up question for John, just looking at the company's capital structure as it exists. Some of the out year debt senior notes, around I think $2.3 billion, is still sitting on the balance sheet at interest rates north of 7.5% and I guess given some of the recent transactions in the space and the current 0 interest rate regime across the world, I wondered if there might be an opportunity to refi that at more favorable rates given the company's enhanced cash flows and just stronger balance sheet position overall?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So I'll start with EpiPen. Look, absolutely nothing changes our thoughts or convictions about the strength and the brand equity of EpiPen. If anything, I think the settlement just underscores our confidence because we're going to have, at minimum, a",130,"Sure. So I'll start with EpiPen. Look, absolutely nothing changes our thoughts or convictions about the strength and the brand equity of EpiPen. If anything, I think the settlement just underscores our confidence because we're going to have, at minimum, and I say minimal because I certainly believe that hurdles to get that and AV rated product our significant. But at a minimum, another 3 years to truly build the education around the need for people at risk to be carrying an EpiPen, so I think that brand equity only continues to become much more significant over the next few years. I think that you've seen the results of us being out there, raising awareness and educating and we're just going to continue to increase and invest in this effort."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And then your question with respect to capital structure and the notes that we issued, quite honestly, less than 2 years ago. You're right that interest rates have fallen significantly over the last 2 years and so some of those notes may have the opportun",85,"And then your question with respect to capital structure and the notes that we issued, quite honestly, less than 2 years ago. You're right that interest rates have fallen significantly over the last 2 years and so some of those notes may have the opportunity, when they are prepayable and taking into consideration what repayment penalties may exist, may have the opportunity for prepayment or refinancing. That's something that we'll look at when we get to a point where they are able to be refinanced."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from David Risinger with Morgan Stanley.",11,"Our next question is coming from David Risinger with Morgan Stanley."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I was hoping 2 things. First, if you could just frame out the key considerations for the second quarter so that we have a better understanding of how to think about the momentum year-over-year in the second quarter of 2012 versus 2011 and also sequentiall",84,"I was hoping 2 things. First, if you could just frame out the key considerations for the second quarter so that we have a better understanding of how to think about the momentum year-over-year in the second quarter of 2012 versus 2011 and also sequentially versus the first quarter of 2012? And then second, for Heather, just to clarify, can you just let us know if you're settlement today covers generic EpiPen only in its current form or in all future forms as well?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'll start with your second question and I'll John come back your first. What we can say about the settlement is that it absolutely covers everything between Meridian and Teva through June of 2015.",36,"So I'll start with your second question and I'll John come back your first. What we can say about the settlement is that it absolutely covers everything between Meridian and Teva through June of 2015."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And I think, David, with respect to the second quarter, as I said in my prepared remarks, the second quarter being similar to the first is fully in line with what the expectations we had on Investor Day when we indicated that the second half of 2012 would",188,"And I think, David, with respect to the second quarter, as I said in my prepared remarks, the second quarter being similar to the first is fully in line with what the expectations we had on Investor Day when we indicated that the second half of 2012 would be stronger than the first half of the year. In particular, the -- my comments do not into consideration a Doryx approval. We continue to be to look forward to the court's ruling on that subject and our being able to launch that product, which has been long delayed, although I would say that as we look at the full year, we do expect -- we have always expected that before the end of the year that we would be in a place where we were or in a position to launch Doryx. We will launch LIPITOR, the generic form of LIPITOR, at the latter part of this year quarter. And so I guess I would just concluded summarize by saying that Q2 is continues to be in line with what we talked about or expected on our Investor Day."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Marc Goodman with UBS.",10,"Our next question is coming from Marc Goodman with UBS."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Heather,  I was just curious with your thoughts on France and there seem to be some new rules that have been implemented to try to drive more generic competition utilization I was just curious on your thoughts are there? Second, if you could just talk abo",101,"Heather,  I was just curious with your thoughts on France and there seem to be some new rules that have been implemented to try to drive more generic competition utilization I was just curious on your thoughts are there? Second, if you could just talk about Japan a little bit more, what was the strength in Japan and how good was it? I mean was this a double-digit growth quarter? Have we had low digit growth in Japan before did you give a sense because you did say there press release you said it was strong and accelerating a little bit."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So in France. We do absolutely see the beginnings of this push for increased generic utilization as I said throughout Southern Europe. Italy is certainly the lead of that pack, but we do -- are very encouraged by the recent new regulation statute to",305,"Sure. So in France. We do absolutely see the beginnings of this push for increased generic utilization as I said throughout Southern Europe. Italy is certainly the lead of that pack, but we do -- are very encouraged by the recent new regulation statute to try to incentivize on several fronts that increase of utilization. And like I said, I do think our efforts are paying off as we have been continuing to educate regulators and officials that utilization as much more sustainable to cost containment healthcare and the price cuts. So I think that those numbers are -- they're starting to see that obviously from other countries. And so I'm very encouraged. And in the meantime, we've maintained our leadership position, 30% of the market share. As John said, we're very focused on that operable growth and believe that, obviously, when Europe does come out of the this -- comes out of the storm they're in right now, that we're going to need the stronger than ever and certainly benefit disproportionately from now the increase in utilization. And as far as Japan goes, yes, as I said, we did see strong results. I would say that for the year, we certainly anticipate low double-digit growth in that country. And I think that it comes from a couple of places. One, as I said, we continue to enhance and are reaping the benefits of the pipeline that we started to build after our acquisition. And we see those coming to fruition and Mylan launching more products, we are launching more internally manufactured products. So the profitability of that, the country continues to increase. And again, utilization, we continue to see it creeping up close to the mid 20s. So all in all, Japan is steadily just increasing and we're very happy with our performance there."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Jami Rubin of Goldman Sachs.",11,"Our next question is coming from Jami Rubin of Goldman Sachs."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I don't want to beat the dead hoarse or anything, but John and Heather, maybe if you could just elaborate a little bit more why you're still so confident that there's such a high regulatory bar for AV rated generics for EpiPen. I guess I was somewhat surp",128,"I don't want to beat the dead hoarse or anything, but John and Heather, maybe if you could just elaborate a little bit more why you're still so confident that there's such a high regulatory bar for AV rated generics for EpiPen. I guess I was somewhat surprised that it wasn't really quite sure why you reached the settlement given your confidence in that regulatory landscape, so if you could be a little bit more specific why you don't expect to see that. And then secondarily, again on generic Doryx, we expected to hear that case of that verdict in February or March and here we are almost, we are in May, almost in May, haven't heard anything and just what you think is going on there?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Our Jami, so look, the confidence, I've never been more confident in our statements about EpiPen and a berated products. And I think that our settlement, the way in which we settle should certainly underscore that. Our settlement has nothing to do whether",162,"Our Jami, so look, the confidence, I've never been more confident in our statements about EpiPen and a berated products. And I think that our settlement, the way in which we settle should certainly underscore that. Our settlement has nothing to do whether the regulatory aspect. The press release, clearly lays out the they still have to get regulatory approval, which we continue to believe is a very high hurdle and why I'm saying we now have a minimum until June of 2015. So our settlement really has just truly on the patent case and judicial, nothing to do with the regulatory process or the hurdles that we believe are still absolutely in place. As far as Doryx, look, like we can't predict Europe, I can't predict when judges are going to rule. They said it would be soon, and I guess his definition of soon or quick may differ from some of ours. but so look, we anticipate that decision anytime."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Shibani Malhotra of RBC Capital.",11,"Our next question is coming from Shibani Malhotra of RBC Capital."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I guess, Heather, you talked about expecting increased consolidation in the generics industry due to excess capacity. Could you comment on whether Mylan is looking to further consolidate businesses and what sort of businesses we would be looking for if yo",87,"I guess, Heather, you talked about expecting increased consolidation in the generics industry due to excess capacity. Could you comment on whether Mylan is looking to further consolidate businesses and what sort of businesses we would be looking for if you were considering M&A? And then second, just to follow up on EpiPen again, I guess and on Jami's question. I was just wondering, were you able to look at Teva and filing before you reached a settlement or was this just kind of a blind case?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Okay, so first, I'll talk about the macro issue. And I want to just clarify, my point on consolidation is not even just a generic industry, but the pharmaceutical industry as a whole. I think that as we've continue to talk about the global competitiveness",245,"Okay, so first, I'll talk about the macro issue. And I want to just clarify, my point on consolidation is not even just a generic industry, but the pharmaceutical industry as a whole. I think that as we've continue to talk about the global competitiveness needed to compete is brand looking at generics, I think more than ever because of the emerging markets and the need to have a high-quality brand product portfolio. So look, that's why we continue to believe there absolutely will be consolidation, perhaps among smaller players, but continued activity among brand and generics. As far as our activity, I think we laid out a lot of parameters and clarity on Investor Day, speaking to the fact that we absolutely are looking and always looking at a lot of different things, whether it's new geographies, products, therapeutic categories, bolt on or dosage forms, certainly looking for products fourth Specialty division. So we are extremely active looking on all fronts and like I said, just continue to be excited that opportunities we see out there given some of the macro economic conditions in some of these geographies. As far as EpiPen, look, I can't and we don't talk about litigation and so forth. But all I can tell you is, obviously, litigation is not typically blind in both parties, there's a lot of activity between the parties, obviously, in pretrial as well as trial. So I'll just leave it leave it at that."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from John Boris with Citi.",10,"Our next question is coming from John Boris with Citi."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First question, just has to do where you invited to look at Octavius and can you just share whether you did look at the Octavius transaction and just discuss your competitive position, obviously, based on some of the slides out there, you did slip to #4 a",61,"First question, just has to do where you invited to look at Octavius and can you just share whether you did look at the Octavius transaction and just discuss your competitive position, obviously, based on some of the slides out there, you did slip to #4 and consolidating industry? Just some commentary there and then I'll have a follow-up on EpiPen."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","I think it's safe or you junto imagine that we look at everything. And I think that probably the only thing I'd say about the processes is that it's not on option or a competitive process. I would just kind of leads to that about what the activity that wa",275,"I think it's safe or you junto imagine that we look at everything. And I think that probably the only thing I'd say about the processes is that it's not on option or a competitive process. I would just kind of leads to that about what the activity that was going on around Octavius for a long time now. And as far as -- so as far as continued activity as I said, I think that we have a tremendous amount of opportunity to continue, to add on. And again, as we said on Investor Day, we're not standing still or gone on vacation. I can assure you we are very active right now in the front and I guess all I'd say about the commenting on the #3, #4, #1 #2, we've said it's really not about the number, I think it's the quality assets and how we're building Mylan. And I think we put together a great platform, as Robert has said, we don't need another transformational deal. But what we are very interested in high-quality assets that we can continue to add and maximize and leverage this platform that we've brought together. And I think between our vertical integration, which is exceeding all of our wildest imagination and the benefits we're reaping from that, just continues to boost our ability to compete in every market around the world with the highest quality product. So we've not lost our sight on our mission to reach 7 billion people and believe that we've got a lot of opportunity to get there whatever number that puts us on a global player in this marketplace."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","For John, on EpiPen, there's a slide you put up during your analyst meeting that seems to indicate that with direct-to-consumer advertising, it was very deep, very responsive to market share gains. I think you're electing to make 2 investments this year,",112,"For John, on EpiPen, there's a slide you put up during your analyst meeting that seems to indicate that with direct-to-consumer advertising, it was very deep, very responsive to market share gains. I think you're electing to make 2 investments this year, 6 months of direct-to-consumer advertising and you've invested in 100-person sales force. How do you measure those investments going forward and what are they petitions for at least the volume growth on EpiPen going forward? And then just for Heather, can you just maybe talk about the Teva device and is a device that prevented from being there pitifully substituted for AB rated if and when they ever get approved?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'll start and then I'll let John -- my comments about AB rated have to do with the FDA and the regulatory environment around the Dragon device. As I've talked about for a long time, that those regulations, and FDA clarified their position and the answ",275,"So I'll start and then I'll let John -- my comments about AB rated have to do with the FDA and the regulatory environment around the Dragon device. As I've talked about for a long time, that those regulations, and FDA clarified their position and the answer to the Something citizen petition a couple of years ago, that it's not that's same. It can't be rated substitutable and especially in the light on them an emergency situation. So my comments have always been around our confidence and our intellectual property around our Dragon device, the regulation of FDA and the ability to have to be the same. So if you have to retrain, it's not the same. And for obviously EpiPen and anaphylaxis, obviously reaches that hurdle of being a life saving on an emergency situation. So that again is why I underscore my confidence in the franchise and the hurdles for getting an AB rated, all that I'll let John speak about our ROI but what I will say is, we were -- after we saw the results from last year, the DTC as well as other initiatives. Because while direct-to-consumer is certainly a large aspect, we're doing on, many fronts, around this education. And obviously, if you look since Q3 of last year, you see just beyond accelerated double-digit growth year-over-year for each quarter. And obviously, this is now being a record quarter 1 for EpiPen and we see that continuing to grow. So it is absolutely, the results I think speak to the pay off here. And we just see that doing nothing but continuing to grow and an accelerated rate."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Just briefly add on to what Heather said, as you know, we are the market for anaphylactic shock with over 98% market share. And therefore, the programs that we're running are both focused on building awareness regarding anaphylactic shock and the value of",140,"Just briefly add on to what Heather said, as you know, we are the market for anaphylactic shock with over 98% market share. And therefore, the programs that we're running are both focused on building awareness regarding anaphylactic shock and the value of the EpiPen for dealing with those types of life-threatening situations. And the way we measure the success of the programs, whether it be the direct-to-consumer advertising campaign or the expansion in our field force, is by looking at the expansion of the market that's taking place. And that expansion of the market, we showed that the Investor Day, has been significant. We're off to a great start for 2012. We talked on Investor Day of the Specialty business growing 30% year-over-year for 2012. And at this point, one quarter into it, I think it's at least that."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Greg Gilbert from Bank of America Merrill Lynch.",14,"Our next question is coming from Greg Gilbert from Bank of America Merrill Lynch."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Getting a lot of free advertising EpiPen, Heather, I'll start with EpiPen. With a settlement structure allow you to launch an AGA is at the low cemetery of thoughts on EpiPen OTC. And for John, I think you could've made a nickel or more on EPS on before t",82,"Getting a lot of free advertising EpiPen, Heather, I'll start with EpiPen. With a settlement structure allow you to launch an AGA is at the low cemetery of thoughts on EpiPen OTC. And for John, I think you could've made a nickel or more on EPS on before the Teva development. You're still pointing to potential upside to the range. So what going on better than expected so far this year? Or were you just being incredibly conservative on your initial guidance?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I would say that there's no restrictions on us on EpiPen, but I have to tell you that there is certainly no reason EpiPen, the kind of product and what we've spoken about from brand equity and the awareness around there would just be no reason to put a",116,"So I would say that there's no restrictions on us on EpiPen, but I have to tell you that there is certainly no reason EpiPen, the kind of product and what we've spoken about from brand equity and the awareness around there would just be no reason to put an AG in. So the, I think that the settlement certainly, and I'm just going to say and you're right a lot of that good advertisement this morning remove that overhang that we know continue to be concerned that they'll what if possibility that what it has been taken off the table, and I can assure you we will maximize opportunity we have ahead of us."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So Greg, I guess Greg, on your second part, first of all, I guess I would start by saying that we're incredibly disappointed by the whole situation. But Mylan has never been, we've said it so many times, about one product. And therefore, the -- we will, w",198,"So Greg, I guess Greg, on your second part, first of all, I guess I would start by saying that we're incredibly disappointed by the whole situation. But Mylan has never been, we've said it so many times, about one product. And therefore, the -- we will, whether it's in or out, we're still very confident at our $2.40 per share midpoint of our guidance range. And whether it be the very successful launch of escitalopram that we have here in the first quarter or the strength of the EpiPen that we're seeing throughout 2012, all of those things make us very confident that 2012 will be a very good year, the best year for Mylan that we've had in our history. And I don't know if I would say we were being incredibly conservative however you describe it, I think we were providing guidance rates at the beginning of the year that we would believe that affected the fact that not all good things happen, not all bad things happen. And that we would be in that guidance range. And we look forward to that year continuing to develop this way and taking advantage of upside opportunities."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","How about that OTC piece of my question?",8,"How about that OTC piece of my question?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So as far as OTC, listen, we've had a lot of discussions and will be continue to have these discussions. I believe that they something responsible thing for EpiPen would be behind the counter. So we'll look much more like sometimes how insulin is treated",240,"So as far as OTC, listen, we've had a lot of discussions and will be continue to have these discussions. I believe that they something responsible thing for EpiPen would be behind the counter. So we'll look much more like sometimes how insulin is treated or Plan B. So we believe that there is absolutely opportunity to continue to work with states because as you might imagine, all the states differ with pharmacy laws and regulation. But we are actively pursuing and looking at doing just that, working with the states, working with the FDA, to hopefully get to a place where there would be both prescription EpiPen is was behind the counter EpiPen that would provide the maximum access to everybody who wanted or needed to carry an EpiPen to be able to have as many as they want and also be able to make sure, from a perspective that whether it's schools being covered, soccer fields, football as you might imagine, that not only is important to have the schools equipped which we're launching a huge program here in the next couple of months with schools, but also everything in the community related to that. So all of this is working in conjunction and why I said that outside of our DTC, and investment that there's a lot of other initiatives that are ongoing that we'll be excited to be tell you more about as the year unfolds."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Ronny Gal from Sanford Bernstein.",11,"Our next question is coming from Ronny Gal from Sanford Bernstein."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I got 2 and I promise not to ask a thing about EpiPen. The first one as for John, something a little bit of the Watson announcement yesterday which surprised me the most is how much cash they can free to paid down the debt early on. And looking at your nu",185,"I got 2 and I promise not to ask a thing about EpiPen. The first one as for John, something a little bit of the Watson announcement yesterday which surprised me the most is how much cash they can free to paid down the debt early on. And looking at your numbers, you've got roughly the same EBITDA they do roughly the same roughly the same interest rate, you came in about $1 billion in operating cash flow, but your spending $400 million of that on CapEx, you're spending 40% of your operating cash flow on CapEx. And the question is, is there -- how do we think about that? you're paying a a lot more than your peers in terms of is additional on-campus attributing about this is a positive or should we be thinking about will be home holding some of that back, paying down your debt more and then look a lot less levered and look lot more financial this ability to return to cash I or someone that most significant upside to the business and I do have a follow on."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","I'm going to start off even though you said John. at least want to underscore, not only our commitment, investment in CapEx but why. If you go back to our Investor Day, we said we were going to double our site to the next 5 years, from a capacity perspect",208,"I'm going to start off even though you said John. at least want to underscore, not only our commitment, investment in CapEx but why. If you go back to our Investor Day, we said we were going to double our site to the next 5 years, from a capacity perspective, our platform. So as you look, we're investing obviously across the board whether it's on our API, whether it's in the finished dosage from facility, but doubling the capacity, we believe is again, just goes to the diversity of our platform of our ability to absorb whatever, headwind, country, issues. That ability to not only invest, and be expected when you talked a lot about our product portfolio doubling, and when you think about not only doubling, it's the quality of what we're doubling and the kind of products, again, our respiratory announcement. Our ability to have the dollars in and invest the dollars we believe is another barrier to entry because we're using large dollar investments, whether it's respiratory, whether it's bio generics, doubling our size. So we believe, as I said earlier, is not necessarily just quantity, we believe not only are we investing in the right things, but certainly in a very quality way."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And I guess and I would just at the what Heather said, at 2.9x gross debt to EBITDA, we're very comfortable with that leverage ratio. And that of leverage ratio has been declining steadily and accelerating in that decline. And so, we generate $600 million",117,"And I guess and I would just at the what Heather said, at 2.9x gross debt to EBITDA, we're very comfortable with that leverage ratio. And that of leverage ratio has been declining steadily and accelerating in that decline. And so, we generate $600 million a year of free cash flow, it's just is a substantial amount. We've been using that cash flow to reinvest back in the business as well as to delever. And so, I think that we're building a platform for the future and responsibly reinvesting in that platform so we have the right ways, the right growth in the future while at the same time managing the balance sheet in a smart way."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And which is why I think we continue to reiterate our confidence and commitment to delivering on our longer-term growth prospects. Because the investments we're making today are for the 2016, '17, '18 opportunities that we believe we'll be able to globall",44,"And which is why I think we continue to reiterate our confidence and commitment to delivering on our longer-term growth prospects. Because the investments we're making today are for the 2016, '17, '18 opportunities that we believe we'll be able to globally monetized."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Gary Nachman from",9,"Our next question is coming from Gary Nachman from"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First, a couple of pricing questions. How's the pricing shaking up the generic Lexapro between you and Teva since share seems to have split evenly between you guys. And on EpiPen, how much more headroom in pricing are you assuming this you have to take at",57,"First, a couple of pricing questions. How's the pricing shaking up the generic Lexapro between you and Teva since share seems to have split evenly between you guys. And on EpiPen, how much more headroom in pricing are you assuming this you have to take at 10% price increase in March? And then I have a follow-up."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Your pricing question, your first one, we don't discuss pricing of individual products. All I can tell you is we continue to see stability in our in our products above the base business and opportunities on some of these new launches. So I would say that",91,"Your pricing question, your first one, we don't discuss pricing of individual products. All I can tell you is we continue to see stability in our in our products above the base business and opportunities on some of these new launches. So I would say that on the first one, EpiPen, look, I think we've been pretty consistent and our pricing. And we see that continuing. So as we continue to invest and continue to look at building that awareness, we'll continue to have a pricing strategy that certainly mirrors that."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Okay, and just you mentioned in terms of your building out the commercial business in India later this year, I thought I remembered you saying at the Analyst Day that, that was going to be earlier in the year, so I'm just curious if there were any changes",69,"Okay, and just you mentioned in terms of your building out the commercial business in India later this year, I thought I remembered you saying at the Analyst Day that, that was going to be earlier in the year, so I'm just curious if there were any changes to that timeline and just talk about the impact you think that's going to have on the business in that region."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","We have talked about July launch and that's where we exactly are. We will be launching sometime between July and August and we don't see any significant impact on the year.",32,"We have talked about July launch and that's where we exactly are. We will be launching sometime between July and August and we don't see any significant impact on the year."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from the line of Michael Faerm Jr. with Credit Suisse.",15,"Our next question is coming from the line of Michael Faerm Jr. with Credit Suisse."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","You commented earlier about your confidence in your ultimate approval and AB rating for your generic something. Can you elaborate on why you're confident in that in May be contrasted to the EpiPen situation where you're confident that the generic won't ge",44,"You commented earlier about your confidence in your ultimate approval and AB rating for your generic something. Can you elaborate on why you're confident in that in May be contrasted to the EpiPen situation where you're confident that the generic won't get AB rating."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure, and I'll start and I'm going to let Rajiv even speak to our confidence. Look, I think that what we said when we announced the acquisition of that platform as we were taking the core competencies of the existing Pfizer platform and marrying that up w",136,"Sure, and I'll start and I'm going to let Rajiv even speak to our confidence. Look, I think that what we said when we announced the acquisition of that platform as we were taking the core competencies of the existing Pfizer platform and marrying that up with what Mylan has always been known to do best, which is taking very complex opportunities and bringing them to fruition. We look at the high-caliber and the asset and the position and the point that Pfizer had developed a product now mirroring that up to complement it with our scientific ability is really what underscored our confidence and I'll let -- and as far as EpiPen goes, look, as I continue to say, it's the drug and device component of EpiPen that makes those regulations and those aspects different."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And our confidence is based on what we acquired, the quality of the device and the solidarity of the device and this one's and Glaxo's, as well as our continued dialogue with FDA and the progress which we are making. So we remain very confident that we on",55,"And our confidence is based on what we acquired, the quality of the device and the solidarity of the device and this one's and Glaxo's, as well as our continued dialogue with FDA and the progress which we are making. So we remain very confident that we on the right part of the first generic"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","I operator, I think we have time for one more question.",11,"I operator, I think we have time for one more question."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Your final question is coming from the line of Randall Stanicky with Canaccord Genuity.",14,"Your final question is coming from the line of Randall Stanicky with Canaccord Genuity."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I just keep it one. Just going back to Europe for a second, i.e., appreciate and I think we all appreciate that admits of the challenges there, the double-digit declines in constant currency growth, if those continue, how much cushion do you have built in",71,"I just keep it one. Just going back to Europe for a second, i.e., appreciate and I think we all appreciate that admits of the challenges there, the double-digit declines in constant currency growth, if those continue, how much cushion do you have built in before that becomes an issue? I understand that you don't need to grow, but at what point is the constant currency decline start to hurt you?"
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Look, I talked about the fact that our gross margins actually increased 300 basis points quarter-to-quarter, Randall. And so it's not about the top line, it's about the bottom line, and we're managing that region and in the context of the macroeconomic he",139,"Look, I talked about the fact that our gross margins actually increased 300 basis points quarter-to-quarter, Randall. And so it's not about the top line, it's about the bottom line, and we're managing that region and in the context of the macroeconomic headwinds. So it's not hurting us. We obviously would love to see growth and we look forward to when the macroeconomic issues in Europe are resolved and generic utilization rates increase. And the top line growth, together with the gross margins increasing, and that's why we talked on Investor Day about Europe being a long-term growth driver for us. 
So with that, we appreciate all of our investors and the questions we received on this call. Q1 was very much in line with what we had expected, and we look forward to continuing to deliver on 2012."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you.",2,"Thank you."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","With that, operator, you can close the call.",8,"With that, operator, you can close the call."
290203,184140392,289690,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Thank you, this does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you, this does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's First Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Easte",79,"Welcome to Mylan's First Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern standard time. The dial in number is (800) 585-8367, or (404) 537-3406 for international callers, with pin number 70819215. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King, you may begin."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Beverly. Good morning, everyone. Welcome to Mylan's first quarter 2012 earnings call. Joining me for today's call are Mylan's CEO, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chi",344,"Thank you, Beverly. Good morning, everyone. Welcome to Mylan's first quarter 2012 earnings call. Joining me for today's call are Mylan's CEO, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making forward-looking statements including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties, and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our report on Form 10-K for the period ended December 31, 2012, and in our other SEC filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures such as adjusted revenues, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings press release, which is available on our website, as it contains detailed GAAP to non-GAAP reconciliations of our actual first quarter results.
Before I turn the call over to Heather, let me also remind you that the materials in this call, with the exception of the participant questions, is a property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'd like to turn the call over to Heather."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us today. Before we get started, I'd like to welcome and recognize all of our fellow employees around the world for their passion and hard work. We delivered very strong results this q",1148,"Thank you, Kris, and good morning, everyone, and thank you for joining us today. Before we get started, I'd like to welcome and recognize all of our fellow employees around the world for their passion and hard work. We delivered very strong results this quarter. On behalf of the Board of Directors and our entire management team, I would like to thank each and every one of them.
Our diverse global platform has once again delivered strong results, representing a great start to 2012. Double-digit growth on our North American Asia/Pacific and Specialty businesses allowed us to deliver robust financial results despite persistent macroeconomic headwinds in certain regions, specifically Europe and Australia. We are reaffirming our 2012 guidance of $2.30 to $2.50 per share and we see opportunities for upside during the year. Further, the strength of our platforms, first-in-class science and robust product portfolio give us continued confidence in our long-term growth target for 2013 and beyond.
During the first quarter, we generated total adjusted revenues of $1.58 billion, an increase of 11% on a constant currency basis as compared to last year's first quarter revenues of $1.45 billion. On the bottom line, we delivered adjusted diluted earnings per share of $0.52, an 18% increase over the $0.44 per share we delivered during the first quarter of '11.
In our North American Generics business, third-party net revenues for the quarter were $777 million, up more than 15% from the comparable year-ago period. This strong result was driven in part by launches of 11 new products in the U.S., including Ibandronate and Escitalopram, our first equivalent product that generated the highest and fastest conversion rate in versus generic launch we've seen in recent history. We also enjoyed strong sales in the U.S. on many of our existing products.
Further, consistent with the strength of our R&D capabilities 2 of the 8 first quarter products submissions we made in the U.S. are first-to-file opportunities. Currently we have 171 ANDAs pending FDA approval, 40 of which are potential first to file. Regarding our neurology franchise which is our strategic growth drivers, we're awaiting the court's ruling in the Copaxone patent infringement case whose trial concluded in September of 2011. We remain convinced that we have an AB-rated product and look forward to securing approval in the second half of this year. While we eagerly anticipate the court's ruling and regulatory approval, I'd like to remind everybody that we are not relying on this product to achieve our 2013 target of $275 million. We also are pleased with our performance in Canada, and it's another example of the robustness of our global pipeline.
In Canada, we launched 9 products during the quarter, which is more than we launched during all of 2011. Our expanded portfolio is fueling sales and growth in our customer base, along with cost of goods efficiency that will help us weather price cuts and remain competitive and ensure consistent supply in every province.
In EMEA, as anticipated, we delivered third-party net revenues of $336 million during the quarter, a decline of approximately 14% compared to last year's first quarter results. On a constant currency basis, revenues fell 10%. New products launched throughout the region served to offset volume pressure on sales of existing products and mitigate some of the effects of unfavorable pricing.
During the quarter, we also enjoyed constant currency revenue growth of 8% in Italy, one of Europe's fastest growing markets. And in Spain, our sales volume grew along with this rapidly expanding market. Results in both cases were driven by increased generic utilization. Moreover, we remain on track to launch nearly 300 new products in Europe this year. By now, it should be very evident that our powerful global platform has and will continue to demonstrate its ability to absorb headwinds such as those occurring in Europe. Despite such headwinds, we have maintained our leadership positions in several markets such as France, Italy, Spain, U.K., Belgium and Portugal.
Moving now to our Asia-Pacific regions. We generated third-party net revenues of nearly $299 million during the first quarter, an increase of more than 8% over last year's results and 12% higher on a constant currency basis. Our double-digit growth was driven largely by the strong performance of our business in India. We continue to see growth in our third-party business and accelerated growth in our ARV franchise, both in finished dosage form and API. We currently supply to more than 90 countries. We keep expanding our ARV business by adding products and geographies and expanding market access. Further, we remain on track to launch our Commercial business in India later this year.
Finally, our Mylan Specialty business reported a 67% year-over-year increase in third-party net revenues, which totaled more than $162 million during the first quarter. This exceptional performance resulted from higher sales of the EpiPen Auto-Injector, another strategic growth driver. Increased volumes and favorable pricing drove the growth in sales, and we continue to see double-digit accelerated quarter-over-quarter sales growth. The settlement announced this morning with Teva only further enhances our confidence in the anticipated continued strong performance of this product and our entire Specialty franchise.
As we've stated before, we see tremendous opportunity ahead for EpiPen as only 7% or 2 million of the 28 million people estimated to be at risk for anaphylaxis actually carries one. Continually increasing public awareness is essential to ensuring access to this product for people who need it, and generating sustained market expansion. Now let me turn to some of our other important strategic growth drivers.
Our global Institutional business continues to deliver double-digit growth. We anticipate that this business can become a billion dollar franchise by 2016. We remain focused on supply chain integrity and optimization of our cost of goods, we benefited and we will continue to benefit from being vertically integrated and we now have successfully internalized the manufacture of 80% of our products globally, giving us even greater control of over our cost and quality at each point in the supply chain. We also expect significant growth in our product portfolio and are on track to launch approximately 650 products and file more than 750 regulatory submissions globally this year. We also are pursuing external opportunities to expand our portfolio such as our acquisition of 2 limited competition dermatological products from Valiant earlier this year.
Looking at our respiratory platform, we have made good progress on the integration of the Pfizer business we acquired in November of 2011, and we believe we are on track to launch the first AB-rated generic version of Advair.
Finally, with respect to biogenerics, we have had productive discussions with the FDA regarding our portfolio and remain confident that we will be in the U.S. market starting in 2016. With that, I look forward to responding to your questions and will now turn the call over to John."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures and I remind you of Kris' comments at the beginning of the cal",1536,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures and I remind you of Kris' comments at the beginning of the call today regarding our use of adjusted measures.
I am extremely pleased with our financial results for the first quarter of 2012, a great start to what we firmly believe will be the most successful year in our company's history. Our Q1 results were achieved and our full year results will be achieved amid the macroeconomic headwinds that continue to plague Europe and in the wake of a 10% price cut in Japan and the most significant price cuts in Australian history, both of which occurred this quarter. This is a testament to the strength of our diverse global business, our first-in-class science, and our robust product portfolio.
The difficult pricing environment in several of our locations were certainly not expected -- unexpected, nor were the positive development which served to offset, and in some cases, fully mitigate the unfavorable impact. In fact, our first quarter results came in line with what we -- with that which we have forecasted in our Investor Day on February 21. Also, our current quarter results were in line with those of the fourth quarter of 2011 on a pre-tax basis. Adjusted pre-tax income in the current quarter was $304 million compared to $294 million sequentially. Getting in the details, let me walk you through our financial results for the first quarter of 2012.
I will also provide an update on our capital structure and liquidity position.
Starting at the top of our income statement, total revenues for the quarter were $1.59 billion, an increase of 10% over last year's first quarter revenues of $1.45 billion. Year-over-year, first quarter third-party net revenue growth on a constant currency basis was approximately 11%. The relatively small unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to certain other functional currencies of our major operations, mainly in Europe and in India.
Included in total revenues for the current quarter is approximately $9 million of other revenue related to a clean energy investment subsidiary, which we invested in near the end of 2011 and whose activities qualify for tax credits under Section 45 of the U.S. Internal Revenue Code. Our adjusted metrics, which I'll discuss momentarily, exclude all activity related to this investment with the exception of the net tax effect related to its operation, which is included in our adjusted effective tax rate. As a reminder, our guidance range for total revenue for the full year 2012 is between $6.8 billion and $7.2 billion.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 first quarter was a very strong 48%, up approximately 1 percentage point from the same prior-year period. Our strong current quarter margins are primarily the result of favorable pricing on EpiPen in our Specialty segment. Within generics, gross margins remained stable as new product launches in North America served to offset the normal pricing trend in the generic pharmaceutical industry.
Our operations, particularly in Europe, continue to employ cost-savings initiatives, especially from the perspective of cost of goods sold. These efforts have proven successful, and adjusted gross margins in Europe, on a sequential quarter-over-quarter basis and excluding the effect of foreign exchange, and as we anticipated, increased nearly 300 basis points despite lower sales. And while I'm certainly not going to predict when the economic situation in Europe will improve, these initiatives are expected to continue to have an incremental positive impact on our adjusted gross margin throughout 2012.
Adjusted operating income was $368 million for the first quarter of 2012, an 8% increase from Q1 2011. This is primarily the result of the favorable gross profit that I previously discussed, partially offset by increased levels of spending on R&D and SG&A.
R&D expense on an adjusted basis was $80 million, or approximately 5% of total revenues and up approximately 7% from the prior year. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues. The timing of certain R&D spending principally amounts related to our biologics and respiratory platforms has shifted into later periods of the current year with no impact on the timing of the programs themselves, and we continue to expect that the full year spend will be within our guidance range.
At the same time, SG&A also on an adjusted basis, was $312 million or approximately 19.7% of total revenues, closer to the high end of our full year guidance range of 18% to 20%. The increase in SG&A in the current quarter is due in large part to our investment in our Specialty franchise, which has resulted in higher volumes and increased market share.
Adjusted EBITDA for the 3 months ended March 31, 2012, was $411 million and remains forecasted to be between $1.75 billion and $1.95 billion for the full year. 
Moving onto our consolidated non-operating financial metrics. Adjusted interest expense for the first quarter of 2012 was $61 million. We continue to benefit from low, short-term interest rates. As of March 31, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70 / 30, fixed to floating debt portfolio, which we believe is an optimal ratio. 
As I mentioned before, our adjusted pre-tax earnings in the current quarter was slightly favorable as compared to that of the fourth quarter of the prior year. However, the effective tax rate in the current quarter was 26% as compared to 23% in the sequential quarter. The net result was adjusted diluted EPS in the current quarter in line with that of the fourth quarter of the prior year. Our full year 2012 tax rate range is unchanged at 26% to 27%, and we continue to believe that this rate will be sustainable at this level going forward.
First quarter adjusted net income was $224 million, or $0.52 per share, an 18% increase from our Q1 2011 adjusted diluted EPS of $0.44 per share and in line with that of the fourth quarter of 2011 after their adjusting for and fully consistent with, our expectations from our -- and adjusting for the higher tax rate in Q1 2012.
Our guidance range for adjusted diluted EPS for 2012 remains at $2.30 to $2.50 per share. And as I previously mentioned, and fully consistent with our expectations from our Investor Day, we expect earnings in the second quarter to be in line with the first before accelerating into the third quarter, which will be by far our strongest of the year and finishing with a fourth quarter that will propel us to our midpoint of $2.40 per share.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis was approximately $67 million. This takes into account certain  account -- certain special items principally the exclusion of payments of approximately $90 million related to previously settled and accrued litigation primarily related to AWP and the inclusion of approximately $62 million related to amounts due in 2012, which were received in late summer 2011 but excluded for adjusted cash flow purposes from that quarter.
Our GAAP cash flow from operations for the current quarter was a cash outflow of $109 million, leaving us with unrestricted cash and marketable securities totaling approximately $267 million. The first quarter is, historically, the heaviest in terms of the usage of cash and as a result of the timing of certain payments including taxes, interest and incentive optimization. But we are still forecasting our full year 2012 adjusted operating cash flow to be within our guidance range of $900 million to $1 billion.
First quarter capital spending was $36 million and we expect full-year capital expenditures to be within our guidance range of $300 million to $400 million. In addition to capital expenditures, approximately $70 million was spent during the quarter to acquire product rights and licenses, the majority of which relates to the purchase of 2 limited competition dermatological products from Valiant Pharmaceuticals.
During the current quarter, we repaid the $600 million due under our convertible notes and made a scheduled payment on our term loans. Both of these payments were made using a combination of cash on hand, borrowings our under our revolver and through cash received from our accounts receivable securitization facility, which we established in February. During the first quarter, we borrowed $285 million under this facility.
At the end of the quarter, following the debt repayment and additional borrowings under the revolver and the AR facility, our leverage ratio remains at 2.9x and we continue to have more than ample borrowing capacity.
To summarize, our first quarter was strong and was in line with what we had anticipated. This is an indication of things to come throughout what we believe will be our strongest year yet and another chapter in the exciting story that is Mylan.
That concludes my remarks. And I'll turn the call over to the operator for Q&A. Operator?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from the line of Douglas Tsao with Barclays.",14,"[Operator Instructions] Our first question comes from the line of Douglas Tsao with Barclays."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Just a couple of questions. First, I was just hoping you could speak a little bit to what you're currently seeing in terms of market conditions in Europe? Just given some concerns regarding economic instability or softness, obviously, you've expected, you",62,"Just a couple of questions. First, I was just hoping you could speak a little bit to what you're currently seeing in terms of market conditions in Europe? Just given some concerns regarding economic instability or softness, obviously, you've expected, you saw good results from Spain and Italy. In particular, I was curious if you could something seeing in Spain right now?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Look, I think, Europe overall, what I'd say is, we're seeing what we've been seeing and saying that we're not trying to predict the future of when that's going to turnaround. And obviously, why we continue to say we did not predict or forecast growth for",155,"Look, I think, Europe overall, what I'd say is, we're seeing what we've been seeing and saying that we're not trying to predict the future of when that's going to turnaround. And obviously, why we continue to say we did not predict or forecast growth for our European region. I think with that being said, we do see increased generic utilization beginning to increase, especially in the southern European markets. We saw growth and maintain leadership position, obviously, in Italy. And we see the same with Spain. We see that volume through increased utilization offsetting some of the price cuts. So I definitely would say that governments are beginning to realize that for sustainable cost-containment, utilization increase is a more proven, it has a better track record than just got a cost. So I would say there are some optimism that, that trend certainly will continue but again, we certainly didn't predict growth this year."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And, Doug, I'll just add that although we're not seeing growth, we are focused on maintaining the profitability of the region through cost savings and vertical integration initiatives, and we saw a very nice growth in the margins in Europe in the first qu",44,"And, Doug, I'll just add that although we're not seeing growth, we are focused on maintaining the profitability of the region through cost savings and vertical integration initiatives, and we saw a very nice growth in the margins in Europe in the first quarter."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","And in terms of the product introductions that you referred to in the prepared remarks, is that broadly across the entire region and applicable to almost all countries?",28,"And in terms of the product introductions that you referred to in the prepared remarks, is that broadly across the entire region and applicable to almost all countries?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Yes, absolutely.",2,"Yes, absolutely."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And then also just a point of clarity on the settlement with Teva that was announced this morning. If they do make changes to their ANDA and there are meaningful, perhaps, design changes to their product, do you still have the opportunity to reiniti",46,"Okay. And then also just a point of clarity on the settlement with Teva that was announced this morning. If they do make changes to their ANDA and there are meaningful, perhaps, design changes to their product, do you still have the opportunity to reinitiate litigation?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Well look, I think as far as our current settlement, it's very clear that we have through June of 2015. And as we made reference in there, they still have to receive regulatory approval, which we continue to believe that hurdle remains very high. So I wou",113,"Well look, I think as far as our current settlement, it's very clear that we have through June of 2015. And as we made reference in there, they still have to receive regulatory approval, which we continue to believe that hurdle remains very high. So I would look at it that kind of regardless of product or changes and, obviously, we would look at any of those things that happen in the future, but I would say we're excited. And I think that this settlement just further enhances and underscores truly the value of this franchise and our ability to now have some great runway to just continue to show accelerated growth quarter-over-quarter."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Chris Schott with JP Morgan.",11,"Our next question is coming from Chris Schott with JP Morgan."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First question, just would be interested in your views on the implications of further consolidation of the U.S. market with the Watson-Actavis transaction announced yesterday. [indiscernible] you really feel for health of the U.S. generic market and Mylan",40,"First question, just would be interested in your views on the implications of further consolidation of the U.S. market with the Watson-Actavis transaction announced yesterday. [indiscernible] you really feel for health of the U.S. generic market and Mylan's business specifically?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. Look, I think it's a fantastic deal. I think it -- as we've said for quite a while, and Robert has been very vocal about, that consolidation is needed, taking capacity out of the market especially a large player like Actavis, it certainly benefits t",93,"Sure. Look, I think it's a fantastic deal. I think it -- as we've said for quite a while, and Robert has been very vocal about, that consolidation is needed, taking capacity out of the market especially a large player like Actavis, it certainly benefits the global marketplace. I think it further underscores the need to be globally competitive, which underscores the platform that we've pulled together over the last 5 years. So look, I think congratulations to them, it's good and I think there is more to come, more consolidation to come."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Great. And then second question, just changing gears a little bit. Asia increasingly appears to be a more relevant driver to your numbers than Europe, is this, kind of, low-teens organic growth we saw this quarter a decent proxy for the growth you could s",65,"Great. And then second question, just changing gears a little bit. Asia increasingly appears to be a more relevant driver to your numbers than Europe, is this, kind of, low-teens organic growth we saw this quarter a decent proxy for the growth you could see the rest of the year given the Australian and Japanese price activity you just kind of referenced on the call?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. First of all, as I said in my remarks, our business in India is just hitting on all cylinders from third-party business. The ARV franchise continues to grow, and we continue to add diversity of our product line. And so we see, as we said, we anticip",168,"Sure. First of all, as I said in my remarks, our business in India is just hitting on all cylinders from third-party business. The ARV franchise continues to grow, and we continue to add diversity of our product line. And so we see, as we said, we anticipate continued double-digit growth. As far as Japan, again, we see a nice steady increase, Increased utilization continues to go up. We continue to build our product portfolio and most importantly, we continue to internalize these products, giving us much more flexibility, controlling the supply and the quality of that supply chain. So as Australia, obviously, continues to be a market that is undergoing significant pressure, I think since '08, we've shown our ability to manage through those headwinds and we're going to continue to do that. So I think all in all, Japan, and certainly, India, offsetting any of that pressure that we're feeling in Australia. And why we continue to be very confident in our growth in that region."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Elliot Wilbur of Needham & Company.",11,"Our next question is coming from Elliot Wilbur of Needham & Company."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Just an additional follow-up question, Heather, on the settlement. At your Analyst Day, you talked about the company's view that the financial community sort of over estimated the potential negative impact to Mylan's numbers, if and when the generic was i",184,"Just an additional follow-up question, Heather, on the settlement. At your Analyst Day, you talked about the company's view that the financial community sort of over estimated the potential negative impact to Mylan's numbers, if and when the generic was introduced of EpiPen. Is there anything in the agreement itself enabling Teva's entry in June 2015 that changes your expectations that a competitive generic entree will get roughly 40% of the market that will result in roughly an 8% [ph] to 12% [ph] negative impact on Mylan's bottom line? Then follow-up question for John, just looking at the company's capital structure as it currently exist. Some of the out-year debt senior notes, around, I think you're around $2.3 billion, is still sitting on the balance sheet at interest rates north of 7 1/2% and I guess given some of the recent transactions in the space and the current 0 interest rate regime across the world, I'm wondering if there might be an opportunity to refi that at more favorable rates given the company's enhanced cash flows and just stronger balance sheet position overall?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So I'll start with EpiPen. Look, absolutely nothing changes our thoughts or convictions about the strength and the brand equity of EpiPen. If anything, I think this settlement just underscores our confidence because we're going to have, at minimum,",129,"Sure. So I'll start with EpiPen. Look, absolutely nothing changes our thoughts or convictions about the strength and the brand equity of EpiPen. If anything, I think this settlement just underscores our confidence because we're going to have, at minimum, and I say minimum because I certainly believe the hurdles to get an AB-rated product are significant. But at a minimum, another 3 years to truly build the education around the need for people at risk to be carrying an EpiPen, so I think that brand equity only continues to become much more significant over the next few years. So I think that you've seen the results of us being out there, raising awareness and educating and we're just going to continue to increase and invest in this effort."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And then your question with respect to our capital structure and the notes that we issued, quite honestly, less than 2 years ago. You're right that interest rates have fallen significantly over the last 2 years and so some of those notes may have the oppo",85,"And then your question with respect to our capital structure and the notes that we issued, quite honestly, less than 2 years ago. You're right that interest rates have fallen significantly over the last 2 years and so some of those notes may have the opportunity, when they are prepayable and taking into consideration what prepayment penalties may exist, may have the opportunity for prepayment or refinancing. That's something that we'll look at when we get to a point where they're able to be refinanced."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from David Risinger of Morgan Stanley.",11,"Our next question is coming from David Risinger of Morgan Stanley."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I was hoping 2 things. First, if you could just frame out the key considerations for the second quarter so that we have a better understanding of how to think about the momentum year-over-year and the second quarter of 2012 versus 2011, and also, sequenti",84,"I was hoping 2 things. First, if you could just frame out the key considerations for the second quarter so that we have a better understanding of how to think about the momentum year-over-year and the second quarter of 2012 versus 2011, and also, sequentially, versus the first quarter of 2012? And then second, for Heather, just to clarify, can you just let us know if you're settlement today covers generic EpiPen only in its current form or in all future forms as well?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'll start with your second question and I'll John come back to your first. What we can say about the settlement is that it absolutely covers everything between Meridian and Teva through June of 2015.",37,"So I'll start with your second question and I'll John come back to your first. What we can say about the settlement is that it absolutely covers everything between Meridian and Teva through June of 2015."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And I think, David, with respect to the second quarter, as I said in my prepared remarks, the second quarter being similar to the first is fully in line with what the expectations we had on Investor Day when we indicated that the second half of 2012 would",195,"And I think, David, with respect to the second quarter, as I said in my prepared remarks, the second quarter being similar to the first is fully in line with what the expectations we had on Investor Day when we indicated that the second half of 2012 would be stronger than the first half of the year. The -- in particular, the -- my comments do not take into consideration a Doryx approval. But we continue to be -- to look forward to the court's ruling on that subject and our being able to launch that product, which has been long delayed, although I would say that as we look at the full year, we do expect -- we have always expected that before the end of the year that we would be in a place where we were or in a position to launch Doryx. We will launch Lipitor, the generic form of Lipitor, at the latter part of this year quarter. And so I guess I would just conclude or summarize by saying that Q2 is -- continues to be in line with what we talked about or expected on our Investor Day."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Marc Goodman with UBS.",10,"Our next question is coming from Marc Goodman with UBS."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Heather, I was curious with your thoughts on France and there seems to be some new rules that have been implemented to try to drive more generic competition utilization. So I was curious on your thoughts there? Second, if you could just talk about Japan a",98,"Heather, I was curious with your thoughts on France and there seems to be some new rules that have been implemented to try to drive more generic competition utilization. So I was curious on your thoughts there? Second, if you could just talk about Japan a little bit more, what was the strength in Japan and how good was it? I mean was this a double-digit growth quarter? Have we had double-digit growth for Japan. Just give a sense because you did say, in the press release, you're saying like it was strong and accelerating a little bit."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So in France. We do absolutely see the beginning of this push for increased generic utilization as I said, kind of, throughout Southern Europe. Italy is certainly the lead of that pack, but we do -- are very encouraged by the recent new regulation s",309,"Sure. So in France. We do absolutely see the beginning of this push for increased generic utilization as I said, kind of, throughout Southern Europe. Italy is certainly the lead of that pack, but we do -- are very encouraged by the recent new regulation statute to try to incentivize on several fronts that increases utilization. And like I said, I do think our efforts are paying off as we have been continuing to educate regulators and officials that, that utilization is much more sustainable to cost containment at healthcare than the price cuts. So I think that those numbers are -- they're starting to see that, obviously, from other countries. And so I'm very encouraged. And in the meantime, we've maintained our leadership position, 30% of the market share. As John said, we're very focused on that profitable growth and believe that, obviously, when Europe does come out of this -- comes out of the storm they're in right now, that we're going to need stronger than ever and certainly benefit just [ph] proportionately [ph] from now the increase in utilization. And as far as Japan goes, yes, as I said, we did see strong results. I would say that for the year, we certainly anticipate low double-digit growth in that country. And I think that it comes from a couple of places. One, as I've said, we've continue to enhance and now reaping the benefits of the pipeline that we've started to build after our acquisition. And we see those coming to fruition so we're launching more products, we're launching more internally manufactured products. So the profitability of that, the country continues to increase. And again, utilization, we continue to see it creeping up close to the mid 20s. So all in all, Japan is steadily just steadily increasing and we're very happy with our performance there."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Jami Rubin of Goldman Sachs.",11,"Our next question is coming from Jami Rubin of Goldman Sachs."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I don't want to beat the dead hoarse or anything, but John and Heather, maybe if you can just elaborate a little bit more why you're still so confident that there is such a high regulatory bar for AB-rated generics for EpiPen. I guess I was somewhat surpr",130,"I don't want to beat the dead hoarse or anything, but John and Heather, maybe if you can just elaborate a little bit more why you're still so confident that there is such a high regulatory bar for AB-rated generics for EpiPen. I guess I was somewhat surprised that -- wasn't really quite sure why you reached the settlement given your confidence in that regulatory landscape, so if you could be a little bit more specific why you don't expect to see that. And then secondarily, again on generic Doryx, we were expecting to hear that case of that verdict in February or March and here we are almost, we are in May, almost in May, haven't heard anything yet and just what you think is going on there?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","All right. Jami, so look, the confidence, I've never been more confident in our statements about EpiPen and an AB-rated product. And I think that our settlement, the way in which we settle it should certainly underscore that. Our settlement has nothing to",167,"All right. Jami, so look, the confidence, I've never been more confident in our statements about EpiPen and an AB-rated product. And I think that our settlement, the way in which we settle it should certainly underscore that. Our settlement has nothing to do with the regulatory aspects. The press release, clearly lays out that they still have to get regulatory approval, which we continue to believe is a very high hurdle and why I'm saying we now have a minimum until June of 2015. So our settlement really has with -- just truly on the patent case and the judicial, nothing to do with the regulatory process or the hurdles that we believe are still absolutely in place. As far as Doryx look, like we can't predict Europe, I can't predict when judges are going to rule. You said it would be soon, and I guess his definition of soon or quick may differ from some of ours. but so look, we anticipate that decision anytime."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Shibani Malhotra of RBC Capital.",11,"Our next question is coming from Shibani Malhotra of RBC Capital."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I guess, Heather, you talked about expecting increased consolidation in the generics industry due to excess capacity. Could you comment on whether Mylan is looking to further consolidate businesses and what sort of businesses? And what sort of businesses",95,"I guess, Heather, you talked about expecting increased consolidation in the generics industry due to excess capacity. Could you comment on whether Mylan is looking to further consolidate businesses and what sort of businesses? And what sort of businesses you would be looking for if you were considering M&A? And then second, just to follow up on EpiPen again, I guess and on Jami's question. I was just wondering, were you able to look at Teva and Teva's filing before you reached a settlement or was this just kind of a blind sort of case?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Okay. So first, I'll talk about the macro issue. And I want to just clarify, my point on consolidation is not even just a generic industry, but the pharmaceutical industry as a whole. I think that as we've continued to talk about the global competitivenes",245,"Okay. So first, I'll talk about the macro issue. And I want to just clarify, my point on consolidation is not even just a generic industry, but the pharmaceutical industry as a whole. I think that as we've continued to talk about the global competitiveness needed to compete is brand looking at generics, I think more than ever because of the emerging markets and the need to have a high-quality breadth product portfolio. So look, that's why we continue to believe there absolutely will be consolidation, perhaps among smaller players, but continued activity among brand and generics. As far as our activity, I think we laid out a lot of parameters and clarity on Investor Day, speaking to the fact that we absolutely are looking and always looking at a lot of different things, whether it's new geographies, products, therapeutic categories, bolt on for dosage forms, certainly looking for products for our Specialty division. So we are extremely active looking on all fronts. And like I said, just continue to be excited at the opportunities we see out there given some of the macro economic conditions in some of these geographies. As far as EpiPen, look, I can't and we don't talk about litigation and so forth. But all I can tell you is, obviously, litigation is not typically blind in both parties, there's a lot of activity between the parties, obviously, in pretrial as well as trial. So I'll just leave it at that."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from John Boris with Citi.",10,"Our next question is coming from John Boris with Citi."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First question, just has to do where you invited to look at Actavis and can you just share whether you did look at the Actavis transaction and just discuss your competitive position, obviously, based on some of the slides, lots of input out there, you do",65,"First question, just has to do where you invited to look at Actavis and can you just share whether you did look at the Actavis transaction and just discuss your competitive position, obviously, based on some of the slides, lots of input out there, you do slip to #4 in a consolidating industry? Just some commentary there. And then I have a follow-up on EpiPen."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I think it's safe, John, for you to imagine that we look at everything. And I think that probably the only thing I'd say about the processes is that it's not an auction or a competitive process. So I would just kind of lead to that about what the activ",285,"So I think it's safe, John, for you to imagine that we look at everything. And I think that probably the only thing I'd say about the processes is that it's not an auction or a competitive process. So I would just kind of lead to that about what the activity that was going on around Actavis for a long time now. And as far as -- so as far as there are continued activity, as I said, I think that we have a tremendous amount of opportunity to continue, to add on. And again, as we said on Investor Day, we're not standing still or gone on vacation. So I can assure you that we are very active right now in many fronts. And I guess all I'd say about commenting on #3, #4, #1, #2, we've said it's really not about the number, I think it's the quality of the assets and it's how we're building Mylan. And I think we put together a great global platform, as Robert has said, we don't need another transformational deal. But what we are very interested in is high-quality assets that we can continue to add and maximize and leverage this platform that we've brought together. And I think between our vertical integration, which is exceeding all of our wildest imaginations and the benefits we're reaping from that, just continues to boost our ability to compete in every market around the world with the highest quality products. So we've not lost our sight on our mission to reach 7 billion people and believe that we've got a lot of opportunity to get there whatever number that puts us as a global player in this marketplace."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","For John, on EpiPen, there was a slide you put up during your analyst meeting that seem to indicate that with direct-to-consumer advertising, it was very deep, very responsive to market share gains. I think you're electing to make 2 investments this year,",115,"For John, on EpiPen, there was a slide you put up during your analyst meeting that seem to indicate that with direct-to-consumer advertising, it was very deep, very responsive to market share gains. I think you're electing to make 2 investments this year, 6 months of direct-to-consumer advertising and you've invested in a 100-person sales force. How do you measure those investments going forward? And what are the implications for at least the volume growth on EpiPen going forward? And then just for Heather, can you just maybe talk about the Teva device and is it the device that would prevent it from being therapeutically substituted for AB-rated if and when they ever get approved?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'll start then I'll let John -- my comments about AB-rated have to do with the FDA and the regulatory environment around the Dragon device. So as I've talked about for a long time, that those regulations, and FDA clarified their position and the answe",267,"So I'll start then I'll let John -- my comments about AB-rated have to do with the FDA and the regulatory environment around the Dragon device. So as I've talked about for a long time, that those regulations, and FDA clarified their position and the answer to the citizen petition a couple of years ago, that it's not that's same. Then it can't be rated substitutable and especially in a life -- on an emergency situation. So my comments have always been around our confidence and our intellectual property around our Dragon device, the regulations at FDA and the ability to have to be the same. So if you have to retrain, it's not the same. And for obviously EpiPen and anaphylaxis, obviously reaches that hurdle of being life saving on an emergency situation. So that again is why I underscore my confidence in the franchise and the hurdles for getting an AB-rated. I'll let John speak to ROI but what I will say is, we were -- after we saw the results from last year's DTC as well as other initiatives. Because while direct-to-consumer is certainly a large aspect, we're doing on many fronts, around this education. And obviously, if you look since Q3 of last year, you see just beyond accelerated double-digit growth year-over-year for each quarter. And obviously, this now being a record Quarter 1 for EpiPen and we see that continuing to grow. So it is absolutely, the results, I think, speak to the pay off here. And we just see that doing nothing but continuing to grow at an accelerated rate."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","I'd just briefly add on to what Heather said, as you know, we are the market for anaphylactic shock with over 98% market share. And therefore, the programs that we're running are both focused on building the awareness regarding anaphylactic shock and the",143,"I'd just briefly add on to what Heather said, as you know, we are the market for anaphylactic shock with over 98% market share. And therefore, the programs that we're running are both focused on building the awareness regarding anaphylactic shock and the value of the EpiPen for dealing with those types of life-threatening situations. And the way we measure the success of the programs, whether it be the direct-to-consumer advertising campaigns or the expansion in our field force, is by looking at the expansion of the market that's taking place. And that expansion of the market, we showed that on Investor Day, has been significant. We're off to a great start for 2012. We talked on Investor Day of the Specialty business growing 30% year-over-year for 2012. And at this point, one quarter into it, I think it's at least that."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Greg Gilbert of Bank of America Merrill Lynch.",14,"Our next question is coming from Greg Gilbert of Bank of America Merrill Lynch."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Getting a lot of free advertising on EpiPen, Heather, I'll start with EpiPen. Would the settlement structure allow you to launch an AG if you wanted to? And what are your thoughts on EpiPen OTC. And for John, I think you could've made a nickel in EPS on M",84,"Getting a lot of free advertising on EpiPen, Heather, I'll start with EpiPen. Would the settlement structure allow you to launch an AG if you wanted to? And what are your thoughts on EpiPen OTC. And for John, I think you could've made a nickel in EPS on Modafinil before the Teva development. You're still pointing to potential upside to the range. So what's going on better than expected so far this year? Or were you just being incredibly conservative on your initial guidance?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So, look, I would say that there's no restrictions on us on EpiPen, but I have to tell you that there is certainly no reason -- EpiPen, the kind of product and what we've spoken about from brand equity and the awareness around there would just be no reaso",121,"So, look, I would say that there's no restrictions on us on EpiPen, but I have to tell you that there is certainly no reason -- EpiPen, the kind of product and what we've spoken about from brand equity and the awareness around there would just be no reason to put an AG in. So, look, I think that the settlement certainly, again, I'm just going to say -- and you're right a lot of good advertisement this morning, we moved that overhang that we know the Street continue to be concerned that there quite a possibility that what if has been taken off the table, and I can assure you we will maximize the opportunity we have ahead of us."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So Greg, I guess, Greg, on your second part, first of all, I guess I would start by saying that we're incredibly disappointed by the whole Modafinil situation. But Mylan has never been, we've said it so many times, about one product. And therefore, the --",203,"So Greg, I guess, Greg, on your second part, first of all, I guess I would start by saying that we're incredibly disappointed by the whole Modafinil situation. But Mylan has never been, we've said it so many times, about one product. And therefore, the -- we will -- we're whether it's Modafinil in or Modafinil out, we're still very confident at our $2.40 per share midpoint of our guidance range. And whether it be the very successful launch of Escitalopram that we had here in the first quarter or the strength of the EpiPen that we're seeing throughout 2012, all of those things make us very confident that 2012 will be a very good year, the best year for Mylan that we've had in our history. And look, I don't know that I would say we were being incredibly conservative however you described it, I think we were providing a guidance range at the beginning of the year that we believe reflected the fact that not all good things happened, not all bad things happened. And that we would be in that guidance range. And we look forward to the year continuing to develop this way and taking advantage of upside opportunities."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","How about that OTC piece of my question?",8,"How about that OTC piece of my question?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Oh, I'm sorry. Yes. So as far as OTC, listen, we've had a lot of discussions and we'll be continuing to have these discussions. I believe that most responsible thing for EpiPen would be behind the counter. So it would look much more like sometimes how ins",247,"Oh, I'm sorry. Yes. So as far as OTC, listen, we've had a lot of discussions and we'll be continuing to have these discussions. I believe that most responsible thing for EpiPen would be behind the counter. So it would look much more like sometimes how insulin is treated or plan B. So we believe that there is absolutely opportunity to continue to work with states because as you might imagine, there is -- all the states differ with pharmacy laws and regulations. But we are actively pursuing and looking at doing just that, working with the states, working with the FDA, to hopefully get to a place where there would be both prescription EpiPen as well as behind-the-counter EpiPen that would provide the maximum access to everybody who wanted or needed to carry an EpiPen to be able to have as many as they want and also be able to make sure, from a collaborative perspective that whether it's schools being covered, soccer fields, football as you might imagine, that not only is important to have the schools equipped, which we're launching a huge program here in the next couple of months with schools, but also everything in the community related to that. So all of this is working in conjunction and why I said that outside of just our DTC investment that there's a lot of other initiatives that are ongoing that we'll be excited to be telling you more about as the year unfolds."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Ronny Gal from Sanford Bernstein.",11,"Our next question is coming from Ronny Gal from Sanford Bernstein."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I got 2 and I promise not to ask a thing about EpiPen. The first one is, John, kind of, would be a little bit under the Watson announcement yesterday where -- which surprised me the most is how much cash they can free to pay down the debt early on. And lo",202,"I got 2 and I promise not to ask a thing about EpiPen. The first one is, John, kind of, would be a little bit under the Watson announcement yesterday where -- which surprised me the most is how much cash they can free to pay down the debt early on. And looking at your numbers, you've got roughly the same EBITDA they do roughly the same tax, roughly the same interest rate, you came in about $1 billion in operating cash flow, but your spending $400 million of that on CapEx, you're spending 40% of your operating cash flow on CapEx. And the question is, is there -- how do we think about that? You, guys, are paying a lot more than your peers in terms of percentage of cash flow on CapEx. Should we think about this as a positive or should you be thinking about -- will be holding some of that back, paying down your debt more and then suddenly you look a lot less levered and look lot more financial  [indiscernible] flexibility to return the cash, buy something or somehow create like a most significant upside to the business. And then I do have a follow on."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'm going to start off even though you said John. I just at least want to underscore, not only our commitment, investment in CapEx but why. If you go back to our Investor Day, we said we were going to double our size in the next 5 years, from a capacit",211,"So I'm going to start off even though you said John. I just at least want to underscore, not only our commitment, investment in CapEx but why. If you go back to our Investor Day, we said we were going to double our size in the next 5 years, from a capacity perspective, our platform. So as you look, we are investing, obviously, across the board whether it's on our API, whether it's in the finished dosage form facility, but doubling that capacity, we believe is, again, just goes to the diversity of our platform, our ability to absorb whatever, headwind, country, issue. That, that ability to not only invest from an R&D perspective and we talked a lot about our product portfolio doubling. And when you think about not only doubling, it's the quality of what we're doubling and the kind of products, again, our respiratory announcement. Our ability to have the dollars and invest the dollars we believe is another barrier to entry because we're using large dollar investments, whether it's respiratory, whether it's biogenerics, doubling our size. So we believe, as I said earlier, it's not necessarily just quantity, we believe not only are we investing in the right things, but certainly in a very quality way."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And I guess I would just add on to what Heather said, at 2.9x gross debt to EBITDA, we're very comfortable with that leverage ratio. And that leverage ratio has been declining steadily and accelerating in that decline. And so, we generate $600 million a y",116,"And I guess I would just add on to what Heather said, at 2.9x gross debt to EBITDA, we're very comfortable with that leverage ratio. And that leverage ratio has been declining steadily and accelerating in that decline. And so, we generate $600 million a year of free cash flow, it's just a substantial amount. We've been using that cash flow to reinvest back in the business as well as to delever. And so, I think that we're building a platform for the future and responsibly reinvesting in that platform so we have the right play -- the right growth in the future while at the same time managing the balance sheet in a smart way."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And which is why I think we continue to reiterate our confidence and commitment to delivering on our longer-term growth prospects. Because the investments we're making today are for the 2016, '17, '18 opportunities that we believe we'll be able to globall",44,"And which is why I think we continue to reiterate our confidence and commitment to delivering on our longer-term growth prospects. Because the investments we're making today are for the 2016, '17, '18 opportunities that we believe we'll be able to globally monetize."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Gary Nachman with Susquehanna.",10,"Our next question is coming from Gary Nachman with Susquehanna."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First, a couple of pricing questions. How is the pricing shaking up for generic Lexapro between you and Teva since share seems to have been split evenly between you guys. And on EpiPen, how much more headroom in pricing are you assuming this year after ta",58,"First, a couple of pricing questions. How is the pricing shaking up for generic Lexapro between you and Teva since share seems to have been split evenly between you guys. And on EpiPen, how much more headroom in pricing are you assuming this year after taking that 10% price increase in March? And then I have a follow-up."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Your pricing question, your first one, we don't discuss pricing of individual products. All I can tell you is we continue to see stability in our products at both the base business and opportunities on some of these new launches. So I would say that on th",90,"Your pricing question, your first one, we don't discuss pricing of individual products. All I can tell you is we continue to see stability in our products at both the base business and opportunities on some of these new launches. So I would say that on the first one. EpiPen, look, I think we've been pretty consistent in our pricing. And we see that continuing. So as we continue to invest and continue to look at building that awareness, we'll continue to have a pricing strategy that certainly mirrors that."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Okay, and just you mentioned in terms of your building out the Commercial business in India later this year, I thought I remembered you saying at the Analyst Day that, that was going to be earlier in the year, so I'm just curious if there were any changes",69,"Okay, and just you mentioned in terms of your building out the Commercial business in India later this year, I thought I remembered you saying at the Analyst Day that, that was going to be earlier in the year, so I'm just curious if there were any changes to that timeline. And just talk about the impact you think that's going to have on the business in that region."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","We have talked about July launch and that's where we exactly are. We will be launching sometime between July and August. And we don't see any significant impact on the year.",32,"We have talked about July launch and that's where we exactly are. We will be launching sometime between July and August. And we don't see any significant impact on the year."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from the line of Michael Faerm, Jr. with Credit Suisse.",15,"Our next question is coming from the line of Michael Faerm, Jr. with Credit Suisse."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","You had commented earlier about your confidence in your ultimate approval and AB rating for your generic Advair. Can you elaborate on why you're confident in that, and maybe contrast it to the EpiPen situation where you're confident that the generic won't",45,"You had commented earlier about your confidence in your ultimate approval and AB rating for your generic Advair. Can you elaborate on why you're confident in that, and maybe contrast it to the EpiPen situation where you're confident that the generic won't get AB rating."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure, I'm going to start and then I'm going to let Rajiv, perhaps, speak to our confidence in it. Look, I think that what we said when we announced the acquisition of that platform as we were taking the core competencies of the existing Pfizer platform an",141,"Sure, I'm going to start and then I'm going to let Rajiv, perhaps, speak to our confidence in it. Look, I think that what we said when we announced the acquisition of that platform as we were taking the core competencies of the existing Pfizer platform and marrying that up with what Mylan has always been known to do best, which is taking very complex opportunities and bringing them to fruition. So when we looked at the high-caliber and the asset and the position and the point that Pfizer had developed a product now marrying that up and complementing it with our scientific ability is really what underscored our confidence. And I'll let -- and as far as EpiPen goes, look, as I continue to say, it's the Dragon device component of EpiPen that makes those regulations and those aspects different."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And our confidence is based on what we acquired, the quality of the device and the similarity of the device between this one's and Glaxo's, as well as our continued dialogue with FDA and the progress which we are making. So we remain very confident that w",58,"And our confidence is based on what we acquired, the quality of the device and the similarity of the device between this one's and Glaxo's, as well as our continued dialogue with FDA and the progress which we are making. So we remain very confident that we are on the right part to build the first generic Advair."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Operator, I think we have time for one more question.",10,"Operator, I think we have time for one more question."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Your final question is coming from the line of Randall Stanicky with Canaccord Genuity.",14,"Your final question is coming from the line of Randall Stanicky with Canaccord Genuity."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I just keep it one. Just going back to Europe for a second. I appreciate, I think we all appreciate the headwinds and the challenges there. The double-digit declines in constant currency growth, if those continue, how much cushion do you have built in bef",70,"I just keep it one. Just going back to Europe for a second. I appreciate, I think we all appreciate the headwinds and the challenges there. The double-digit declines in constant currency growth, if those continue, how much cushion do you have built in before that becomes an issue? I understand that you don't need to grow, but at what point is the constant currency decline start to hurt you?"
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Look, I talked about the fact that our gross margins actually increased to 300 basis points quarter-to-quarter, Randall. And so it's not about the top line, it's about the bottom line, and we're managing that region in the context of the macroeconomic hea",142,"Look, I talked about the fact that our gross margins actually increased to 300 basis points quarter-to-quarter, Randall. And so it's not about the top line, it's about the bottom line, and we're managing that region in the context of the macroeconomic headwind. So it's not hurting us. We obviously would love to see growth and we look forward to when the macroeconomic issues in Europe are resolved and generic utilization rates increase. And the top line growth, together with the gross margins increasing, and that's why we talked on the Investor Day about Europe being a long-term growth driver for us.
So with that, look, we appreciate all of our investors and the questions we received in this call. Q1 was very much in line with what we had expected, and we look forward to continuing to deliver on 2012. So..."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you.",2,"Thank you."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","With that, operator, you can close the call.",8,"With that, operator, you can close the call."
290203,184140392,290176,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Thank you, this does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you, this does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's First Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Easte",78,"Welcome to Mylan's First Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern standard time. The dial-in number is (800) 585-8367, or (404) 537-3406 for international callers, with pin number 70819215. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King; you may begin."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Beverly. Good morning, everyone. Welcome to Mylan's First Quarter 2012 Earnings Call. Joining me for today's call are Mylan's CEO, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chi",344,"Thank you, Beverly. Good morning, everyone. Welcome to Mylan's First Quarter 2012 Earnings Call. Joining me for today's call are Mylan's CEO, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making forward-looking statements including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties, and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our report on Form 10-K for the period ended December 31, 2012, and in our other SEC filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures such as adjusted revenue, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings press release, which is available on our website, as it contains detailed GAAP to non-GAAP reconciliations of our actual first quarter results.
Before I turn the call over to Heather, let me also remind you that the materials in this call, with the exception of a participant question, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'd like to turn the call over to Heather."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us today. Before we get started, I'd like to welcome and recognize all of our fellow employees around the world. Through their passion and hard work, we delivered very strong results t",1150,"Thank you, Kris, and good morning, everyone, and thank you for joining us today. Before we get started, I'd like to welcome and recognize all of our fellow employees around the world. Through their passion and hard work, we delivered very strong results this quarter. On behalf of the Board of Directors and our entire management team, I would like to thank each and every one of them.
Our diverse global platform has once again delivered strong results, representing a great start to 2012. Double-digit growth on our North American, Asia-Pacific and Specialty businesses allowed us to deliver robust financial results despite persistent macroeconomic headwinds in certain regions, specifically Europe and Australia. We are reaffirming our 2012 guidance of $2.30 to $2.50 per share and we see opportunities for upside during the year. Further, the strength of our platforms, first-in-class science and robust product portfolio give us continued confidence in our long-term growth target for 2013 and beyond.
During the first quarter, we generated total adjusted revenues of $1.58 billion, an increase of 11% on a constant currency basis as compared to last year's first quarter revenues of $1.45 billion. On the bottom line, we delivered adjusted diluted earnings per share of $0.52, an 18% increase over the $0.44 per share we delivered during the first quarter of '11.
In our North American Generics business, third-party net revenues for the quarter were $777 million, up more than 15% from the comparable year-ago period. This strong result was driven in part by launches of 11 new products in the U.S., including Ibandronate and Escitalopram, a first equivalent product that generated the highest and fastest conversion rate in versus generic launch we've seen in recent history. We also enjoyed strong sales in the U.S. on many of our existing products.
Further, consistent with the strength of our R&D capabilities, 2 of the 8 first quarter products submissions we made in the U.S. are first-to-file opportunities. Currently we have 171 ANDAs pending FDA approval, 40 of which are potential first to file. Regarding our neurology franchise which is one of our strategic growth drivers, we're awaiting the court's ruling in the Copaxone patent infringement case whose trial concluded in September of 2011. We remain convinced that we have an AB-rated product and look forward to securing approval in the second half of this year. While we eagerly anticipate the court's ruling and regulatory approval, I'd like to remind everybody that we are not relying on this product to achieve our 2013 target of $275 million. We also are pleased with our performance in Canada, and it's another example of the robustness of our global pipeline.
In Canada, we launched 9 products during the quarter, which is more than we launched during all of 2011. Our expanded portfolio is fueling sales and growth in our customer base, along with cost of goods efficiency that will help us weather price cuts and remain competitive and ensure consistent supply in every province.
In EMEA, as anticipated, we delivered third-party net revenues of $336 million during the quarter, a decline of approximately 14% compared to last year's first quarter results. On a constant currency basis, revenues fell 10%. New products launched throughout the region served to offset volume pressure on sales of existing products and mitigate some of the effects of unfavorable pricing.
During the quarter, we also enjoyed constant currency revenue growth of 8% in Italy, one of Europe's fastest growing markets. And in Spain, our sales volume grew along with this rapidly expanding market. Results in both cases were driven by increased generic utilization. Moreover, we remain on track to launch nearly 300 new products in Europe this year. By now, it should be very evident that our powerful global platform has and will continue to demonstrate its ability to absorb headwinds such as those occurring in Europe. Despite such headwinds, we have maintained our leadership positions in several markets such as France, Italy, Spain, U.K., Belgium and Portugal.
Moving now to our Asia-Pacific regions. We generated third-party net revenues of nearly $299 million during the first quarter, an increase of more than 8% over last year's results and 12% higher on a constant currency basis. Our double-digit growth was driven largely by the strong performance of our business in India. We continue to see growth in our third-party business and accelerated growth in our ARV franchise, both in finished dosage form and API. We currently supply to more than 90 countries. We keep expanding our ARV business by adding products and geographies and expanding market access. Further, we remain on track to launch our Commercial business in India later this year.
Finally, our Mylan Specialty business reported a 67% year-over-year increase in third-party net revenues, which totaled more than $162 million during the first quarter. This exceptional performance resulted from higher sales of the EpiPen Auto-Injector, another strategic growth driver. Increased volumes and favorable pricing drove the growth in sales, and we continue to see double-digit accelerated quarter-over-quarter sales growth. The settlement announced this morning with Teva only further enhances our confidence in the anticipated continued strong performance of this product and our entire Specialty franchise.
As we've stated before, we see tremendous opportunity ahead for EpiPen as only 7% or 2 million of the 28 million people estimated to be at risk for anaphylaxis actually carries one. Continually increasing public awareness is essential to ensuring access to this product for people who need it, and generating sustained market expansion. Now let me turn to some of our other important strategic growth drivers.
Our global Institutional business continues to deliver double-digit growth. We anticipate that this business can become a billion dollar franchise by 2016. We remain focused on supply chain integrity and optimization of our cost of goods; weve benefited and we will continue to benefit from being vertically integrated; and we now have successfully internalized the manufacture of 80% of our products globally, giving us even greater control of over our cost and quality at each point in the supply chain. We also expect significant growth in our product portfolio and are on track to launch approximately 650 products and file more than the 750 regulatory submissions globally this year. We also are pursuing external opportunities to expand our portfolio, such as our acquisition of 2 limited-competition dermatological products from Valeant earlier this year.
Looking at our respiratory platform, we have made good progress on the integration of the Pfizer business we acquired in November of 2011, and we believe we are on track to launch the first AB-rated generic version of Advair.
Finally, with respect to biogenerics, we have had productive discussions with the FDA regarding our portfolio and remain confident that we will be in the U.S. market starting in 2016. With that, I look forward to responding to your questions and will now turn the call over to John."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures and I remind you of Kris' comments at the beginning of the cal",1533,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures and I remind you of Kris' comments at the beginning of the call today regarding our use of adjusted measures.
I am extremely pleased with our financial results for the first quarter of 2012, a great start to what we firmly believe will be the most successful year in our company's history. Our Q1 results were achieved and our full year results will be achieved amid the macroeconomic headwinds that continue to plague Europe and in the wake of a 10% price cut in Japan and the most significant price cuts in Australian history, both of which occurred this quarter. This is a testament to the strength of our diverse global business, our first-in-class science, and our robust product portfolio.
The difficult pricing environment in several of our locations was certainly not expected -- unexpected, nor were the positive development which served to offset, and in some cases, fully mitigate the unfavorable impact. In fact, our first quarter results came in line with what we -- with that which we have forecasted in our Investor Day on February 21. Also, our current quarter results were in line with those of the fourth quarter of 2011 on a pre-tax basis. Adjusted pre-tax income in the current quarter was $304 million compared to $294 million sequentially. Getting in the details, let me walk you through our financial results for the first quarter of 2012.
I will also provide an update on our capital structure and liquidity position.
Starting at the top of our income statement, total revenues for the quarter were $1.59 billion, an increase of 10% over last year's first quarter revenues of $1.45 billion. Year-over-year, first quarter third-party net revenue growth on a constant currency basis was approximately 11%. The relatively small unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to certain other functional currencies of our major operations, mainly in Europe and in India.
Included in total revenues for the current quarter is approximately $9 million of other revenue related to a clean energy investment subsidiary, which we invested in near the end of 2011 and whose activities qualify for tax credits under Section 45 of the U.S. Internal Revenue Code. Our adjusted metrics, which I'll discuss momentarily, exclude all activity related to this investment with the exception of the net tax effect related to its operation, which is included in our adjusted effective tax rate. As a reminder, our guidance range for total revenue for the full year 2012 is between $6.8 billion and $7.2 billion.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 first quarter was a very strong 48%, up approximately 1 percentage point from the same prior-year period. Our strong current quarter margins are primarily the result of favorable pricing on EpiPen in our Specialty segment. Within generics, gross margins remained stable as new product launches in North America served to offset the normal pricing trend in the generic pharmaceutical industry.
Our operations, particularly in Europe, continue to employ cost-savings initiatives, especially from the perspective of cost of goods sold. These efforts have proven successful, and adjusted gross margins in Europe, on a sequential quarter-over-quarter basis and excluding the effect of foreign exchange, and as we anticipated, increased nearly 300 basis points despite lower sales. And while I'm certainly not going to predict when the economic situation in Europe will improve, these initiatives are expected to continue to have an incremental positive impact on our adjusted gross margin throughout 2012.
Adjusted operating income was $368 million for the first quarter of 2012, an 8% increase from Q1 2011. This is primarily the result of the favorable gross profit that I previously discussed, partially offset by increased levels of spending on R&D and SG&A.
R&D expense on an adjusted basis was $80 million, or approximately 5% of total revenues and up approximately 7% from the prior year. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues. The timing of certain R&D spending, principally amounts related to our biologics and respiratory platform, has shifted into later periods of the current year with no impact on the timing of the programs themselves, and we continue to expect that the full year spend will be within our guidance range.
At the same time, SG&A also on an adjusted basis, was $312 million or approximately 19.7% of total revenues, closer to the high end of our full year guidance range of 18% to 20%. The increase in SG&A in the current quarter is due in large part to our investment in our Specialty franchise, which has resulted in higher volume and increased market share.
Adjusted EBITDA for the 3 months ended March 31, 2012, was $411 million and remains forecasted to be between $1.75 billion and $1.95 billion for the full year. 
Moving onto our consolidated non-operating financial metrics. Adjusted interest expense for the first quarter of 2012 was $61 million. We continue to benefit from low short-term interest rates. As of March 31, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70:30 fixed to floating debt portfolio, which we believe is an optimal ratio. 
As I mentioned before, our adjusted pre-tax earnings in the current quarter was slightly favorable as compared to that of the fourth quarter of the prior year. However, the effective tax rate in the current quarter was 26% as compared to 23% in the sequential quarter. The net result was adjusted diluted EPS in the current quarter in line with that of the fourth quarter of the prior year. Our full year 2012 tax rate range is unchanged at 26% to 27%, and we continue to believe that this rate will be sustainable at this level going forward.
First quarter adjusted net income was $224 million, or $0.52 per share, an 18% increase from our Q1 2011 adjusted diluted EPS of $0.44 per share and in line with that of the fourth quarter 2011 after their adjusting for and fully consistent with, our expectations from our -- and adjusting for the higher tax rate in Q1 2012.
Our guidance range for adjusted diluted EPS for 2012 remains at $2.30 to $2.50 per share. And as I previously mentioned, and fully consistent with our expectations from our Investor Day, we expect earnings in the second quarter to be in line with the first before accelerating into the third quarter, which will be by far our strongest of the year and finishing with a fourth quarter that will propel us to our midpoint of $2.40 per share.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis was approximately $67 million. This takes into account certain  account certain special items principally the exclusion of payments of approximately $90 million related to previously settled and accrued litigation primarily related to AWP and the inclusion of approximately $62 million related to amounts due in 2012, which were received in late December 2011 but excluded for adjusted cash flow purposes from that quarter.
Our GAAP cash flow from operations for the current quarter was a cash outflow of $109 million, leaving us with unrestricted cash and marketable securities totaling approximately $267 million. The first quarter is, historically, the heaviest in terms of the usage of cash and as a result of the timing of certain payments including taxes, interest and incentive optimization. But we are still forecasting our full year 2012 adjusted operating cash flow to be within our guidance range of $900 million to $1 billion.
First quarter capital spending was $36 million and we expect full year capital expenditures to be within our guidance range of $300 million to $400 million. In addition to capital expenditures, approximately $70 million was spent during the quarter to acquire product rights and licenses, the majority of which relates to the purchase of 2 limited competition dermatological products from Valiant Pharmaceuticals.
During the current quarter, we repaid the $600 million due under our convertible notes and made a scheduled payment under our term loan. Both of these payments were made using a combination of cash on hand, borrowings under our revolver and through cash received from our accounts receivable securitization facility, which we established in February. During the first quarter, we borrowed $285 million under this facility.
At the end of the quarter, following the debt repayment and additional borrowings under the revolver and the AR facility, our leverage ratio remains at 2.9x and we continue to have more than ample borrowing capacity.
To summarize, our first quarter was strong and was in line with what we had anticipated. This is an indication of things to come throughout what we believe will be our strongest year yet and another chapter in the exciting story that is Mylan.
That concludes my remarks. And I'll turn the call over to the operator for Q&A. Operator?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from the line of Douglas Tsao with Barclays.",14,"[Operator Instructions] Our first question comes from the line of Douglas Tsao with Barclays."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Just a couple of questions. First, I was just hoping you could speak a little bit to what you're currently seeing in terms of market conditions in Europe. Just given some concerns regarding economic instability or softness, obviously, you expected -- you",66,"Just a couple of questions. First, I was just hoping you could speak a little bit to what you're currently seeing in terms of market conditions in Europe. Just given some concerns regarding economic instability or softness, obviously, you expected -- you saw good results from Spain and Italy. In particular, I was curious if you could speak to what youre seeing in Spain right now."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Well look, I think, Europe overall, what I'd say is, we're seeing what we've been seeing and saying that we're not trying to predict the future of when that's going to turnaround and obviously, why we continue to say we did not predict or forecast growth",154,"Well look, I think, Europe overall, what I'd say is, we're seeing what we've been seeing and saying that we're not trying to predict the future of when that's going to turnaround and obviously, why we continue to say we did not predict or forecast growth for our European region. I think with that being said, we do see increased generic utilization beginning to increase, especially in the southern European markets. We saw growth and maintain leadership position, obviously, in Italy. And we see the same with Spain. We see that volume through increased utilization offsetting some of the price cuts. So I definitely would say that governments are beginning to realize that for sustainable cost-containment, utilization increase is a more proven, has a better track record than just cutting cost. So I would say there is some optimism that, that trend certainly will continue but again, we certainly didn't predict growth this year."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And, Doug, I'd just add that although we're not seeing growth, we are very focused on maintaining the profitability of the region through cost savings and vertical integration initiatives, and we saw very nice growth in the margins in Europe, in the first",44,"And, Doug, I'd just add that although we're not seeing growth, we are very focused on maintaining the profitability of the region through cost savings and vertical integration initiatives, and we saw very nice growth in the margins in Europe, in the first quarter."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","And in terms of the product introductions that you referred to in the prepared remarks, is that broadly across the entire region and applicable to almost all the countries?",29,"And in terms of the product introductions that you referred to in the prepared remarks, is that broadly across the entire region and applicable to almost all the countries?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Yes, absolutely.",2,"Yes, absolutely."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And then also just a point of clarity on the settlement with Teva that was announced this morning. If they do make changes to their ANDA and there are meaningful, perhaps, design changes to their product, do you still have the opportunity to reiniti",46,"Okay. And then also just a point of clarity on the settlement with Teva that was announced this morning. If they do make changes to their ANDA and there are meaningful, perhaps, design changes to their product, do you still have the opportunity to reinitiate litigation?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Well look, I think as far as our current settlement, it's very clear that we have through June of 2015. And as we made reference in there, they still have to receive regulatory approval, which we continue to believe that hurdle remains very high. So I wou",114,"Well look, I think as far as our current settlement, it's very clear that we have through June of 2015. And as we made reference in there, they still have to receive regulatory approval, which we continue to believe that hurdle remains very high. So I would look at it that kind of regardless of product or changes and, obviously, we would look at any of those things that happen in the future, but I would say we are excited. And I think that this settlement just further enhances and underscores truly the value of this franchise and our ability to now have some great runway to just continue to show accelerated growth quarter-over-quarter."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Chris Schott with JP Morgan.",11,"Our next question is coming from Chris Schott with JP Morgan."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First question, just would be interested in your views on the implications of further consolidation of the U.S. market with the Watson, Actavis transaction announced yesterday. Just as it relates to the overall health of the U.S. generic market and Mylan'",43,"First question, just would be interested in your views on the implications of further consolidation of the U.S. market with the Watson, Actavis transaction announced yesterday. Just as it relates to the overall health of the U.S. generic market and Mylan's business, specifically?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. Look, I think it's a fantastic deal. I think it -- as we've said for quite a while, and Robert has been very vocal about, that consolidation is needed. Taking capacity out of the market especially a large player like Actavis, it certainly benefits t",93,"Sure. Look, I think it's a fantastic deal. I think it -- as we've said for quite a while, and Robert has been very vocal about, that consolidation is needed. Taking capacity out of the market especially a large player like Actavis, it certainly benefits the global marketplace. I think it further underscores the need to be globally competitive, which underscores the platform that we've pulled together over the last 5 years. So look, I think congratulations to them; it's good and I think there is more to come, more consolidation to come."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Great. And then second question, just changing gears a little bit. Asia increasingly appears to be a more relevant driver to your numbers than Europe. Is this kind of low-teens organic growth we saw this quarter a decent proxy for the growth you could see",65,"Great. And then second question, just changing gears a little bit. Asia increasingly appears to be a more relevant driver to your numbers than Europe. Is this kind of low-teens organic growth we saw this quarter a decent proxy for the growth you could see the rest of the year given the Australian and Japanese price activity you just kind of referenced on the call?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So first of all, as I stated in my remarks, our business in India is just hitting on all cylinders from third-party business. The ARV franchise continues to grow, and we continue to add diversity of our product line. And so we see -- as we said, we",168,"Sure. So first of all, as I stated in my remarks, our business in India is just hitting on all cylinders from third-party business. The ARV franchise continues to grow, and we continue to add diversity of our product line. And so we see -- as we said, we anticipate continued double-digit growth. As far as Japan, again, we see a nice steady increase. Increased utilization continues to go up. We continue to build our product portfolio and most importantly, we continue to internalize those products, giving us much more flexibility, controlling the supply and the quality of that supply chain. So as Australia, obviously, continues to be a market that is undergoing significant pressure, I think since '08, we've shown our ability to manage through those headwinds and we're going to continue to do that. So I think all-in-all, Japan, and certainly, India, offsetting any of that pressure that we're feeling in Australia. And why we continue to be very confident in our growth in that region."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Elliot Wilbur of Needham & Company.",11,"Our next question is coming from Elliot Wilbur of Needham & Company."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Just an additional follow-up question, Heather, on the settlement. At your Analyst Day, you talked about the company's view that the financial community sort of over-estimated the potential negative impact to Mylan's numbers, if and when the generic was i",181,"Just an additional follow-up question, Heather, on the settlement. At your Analyst Day, you talked about the company's view that the financial community sort of over-estimated the potential negative impact to Mylan's numbers, if and when the generic was introduced of EpiPen. Is there anything in the agreement itself enabling Teva's entry in June 2015 that changes your expectation that a competitive generic entree would get roughly 40% of the market that would result in roughly an $0.08 to $0.12 negative impact on Mylan's bottom line? Then follow-up question for John. Just looking at the company's capital structure as it currently exist, some of the out-year debt senior notes, around, I think you're around $2.3 billion, is still sitting on the balance sheet at interest rates north of 7 1/2% and I guess given some of the recent transactions in the space and the current 0% interest rate regime across the world, I'm wondering if there might be an opportunity to refi that at more favorable rates given the company's enhanced cash flows and just stronger balance sheet position overall."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So I'll start with EpiPen. Look, absolutely nothing changes our thoughts or convictions about the strength and the brand equity of EpiPen. If anything, I think this settlement just underscores our confidence because we're going to have, at minimum,",128,"Sure. So I'll start with EpiPen. Look, absolutely nothing changes our thoughts or convictions about the strength and the brand equity of EpiPen. If anything, I think this settlement just underscores our confidence because we're going to have, at minimum, and I say minimum because I certainly believe the hurdles to get an AB-rated product are significant. But at a minimum, another 3 years to truly build the education around the need for people at risk to be carrying an EpiPen, so I think that brand equity only continues to become much more significant over the next few years. I think that you've seen the results of us being out there, raising awareness and educating and we're just going to continue to increase and invest in those efforts."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And then your question with respect to our capital structure and the notes that we issued, quite honestly, less than 2 years ago. You're right that interest rates have fallen significantly over the last 2 years and so some of those notes may have the oppo",85,"And then your question with respect to our capital structure and the notes that we issued, quite honestly, less than 2 years ago. You're right that interest rates have fallen significantly over the last 2 years and so some of those notes may have the opportunity, when they are prepayable and taking into consideration what prepayment penalties may exist, may have the opportunity for prepayment or refinancing. That's something that we'll look at when we get to a point where they're able to be refinanced."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from David Risinger of Morgan Stanley.",11,"Our next question is coming from David Risinger of Morgan Stanley."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I was hoping 2 things. First, if you could just frame out the key considerations for the second quarter so that we have a better understanding of how to think about the momentum year-over-year in the second quarter of 2012 versus 2011, and also, sequentia",84,"I was hoping 2 things. First, if you could just frame out the key considerations for the second quarter so that we have a better understanding of how to think about the momentum year-over-year in the second quarter of 2012 versus 2011, and also, sequentially, versus the first quarter of 2012. And then second, for Heather, just to clarify, can you just let us know if you're settlement today covers generic EpiPen only in its current form or in all future forms as well?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'll start with your second question and I'll let John come back to your first. Look, what we can say about the settlement is that it absolutely covers everything between Meridian and Teva through June of 2015.",39,"So I'll start with your second question and I'll let John come back to your first. Look, what we can say about the settlement is that it absolutely covers everything between Meridian and Teva through June of 2015."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And I think, David, with respect to the second quarter, as I said in my prepared remarks, the second quarter being similar to the first is fully in line with what the expectations we had on Investor Day when we indicated that the second half of 2012 would",194,"And I think, David, with respect to the second quarter, as I said in my prepared remarks, the second quarter being similar to the first is fully in line with what the expectations we had on Investor Day when we indicated that the second half of 2012 would be stronger than the first half of the year. The -- in particular, the -- my comments do not take into consideration a Doryx approval. But we continue to be -- to look forward to the court's ruling on that subject and our being able to launch that product, which has been long delayed, although I would say that as we look at the full year, we do expect -- we have always expected that before the end of the year that we would be in a place where we were or in a position to launch Doryx. We will launch Lipitor, the generic form of Lipitor, at the latter part of this quarter. And so I guess I would just conclude or summarize by saying that Q2 is -- continues to be in line with what we talked about or expected on our Investor Day."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Marc Goodman with UBS.",10,"Our next question is coming from Marc Goodman with UBS."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Heather, I was curious your thoughts on France and there seems to be some new rules that have been implemented to try to drive more generic competition utilization. So I was curious on your thoughts there. Second, if you could just talk about Japan a litt",97,"Heather, I was curious your thoughts on France and there seems to be some new rules that have been implemented to try to drive more generic competition utilization. So I was curious on your thoughts there. Second, if you could just talk about Japan a little bit more, what was the strength in Japan and how good was it? I mean was this a double-digit growth quarter? Have we had double-digit growth for Japan? Just give a sense because you did say, in the press release, it seemed like it was strong and accelerating a little bit."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So in France. We do absolutely see the beginnings of this push for increased generic utilization as I said, kind of, throughout Southern Europe. Italy is certainly the lead of that pack, but we do -- are very encouraged by the recent new regulation",306,"Sure. So in France. We do absolutely see the beginnings of this push for increased generic utilization as I said, kind of, throughout Southern Europe. Italy is certainly the lead of that pack, but we do -- are very encouraged by the recent new regulation statute to try to incentivize on several fronts that increase of utilization. And like I said, I do think our efforts are paying off as we have been continuing to educate regulators and officials that, that utilization is much more sustainable to cost containment at healthcare than the price cuts. So I think that those numbers are -- they're starting to see that, obviously, from other countries. And so I'm very encouraged. And in the meantime, we've maintained our leadership position, 30% of the market share. As John said, we're very focused on that profitable growth and believe that, obviously, when Europe does come out of this -- comes out of the storm they're in right now, that we're going to be stronger than ever and certainly benefit disproportionately from now the increase in utilization. And as far as Japan goes, yes, as I said, we did see strong results. I would say that for the year, we certainly anticipate low double-digit growth in that country. And I think that it comes from a couple of places. One, as I've said, we've continued to enhance and now reaping the benefits of the pipeline that we started to build after our acquisition. And we see those coming to fruition so we're launching more products, we're launching more internally manufactured products. So the profitability of that -- the country continues to increase. And again, utilization, we continue to see it creeping up close to the mid 20s. So all-in-all, Japan is steadily, just steadily increasing and we're very happy with our performance there."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Jami Rubin of Goldman Sachs.",11,"Our next question is coming from Jami Rubin of Goldman Sachs."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I don't want to beat a dead hoarse or anything, but John and Heather, maybe if you can just elaborate a little bit more why you're still so confident that there is such a high regulatory bar for AB-rated generics for EpiPen. I guess I was somewhat surpris",130,"I don't want to beat a dead hoarse or anything, but John and Heather, maybe if you can just elaborate a little bit more why you're still so confident that there is such a high regulatory bar for AB-rated generics for EpiPen. I guess I was somewhat surprised that -- wasn't really quite sure why you reached a settlement given your confidence in that regulatory landscape, so if you could be a little bit more specific why you don't expect to see that. And then secondarily, again on generic Doryx, we were expected to hear that case or that verdict in February or March and here we are almost, we are in May, almost in May, haven't heard anything yet and just what you think is going on there."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","All right. Jami, so look, the confidence, I've never been more confident in our statements about EpiPen and an AB-rated product. And I think that our settlement, the way in which we settled should certainly underscore that. So our settlement has nothing t",168,"All right. Jami, so look, the confidence, I've never been more confident in our statements about EpiPen and an AB-rated product. And I think that our settlement, the way in which we settled should certainly underscore that. So our settlement has nothing to do with the regulatory aspects. The press release clearly lays out that they still have to get regulatory approval, which we continue to believe is a very high hurdle and why I'm saying we now have a minimum til June of 2015. So our settlement really has with -- just truly on the patent case and the judicial, nothing to do with the regulatory process or the hurdles that we believe are still absolutely in place. As far as Doryx, look, like we can't predict Europe, I can't predict when judges are going to rule. He said it would be soon, and I guess his definition of soon or quick may differ from some of ours but so look, we anticipate that decision any time."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Shibani Malhotra of RBC Capital.",11,"Our next question is coming from Shibani Malhotra of RBC Capital."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I guess, Heather, you talked about expecting increased consolidation in the generics industry due to excess capacity. Could you comment on whether Mylan is looking to further consolidate businesses and what sort of businesses you would be looking for if y",89,"I guess, Heather, you talked about expecting increased consolidation in the generics industry due to excess capacity. Could you comment on whether Mylan is looking to further consolidate businesses and what sort of businesses you would be looking for if you were considering M&A? And then second, just to follow up on EpiPen again, I guess and on Jami's question. I was just wondering were you able to look at Tevas Actavis filing before you reached a settlement or was this just kind of a blind sort of case?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Okay. So first, I'll talk about the macro issue. And I want to just clarify, my point on consolidation is not even just a generic industry, but the pharmaceutical industry as a whole. I think that as we've continued to talk about the global competitivenes",244,"Okay. So first, I'll talk about the macro issue. And I want to just clarify, my point on consolidation is not even just a generic industry, but the pharmaceutical industry as a whole. I think that as we've continued to talk about the global competitiveness needed to compete is brands looking at generics, I think more than ever because of the emerging markets and the need to have a high-quality breadth product portfolio. So look, that's why we continue to believe there absolutely will be consolidation, perhaps among smaller players, but continued activity among brand and generics. As far as our activity, I think we laid out a lot of parameters and clarity on Investor Day, speaking to the fact that we absolutely are looking and always looking at a lot of different things, whether it's new geographies, products, therapeutic categories, bolt-on for dosage forms, certainly looking for products for our Specialty division. So we are extremely active looking on all fronts. And like I said, just continue to be excited at the opportunities we see out there given some of the macro economic conditions in some of these geographies. As far as EpiPen, look, I can't and we don't talk about litigation and so forth. But all I can tell you is, obviously, litigation is not typically blind in both parties; there's a lot of activity between the parties, obviously, in pretrial as well as trial. So I'll just leave it at that."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from John Boris with Citi.",10,"Our next question is coming from John Boris with Citi."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First question just has to do where you invited to look at Actavis and can you just share whether you did look at the Actavis transaction and just discuss your competitive position? Obviously, based on some of the slides, lots of input out there, you do s",65,"First question just has to do where you invited to look at Actavis and can you just share whether you did look at the Actavis transaction and just discuss your competitive position? Obviously, based on some of the slides, lots of input out there, you do slip to #4 in a consolidating industry. Just some commentary there. And then I have a follow-up on EpiPen."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So look, I think it's safe, John, for you to imagine that we look at everything. And I think that probably the only thing I'd say about the process is that it's not an auction or a competitive process. So I would just kind of lead to that about what the a",284,"So look, I think it's safe, John, for you to imagine that we look at everything. And I think that probably the only thing I'd say about the process is that it's not an auction or a competitive process. So I would just kind of lead to that about what the activity that was going on around Actavis for a long time now. And as far as -- so as far as our continued activity, as I said, I think that we have a tremendous amount of opportunity to continue to add on. And again, as we said on Investor Day, we're not standing still or gone on vacation. So I can assure you that we are very active right now on many fronts. And I guess all I'd say about commenting on #3, #4, #1, #2, we've said it's really not about the number, I think it's the quality of the assets and it's how we're building Mylan. And I think we put together a great global platform, as Robert has said. We don't need another transformational deal. But what we are very interested in is high-quality assets that we can continue to add and maximize and leverage this platform that we've brought together. And I think between our vertical integration, which is exceeding all of our wildest imaginations and the benefits we're reaping from that, just continues to boost our ability to compete in every market around the world with the highest quality products. So we've not lost our sight on our mission to reach 7 billion people and believe that we've got a lot of opportunity to get there whatever number that puts us as a global player in this marketplace."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","For John, on EpiPen, there was a slide you put up during your analyst meeting that seemed to indicate that with direct-to-consumer advertising, it was very deep, very responsive to market share gains. I think you're electing to make 2 investments this yea",115,"For John, on EpiPen, there was a slide you put up during your analyst meeting that seemed to indicate that with direct-to-consumer advertising, it was very deep, very responsive to market share gains. I think you're electing to make 2 investments this year, 6 months of direct-to-consumer advertising and you've invested in a 100-person sales force. How do you measure those investments going forward? And what are the implications for at least the volume growth on EpiPen going forward? And then just for Heather, can you just maybe talk about the Teva device and is it the device that would prevent it from being therapeutically substituted or AB-rated if and when they ever get approved?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'll start then I'll let John -- my comments about AB-rated have to do with the FDA and the regulatory environment around the Dragon [ph] device. So as I've talked about for a long time, that those regulations, and FDA clarified their position and the",270,"So I'll start then I'll let John -- my comments about AB-rated have to do with the FDA and the regulatory environment around the Dragon [ph] device. So as I've talked about for a long time, that those regulations, and FDA clarified their position and the answer to the citizen petition a couple of years ago, that it's not that's same. Then it can't be rated substitutable and especially in a life  or an emergency situation. So my comments have always been around our confidence and our intellectual property around our Dragon [ph] device, the regulations at FDA and the ability to have to be the same. So if you have to retrain, it's not the same. And for obviously EpiPen and anaphylaxis, obviously reaches that hurdle of being a life saving or an emergency situation. So that again is why I underscore my confidence in the franchise and the hurdles for getting an AB-rated. I'll let John speak to ROI but what I will say is, we were -- after we saw the results from last year's DTC as well as other initiatives. Because while direct-to-consumer is certainly a large aspect, we're doing on many fronts, around this education. And obviously, if you look since Q3 of last year, you see just beyond accelerated double-digit growth year-over-year for each quarter. And obviously, this now being a record Quarter 1 for EpiPen and we see that continuing to grow. So it is absolutely, the results, I think, speak to the pay off here. And we just see that doing nothing but continuing to grow at an accelerated rate."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","I'll just briefly add on to what Heather said. As you know, we are the market for anaphylactic shock with over 98% market share. And therefore, the programs that we're running are both focused on building the awareness regarding anaphylactic shock and the",145,"I'll just briefly add on to what Heather said. As you know, we are the market for anaphylactic shock with over 98% market share. And therefore, the programs that we're running are both focused on building the awareness regarding anaphylactic shock and the value of the EpiPen for dealing with those types of life-threatening situations. And the way we measure the success of the programs, whether it be the direct-to-consumer advertising campaign or the expansion in our field force, is by looking at the expansion of the market that's taking place. And that expansion of the market, we showed that on the Investor Day, has been significant. We're off to a great start for 2012. We talked on the Investor Day of the Specialty business growing 30% year-over-year for 2012. And at this point, one quarter into it, I think it's at least that."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Greg Gilbert of Bank of America Merrill Lynch.",14,"Our next question is coming from Greg Gilbert of Bank of America Merrill Lynch."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Getting a lot of free advertising on EpiPen today, Heather. I'll start with EpiPen. Would the settlement structure allow you to launch an AG [ph] if you wanted to? And what are your thoughts on EpiPen OTC. And for John, I think you could've made a nickel",87,"Getting a lot of free advertising on EpiPen today, Heather. I'll start with EpiPen. Would the settlement structure allow you to launch an AG [ph] if you wanted to? And what are your thoughts on EpiPen OTC. And for John, I think you could've made a nickel or more in EPS on Modafinil before the Teva development. You're still pointing to potential upside to the range. So what's going better than expected so far this year? Or were you just being incredibly conservative on your initial guidance?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So look, I would say that there's no restrictions on us on EpiPen, but I have to tell you that there is certainly no reason  EpiPen --the kind of product and what we've spoken about from brand equity and the awareness around there would just be no reas",120,"So look, I would say that there's no restrictions on us on EpiPen, but I have to tell you that there is certainly no reason  EpiPen --the kind of product and what we've spoken about from brand equity and the awareness around there would just be no reason to put an AG [ph] in. So look, I think that the settlement certainly, again, I'm just going to say -- and you're right a lot of good advertisement this morning, removes that overhang that we know the Street continued to be concerned that the what-if possibility that, that what-if has been taken off the table, and I can assure you we will maximize the opportunity we have ahead of us."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Yes, so Greg, I guess, Greg, on your second part, first of all, I guess I would start by saying that we're incredibly disappointed by the whole Modafinil situation. But Mylan has never been, we've said it so many times, about one product. And therefore, t",205,"Yes, so Greg, I guess, Greg, on your second part, first of all, I guess I would start by saying that we're incredibly disappointed by the whole Modafinil situation. But Mylan has never been, we've said it so many times, about one product. And therefore, the -- we will -- we're whether it's Modafinil in or Modafinil out, we're still very confident at our $2.40 per share midpoint of our guidance range. And whether it be the very successful launch of Escitalopram that we had here in the first quarter or the strength of the EpiPen that we're seeing throughout 2012, all of those things make us very confident that 2012 will be a very good year, the best year for Mylan that we've had in our history. And look, I don't know that I would say we were being incredibly conservative or however you described it, I think we were providing a guidance range at the beginning of the year that we believe reflected the fact that not all good things happened, not all bad things happened. And that we would be in that guidance range. And we look forward to the year continuing to develop this way and taking advantage of upside opportunities."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","How about that OTC piece of my question?",8,"How about that OTC piece of my question?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Oh, I'm sorry. Yes. So as far as OTC, listen, we've had a lot of discussions and we'll be continuing to have these discussions. I believe that the most responsible thing for EpiPen would be behind the counter. So it would look much more like sometimes how",248,"Oh, I'm sorry. Yes. So as far as OTC, listen, we've had a lot of discussions and we'll be continuing to have these discussions. I believe that the most responsible thing for EpiPen would be behind the counter. So it would look much more like sometimes how insulin is treated or plan B. So we believe that there is absolutely opportunity to continue to work with states because as you might imagine, there is -- all the states differ with pharmacy laws and regulations. But we are actively pursuing and looking at doing just that, working with the states, working with the FDA, to hopefully get to a place where there would be both prescription EpiPen as well as behind-the-counter EpiPen that would provide the maximum access to everybody who wanted or needed to carry an EpiPen to be able to have as many as they want and also be able to make sure, from a collaborative perspective that whether it's schools being covered, soccer fields, football as you might imagine, that not only its important to have the schools equipped, which we're launching a huge program here in the next couple of months with schools, but also everything in the community related to that. So all of this is working in conjunction and why I said that outside of just our DTC investment that there's a lot of other initiatives that are ongoing that we'll be excited to be telling you more about as the year unfolds."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Ronny Gal with Sanford Bernstein.",11,"Our next question is coming from Ronny Gal with Sanford Bernstein."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Ive got 2 and I promise not to ask a thing about EpiPen. The first one is John, kind of, we were a little bit on the Watson announcement yesterday where -- which surprised me the most is how much cash they can free to pay down the debt early on. And lo",203,"Ive got 2 and I promise not to ask a thing about EpiPen. The first one is John, kind of, we were a little bit on the Watson announcement yesterday where -- which surprised me the most is how much cash they can free to pay down the debt early on. And looking at your numbers, you've got roughly the same EBITDA they do roughly the same tax, roughly the same interest rate. You generate about $1 billion in operating cash flow, but youre spending $400 million of that on CapEx; you're spending 40% of your operating cash flow on CapEx. And the question is, is there -- how do we think about that? You guys are spending a lot more than your peers in terms of percentage of cash flow on CapEx. Should we think about this as a positive or should you be thinking about maybe holding some of that back, paying down your debt more and then suddenly you look a lot less levered and look lot more financial, lets call it digi-flexibility to return the cash, buy something or somehow to create like a most significant upside to the business. And then I do have a follow on."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'm going to start off even though you said John. I just at least want to underscore, not only our commitment to investment in CapEx but why. If you go back to our Investor Day, we said we were going to double our size in the next 5 years, from a capac",212,"So I'm going to start off even though you said John. I just at least want to underscore, not only our commitment to investment in CapEx but why. If you go back to our Investor Day, we said we were going to double our size in the next 5 years, from a capacity perspective, our platform. So as you look, we are investing, obviously, across the board whether it's on our API, whether it's in the finished dosage form facilities, but doubling that capacity, we believe is, again, just goes to the diversity of our platform, our ability to absorb whatever, headwind, countries, issues. That, that ability to not only invest from an R&D perspective and we talked a lot about our product portfolio doubling. And when you think about not only doubling, it's the quality of what we're doubling and the kind of products, again, our respiratory announcement. Our ability to have the dollars and invest the dollars we believe is another barrier to entry because we're using large dollar investments, whether it's respiratory, whether it's biogenerics, doubling our size. So we believe, as I said earlier, it's not necessarily just quantity, we believe not only are we investing in the right things, but certainly in a very quality way."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And I guess I would just add on to what Heather said, at 2.9x gross debt to EBITDA, we're very comfortable with that leverage ratio. And that leverage ratio has been declining steadily and accelerating in that decline. And so we generate $600 million a ye",116,"And I guess I would just add on to what Heather said, at 2.9x gross debt to EBITDA, we're very comfortable with that leverage ratio. And that leverage ratio has been declining steadily and accelerating in that decline. And so we generate $600 million a year of free cash flow; its just a substantial amount. We've been using that cash flow to reinvest back in the business as well as to delever. And so I think that we're building a platform for the future and responsibly reinvesting in that platform so we have the right play -- the right growth in the future while at the same time managing the balance sheet in a smart way."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And which is why I think we continue to reiterate our confidence and commitment to delivering on our longer-term growth prospects. Because the investments we're making today are for the 2016, '17, '18 opportunities that we believe we'll be able to globall",44,"And which is why I think we continue to reiterate our confidence and commitment to delivering on our longer-term growth prospects. Because the investments we're making today are for the 2016, '17, '18 opportunities that we believe we'll be able to globally monetize."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Gary Nachman with Susquehanna.",10,"Our next question is coming from Gary Nachman with Susquehanna."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First, a couple of pricing questions. How is the pricing shaking up for generic Lexapro between you and Teva since the share seems to have been split evenly between you guys? And on EpiPen, how much more headroom in pricing are you assuming this year afte",59,"First, a couple of pricing questions. How is the pricing shaking up for generic Lexapro between you and Teva since the share seems to have been split evenly between you guys? And on EpiPen, how much more headroom in pricing are you assuming this year after taking that 10% price increase in March? And then I have a follow-up."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Your pricing question, your first one, we don't discuss pricing of individual products. All I can tell you is we continue to see stability in our products at both the base business and opportunities on some of these new launches. So I would say that on th",90,"Your pricing question, your first one, we don't discuss pricing of individual products. All I can tell you is we continue to see stability in our products at both the base business and opportunities on some of these new launches. So I would say that on the first one. EpiPen, look, I think we've been pretty consistent in our pricing. And we see that continuing. So as we continue to invest and continue to look at building that awareness, we'll continue to have a pricing strategy that certainly mirrors that."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Okay, and just you mentioned in terms of your building out the Commercial business in India later this year, I thought I remembered you saying at the Analyst Day that, that was going to be earlier in the year, so I'm just curious if there were any changes",69,"Okay, and just you mentioned in terms of your building out the Commercial business in India later this year, I thought I remembered you saying at the Analyst Day that, that was going to be earlier in the year, so I'm just curious if there were any changes to that timeline. And just talk about the impact you think that's going to have on the business in that region."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","We have talked about July launch and that's where we exactly are. We will be launching sometime between July and August. And we don't see any significant impact on the year.",32,"We have talked about July launch and that's where we exactly are. We will be launching sometime between July and August. And we don't see any significant impact on the year."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from the line of Michael Faerm, Jr. with Credit Suisse.",15,"Our next question is coming from the line of Michael Faerm, Jr. with Credit Suisse."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","You had commented earlier about your confidence in your ultimate approval and AB rating for your generic Advair. Can you elaborate on why you're confident in that, and maybe contrast it to the EpiPen situation where you're confident that the generic won't",45,"You had commented earlier about your confidence in your ultimate approval and AB rating for your generic Advair. Can you elaborate on why you're confident in that, and maybe contrast it to the EpiPen situation where you're confident that the generic won't get AB rating."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure, I'm going to start and then I'm going to let Rajiv, perhaps, speak to our confidence in it. Look, I think that what we said when we announced the acquisition of that platform as we were taking the core competencies of the existing Pfizer platform an",142,"Sure, I'm going to start and then I'm going to let Rajiv, perhaps, speak to our confidence in it. Look, I think that what we said when we announced the acquisition of that platform as we were taking the core competencies of the existing Pfizer platform and marrying that up with what Mylan has always been known to do best, which is taking very complex opportunities and bringing them to fruition. So when we looked at the high-caliber and the asset and the position and the point that Pfizer had developed a product now marrying that up and complementing it with our scientific ability is really what underscored our confidence. And I'll let -- and as far as EpiPen goes, look, as I continue to say, it's the Dragon [ph] device component of EpiPen that makes those regulations and those aspects different."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And our confidence is based on what we acquired, the quality of the device and the similarity of the device between this one's and Glaxo's, as well as our continued dialogue with FDA and the progress which we are making. So we remain very confident that w",58,"And our confidence is based on what we acquired, the quality of the device and the similarity of the device between this one's and Glaxo's, as well as our continued dialogue with FDA and the progress which we are making. So we remain very confident that we are on the right path to build the first generic Advair."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Operator, I think we have time for one more question.",10,"Operator, I think we have time for one more question."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Your final question is coming from the line of Randall Stanicky with Canaccord Genuity.",14,"Your final question is coming from the line of Randall Stanicky with Canaccord Genuity."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I just keep it one. Just going back to Europe for a second. I appreciate and I think we all appreciate the headwinds and the challenges there. The double-digit declines in constant currency growth, if those continue, how much cushion do you have built in",71,"I just keep it one. Just going back to Europe for a second. I appreciate and I think we all appreciate the headwinds and the challenges there. The double-digit declines in constant currency growth, if those continue, how much cushion do you have built in before that becomes an issue? I understand that you don't need to grow, but at what point does the constant currency decline start to hurt you?"
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Look, I talked about the fact that our gross margins actually increased 300 basis points quarter-to-quarter, Randall. And so it's not about the top line; it's about the bottom line, and we're managing that region in the context of the macroeconomic headwi",141,"Look, I talked about the fact that our gross margins actually increased 300 basis points quarter-to-quarter, Randall. And so it's not about the top line; it's about the bottom line, and we're managing that region in the context of the macroeconomic headwind. So it's not hurting us. We obviously would love to see growth and we look forward to when the macroeconomic issues in Europe are resolved and generic utilization rates increase. And the top line growth, together with the gross margins increasing, and that's why we talked on the Investor Day about Europe being a long-term growth driver for us.
So with that, look, we appreciate all of our investors and the questions we received in this call. Q1 was very much in line with what we had expected, and we look forward to continuing to deliver on 2012 so..."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you.",2,"Thank you."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","With that, operator, you can close the call.",8,"With that, operator, you can close the call."
290203,184140392,290474,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Thank you, this does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you, this does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's First Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Easte",78,"Welcome to Mylan's First Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern standard time. The dial-in number is (800) 585-8367, or (404) 537-3406 for international callers, with pin number 70819215. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King; you may begin."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Beverly. Good morning, everyone. Welcome to Mylan's First Quarter 2012 Earnings Call. Joining me for today's call are Mylan's CEO, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chi",344,"Thank you, Beverly. Good morning, everyone. Welcome to Mylan's First Quarter 2012 Earnings Call. Joining me for today's call are Mylan's CEO, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making forward-looking statements including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties, and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our report on Form 10-K for the period ended December 31, 2012, and in our other SEC filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures such as adjusted revenue, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings press release, which is available on our website, as it contains detailed GAAP to non-GAAP reconciliations of our actual first quarter results.
Before I turn the call over to Heather, let me also remind you that the materials in this call, with the exception of a participant question, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'd like to turn the call over to Heather."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us today. Before we get started, I'd like to welcome and recognize all of our fellow employees around the world. Through their passion and hard work, we delivered very strong results t",1150,"Thank you, Kris, and good morning, everyone, and thank you for joining us today. Before we get started, I'd like to welcome and recognize all of our fellow employees around the world. Through their passion and hard work, we delivered very strong results this quarter. On behalf of the Board of Directors and our entire management team, I would like to thank each and every one of them.
Our diverse global platform has once again delivered strong results, representing a great start to 2012. Double-digit growth on our North American, Asia-Pacific and Specialty businesses allowed us to deliver robust financial results despite persistent macroeconomic headwinds in certain regions, specifically Europe and Australia. We are reaffirming our 2012 guidance of $2.30 to $2.50 per share and we see opportunities for upside during the year. Further, the strength of our platforms, first-in-class science and robust product portfolio give us continued confidence in our long-term growth target for 2013 and beyond.
During the first quarter, we generated total adjusted revenues of $1.58 billion, an increase of 11% on a constant currency basis as compared to last year's first quarter revenues of $1.45 billion. On the bottom line, we delivered adjusted diluted earnings per share of $0.52, an 18% increase over the $0.44 per share we delivered during the first quarter of '11.
In our North American Generics business, third-party net revenues for the quarter were $777 million, up more than 15% from the comparable year-ago period. This strong result was driven in part by launches of 11 new products in the U.S., including Ibandronate and Escitalopram, a first equivalent product that generated the highest and fastest conversion rate in versus generic launch we've seen in recent history. We also enjoyed strong sales in the U.S. on many of our existing products.
Further, consistent with the strength of our R&D capabilities, 2 of the 8 first quarter products submissions we made in the U.S. are first-to-file opportunities. Currently we have 171 ANDAs pending FDA approval, 40 of which are potential first to file. Regarding our neurology franchise which is one of our strategic growth drivers, we're awaiting the court's ruling in the Copaxone patent infringement case whose trial concluded in September of 2011. We remain convinced that we have an AB-rated product and look forward to securing approval in the second half of this year. While we eagerly anticipate the court's ruling and regulatory approval, I'd like to remind everybody that we are not relying on this product to achieve our 2013 target of $275 million. We also are pleased with our performance in Canada, and it's another example of the robustness of our global pipeline.
In Canada, we launched 9 products during the quarter, which is more than we launched during all of 2011. Our expanded portfolio is fueling sales and growth in our customer base, along with cost of goods efficiency that will help us weather price cuts and remain competitive and ensure consistent supply in every province.
In EMEA, as anticipated, we delivered third-party net revenues of $336 million during the quarter, a decline of approximately 14% compared to last year's first quarter results. On a constant currency basis, revenues fell 10%. New products launched throughout the region served to offset volume pressure on sales of existing products and mitigate some of the effects of unfavorable pricing.
During the quarter, we also enjoyed constant currency revenue growth of 8% in Italy, one of Europe's fastest growing markets. And in Spain, our sales volume grew along with this rapidly expanding market. Results in both cases were driven by increased generic utilization. Moreover, we remain on track to launch nearly 300 new products in Europe this year. By now, it should be very evident that our powerful global platform has and will continue to demonstrate its ability to absorb headwinds such as those occurring in Europe. Despite such headwinds, we have maintained our leadership positions in several markets such as France, Italy, Spain, U.K., Belgium and Portugal.
Moving now to our Asia-Pacific regions. We generated third-party net revenues of nearly $299 million during the first quarter, an increase of more than 8% over last year's results and 12% higher on a constant currency basis. Our double-digit growth was driven largely by the strong performance of our business in India. We continue to see growth in our third-party business and accelerated growth in our ARV franchise, both in finished dosage form and API. We currently supply to more than 90 countries. We keep expanding our ARV business by adding products and geographies and expanding market access. Further, we remain on track to launch our Commercial business in India later this year.
Finally, our Mylan Specialty business reported a 67% year-over-year increase in third-party net revenues, which totaled more than $162 million during the first quarter. This exceptional performance resulted from higher sales of the EpiPen Auto-Injector, another strategic growth driver. Increased volumes and favorable pricing drove the growth in sales, and we continue to see double-digit accelerated quarter-over-quarter sales growth. The settlement announced this morning with Teva only further enhances our confidence in the anticipated continued strong performance of this product and our entire Specialty franchise.
As we've stated before, we see tremendous opportunity ahead for EpiPen as only 7% or 2 million of the 28 million people estimated to be at risk for anaphylaxis actually carries one. Continually increasing public awareness is essential to ensuring access to this product for people who need it, and generating sustained market expansion. Now let me turn to some of our other important strategic growth drivers.
Our global Institutional business continues to deliver double-digit growth. We anticipate that this business can become a billion dollar franchise by 2016. We remain focused on supply chain integrity and optimization of our cost of goods; weve benefited and we will continue to benefit from being vertically integrated; and we now have successfully internalized the manufacture of 80% of our products globally, giving us even greater control of over our cost and quality at each point in the supply chain. We also expect significant growth in our product portfolio and are on track to launch approximately 650 products and file more than the 750 regulatory submissions globally this year. We also are pursuing external opportunities to expand our portfolio, such as our acquisition of 2 limited-competition dermatological products from Valeant earlier this year.
Looking at our respiratory platform, we have made good progress on the integration of the Pfizer business we acquired in November of 2011, and we believe we are on track to launch the first AB-rated generic version of Advair.
Finally, with respect to biogenerics, we have had productive discussions with the FDA regarding our portfolio and remain confident that we will be in the U.S. market starting in 2016. With that, I look forward to responding to your questions and will now turn the call over to John."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures and I remind you of Kris' comments at the beginning of the cal",1533,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures and I remind you of Kris' comments at the beginning of the call today regarding our use of adjusted measures.
I am extremely pleased with our financial results for the first quarter of 2012, a great start to what we firmly believe will be the most successful year in our company's history. Our Q1 results were achieved and our full year results will be achieved amid the macroeconomic headwinds that continue to plague Europe and in the wake of a 10% price cut in Japan and the most significant price cuts in Australian history, both of which occurred this quarter. This is a testament to the strength of our diverse global business, our first-in-class science, and our robust product portfolio.
The difficult pricing environment in several of our locations was certainly not expected -- unexpected, nor were the positive development which served to offset, and in some cases, fully mitigate the unfavorable impact. In fact, our first quarter results came in line with what we -- with that which we have forecasted in our Investor Day on February 21. Also, our current quarter results were in line with those of the fourth quarter of 2011 on a pre-tax basis. Adjusted pre-tax income in the current quarter was $304 million compared to $294 million sequentially. Getting in the details, let me walk you through our financial results for the first quarter of 2012.
I will also provide an update on our capital structure and liquidity position.
Starting at the top of our income statement, total revenues for the quarter were $1.59 billion, an increase of 10% over last year's first quarter revenues of $1.45 billion. Year-over-year, first quarter third-party net revenue growth on a constant currency basis was approximately 11%. The relatively small unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to certain other functional currencies of our major operations, mainly in Europe and in India.
Included in total revenues for the current quarter is approximately $9 million of other revenue related to a clean energy investment subsidiary, which we invested in near the end of 2011 and whose activities qualify for tax credits under Section 45 of the U.S. Internal Revenue Code. Our adjusted metrics, which I'll discuss momentarily, exclude all activity related to this investment with the exception of the net tax effect related to its operation, which is included in our adjusted effective tax rate. As a reminder, our guidance range for total revenue for the full year 2012 is between $6.8 billion and $7.2 billion.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 first quarter was a very strong 48%, up approximately 1 percentage point from the same prior-year period. Our strong current quarter margins are primarily the result of favorable pricing on EpiPen in our Specialty segment. Within generics, gross margins remained stable as new product launches in North America served to offset the normal pricing trend in the generic pharmaceutical industry.
Our operations, particularly in Europe, continue to employ cost-savings initiatives, especially from the perspective of cost of goods sold. These efforts have proven successful, and adjusted gross margins in Europe, on a sequential quarter-over-quarter basis and excluding the effect of foreign exchange, and as we anticipated, increased nearly 300 basis points despite lower sales. And while I'm certainly not going to predict when the economic situation in Europe will improve, these initiatives are expected to continue to have an incremental positive impact on our adjusted gross margin throughout 2012.
Adjusted operating income was $368 million for the first quarter of 2012, an 8% increase from Q1 2011. This is primarily the result of the favorable gross profit that I previously discussed, partially offset by increased levels of spending on R&D and SG&A.
R&D expense on an adjusted basis was $80 million, or approximately 5% of total revenues and up approximately 7% from the prior year. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues. The timing of certain R&D spending, principally amounts related to our biologics and respiratory platform, has shifted into later periods of the current year with no impact on the timing of the programs themselves, and we continue to expect that the full year spend will be within our guidance range.
At the same time, SG&A also on an adjusted basis, was $312 million or approximately 19.7% of total revenues, closer to the high end of our full year guidance range of 18% to 20%. The increase in SG&A in the current quarter is due in large part to our investment in our Specialty franchise, which has resulted in higher volume and increased market share.
Adjusted EBITDA for the 3 months ended March 31, 2012, was $411 million and remains forecasted to be between $1.75 billion and $1.95 billion for the full year. 
Moving onto our consolidated non-operating financial metrics. Adjusted interest expense for the first quarter of 2012 was $61 million. We continue to benefit from low short-term interest rates. As of March 31, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70:30 fixed to floating debt portfolio, which we believe is an optimal ratio. 
As I mentioned before, our adjusted pre-tax earnings in the current quarter was slightly favorable as compared to that of the fourth quarter of the prior year. However, the effective tax rate in the current quarter was 26% as compared to 23% in the sequential quarter. The net result was adjusted diluted EPS in the current quarter in line with that of the fourth quarter of the prior year. Our full year 2012 tax rate range is unchanged at 26% to 27%, and we continue to believe that this rate will be sustainable at this level going forward.
First quarter adjusted net income was $224 million, or $0.52 per share, an 18% increase from our Q1 2011 adjusted diluted EPS of $0.44 per share and in line with that of the fourth quarter 2011 after their adjusting for and fully consistent with, our expectations from our -- and adjusting for the higher tax rate in Q1 2012.
Our guidance range for adjusted diluted EPS for 2012 remains at $2.30 to $2.50 per share. And as I previously mentioned, and fully consistent with our expectations from our Investor Day, we expect earnings in the second quarter to be in line with the first before accelerating into the third quarter, which will be by far our strongest of the year and finishing with a fourth quarter that will propel us to our midpoint of $2.40 per share.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis was approximately $67 million. This takes into account certain  account certain special items principally the exclusion of payments of approximately $90 million related to previously settled and accrued litigation primarily related to AWP and the inclusion of approximately $62 million related to amounts due in 2012, which were received in late December 2011 but excluded for adjusted cash flow purposes from that quarter.
Our GAAP cash flow from operations for the current quarter was a cash outflow of $109 million, leaving us with unrestricted cash and marketable securities totaling approximately $267 million. The first quarter is, historically, the heaviest in terms of the usage of cash and as a result of the timing of certain payments including taxes, interest and incentive optimization. But we are still forecasting our full year 2012 adjusted operating cash flow to be within our guidance range of $900 million to $1 billion.
First quarter capital spending was $36 million and we expect full year capital expenditures to be within our guidance range of $300 million to $400 million. In addition to capital expenditures, approximately $70 million was spent during the quarter to acquire product rights and licenses, the majority of which relates to the purchase of 2 limited competition dermatological products from Valiant Pharmaceuticals.
During the current quarter, we repaid the $600 million due under our convertible notes and made a scheduled payment under our term loan. Both of these payments were made using a combination of cash on hand, borrowings under our revolver and through cash received from our accounts receivable securitization facility, which we established in February. During the first quarter, we borrowed $285 million under this facility.
At the end of the quarter, following the debt repayment and additional borrowings under the revolver and the AR facility, our leverage ratio remains at 2.9x and we continue to have more than ample borrowing capacity.
To summarize, our first quarter was strong and was in line with what we had anticipated. This is an indication of things to come throughout what we believe will be our strongest year yet and another chapter in the exciting story that is Mylan.
That concludes my remarks. And I'll turn the call over to the operator for Q&A. Operator?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from the line of Douglas Tsao with Barclays.",14,"[Operator Instructions] Our first question comes from the line of Douglas Tsao with Barclays."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Just a couple of questions. First, I was just hoping you could speak a little bit to what you're currently seeing in terms of market conditions in Europe. Just given some concerns regarding economic instability or softness, obviously, you expected -- you",66,"Just a couple of questions. First, I was just hoping you could speak a little bit to what you're currently seeing in terms of market conditions in Europe. Just given some concerns regarding economic instability or softness, obviously, you expected -- you saw good results from Spain and Italy. In particular, I was curious if you could speak to what youre seeing in Spain right now."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Well look, I think, Europe overall, what I'd say is, we're seeing what we've been seeing and saying that we're not trying to predict the future of when that's going to turnaround and obviously, why we continue to say we did not predict or forecast growth",154,"Well look, I think, Europe overall, what I'd say is, we're seeing what we've been seeing and saying that we're not trying to predict the future of when that's going to turnaround and obviously, why we continue to say we did not predict or forecast growth for our European region. I think with that being said, we do see increased generic utilization beginning to increase, especially in the southern European markets. We saw growth and maintain leadership position, obviously, in Italy. And we see the same with Spain. We see that volume through increased utilization offsetting some of the price cuts. So I definitely would say that governments are beginning to realize that for sustainable cost-containment, utilization increase is a more proven, has a better track record than just cutting cost. So I would say there is some optimism that, that trend certainly will continue but again, we certainly didn't predict growth this year."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And, Doug, I'd just add that although we're not seeing growth, we are very focused on maintaining the profitability of the region through cost savings and vertical integration initiatives, and we saw very nice growth in the margins in Europe, in the first",44,"And, Doug, I'd just add that although we're not seeing growth, we are very focused on maintaining the profitability of the region through cost savings and vertical integration initiatives, and we saw very nice growth in the margins in Europe, in the first quarter."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","And in terms of the product introductions that you referred to in the prepared remarks, is that broadly across the entire region and applicable to almost all the countries?",29,"And in terms of the product introductions that you referred to in the prepared remarks, is that broadly across the entire region and applicable to almost all the countries?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Yes, absolutely.",2,"Yes, absolutely."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And then also just a point of clarity on the settlement with Teva that was announced this morning. If they do make changes to their ANDA and there are meaningful, perhaps, design changes to their product, do you still have the opportunity to reiniti",46,"Okay. And then also just a point of clarity on the settlement with Teva that was announced this morning. If they do make changes to their ANDA and there are meaningful, perhaps, design changes to their product, do you still have the opportunity to reinitiate litigation?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Well look, I think as far as our current settlement, it's very clear that we have through June of 2015. And as we made reference in there, they still have to receive regulatory approval, which we continue to believe that hurdle remains very high. So I wou",114,"Well look, I think as far as our current settlement, it's very clear that we have through June of 2015. And as we made reference in there, they still have to receive regulatory approval, which we continue to believe that hurdle remains very high. So I would look at it that kind of regardless of product or changes and, obviously, we would look at any of those things that happen in the future, but I would say we are excited. And I think that this settlement just further enhances and underscores truly the value of this franchise and our ability to now have some great runway to just continue to show accelerated growth quarter-over-quarter."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Chris Schott with JP Morgan.",11,"Our next question is coming from Chris Schott with JP Morgan."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First question, just would be interested in your views on the implications of further consolidation of the U.S. market with the Watson, Actavis transaction announced yesterday. Just as it relates to the overall health of the U.S. generic market and Mylan'",43,"First question, just would be interested in your views on the implications of further consolidation of the U.S. market with the Watson, Actavis transaction announced yesterday. Just as it relates to the overall health of the U.S. generic market and Mylan's business, specifically?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. Look, I think it's a fantastic deal. I think it -- as we've said for quite a while, and Robert has been very vocal about, that consolidation is needed. Taking capacity out of the market especially a large player like Actavis, it certainly benefits t",93,"Sure. Look, I think it's a fantastic deal. I think it -- as we've said for quite a while, and Robert has been very vocal about, that consolidation is needed. Taking capacity out of the market especially a large player like Actavis, it certainly benefits the global marketplace. I think it further underscores the need to be globally competitive, which underscores the platform that we've pulled together over the last 5 years. So look, I think congratulations to them; it's good and I think there is more to come, more consolidation to come."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Great. And then second question, just changing gears a little bit. Asia increasingly appears to be a more relevant driver to your numbers than Europe. Is this kind of low-teens organic growth we saw this quarter a decent proxy for the growth you could see",65,"Great. And then second question, just changing gears a little bit. Asia increasingly appears to be a more relevant driver to your numbers than Europe. Is this kind of low-teens organic growth we saw this quarter a decent proxy for the growth you could see the rest of the year given the Australian and Japanese price activity you just kind of referenced on the call?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So first of all, as I stated in my remarks, our business in India is just hitting on all cylinders from third-party business. The ARV franchise continues to grow, and we continue to add diversity of our product line. And so we see -- as we said, we",168,"Sure. So first of all, as I stated in my remarks, our business in India is just hitting on all cylinders from third-party business. The ARV franchise continues to grow, and we continue to add diversity of our product line. And so we see -- as we said, we anticipate continued double-digit growth. As far as Japan, again, we see a nice steady increase. Increased utilization continues to go up. We continue to build our product portfolio and most importantly, we continue to internalize those products, giving us much more flexibility, controlling the supply and the quality of that supply chain. So as Australia, obviously, continues to be a market that is undergoing significant pressure, I think since '08, we've shown our ability to manage through those headwinds and we're going to continue to do that. So I think all-in-all, Japan, and certainly, India, offsetting any of that pressure that we're feeling in Australia. And why we continue to be very confident in our growth in that region."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Elliot Wilbur of Needham & Company.",11,"Our next question is coming from Elliot Wilbur of Needham & Company."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Just an additional follow-up question, Heather, on the settlement. At your Analyst Day, you talked about the company's view that the financial community sort of over-estimated the potential negative impact to Mylan's numbers, if and when the generic was i",181,"Just an additional follow-up question, Heather, on the settlement. At your Analyst Day, you talked about the company's view that the financial community sort of over-estimated the potential negative impact to Mylan's numbers, if and when the generic was introduced of EpiPen. Is there anything in the agreement itself enabling Teva's entry in June 2015 that changes your expectation that a competitive generic entree would get roughly 40% of the market that would result in roughly an $0.08 to $0.12 negative impact on Mylan's bottom line? Then follow-up question for John. Just looking at the company's capital structure as it currently exist, some of the out-year debt senior notes, around, I think you're around $2.3 billion, is still sitting on the balance sheet at interest rates north of 7 1/2% and I guess given some of the recent transactions in the space and the current 0 interest rate regime across the world, I'm wondering if there might be an opportunity to refi that at more favorable rates given the company's enhanced cash flows and just stronger balance sheet position overall."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So I'll start with EpiPen. Look, absolutely nothing changes our thoughts or convictions about the strength and the brand equity of EpiPen. If anything, I think this settlement just underscores our confidence because we're going to have, at minimum,",128,"Sure. So I'll start with EpiPen. Look, absolutely nothing changes our thoughts or convictions about the strength and the brand equity of EpiPen. If anything, I think this settlement just underscores our confidence because we're going to have, at minimum, and I say minimum because I certainly believe the hurdles to get an AB-rated product are significant. But at a minimum, another 3 years to truly build the education around the need for people at risk to be carrying an EpiPen, so I think that brand equity only continues to become much more significant over the next few years. I think that you've seen the results of us being out there, raising awareness and educating and we're just going to continue to increase and invest in those efforts."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And then your question with respect to our capital structure and the notes that we issued, quite honestly, less than 2 years ago. You're right that interest rates have fallen significantly over the last 2 years and so some of those notes may have the oppo",85,"And then your question with respect to our capital structure and the notes that we issued, quite honestly, less than 2 years ago. You're right that interest rates have fallen significantly over the last 2 years and so some of those notes may have the opportunity, when they are prepayable and taking into consideration what prepayment penalties may exist, may have the opportunity for prepayment or refinancing. That's something that we'll look at when we get to a point where they're able to be refinanced."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from David Risinger of Morgan Stanley.",11,"Our next question is coming from David Risinger of Morgan Stanley."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I was hoping 2 things. First, if you could just frame out the key considerations for the second quarter so that we have a better understanding of how to think about the momentum year-over-year in the second quarter of 2012 versus 2011, and also, sequentia",84,"I was hoping 2 things. First, if you could just frame out the key considerations for the second quarter so that we have a better understanding of how to think about the momentum year-over-year in the second quarter of 2012 versus 2011, and also, sequentially, versus the first quarter of 2012. And then second, for Heather, just to clarify, can you just let us know if you're settlement today covers generic EpiPen only in its current form or in all future forms as well?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'll start with your second question and I'll let John come back to your first. Look, what we can say about the settlement is that it absolutely covers everything between Meridian and Teva through June of 2015.",39,"So I'll start with your second question and I'll let John come back to your first. Look, what we can say about the settlement is that it absolutely covers everything between Meridian and Teva through June of 2015."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And I think, David, with respect to the second quarter, as I said in my prepared remarks, the second quarter being similar to the first is fully in line with what the expectations we had on Investor Day when we indicated that the second half of 2012 would",194,"And I think, David, with respect to the second quarter, as I said in my prepared remarks, the second quarter being similar to the first is fully in line with what the expectations we had on Investor Day when we indicated that the second half of 2012 would be stronger than the first half of the year. The -- in particular, the -- my comments do not take into consideration a Doryx approval. But we continue to be -- to look forward to the court's ruling on that subject and our being able to launch that product, which has been long delayed, although I would say that as we look at the full year, we do expect -- we have always expected that before the end of the year that we would be in a place where we were or in a position to launch Doryx. We will launch Lipitor, the generic form of Lipitor, at the latter part of this quarter. And so I guess I would just conclude or summarize by saying that Q2 is -- continues to be in line with what we talked about or expected on our Investor Day."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Marc Goodman with UBS.",10,"Our next question is coming from Marc Goodman with UBS."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Heather, I was curious your thoughts on France and there seems to be some new rules that have been implemented to try to drive more generic competition utilization. So I was curious on your thoughts there. Second, if you could just talk about Japan a litt",97,"Heather, I was curious your thoughts on France and there seems to be some new rules that have been implemented to try to drive more generic competition utilization. So I was curious on your thoughts there. Second, if you could just talk about Japan a little bit more, what was the strength in Japan and how good was it? I mean was this a double-digit growth quarter? Have we had double-digit growth for Japan? Just give a sense because you did say, in the press release, it seemed like it was strong and accelerating a little bit."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So in France. We do absolutely see the beginnings of this push for increased generic utilization as I said, kind of, throughout Southern Europe. Italy is certainly the lead of that pack, but we do -- are very encouraged by the recent new regulation",306,"Sure. So in France. We do absolutely see the beginnings of this push for increased generic utilization as I said, kind of, throughout Southern Europe. Italy is certainly the lead of that pack, but we do -- are very encouraged by the recent new regulation statute to try to incentivize on several fronts that increase of utilization. And like I said, I do think our efforts are paying off as we have been continuing to educate regulators and officials that, that utilization is much more sustainable to cost containment at healthcare than the price cuts. So I think that those numbers are -- they're starting to see that, obviously, from other countries. And so I'm very encouraged. And in the meantime, we've maintained our leadership position, 30% of the market share. As John said, we're very focused on that profitable growth and believe that, obviously, when Europe does come out of this -- comes out of the storm they're in right now, that we're going to be stronger than ever and certainly benefit disproportionately from now the increase in utilization. And as far as Japan goes, yes, as I said, we did see strong results. I would say that for the year, we certainly anticipate low double-digit growth in that country. And I think that it comes from a couple of places. One, as I've said, we've continued to enhance and now reaping the benefits of the pipeline that we started to build after our acquisition. And we see those coming to fruition so we're launching more products, we're launching more internally manufactured products. So the profitability of that -- the country continues to increase. And again, utilization, we continue to see it creeping up close to the mid 20s. So all-in-all, Japan is steadily, just steadily increasing and we're very happy with our performance there."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Jami Rubin of Goldman Sachs.",11,"Our next question is coming from Jami Rubin of Goldman Sachs."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I don't want to beat a dead horse or anything, but John and Heather, maybe if you can just elaborate a little bit more why you're still so confident that there is such a high regulatory bar for AB-rated generics for EpiPen. I guess I was somewhat surprise",130,"I don't want to beat a dead horse or anything, but John and Heather, maybe if you can just elaborate a little bit more why you're still so confident that there is such a high regulatory bar for AB-rated generics for EpiPen. I guess I was somewhat surprised that -- wasn't really quite sure why you reached a settlement given your confidence in that regulatory landscape, so if you could be a little bit more specific why you don't expect to see that. And then secondarily, again on generic Doryx, we were expected to hear that case or that verdict in February or March and here we are almost, we are in May, almost in May, haven't heard anything yet and just what you think is going on there."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","All right. Jami, so look, the confidence, I've never been more confident in our statements about EpiPen and an AB-rated product. And I think that our settlement, the way in which we settled should certainly underscore that. So our settlement has nothing t",168,"All right. Jami, so look, the confidence, I've never been more confident in our statements about EpiPen and an AB-rated product. And I think that our settlement, the way in which we settled should certainly underscore that. So our settlement has nothing to do with the regulatory aspects. The press release clearly lays out that they still have to get regulatory approval, which we continue to believe is a very high hurdle and why I'm saying we now have a minimum until June of 2015. So our settlement really has with -- just truly on the patent case and the judicial, nothing to do with the regulatory process or the hurdles that we believe are still absolutely in place. As far as Doryx, look, like we can't predict Europe, I can't predict when judges are going to rule. He said it would be soon, and I guess his definition of soon or quick may differ from some of ours but so look, we anticipate that decision any time."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Shibani Malhotra of RBC Capital.",11,"Our next question is coming from Shibani Malhotra of RBC Capital."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I guess, Heather, you talked about expecting increased consolidation in the generics industry due to excess capacity. Could you comment on whether Mylan is looking to further consolidate businesses and what sort of businesses you would be looking for if y",89,"I guess, Heather, you talked about expecting increased consolidation in the generics industry due to excess capacity. Could you comment on whether Mylan is looking to further consolidate businesses and what sort of businesses you would be looking for if you were considering M&A? And then second, just to follow up on EpiPen again, I guess and on Jami's question. I was just wondering were you able to look at Tevas Actavis filing before you reached a settlement or was this just kind of a blind sort of case?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Okay. So first, I'll talk about the macro issue. And I want to just clarify, my point on consolidation is not even just a generic industry, but the pharmaceutical industry as a whole. I think that as we've continued to talk about the global competitivenes",244,"Okay. So first, I'll talk about the macro issue. And I want to just clarify, my point on consolidation is not even just a generic industry, but the pharmaceutical industry as a whole. I think that as we've continued to talk about the global competitiveness needed to compete is brands looking at generics, I think more than ever because of the emerging markets and the need to have a high-quality breadth product portfolio. So look, that's why we continue to believe there absolutely will be consolidation, perhaps among smaller players, but continued activity among brand and generics. As far as our activity, I think we laid out a lot of parameters and clarity on Investor Day, speaking to the fact that we absolutely are looking and always looking at a lot of different things, whether it's new geographies, products, therapeutic categories, bolt-on for dosage forms, certainly looking for products for our Specialty division. So we are extremely active looking on all fronts. And like I said, just continue to be excited at the opportunities we see out there given some of the macro economic conditions in some of these geographies. As far as EpiPen, look, I can't and we don't talk about litigation and so forth. But all I can tell you is, obviously, litigation is not typically blind in both parties; there's a lot of activity between the parties, obviously, in pretrial as well as trial. So I'll just leave it at that."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from John Boris with Citi.",10,"Our next question is coming from John Boris with Citi."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First question just has to do where you invited to look at Actavis and can you just share whether you did look at the Actavis transaction and just discuss your competitive position? Obviously, based on some of the slides, lots of input out there, you do s",65,"First question just has to do where you invited to look at Actavis and can you just share whether you did look at the Actavis transaction and just discuss your competitive position? Obviously, based on some of the slides, lots of input out there, you do slip to #4 in a consolidating industry. Just some commentary there. And then I have a follow-up on EpiPen."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So look, I think it's safe, John, for you to imagine that we look at everything. And I think that probably the only thing I'd say about the process is that it's not an auction or a competitive process. So I would just kind of lead to that about what the a",284,"So look, I think it's safe, John, for you to imagine that we look at everything. And I think that probably the only thing I'd say about the process is that it's not an auction or a competitive process. So I would just kind of lead to that about what the activity that was going on around Actavis for a long time now. And as far as -- so as far as our continued activity, as I said, I think that we have a tremendous amount of opportunity to continue to add on. And again, as we said on Investor Day, we're not standing still or gone on vacation. So I can assure you that we are very active right now on many fronts. And I guess all I'd say about commenting on #3, #4, #1, #2, we've said it's really not about the number, I think it's the quality of the assets and it's how we're building Mylan. And I think we put together a great global platform, as Robert has said. We don't need another transformational deal. But what we are very interested in is high-quality assets that we can continue to add and maximize and leverage this platform that we've brought together. And I think between our vertical integration, which is exceeding all of our wildest imaginations and the benefits we're reaping from that, just continues to boost our ability to compete in every market around the world with the highest quality products. So we've not lost our sight on our mission to reach 7 billion people and believe that we've got a lot of opportunity to get there whatever number that puts us as a global player in this marketplace."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","For John, on EpiPen, there was a slide you put up during your analyst meeting that seemed to indicate that with direct-to-consumer advertising, it was very deep, very responsive to market share gains. I think you're electing to make 2 investments this yea",115,"For John, on EpiPen, there was a slide you put up during your analyst meeting that seemed to indicate that with direct-to-consumer advertising, it was very deep, very responsive to market share gains. I think you're electing to make 2 investments this year, 6 months of direct-to-consumer advertising and you've invested in a 100-person sales force. How do you measure those investments going forward? And what are the implications for at least the volume growth on EpiPen going forward? And then just for Heather, can you just maybe talk about the Teva device and is it the device that would prevent it from being therapeutically substituted or AB-rated if and when they ever get approved?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'll start then I'll let John -- my comments about AB-rated have to do with the FDA and the regulatory environment around the Dragon [ph] device. So as I've talked about for a long time, that those regulations, and FDA clarified their position and the",270,"So I'll start then I'll let John -- my comments about AB-rated have to do with the FDA and the regulatory environment around the Dragon [ph] device. So as I've talked about for a long time, that those regulations, and FDA clarified their position and the answer to the citizen petition a couple of years ago, that it's not that's same. Then it can't be rated substitutable and especially in a life  or an emergency situation. So my comments have always been around our confidence and our intellectual property around our Dragon [ph] device, the regulations at FDA and the ability to have to be the same. So if you have to retrain, it's not the same. And for obviously EpiPen and anaphylaxis, obviously reaches that hurdle of being a life saving or an emergency situation. So that again is why I underscore my confidence in the franchise and the hurdles for getting an AB-rated. I'll let John speak to ROI but what I will say is, we were -- after we saw the results from last year's DTC as well as other initiatives. Because while direct-to-consumer is certainly a large aspect, we're doing on many fronts, around this education. And obviously, if you look since Q3 of last year, you see just beyond accelerated double-digit growth year-over-year for each quarter. And obviously, this now being a record Quarter 1 for EpiPen and we see that continuing to grow. So it is absolutely, the results, I think, speak to the pay off here. And we just see that doing nothing but continuing to grow at an accelerated rate."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","I'll just briefly add on to what Heather said. As you know, we are the market for anaphylactic shock with over 98% market share. And therefore, the programs that we're running are both focused on building the awareness regarding anaphylactic shock and the",145,"I'll just briefly add on to what Heather said. As you know, we are the market for anaphylactic shock with over 98% market share. And therefore, the programs that we're running are both focused on building the awareness regarding anaphylactic shock and the value of the EpiPen for dealing with those types of life-threatening situations. And the way we measure the success of the programs, whether it be the direct-to-consumer advertising campaign or the expansion in our field force, is by looking at the expansion of the market that's taking place. And that expansion of the market, we showed that on the Investor Day, has been significant. We're off to a great start for 2012. We talked on the Investor Day of the Specialty business growing 30% year-over-year for 2012. And at this point, one quarter into it, I think it's at least that."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Greg Gilbert of Bank of America Merrill Lynch.",14,"Our next question is coming from Greg Gilbert of Bank of America Merrill Lynch."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Getting a lot of free advertising on EpiPen today, Heather. I'll start with EpiPen. Would the settlement structure allow you to launch an AG [ph] if you wanted to? And what are your thoughts on EpiPen OTC. And for John, I think you could've made a nickel",87,"Getting a lot of free advertising on EpiPen today, Heather. I'll start with EpiPen. Would the settlement structure allow you to launch an AG [ph] if you wanted to? And what are your thoughts on EpiPen OTC. And for John, I think you could've made a nickel or more in EPS on Modafinil before the Teva development. You're still pointing to potential upside to the range. So what's going better than expected so far this year? Or were you just being incredibly conservative on your initial guidance?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So look, I would say that there's no restrictions on us on EpiPen, but I have to tell you that there is certainly no reason  EpiPen --the kind of product and what we've spoken about from brand equity and the awareness around there would just be no reas",120,"So look, I would say that there's no restrictions on us on EpiPen, but I have to tell you that there is certainly no reason  EpiPen --the kind of product and what we've spoken about from brand equity and the awareness around there would just be no reason to put an AG [ph] in. So look, I think that the settlement certainly, again, I'm just going to say -- and you're right a lot of good advertisement this morning, removes that overhang that we know the Street continued to be concerned that the what-if possibility that, that what-if has been taken off the table, and I can assure you we will maximize the opportunity we have ahead of us."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Yes, so Greg, I guess, Greg, on your second part, first of all, I guess I would start by saying that we're incredibly disappointed by the whole Modafinil situation. But Mylan has never been, we've said it so many times, about one product. And therefore, t",205,"Yes, so Greg, I guess, Greg, on your second part, first of all, I guess I would start by saying that we're incredibly disappointed by the whole Modafinil situation. But Mylan has never been, we've said it so many times, about one product. And therefore, the -- we will -- we're whether it's Modafinil in or Modafinil out, we're still very confident at our $2.40 per share midpoint of our guidance range. And whether it be the very successful launch of Escitalopram that we had here in the first quarter or the strength of the EpiPen that we're seeing throughout 2012, all of those things make us very confident that 2012 will be a very good year, the best year for Mylan that we've had in our history. And look, I don't know that I would say we were being incredibly conservative or however you described it, I think we were providing a guidance range at the beginning of the year that we believe reflected the fact that not all good things happened, not all bad things happened. And that we would be in that guidance range. And we look forward to the year continuing to develop this way and taking advantage of upside opportunities."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","How about that OTC piece of my question?",8,"How about that OTC piece of my question?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Oh, I'm sorry. Yes. So as far as OTC, listen, we've had a lot of discussions and we'll be continuing to have these discussions. I believe that the most responsible thing for EpiPen would be behind the counter. So it would look much more like sometimes how",248,"Oh, I'm sorry. Yes. So as far as OTC, listen, we've had a lot of discussions and we'll be continuing to have these discussions. I believe that the most responsible thing for EpiPen would be behind the counter. So it would look much more like sometimes how insulin is treated or plan B. So we believe that there is absolutely opportunity to continue to work with states because as you might imagine, there is -- all the states differ with pharmacy laws and regulations. But we are actively pursuing and looking at doing just that, working with the states, working with the FDA, to hopefully get to a place where there would be both prescription EpiPen as well as behind-the-counter EpiPen that would provide the maximum access to everybody who wanted or needed to carry an EpiPen to be able to have as many as they want and also be able to make sure, from a collaborative perspective that whether it's schools being covered, soccer fields, football as you might imagine, that not only its important to have the schools equipped, which we're launching a huge program here in the next couple of months with schools, but also everything in the community related to that. So all of this is working in conjunction and why I said that outside of just our DTC investment that there's a lot of other initiatives that are ongoing that we'll be excited to be telling you more about as the year unfolds."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Ronny Gal with Sanford Bernstein.",11,"Our next question is coming from Ronny Gal with Sanford Bernstein."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Ive got 2 and I promise not to ask a thing about EpiPen. The first one is John, kind of, we were a little bit on the Watson announcement yesterday where -- which surprised me the most is how much cash they can free to pay down the debt early on. And lo",203,"Ive got 2 and I promise not to ask a thing about EpiPen. The first one is John, kind of, we were a little bit on the Watson announcement yesterday where -- which surprised me the most is how much cash they can free to pay down the debt early on. And looking at your numbers, you've got roughly the same EBITDA they do roughly the same tax, roughly the same interest rate. You generate about $1 billion in operating cash flow, but youre spending $400 million of that on CapEx; you're spending 40% of your operating cash flow on CapEx. And the question is, is there -- how do we think about that? You guys are spending a lot more than your peers in terms of percentage of cash flow on CapEx. Should we think about this as a positive or should you be thinking about maybe holding some of that back, paying down your debt more and then suddenly you look a lot less levered and look lot more financial, lets call it digi-flexibility to return the cash, buy something or somehow to create like a most significant upside to the business. And then I do have a follow on."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","So I'm going to start off even though you said John. I just at least want to underscore, not only our commitment to investment in CapEx but why. If you go back to our Investor Day, we said we were going to double our size in the next 5 years, from a capac",212,"So I'm going to start off even though you said John. I just at least want to underscore, not only our commitment to investment in CapEx but why. If you go back to our Investor Day, we said we were going to double our size in the next 5 years, from a capacity perspective, our platform. So as you look, we are investing, obviously, across the board whether it's on our API, whether it's in the finished dosage form facilities, but doubling that capacity, we believe is, again, just goes to the diversity of our platform, our ability to absorb whatever, headwind, countries, issues. That, that ability to not only invest from an R&D perspective and we talked a lot about our product portfolio doubling. And when you think about not only doubling, it's the quality of what we're doubling and the kind of products, again, our respiratory announcement. Our ability to have the dollars and invest the dollars we believe is another barrier to entry because we're using large dollar investments, whether it's respiratory, whether it's biogenerics, doubling our size. So we believe, as I said earlier, it's not necessarily just quantity, we believe not only are we investing in the right things, but certainly in a very quality way."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And I guess I would just add on to what Heather said, at 2.9x gross debt to EBITDA, we're very comfortable with that leverage ratio. And that leverage ratio has been declining steadily and accelerating in that decline. And so we generate $600 million a ye",116,"And I guess I would just add on to what Heather said, at 2.9x gross debt to EBITDA, we're very comfortable with that leverage ratio. And that leverage ratio has been declining steadily and accelerating in that decline. And so we generate $600 million a year of free cash flow; its just a substantial amount. We've been using that cash flow to reinvest back in the business as well as to delever. And so I think that we're building a platform for the future and responsibly reinvesting in that platform so we have the right play -- the right growth in the future while at the same time managing the balance sheet in a smart way."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And which is why I think we continue to reiterate our confidence and commitment to delivering on our longer-term growth prospects. Because the investments we're making today are for the 2016, '17, '18 opportunities that we believe we'll be able to globall",44,"And which is why I think we continue to reiterate our confidence and commitment to delivering on our longer-term growth prospects. Because the investments we're making today are for the 2016, '17, '18 opportunities that we believe we'll be able to globally monetize."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from Gary Nachman with Susquehanna.",10,"Our next question is coming from Gary Nachman with Susquehanna."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","First, a couple of pricing questions. How is the pricing shaking up for generic Lexapro between you and Teva since the share seems to have been split evenly between you guys? And on EpiPen, how much more headroom in pricing are you assuming this year afte",59,"First, a couple of pricing questions. How is the pricing shaking up for generic Lexapro between you and Teva since the share seems to have been split evenly between you guys? And on EpiPen, how much more headroom in pricing are you assuming this year after taking that 10% price increase in March? And then I have a follow-up."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Your pricing question, your first one, we don't discuss pricing of individual products. All I can tell you is we continue to see stability in our products at both the base business and opportunities on some of these new launches. So I would say that on th",90,"Your pricing question, your first one, we don't discuss pricing of individual products. All I can tell you is we continue to see stability in our products at both the base business and opportunities on some of these new launches. So I would say that on the first one. EpiPen, look, I think we've been pretty consistent in our pricing. And we see that continuing. So as we continue to invest and continue to look at building that awareness, we'll continue to have a pricing strategy that certainly mirrors that."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","Okay, and just you mentioned in terms of your building out the Commercial business in India later this year, I thought I remembered you saying at the Analyst Day that, that was going to be earlier in the year, so I'm just curious if there were any changes",69,"Okay, and just you mentioned in terms of your building out the Commercial business in India later this year, I thought I remembered you saying at the Analyst Day that, that was going to be earlier in the year, so I'm just curious if there were any changes to that timeline. And just talk about the impact you think that's going to have on the business in that region."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","We have talked about July launch and that's where we exactly are. We will be launching sometime between July and August. And we don't see any significant impact on the year.",32,"We have talked about July launch and that's where we exactly are. We will be launching sometime between July and August. And we don't see any significant impact on the year."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Our next question is coming from the line of Michael Faerm, Jr. with Credit Suisse.",15,"Our next question is coming from the line of Michael Faerm, Jr. with Credit Suisse."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","You had commented earlier about your confidence in your ultimate approval and AB rating for your generic Advair. Can you elaborate on why you're confident in that, and maybe contrast it to the EpiPen situation where you're confident that the generic won't",45,"You had commented earlier about your confidence in your ultimate approval and AB rating for your generic Advair. Can you elaborate on why you're confident in that, and maybe contrast it to the EpiPen situation where you're confident that the generic won't get AB rating."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Sure, I'm going to start and then I'm going to let Rajiv, perhaps, speak to our confidence in it. Look, I think that what we said when we announced the acquisition of that platform as we were taking the core competencies of the existing Pfizer platform an",142,"Sure, I'm going to start and then I'm going to let Rajiv, perhaps, speak to our confidence in it. Look, I think that what we said when we announced the acquisition of that platform as we were taking the core competencies of the existing Pfizer platform and marrying that up with what Mylan has always been known to do best, which is taking very complex opportunities and bringing them to fruition. So when we looked at the high-caliber and the asset and the position and the point that Pfizer had developed a product now marrying that up and complementing it with our scientific ability is really what underscored our confidence. And I'll let -- and as far as EpiPen goes, look, as I continue to say, it's the Dragon [ph] device component of EpiPen that makes those regulations and those aspects different."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","And our confidence is based on what we acquired, the quality of the device and the similarity of the device between this one's and Glaxo's, as well as our continued dialogue with FDA and the progress which we are making. So we remain very confident that w",58,"And our confidence is based on what we acquired, the quality of the device and the similarity of the device between this one's and Glaxo's, as well as our continued dialogue with FDA and the progress which we are making. So we remain very confident that we are on the right path to build the first generic Advair."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Operator, I think we have time for one more question.",10,"Operator, I think we have time for one more question."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Your final question is coming from the line of Randall Stanicky with Canaccord Genuity.",14,"Your final question is coming from the line of Randall Stanicky with Canaccord Genuity."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Analysts","I just keep it one. Just going back to Europe for a second. I appreciate and I think we all appreciate the headwinds and the challenges there. The double-digit declines in constant currency growth, if those continue, how much cushion do you have built in",71,"I just keep it one. Just going back to Europe for a second. I appreciate and I think we all appreciate the headwinds and the challenges there. The double-digit declines in constant currency growth, if those continue, how much cushion do you have built in before that becomes an issue? I understand that you don't need to grow, but at what point does the constant currency decline start to hurt you?"
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Look, I talked about the fact that our gross margins actually increased 300 basis points quarter-to-quarter, Randall. And so it's not about the top line; it's about the bottom line, and we're managing that region in the context of the macroeconomic headwi",141,"Look, I talked about the fact that our gross margins actually increased 300 basis points quarter-to-quarter, Randall. And so it's not about the top line; it's about the bottom line, and we're managing that region in the context of the macroeconomic headwind. So it's not hurting us. We obviously would love to see growth and we look forward to when the macroeconomic issues in Europe are resolved and generic utilization rates increase. And the top line growth, together with the gross margins increasing, and that's why we talked on the Investor Day about Europe being a long-term growth driver for us.
So with that, look, we appreciate all of our investors and the questions we received in this call. Q1 was very much in line with what we had expected, and we look forward to continuing to deliver on 2012 so..."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","Thank you.",2,"Thank you."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Executives","With that, operator, you can close the call.",8,"With that, operator, you can close the call."
290203,184140392,290552,"Mylan, Inc., Q1 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Viatris Inc.","Operator","Thank you, this does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you, this does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan Second Quarter Earnings Conference Call and webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Easter",76,"Welcome to Mylan Second Quarter Earnings Conference Call and webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern standard time. The dial in number is 800-585-8367 or (404)537-3406 for international callers, with pin number 94584310. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","A Beverly good morning, everyone. Welcome to Mylan Second Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice Presiden",307,"A Beverly good morning, everyone. Welcome to Mylan Second Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making numerous forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Risks and uncertainties, and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our report on Form 10-K for the period ended December 31, 2012, and in our other SEC filings. You can access our Form 10-K and other SEC filings through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures such as adjusted revenue, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with GAAP. Please refer to today's earnings press release, which is available on our website, as it contains detailed GAAP to non-GAAP reconciliations of our actual first quarter results.
Before I turn the call over to Heather, let me also remind you that the materials in this call, with the exception of a participant question, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'm going to turn the call over to Heather."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us. I would also like to welcome and recognize Mylan employees around the world because of their dedication and hard work, we once again delivered very strong results. On behalf of the",1572,"Thank you, Kris, and good morning, everyone, and thank you for joining us. I would also like to welcome and recognize Mylan employees around the world because of their dedication and hard work, we once again delivered very strong results. On behalf of the Board of Directors and entire management team, I would like to congratulate them on a job well done. 
Mylan had an outstanding second quarter, delivering double-digit top line and bottom line year-over-year growth. Sales were about $1.7 billion, up 12% on a constant currency basis. And our adjusted diluted EPS increased 15% from the same prior year quarter to $0.60 a share. Building on our strong first quarter, this stellar performance supports our confidence that 2012 will be the best year-to-date in Mylan's history, with many more to come. 
Among the second quarter highlights were growth of more than 50% in our Specialty business, double-digit growth in North America and strong performance of our ARV franchise. Our performance this quarter was strong compared to last year second quarter when we had several very significant product launches. Further, we delivered this growth while continuing to invest in our global platform through increased R&D and sales and marketing programs. In addition, our gross margin was also almost half a percentage point. 
We also saw improvement in some European countries, constant currency, third-party net sales in our EMEA region were down about 3% year-over-year, a smaller decline that we've seen in recent quarters. EMEA top line was essentially flat from Q1 to Q2 this year. These results are yet another demonstration of our ability to manage our global platform for growth by optimizing new launches and seizing opportunities as we continue to build our base business and effectively manage pricing pressures. it's against this factor that we look forward to the third quarter, which we project to be by far is the strongest of the year, and a fourth quarter that is similar to or slightly higher than the second quarter. 
We are reaffirming our 2012 adjusted EPS guidance of $2.45 to $2.55 per share as well as 2013 target of $2.75. 
Earlier this year, when we hosted our Investor Day, we outlined plan was strategic growth drivers. I'd like to walk you through several of them now and comment on results achieved or progress made during the second quarter. Our core growth drivers is our global operating platform, which we continue to leverage this quarter. In our North America generics business, third-party net sales for the quarter were $845 million, up 13% from the year ago period, more than 70% of these sales come from existing products with the remainder coming from multiple new launches. In the U.S., drivers in the quarter included Escitalopram, Doryx and which is enjoying an 180 days of exclusivity. We also look forward to important launches throughout the rest of the year, including Modafinil. For our settlement with Teva, we may launch our product on August 10, which is prior to the expiration of the 180-day exclusivity period for We also expect to launch active 
In Canada, our robust pipeline has produced 17 new product launches thus far in 2012, an unprecedented number for us, and we expect to sustain a similar level annually through at least 2015. Among our more significant second quarter launches were Crestor and
In EMEA, constant currency, third-party net sales for the quarter totaled $327 million, which as I mentioned earlier, represented a decline of about 3% year-over-year. Nearly 90% of these outcomes from existing products, with the remainder coming from new product introduction throughout the region which included Lipitor, Ibandronate, which is our first the generic ARV launched in Europe. 
while existing product volume remained flat year-over-year, pricing was as expected, lower due to government action and ongoing pressure. In this environment, we continue to manage our cost structure aggressively through vertical integration, repatriation of products and other measures taken to manage and reduce cost of goods sold. 
In both Italy and Spain, we experienced double-digit constant currency sales growth year-over-year due to higher volume on existing products and new product launches, which offset rising impact. In addition to Italy and Spain, we saw some growth in smaller countries. And in Germany, our enhanced cost structure continue to allow us to compete in multiple tenders. 
In our Asia-Pacific region, third-party net sales for the quarter totaled nearly $308 million, and 9% constant currency increase. The primary driver of this growth was our ARV franchise. In Japan, higher volumes continue to offset price cuts that went into effect on April 1 and of which the market began adjusting during the first quarter. 
Our third-party sales in Australia slowed slightly as new product revenue and favorable volume and mix nearly offset the impact of price cuts of nearly 25% made in the second quarter by Australia pharmaceutical benefit scheme and a significant agencies history. 
As for our Specialty business, second quarter performance was very strong. Sales rose 51% year-over-year to almost $200 million. Year-over-year sales for the first half of 2012 were up 58%. 
Domestic sales of EpiPen Auto-Injector accounted for most of this increase driven by unprecedented script expansion and ongoing growth of the anaphylactic marketplace. Performance sales also grew, and the product continues to do well in all 4 major channels, retail, home health care, hospitals and long-term care. The nebulizer level market in the us is expected to expand about 15% this year and 10% in 2013. We expect our growth to continue to outpace the market. 
We also were pleased to announce in May that we had entered into settlement agreements with Sanofi and concerning their product. 
Moving onto our other strategic growth drivers, we continue to believe we are well positioned to benefit from ongoing measures being taken to boost generic utilization. In the last year, utilization has increased in several European countries such as France, Italy, Spain, Portugal and Belgium, as government modified reimbursement practices. Recently in France, for instance, when a consumer wants to but a certain brand of products, he must pay for them out of pocket and then get reimbursed for as if he is willing to accept the generic alternative, he will pay nothing. 
In addition, Japan continues to represent a significant opportunity. Over the last 12 months, Japan has experienced growth in generic utilization which now stands at about 24%. 
As for our global Institutional business, we continue to invest in research and development and in additional capacity, which will allow us to increase the vertical integration of this business and support the future double-digit sales growth we expect. In addition, year-to-date in the U.S., we have received approvals on 5 injectable products, and we launched several products throughout the rest of the world. 
Moving onto our ARV franchise. We continue to strengthen our position as a market leader with our new and innovative dosage forms, and our portfolio now contains 43 products. Currently, approximately 1/3 of all HIV patients being treated in the developing world for the disease rely on a Mylan product. 
With respect to geographic expansion, we look forward this summer to launching our commercial business in India. And initially, we'll concentrate on certain therapeutic categories, starting with our ARV portfolio. We also are pleased with the progress we are making in our export markets, and we are on track to this year to file 150 dossiers in countries around the globe. 
Portfolio diversity, continues to be an important driver of our business. Year-to-date, we've launched about 300 products, and we're on track to launch approximately 350 more by year end. As we have continued to diversify, today we offer a wide variety of dosage forms with oral solids making up only about 57% of our portfolio. Examples of other forms include injectables, patches, softgel caps, dermatologies, respiratory and liquids. 
In neurology, earlier this year, lower courts ruled against us in the U.S. and the U.K., respectively on Copaxone and we intend to appeal those decisions. We remain confident in our application and expect to receive FDA approval before we have the ability to launch our product, given the anticipated length of the appeals process.
Turning to our respiratory franchise, we continue to be on track and expect to launch generic Advair in 2015 in Europe and in 2016 in the U.S. We also continue to invest in internal respiratory capabilities in Ireland. In addition, the development of our COPD combination product remains on track. 
As for biogenerics, our product development remains on track and we look forward to commercializing affordable products globally. 
Finally, earlier this month, we applauded the signing of the Food and Drug Administration and Innovation Act, which received near unanimous bipartisan support in Congress. had long been a passionate leader and an advocate for many pieces of legislation, which updates the 1938 law governing FDA to help protect the health and safety of its consumers by requiring all facilities that supply product in the U.S., regardless of where they're located, be routinely expected by the agency and have one quality standard. Through the landmark generic drug user fee program, the new law also will help expedite approvals of generic drugs by reducing review times of ANDAs from 31 months to 10 months over the next 5 years. I'll now turn the call over to John to discuss the quarter's results in more detail, and I will look forward to responding to your questions."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morn, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris' comment at the beginning of today's ca",2078,"Thank you, Heather, and good morning, everyone. This morn, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris' comment at the beginning of today's call regarding our use of adjusted measures. 
I am pleased with our results for the second quarter of 2012 which are in line with our expectations. As you'll recall, in early May, we increased and narrowed our adjusted diluted EPS guidance range for 2012 from $2.30 to $2.50 per share to a range of $2.45 to $2.55 per share. With the exception of our fully diluted share count, which I'll speak about in a few minutes, our other guidance metrics remains unchanged and I'll walk through each of them today.
Our Q2 results reflect double-digit growth on the top line and the bottom line, excluding the effects of foreign currency and were achieved while continuing to invest in new product development and sales and marketing programs, both of which also grew by double digits. 
As Heather discussed previously, our ability to continually introduce new products, in particular this quarter Doryx in the U.S. and Lipitor worldwide, has served to mitigate some of the challenges of the macroeconomic environment in Europe, as well as government-mandated price reduction which took place in Japan and Australia earlier in the year. We continue to manage against these macro economic headwinds and remain poised to achieve our forecasted full year result while also fully absorbing their impact. 
Getting into the details, let me now walk you through our financial results for the second quarter and first half of 2012. I'll also provide an update on our capital structure and liquidity position. Starting in the top of our income statement, total adjusted revenues for the quarter were approximately $1.7 billion, an increase of 7% over last year's second quarter revenues of approximately $1.6 billion. Year-over-year, third-party net revenue growth on a constant currency basis was approximately 12%. The 5% unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to many of the other functional currencies of our major operations but mainly in Europe and India. 
For the first half of 2012, total adjusted revenues were approximately $3.3 billion, an increase of 8% over revenues from the first half of 2011 or 12% on a constant currency basis. As a reminder, our guidance range for total revenues for the full year 2012 is between $6.8 billion and $7.2 million. 
Recognizing current exchange rates and using them to forecast the remainder of the year, we expect to be near the low end of this revenue range as the impact of changes in foreign exchange rates is estimated to have an unfavorable impact approaching $200 million. 
Looking at our operating profitability measures. Adjusted gross margin for the 2012 second quarter was a very strong 48.5%, a 30 basis point increase over the same prior year period. This increase was driven by favorable volume and pricing on our EpiPen Auto-Injector and by new product launches, partially offset by lower margin on existing products. 
The current quarter also saw margin improvement in Asia-Pacific. Sales and gross profit from Mylan Laboratory Limited, our Indian subsidiary, benefited from the effects of a stronger dollar as compared to the rupee as a significant portion of it sales is denominated in U.S. dollars. 
For the 6 months ended June 30, 2012, adjusted gross margins were 48.3% as compared to 47.7% in the prior year. Our guidance range for adjusted gross margin is 48% to 50%. We currently expect our gross margin in the second half of 2012 could potentially be above or at the upper end of our guidance range, and as a result, our full year gross margin to be at the upper end of our guidance range. 
Adjusted operating income was $398 million for the second quarter of 2012, a 4% increase from a very strong Q2 2011 and up 8% from the first quarter of 2012. This increase, which is primarily the result of the favorable gross profit that I've just discussed, was realized in spite of R&D expense for the quarter -- was realized by an increased levels of spending on R&D and SG&A. 
R&D expense for the quarter, on an adjusted basis was $93 million or approximately 5.5% of total revenues, and up approximately 29% from the prior year and 39% on a constant currency basis. This increase was realized mainly as a result of ongoing clinical studies with respect to our respiratory and Biologics programs. 
At the same time, SG&A also on an adjusted basis, with $328 million for the quarter, or approximately 19.4% of total revenues, and up approximately 9% over the prior year or 13% on a constant currency basis. The increase in SG&A in the current quarter is due in large part to increased sales and marketing in our Specialty franchise, in particular for the EpiPen Auto-Injector, which has resulted in overall growth of the anaphylaxis market. 
For the 6-month period, adjusted R&D expense was $173 million, up 17% over the prior year. As a percentage of revenues, R&D expense to date for 2012 is 5.3%. Our guidance range for R&D expense for the full year is between 5.5%  and 6.5% of total revenues. We expect R&D spending to continue to increase throughout the rest of the year primarily related to our biologic and respiratory platforms, and we continue to believe that the full year spend will be within our guidance range. 
SG&A expense on an adjusted basis for the 6 months ended June 30, 2012, was $640 million, an increase of nearly 13% and within our full year guidance range of 18% to 20% of total revenues, albeit at the high end as the result of the increased sales and marketing spend.
Adjusted EBITDA was $448 million and $859 million for the 3 and 6 months ended June 30, 2012, respectively, and remains forecasted to be between $1.75 billion and $1.95 billion for the full year.
I'd like to briefly discuss a few of the one-off items that are being excluded from our adjusted results this quarter. In April, we entered into a new 5-year collective bargaining agreement with our production employees in Morgantown, West Virginia. In can junction with this new agreement, we incurred approximately $15 million of cost including amounts associated with our planned withdrawal from a multi-employer defined benefit pension plan. Second, we incurred approximately $14 million of restructuring cost associated with the planned closure of our manufacturing facility in Napa, California. This amount relates to severance and related benefits. 
And finally, in accordance with applicable accounting guidance, we incurred a noncash charge of approximately $16 million, which represented an increase to our contingent consideration liability with respect to our acquisition of Pfizer's respiratory platform. Approximately half of this amount relates to the accretion of the liability to its undiscounted value, which would occur each quarter.
Moving onto our consolidated, nonoperating financial metrics. Adjusted interest expense for the second quarter of 2012 was $61 million. As of June 30, 2012, the average rate on outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70-30 exploding debt portfolio, which we believe is an optimal ratio. During Q2, we entered into forward starting financial instrument to extent to 2016 the period of over which we will maintain our 70-30 exploding ratio of our debt portfolio, as well as our average effective interest rate. 
Adjusted interest expense for the 6-month period was $122 million, and is forecasted to be between $245 million and $265 million for the full year. The effective tax rate in the current quarter was 26% compared to 27% a year ago. Our full year 2012 tax rate range is between 26% and 27%, and we continue to believe that this rate will be sustainable at this level going forward. 
Second quarter adjusted net income was $254 million, or $0.60 per share, a 15% increase from our Q2 2011 adjusted diluted EPS of $0.52 per share. For the 6 months, adjusted net income was $478 million, or $1.12 per share, a 17% increase over the same prior year period. 
As I mentioned previously, our guidance range for diluted EPS is now $2.45 to $2.55 per share. During the quarter, we completed a $500 million share repurchase program under which we repurchased 23.4 million shares at an average cost of $21.36 per share. The impact of this share repurchase program is included in our calculation of adjusted diluted earnings per share on a weighted basis and to approximately $0.01 for the current quarter. Our revised estimate of diluted shares for the full year is approximately 420 million shares.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis, which takes into account the special items which are outlined in our press release and which I discussed in detail in our first quarter earnings call, was approximately $282 million for the quarter and $349 million per for the year-to-date period. In addition to cash-based previously accrued litigation, which is excluded from adjusted cash from operations, we have also excluding cash received during the quarter with respect to the settlement of a patent litigation matter. 
Also in the quarter, Mylan and settled outstanding litigation with respect to product. As a result of this settlement, Mylan is licensed to continue sales of its concentrate product and will have a loyalty bearing license nonpositive product upon receiving final FDA approval from the U.S. FDA. The settlement also releases Mylan from payment of the $18 million in damages that has been awarded by a jury earlier this year. The penal impact of these items as well as a few miscellaneous other litigation matters was income of $12.2 million for the quarter, all of which is excluded from our adjusted earnings. 
Our GAAP cash flow from operations for the current quarter and year-to-date period was a very strong cash inflow of $302 million and $193 million, respectively, and leaving us with unrestricted cash and marketable securities totaling approximately $347 million at June 30, 2012. We are still forecasting our full year 2012 adjusted operating cash flow to be within our guidance range of $900 million to $1 billion driven by increased second half earnings, as well as increased cash received receipts from accounts receivable related to our significant recent product launches. 
Second quarter capital spending was $61 million, bringing the total for the year-to-date to nearly $100 million. And as a result of the timing of cutting capital expenditures, we expect full year capital expenditures to be within our guidance range of $300 million to $400 million. In addition to capital expenditures, approximately $70 million was spent during the first half of 2012 to acquire product rights and licenses.
During the current quarter, we borrowed $365 million under our revolving credit facility do this along with cash on hand and through cash received from our accounts receivable securitization facility, we used to fund the share repurchase program, which I previously discussed. In July 2012, the size of the accounts receivable securitization facility was increased to $400 million. 
Even with the additional borrowings under the revolver and the AR facility, we continue to have a significant financial flexibility. Our leverage ratio at the June 30, 2012, as a result of the additional borrowings was 3.09 to 1, which is slightly above our long-term target of 3 to 1. However, we expect to be back below 3 to 1 by December 31, 2012. As such, we will continue to evaluate the uses of free cash flow for transaction based on the parameters which we've to you in the past. 
Additionally, I'm pleased that in May, Mylan's credit rating was upgraded by Moody's to BA1 from BA2. And following this action, Moody's rating outlook is stable. This change is reflective of Mylan's track record of meeting our prior stated commitment, as well as our solid position within the global generic industry, in particular our strong geographic diversification and robust product pipeline. 
To summarize, our second quarter, much like our first, was strong and in line with what we had anticipated. This positions us well heading into what will be an exciting second half of the year, culminating in what should be our strongest year yet. That concludes my remarks. I'll turn the call over to the operator for Q&A. Beverly?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] The first question comes from the line of David Risinger of Morgan Stanley.",15,"[Operator Instructions] The first question comes from the line of David Risinger of Morgan Stanley."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","My question is, can you just talk a little bit about that improvement in performance? Obviously, you're going to a bit of an easier comp because of the declines in 2011. But if you could speak to how we should think about the prospects for constant curren",82,"My question is, can you just talk a little bit about that improvement in performance? Obviously, you're going to a bit of an easier comp because of the declines in 2011. But if you could speak to how we should think about the prospects for constant currency performance in EMEA going forward? And then second, obviously, there was a big hit to prices in Australia, but your Asian business performed well. Could you talk about that outlook on a go forward basis?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","David, so I'll start with Europe -- you know, I want to be careful about not talking about this quarter as a trend yet in Europe, but I will say this. We certainly are getting positive indicators. And starting with France, our, as you know our largest mar",463,"David, so I'll start with Europe -- you know, I want to be careful about not talking about this quarter as a trend yet in Europe, but I will say this. We certainly are getting positive indicators. And starting with France, our, as you know our largest market, we continue to take initiatives to increase utilization, we see those starting to take hold. We see volumes holding. So that ability of perhaps turning the quarter, maybe throughout the rest of this year, we will see a trend. But what I can tell you, we have our arms around what we can control, our cost of goods structure, our continual repatriation and vertical integration has benefited us. And that's said in the past, once that market started to turn around, we certainly, we get our disproportionate share because of what we've been doing during these headwinds. Italy and Spain continue to be -- show a lot of growth, especially in volume. So while there continues to be austerity measures and price impact, we see that volume in our product mix and our ability to continue to grow those markets as very promising. So I think when you look overall, of where there's still see -- where we still see opportunity is utilization being a much better offset the cost containment than just slashing prices. And as when you look at some of the other European countries that are much more mature in like the U.K., it's not opportunity for utilization. They're pretty mature market, so that's to maintain in some of those areas is very different than some of the growth opportunities we see for our strong. And then let's turn to the Asia-Pacific. Yes, Australia continue to see price pressure as one of the most significant to date with this 25%. I will tell you, we continuously have them since it 2008 when I believe they took the first big hit to pricing to right size of the organization because remain very nimble and agile and be able to adapt to the changing environment. We continue to invest in our R&D and product launches and cost of goods structure, which we'll continue to do, which has helped us hold and offset that price cut. As you mentioned, Japan had a nice increase. And again, we see opportunity, we see utilization for that country at about 24%. As you know the government has talked about getting that up to at least 30% here in the very near so again, continuing to capture some of that growth and as I mentioned, our growth driver be our ARV franchise out of our India subsidiary. And that continues to grow nicely and we continue to be a very competitive and market leader around tenders throughout the world."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes of the line of Gary Nachman from Susquehanna Financial Group.",14,"Your next question comes of the line of Gary Nachman from Susquehanna Financial Group."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","It does of the contribution from new products in North America, the $240 million, can you quantify roughly how much of that was Doryx? What was the other big contributors, and those will probably drop off. But should we still see sequential growth in Nort",56,"It does of the contribution from new products in North America, the $240 million, can you quantify roughly how much of that was Doryx? What was the other big contributors, and those will probably drop off. But should we still see sequential growth in North America for the rest of the year from other new products?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I think, again, as you know, we don't break out our revenue from products individually. We are very pleased with the launches that we had in the second quarter and we do have a very strong quarter. We do have a very strong quarter coming up here in the th",76,"I think, again, as you know, we don't break out our revenue from products individually. We are very pleased with the launches that we had in the second quarter and we do have a very strong quarter. We do have a very strong quarter coming up here in the third quarter for North America. So I think that it will be a very robust year for North America overall, including the second half of the year."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And then maybe for Heather, how is the DTC been going for EpiPen? Have you been able to affect this on that campaign in terms of drawing in new patients and also growing the market? Just some qualitative metrics around that?",42,"Okay. And then maybe for Heather, how is the DTC been going for EpiPen? Have you been able to affect this on that campaign in terms of drawing in new patients and also growing the market? Just some qualitative metrics around that?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So we've been very focused, as I mentioned in my remarks, it's actually growing in the anaphylaxis market. So really just at the moment without saying that epinephrine auto-injector in the market at this time, we've really been able to focus on education",162,"So we've been very focused, as I mentioned in my remarks, it's actually growing in the anaphylaxis market. So really just at the moment without saying that epinephrine auto-injector in the market at this time, we've really been able to focus on education around anaphylaxis. So we have seen, as you've seen in these results, we've seen a great response to that, and we obviously look at Q3 to be one of the best ever or EpiPen as we continue to note that it's a very, at the moment, still very seasonal with back to school. We see Q3 always to the start of a larger but we've seen script trend and expansion is peak starting earlier, lasting longer. So we certainly have seen a benefit and obviously now with the runway clear for us through 2015, through our settlement with Teva, I can assure you, we are going to continue this response continue to invest in EpiPen as a franchise."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes on the line of Frank Pinkerton of SunTrust.",12,"Your next question comes on the line of Frank Pinkerton of SunTrust."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Just first one, can you give us any details on your confidence and the comments you made earlier about the timing for the Copaxone approval? Have.",26,"Just first one, can you give us any details on your confidence and the comments you made earlier about the timing for the Copaxone approval? Have."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Yes, we remain absolutely confident in our rental and your ability to receive an approval. As you know, our ability to get an approval prior to the appeals process is not possible. So we're very focused on still received our approval and absolutely as I m",59,"Yes, we remain absolutely confident in our rental and your ability to receive an approval. As you know, our ability to get an approval prior to the appeals process is not possible. So we're very focused on still received our approval and absolutely as I mentioned in my comments, believe that we'll get that prior to the approval process."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay, great, maybe a little broader question. In Europe, and I don't want to talk about your business, but you may comment on other competitors there. What are you seeing out of the regional players, some of the smaller players? Is consolidation happening",61,"Okay, great, maybe a little broader question. In Europe, and I don't want to talk about your business, but you may comment on other competitors there. What are you seeing out of the regional players, some of the smaller players? Is consolidation happening from a standpoint of taking capacity out kind of outside of the top 10 players in that market?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, as we've said before, it's really tough to talk about one country and one market. You've got many, many markets, many different regions, many different dynamics. What I would say is as we do participate in many of those markets throughout Europe, we",175,"Well, as we've said before, it's really tough to talk about one country and one market. You've got many, many markets, many different regions, many different dynamics. What I would say is as we do participate in many of those markets throughout Europe, we have continued to see, yes, through some of these macroeconomic headwinds, we saw irrational behavior in some countries. We stated that we've always believed that those weren't sustainable business model, that our ability to leverage our global platform very much made us unique throughout the European countries. So our ability to whether the storm that Europe's been going through and come out on the other side stronger, much better cost of goods structure and a position to compete much better than any regional or local player that doesn't have the benefit of the global scale that the Mylan platform has. So I think that's the best way at can describe how we see Mylan fitting in for your overall how Mylan would be very differentiated from a regional or local player."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","On gross margin, you talked about how much of this is going to improve as the year progresses, how much of that is just the product mix and good products coming out of the U.S.? Versus what is more sustainable and I mean relative to your comments about ta",107,"On gross margin, you talked about how much of this is going to improve as the year progresses, how much of that is just the product mix and good products coming out of the U.S.? Versus what is more sustainable and I mean relative to your comments about taking cost down in Europe, et cetera, et cetera, the margin line? And then secondly, are you doing anything in Europe to change the SG&A cost structure because of all the austerity and difficult markets over there? because you've really talked about taking cost out of the gross margin line and you haven't talked about SG&A as far as."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Mark, with respect to the gross margin, certainly a portion of the margin increase in the second half of the year is the seasonality associated with our product mix. Certainly, the Specialty business including EpiPen, has it's strongest quarter in the yea",173,"Mark, with respect to the gross margin, certainly a portion of the margin increase in the second half of the year is the seasonality associated with our product mix. Certainly, the Specialty business including EpiPen, has it's strongest quarter in the year in the third quarter and that it will benefit us. We also have a very strong year for launches in North America. And new product launches, obviously, are beneficial. Aside from North America, as we talked about in the first quarter, we have been seeing through the cost-reduction efforts that even taking whether it be the vertical integration, the repatriation efforts, we have been able to maintain and grow margin in Europe and we've been able to also even with the price cuts that we've seen and Asian countries been able to whether that web stable margins. So I think that it is a strength of our gross margin is a combination the tween product mix, new products and then also managing aggressively the cost associated with our existing product portfolio."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Before has any other questions, just on the gross margin. If you didn't have this massive increase in the number of U.S. products, which arguably you're not going to have as much next year versus this year, which is where I'm going with the question, what",68,"Before has any other questions, just on the gross margin. If you didn't have this massive increase in the number of U.S. products, which arguably you're not going to have as much next year versus this year, which is where I'm going with the question, what is the kind of the core accord gross margin? Is that 48% kind of becomes the baseline that you're thinking about now?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I think, we'll certainly provide more detailed guidance with respect to '13 when we get closer to that year. We did talk about that a bit in our investor day and I think we are confident in our 48% to 50% gross margin range that we have as our current gui",53,"I think, we'll certainly provide more detailed guidance with respect to '13 when we get closer to that year. We did talk about that a bit in our investor day and I think we are confident in our 48% to 50% gross margin range that we have as our current guidance out there."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","And as far as your question about the rest of European cost, first I would say that our global doesn't just apply to the product side. Our global scale is holding on sales marketing excellence, looking at really as these markets continue to change and ada",118,"And as far as your question about the rest of European cost, first I would say that our global doesn't just apply to the product side. Our global scale is holding on sales marketing excellence, looking at really as these markets continue to change and adapt, we're able to do so with along with them. So I'd say we have been able to take some restructuring in different countries and adapt and our sales model. And we continue to do so. So we are absolutely looking across the board at where that makes sense. and like I said, at the end of the day, our ability to really follow-up on that scale benefits us across the entire organization."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Have you got any of the sales force and stuff how does that work?",14,"Have you got any of the sales force and stuff how does that work?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","It depends. We have countries, take Belgium, was something generic marketplace and they have increasingly switching to an INN substitution. So our ability, obviously, to up with the dynamics of that market is important. And we're able to do so. So I would",65,"It depends. We have countries, take Belgium, was something generic marketplace and they have increasingly switching to an INN substitution. So our ability, obviously, to up with the dynamics of that market is important. And we're able to do so. So I would say that we can do everything from sales, from marketing to sales reps to how we're selling the market into those countries."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes on the line of Elliot Wilbur of Needham & Company.",13,"Your next question comes on the line of Elliot Wilbur of Needham & Company."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","First question is for Heather. Heather, do you still believe that genetic version of Lidoderm is opportunity for the company in 2013? And if so, could you indicate whether or not you've included it as one of many potential adjusted products in your $2.75",47,"First question is for Heather. Heather, do you still believe that genetic version of Lidoderm is opportunity for the company in 2013? And if so, could you indicate whether or not you've included it as one of many potential adjusted products in your $2.75 per share guidance."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. I do absolutely believe that Lidoderm could be an opportunity for us in the second half of '13. And I guess just to build up on that a little bit, because I know there's been a lot of discussion around Lidoderm, just for your recollection, the citiz",172,"Sure. I do absolutely believe that Lidoderm could be an opportunity for us in the second half of '13. And I guess just to build up on that a little bit, because I know there's been a lot of discussion around Lidoderm, just for your recollection, the citizens petition, which has been discussed that was filed back in 2006. After that citizens petition was filed, talking about put forward against them about bioequivalence and how that's an adjudication and what should be required, FDA issued guidance very clearly and as about what they wanted to see with the Lidoderm hatch in the ANDA. So all of that transpired before Watson filed their ANDA in 2009 and absolutely nothing has changed from an FDA's perspective on guidance to requirement since that time. So the idea that the citizens petition is holding up the application to manage not really possible. So I again, we look forward to our regulatory approval and still believe that is very viable option in the second half of '13."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","With respect to the second half of your question whether Lidoderm is in our '13 numbers or not, I guess what I would say to you is that we risk adjust all of our products and take into consideration that there could be a range of periods in when products",77,"With respect to the second half of your question whether Lidoderm is in our '13 numbers or not, I guess what I would say to you is that we risk adjust all of our products and take into consideration that there could be a range of periods in when products are introduced, and therefore, without say specifically whether Lidoderm is in there or not, I would just say that Lidoderm is risk-adjusted into our future business plan."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay, and I have an additional question, probably for you John as well. can you just describe for us what, in terms of the management and the Board's perspective and what is the most attractive use of the company's discretionary free cash flow at this poi",106,"Okay, and I have an additional question, probably for you John as well. can you just describe for us what, in terms of the management and the Board's perspective and what is the most attractive use of the company's discretionary free cash flow at this point in time, I mean assuming you have a range of options between paying down debt, buying back shares or something more strategic, you kind of have done a bit of everything over the past couple of years, I'm just kind of wondering what your current thinking is in terms of what's the best use of cash for enhancing shareholder returns?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I guess not being a member of the Board of Directors I'm not sure I want to speak on behalf of the Board of Directors, but we laid out on Investor Day earlier this year the parameters for how we would evaluate transactions. And I think those parameters co",131,"I guess not being a member of the Board of Directors I'm not sure I want to speak on behalf of the Board of Directors, but we laid out on Investor Day earlier this year the parameters for how we would evaluate transactions. And I think those parameters continue to exist. In May, we believe that executing on the share repurchase program was the best and most appropriate use of the capital we had available to us at that time. And so we execute on that and we were very pleased with the execution. On a going forward basis, we'll continue to evaluate opportunities that are available for transactions in the marketplace. Again, using the parameters we outlined, and will also evaluate written the appropriateness of the share repurchase program."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","And I would just add, Robert and the Board are extremely involved looking at everything and constantly looking at all of our options.",23,"And I would just add, Robert and the Board are extremely involved looking at everything and constantly looking at all of our options."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Ronny Gal of Sanford",12,"Your next question comes from the line of Ronny Gal of Sanford"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","First, regarding EpiPen, you would look at the AP ACA and some potential applications and I'm just wonder if EpiPen is not one of the products that is likely to have a disproportionately higher growth from ACA. I was wondering if you guys have done any lo",128,"First, regarding EpiPen, you would look at the AP ACA and some potential applications and I'm just wonder if EpiPen is not one of the products that is likely to have a disproportionately higher growth from ACA. I was wondering if you guys have done any look at that tail when of the ACA provides you EpiPen? And second, you kind of mentioned your building injectable capacity, and obviously, this is a good time to bring injectable capacity is online, I was wondering if you look at your current build map, when you think you'll have more capacity, minimal step up in capacity around the essentially would you be able to gain get into the same cycle before some other competitors are able to bring their capacity backup?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Let me start with your second question because I'm not sure I clearly understood your EpiPen question and so I'll come back to that. on your about our capacity build, as we've announced earlier this year, we are continuing to invest in our injectable capa",131,"Let me start with your second question because I'm not sure I clearly understood your EpiPen question and so I'll come back to that. on your about our capacity build, as we've announced earlier this year, we are continuing to invest in our injectable capacity in Ireland as well as other areas around the globe. We certainly agree that our continual ability to vertically integrate on the injectable front and bring more and more of that into the Mylan supply chain, it's certainly a benefit to us. So it absolutely is part of our footprint expansion and capacity building this year as well as into the future. As far as EpiPen, I wasn't clear, they didn't cross up on what you're asking. I believe you used some initial with ACA?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I mean the health care reform act, okay? Essentially, have a good thing they expansion of Medicaid and a few actually strategic, a lot more people would be covered become more and then provide be on so that people that it might of not might be using EpiPe",65,"I mean the health care reform act, okay? Essentially, have a good thing they expansion of Medicaid and a few actually strategic, a lot more people would be covered become more and then provide be on so that people that it might of not might be using EpiPen more than the general population. I was wondering the effect of the health care reform on EpiPen?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Okay, I think maybe what you're speaking of ACA, but in any event, we absolutely do not. As you may be aware or not aware, most programs allow for patient to be reimbursed for 2 EpiPens per year. And that's usually something across all programs whether th",82,"Okay, I think maybe what you're speaking of ACA, but in any event, we absolutely do not. As you may be aware or not aware, most programs allow for patient to be reimbursed for 2 EpiPens per year. And that's usually something across all programs whether the government or private sector where people are carrying more EpiPens or paying out of pocket or get a waiver from their insurance companies. so certainly nothing in the current health care watching just those dynamics."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes of the line of Ken Cacciatore of Cowen & Company.",13,"Your next question comes of the line of Ken Cacciatore of Cowen & Company."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","My question is looking out to mid-2015, I would you as the management team, you have to look at that EpiPen settlement and clearly have a potential worst case model or worst case scenario, although many good things could happen and maybe discount out some",121,"My question is looking out to mid-2015, I would you as the management team, you have to look at that EpiPen settlement and clearly have a potential worst case model or worst case scenario, although many good things could happen and maybe discount out some of the other potential positives. As I was wondering, in terms of capital deployment and knowing how long the integration or took, as you're looking at potential acquisitions or other diversification, what should we be thinking in terms of timing? And John, you talked about not wanting to talk about parameters, but maybe can just walk us through just briefly some of the parameters of assets or acquisitions that you gave at the analyst meeting?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure, can, so as far as a long-term visibility you're looking for. I think starting what we've been doing since 2008 is continued to get that long-term visibility, and hopefully, what people have been able to start gaining confidence in our ability to be",365,"Sure, can, so as far as a long-term visibility you're looking for. I think starting what we've been doing since 2008 is continued to get that long-term visibility, and hopefully, what people have been able to start gaining confidence in our ability to be not only laying out guidance and potential targets that our ability to make meet or exceed them because came out Investor Day with a whole assortment of opportunities that are drivers for 2013 and beyond because as you mentioned, on the on those things so whether it's EpiPen, the us there's a possibility there could be in while I remain fairly confident that is to be a high hurdle, we have many, many other opportunities and maybe talk about Biologics, Copaxone, all definitely coming after that 2015 period, not to mention our continuous voluminous amount of launches across the board. And that's why today in my remarks, I try to layout not only the platform is degenerated, by the other different strategic drivers that we discussed that all get benefits, so you don't have to rely on all of them hitting obviously just a couple of them hitting certainly put at great growth to Mylan from this point going forward. And I guess the other thing I would say on your comment about integration, I could say that our work and we certainly is and something in the you buy company 2.5 times your size and do a transformational acquisition as we did. Certainly, that integration, I think took a couple of 3 years that we certainly were able to continue to show every step along the way our ability to realize those synergies. I think when you look at acquisitions outside of that, we certainly stated we're doing a large 2.5 times our size transformative acquisition. So things like something respiratory franchise from Pfizer, we continue to be able to bulk and tick those in without ever even mentioning integration or missing a beat. Because I think the platform we have in place today is scalable and sustainable and stable to absorb these kind of acquisitions very, very easily. So that's not a long-term planning period for any of those."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I know we should never say never but should we be thinking along the lines of something going forward are and should be see something more sizable?",27,"I know we should never say never but should we be thinking along the lines of something going forward are and should be see something more sizable?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I think we've been great and a lot John speak about that. We have a whole range of opportunities and potential from sizing perspective and our continued strengthening our financing flexibility. So all I'm saying is that, that everything and these types of",55,"I think we've been great and a lot John speak about that. We have a whole range of opportunities and potential from sizing perspective and our continued strengthening our financing flexibility. So all I'm saying is that, that everything and these types of acquisitions are certainly nothing compared to what the Merck integration required."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Remember, today we indicated that we were committed to a long-term debt to EBITDA ratio of 3 to 1 that we would not go above that which is permitted under credit facility of 4.25 to 1. That we would look at this possession that expanded our portfolio or g",72,"Remember, today we indicated that we were committed to a long-term debt to EBITDA ratio of 3 to 1 that we would not go above that which is permitted under credit facility of 4.25 to 1. That we would look at this possession that expanded our portfolio or geographically into areas that we're not in. Our other shareholder value accretion transaction such as the share repurchases that you saw earlier this year."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes of the line of Shibani Malhotra with RBC.",12,"Your next question comes of the line of Shibani Malhotra with RBC."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I'm just going to follow on from cans question, but just in terms of looking at the portfolio and either the acquisitions you've done, can you just talk us through coming terms of the synergies, should we assume that these have already been realized or is",146,"I'm just going to follow on from cans question, but just in terms of looking at the portfolio and either the acquisitions you've done, can you just talk us through coming terms of the synergies, should we assume that these have already been realized or is there more to go? And can you talk from the pipeline standpoint, branded are coming terms of the findings you expect it to get approved in your Europe and also the end of new filings that you are thinking about and how much room is there for new products that we haven't heard of as yet and where we are -- where we are rather, on that? And specifically, on the M&A, can you talk about the kind of areas are we looking at whether there branded or generic and what sort of disease areas are you looking at.?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Let me start I guess on the portfolio aspect of your question. Just throughout the rest this year, we're on track to launch over 300 products throughout the world. We don't speak specifically before launches in Europe as you know competitive advantage and",403,"Let me start I guess on the portfolio aspect of your question. Just throughout the rest this year, we're on track to launch over 300 products throughout the world. We don't speak specifically before launches in Europe as you know competitive advantage and it's not the same system that has the same visibility like here in the United States of your something I can't tell you we had very successful launches already this year that I spoke about and something in Doxycycline and Ibandronate and like I said, we continue to have many more. Our total R&D portfolio and filings, we look to be doubling our size by 2015. So that should get and give you a sense of the amount of products that we have in the pipeline or already filed with regulatory agencies around the world of what we're going to be launching over the next couple of years. So as far as forgoes, certainly, we have been showing again in Investor Day, that's states launched know or our first to file, share to file opportunities, 2012 was one of our largest years as far as the states so far been but we continue to already be have settlements that go out through '13, '14, '15 certain. We continue to get our share first-to-file opportunities so I would just that we continue to maximize and leverage our platform on all of the fronts that we have in the past. Difficult to formulate products, the Paragraph IV opportunity and like I said, just a voluminous amount of dosage forms. And we are investing in everything from injectables, as I mentioned earlier, to our patches, on oral soft gels, dermatological is price from M&A, when you think about we really have a lot of opportunities to complement this platform across the globe, from our Specialty division, to continue to complement our infrastructure and disease expertise in respiratory and allergy. You look at our Biologics partnerships and our ability to continue to leverage and build upon that. As well as therapeutic categories that we're not in yet. So we see an opportunity to still our U.S. unit generic yes this is with things like antibiotics or dermatological things that we're not at large in today. Across the board, I would say we have morning many opportunities to continue to fuel the energy that you put together across all of that fronts I just mentioned."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your final question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your final question comes from the line of Jami Rubin with Goldman Sachs."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","John, just a follow-up on some of the earlier that questions regarding uses of cash and share repurchase, and the company expand its share repurchase program without violating your debt covenants and we're calculating that you have about another $400 mill",60,"John, just a follow-up on some of the earlier that questions regarding uses of cash and share repurchase, and the company expand its share repurchase program without violating your debt covenants and we're calculating that you have about another $400 million to $500 million in share repurchase potential that you could do right now, can you confirm that is correct?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","There are restrictions and under our bank facilities and borrowing facilities, with respect to our ability to do additional share repurchase programs, as the current time, our Board of Directors have not approved any other share repurchase programs. And q",59,"There are restrictions and under our bank facilities and borrowing facilities, with respect to our ability to do additional share repurchase programs, as the current time, our Board of Directors have not approved any other share repurchase programs. And quite honestly, we're not in a position to confirm the $400 million to $500 million capacity at the current time."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","With the exception of the Board approved the buyback program, with your covenants, just given your cash flow generation, would your covenants allow you to announce further share buyback program now?",31,"With the exception of the Board approved the buyback program, with your covenants, just given your cash flow generation, would your covenants allow you to announce further share buyback program now?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I don't think that our covenants would allow us to announce a share repurchase program currently of the size that you were suggesting, no.",25,"I don't think that our covenants would allow us to announce a share repurchase program currently of the size that you were suggesting, no."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","And just as a follow-up, EpiPen obviously performed very well this what it would to just noticed in terms of IMS prescription trends during the month of June, demand for dropped pretty considerably compared to the previous months. Just wondering what's go",60,"And just as a follow-up, EpiPen obviously performed very well this what it would to just noticed in terms of IMS prescription trends during the month of June, demand for dropped pretty considerably compared to the previous months. Just wondering what's going on, what you're seeing just a seasonal adjustment and how we should think about it going forward?"
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, couple of things. You heard me say before that I don't believe that EpiPen should be as a seasonal product as it's been historically. But we continue to educate people about obviously some of the unfortunate and necessarily taken place in and school",144,"Well, couple of things. You heard me say before that I don't believe that EpiPen should be as a seasonal product as it's been historically. But we continue to educate people about obviously some of the unfortunate and necessarily taken place in and schools have not been to things like these things that occur more in the springtime so what I would say as we've seen, as you there's a lot of something allergy season started much earlier this is as we had such a mild winter. I think that was a contributed to some of the strengths but I would say I also put a lot more weight on, like I said, pure expansion in education that's taken place in the market and I continue to see a hopefully more and more months becoming drivers short of what historically then just been Q3."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So operator, that will conclude our call and we appreciate very much the support of everybody who participated.",18,"So operator, that will conclude our call and we appreciate very much the support of everybody who participated."
290203,213782906,331504,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Thank you, everyone, for joining today's conference call. You may now disconnect.",12,"Thank you, everyone, for joining today's conference call. You may now disconnect."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's Second Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. East",78,"Welcome to Mylan's Second Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern Standard Time. The dial-in number is (800) 585-8367 or (404) 537-3406 for international callers, with pin number 94584310. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Beverly. Good morning, everyone. Welcome to Mylan's Second Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive V",489,"Thank you, Beverly. Good morning, everyone. Welcome to Mylan's Second Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making numerous forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often may be identified with the use of words such as may, will, could, should, would, project, believe, anticipate, expect, plan, estimate, guidance, trends, forecast, potential, intend, continue and variations of these words or comparable words.
Our forward-looking statements may today include, among others, statements related to anticipated business levels, trends in some European countries, planned launches of and anticipated exclusivity period for new products, our ability to achieve forecasted full year results while absorbing the impact of negative pricing pressures, expectations for capital expenditures, expectations for R&D, SG&A and other spending.
Our guidance range, future earnings, planned activities, anticipated growth and other expectations and targets for future periods, including our expectations regarding the third and fourth quarters for the 2012 overall. Because these statements are forward looking, they inherently involve risks and uncertainties and, accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the factors set forth under forward-looking statements in our recent earnings release dated July 26, 2012, as well as the risk factors set forth in our report on Form 10-Q for the period ended March 31, 2012, and in our other SEC filings. You can access our Form 10-Q and other SEC filings, including our earnings press release, which we filed on Form 8-K through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures such as adjusted revenue, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with Generally Accepted Accounting Principles or GAAP.
Please refer to today's earnings press release, which is available on our website, as well as on SEC website, as it contains detailed reconciliations of the non-GAAP financial measures we use for our second quarter results prepared in accordance with GAAP.
Before I turn the call over to Heather, let me also remind you that the materials in the call, with the exception of the participant questions, is a property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I will turn the call over to Heather."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us. I would also like to welcome and recognize Mylan's employees around the world. Because of their dedication and hard work, we once again delivered very strong results. On behalf of",1590,"Thank you, Kris, and good morning, everyone, and thank you for joining us. I would also like to welcome and recognize Mylan's employees around the world. Because of their dedication and hard work, we once again delivered very strong results. On behalf of the Board of Directors and our entire management team, I would like to congratulate them on a job well done.
Mylan had an outstanding second quarter, delivering double-digit top line and bottom line year-over-year growth. Sales were about $1.7 billion, up 12% on a constant currency basis, and our adjusted diluted EPS increased 15% from the same prior year quarter to $0.60 a share. Building on our strong first quarter, this stellar performance supports our confidence that 2012 will be the best year-to-date in Mylan's history, with many more to come.
Among the second quarter's highlights were growth of more than 50% in our Specialty business, double-digit growth in North America and strong performance of our ARV franchise. Our performance this quarter was strong compared to last year's second quarter when we had several very significant product launches. Further, we delivered this growth while continuing to invest in our global platform through increased R&D and sales and marketing programs. In addition, our gross margin was up almost half a percentage point.
We also saw improvement in some European countries. Constant currency third-party net sales in our EMEA region were down about 3% year-over-year, a smaller decline than we've seen in recent quarters. EMEA's top line was essentially flat from Q1 to Q2 of this year. These results are yet another demonstration of our ability to manage our global platform for growth by optimizing new launches and seizing opportunities as we continue to build our base business and effectively manage pricing pressures. It's against this factor of that we look forward to the third quarter, which we project to be by far our strongest of the year, and a fourth quarter that is similar to or slightly higher than the second quarter. We are reaffirming our 2012 adjusted EPS guidance of $2.45 to $2.55 per share, as well as our 2013 target of $2.75.
Earlier this year, when we hosted our Investor Day, we outlined Mylan's strategic growth drivers. I'd like to walk you through several of them now and comment on results achieved or progress made during the second quarter. Our core growth driver is our global operating platform, which we continue to leverage this quarter. In our North America generics business, third-party net sales for the quarter were $845 million, up 13% from the comparable year ago period. More than 70% of these sales come from existing products, with the remainder coming from multiple new launches.
In the U.S., drivers in the quarter included Escitalopram, Doryx and Evicabir [ph], which is enjoying 180 days of exclusivity. We also look forward to important launches throughout the rest of the year, including Modafinil. For our settlement with Teva, we may launch our product on August 10, which is prior to the expiration of the 180-day exclusivity period brand [indiscernible]. We also expect to launch Actos, Actoplus Met and [indiscernible].
In Canada, our robust pipeline has produced 17 new product launches thus far in 2012, an unprecedented number for us, and we expect to sustain a similar level annually through at least 2015. Among our more significant second quarter launches were Crestor and
[indiscernible].
In EMEA, constant currency third-party net sales for the quarter totaled $327 million which, as I mentioned earlier, represented a decline of about 3% year-over-year. Nearly 90% of these outcomes from existing products, with the remainder coming from new product introductions throughout the region which included Lipitor, [indiscernible], Ibandronate, Lamivudine, which is our first generic ARV launched in Europe.
While existing product volume remained flat year-over-year pricing was, as expected, lower due to government action and ongoing competitive pressure. In this environment, we continue to manage our cost structure aggressively through vertical integration, repatriation of product and other measures taken to manage and reduce cost of goods sold.
In both Italy and Spain, we experienced double-digit constant currency sales growth year-over-year due to higher volumes on existing products and new product launches, which offset pricing impact. In addition to Italy and Spain, we saw some growth in smaller countries. And in Germany, our enhanced cost structure continue to allow us to compete in multiple tenders.
In our Asia-Pacific region, third-party net sales for the quarter totaled nearly $308 million and 9% constant currency increase. The primary driver of this growth was our ARV franchise. In Japan, higher volumes continue to offset price cuts that went into effect on April 1, and of which the market began adjusting during the first quarter.
Our third-party sales in Australia slowed slightly as new product revenue and favorable volume and mix nearly offset the impact of price cuts of nearly 25% made in the second quarter by Australia Pharmaceutical Benefits Scheme and the significant agent [indiscernible].
As for our Specialty business, our second quarter performance was very strong. Sales rose 51% year-over-year to almost $200 million. Year-over-year sales for the first half of 2012 were up 58%.
Domestic sales of EpiPen Auto-Injector accounted for most of this increase, driven by unprecedented script to expansion and ongoing growth of the anaphylaxis marketplace. Performance sales also grow, and the product continues to do well in all 4 major channels: retail, home health care, hospitals and long-term care. The nebulized LABA market in the U.S. is expected to expand about 15% this year and 10% in 2013. We expect our growth to continue to outpace the market. We also were pleased to announce in May that we had entered into settlement agreements with Sanofi and concerning their [indiscernible] products.
Moving on to our other strategic growth drivers, we continue to believe we are well positioned to benefit from ongoing measures being taken to boost generic utilization. In the last year, utilization has increased in several European countries such as France, Italy, Spain, Portugal and Belgium, as governments modify reimbursement practices. Recently in France, for instance, when a consumer wants to buy a certain brand of product, he must pay for them out of pocket and then get reimbursed, whereas if he's willing to accept the generic alternative, he will pay nothing.
In addition, Japan continues to represent a significant opportunity. Over the last 12 months, Japan has experienced growth in generic utilization, which now stands at about 24%.
As for our global Institutional business, we continue to invest in research and development and an additional capacity, which will allow us to increase the vertical integration of this business and support the future double-digit sales growth we expect. In addition, year-to-date in the U.S., we have received approvals on 5 injectable products, and we launched several products throughout the rest of the world.
Moving on to our ARV franchise. We continue to strengthen our position as the market leader with our new and innovative dosage forms, and our portfolio now contains 43 products. Currently, approximately 1/3 of all HIV patients being treated in the developing world for the disease rely on a Mylan product.
With respect to geographic expansion, we look forward this summer to launching our commercial business in India. And initially, we'll concentrate on certain therapeutic categories, starting with our ARV portfolio. We also are pleased with progress we are making in our export markets, and we are on track to this year to file 150 dossiers in countries around the globe.
Portfolio diversity continues to be an important driver of our business. Year-to-date, we've launched about 300 products, and we're on track to launch approximately 350 more by year end. As we have continued to diversify, today we offer a wide variety of dosage forms, with oral solids making up only about 57% of our portfolio. Examples of other forms include injectables, ophthalmic, patches, soft gel caps, dermatologics, respiratory and liquids.
In neurology, earlier this year, lower courts ruled against us in the U.S. and U.K., respectively on Copaxone, and we intend to appeal those decisions. We remain confident in our application and expect to receive FDA approval before we have the ability to launch our product, given the anticipated length of the appeals process.
Turning to our respiratory franchise. We continue to be on track and expect to launch generic Advair in 2015 in Europe and in 2016 in the U.S. We also continue to invest in internal respiratory capabilities in Ireland. In addition, the development of our COPD combination product remains on track.
As for biogenerics, our product development remains on track, and we look forward to commercializing affordable products globally. 
Finally, earlier this month, we applauded the signing of the Food and Drug Administration Safety and Innovation Act, FDASIA,  which received near-unanimous bipartisan support in Congress. Mylan has long been a passionate leader and an advocate for many pieces of the legislation, which updates the 1938 law governing FDA to help protect the health and safety of consumers by requiring that all facilities that supply product in the U.S., regardless of where they're located, be routinely inspected by the agency and have the one quality standard. Through the landmark Generic Drug User Fee program, the new law also will help expedite approvals of generic drugs by reducing review times of ANDA from 31 months to 10 months over the next 5 years.
I'll now turn the call over to John to discuss this quarter's results in more detail, and I look forward to responding to your questions."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris's comment at the beginning of today'",2098,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris's comment at the beginning of today's call regarding our use of adjusted measures.
I am pleased with our results for the second quarter of 2012, which are in line with our expectations. As you'll recall, in early May, we increased and narrowed our adjusted diluted EPS guidance range for 2012 from $2.30 to $2.50 per share to a range of $2.45 to $2.55 per share. With the exception of our fully diluted share count, which I'll speak about in a few minutes, our other guidance metrics remains unchanged, and I'll walk through each of them today.
Our Q2 results reflect double-digit growth on the top line and bottom line, excluding the effects of foreign currency, and were achieved while continuing to invest in new product development and sales and marketing programs, both of which also grew by double digits.
As Heather discussed previously, our ability to continually introduce new products, in particular this quarter Doryx in the U.S., Lipitor worldwide, has served to mitigate some of the challenges of the macroeconomic environment in Europe, as well as government-mandated price reductions, which took place in Japan and Australia earlier in the year. We continue to manage against these macroeconomic headwinds and remain poised to achieve our forecasted full year result while also fully absorbing their impact.
Getting into the details, let me now walk you through our financial results for the second quarter and first half of 2012. I'll also provide an update on our capital structure and liquidity position. Starting at the top of our income statement, total adjusted revenues for the quarter were approximately $1.7 billion, an increase of 7% over last year's second quarter revenues of approximately $1.6 billion. Year-over-year, third-party net revenue growth on a constant currency basis was approximately 12%. The 5% unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to many of the other functional currencies of our major operations but mainly in Europe and India.
For the first half of 2012, total adjusted revenues were approximately $3.3 billion, an increase of 8% over revenues from the first half of 2011 or 12% on a constant currency basis. As a reminder, our guidance range for total revenues for the full year 2012 is between $6.8 billion and $7.2 billion.
Recognizing current exchange rates and using them to forecast the remainder of the year, we expect to be near the low end of this revenue range as the impact of changes in foreign exchange rates is estimated to have an unfavorable impact approaching $200 million.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 second quarter was a very strong 48.5%, a 30 basis point increase over the same prior year period. This increase was driven by favorable volume and pricing on our EpiPen Auto-Injector and by new product launches, partially offset by lower margins on existing products.
The current quarter also saw margin improvement in Asia Pacific. Sales and gross profit from Mylan Laboratories Limited, our Indian subsidiary, benefited from the effects of a stronger dollar as compared to the rupee, as a significant portion of its sales are denominated in U.S. dollars.
For the 6 months ended June 30, 2012, adjusted gross margins were 48.3% as compared to 47.7% in the prior year. Our guidance range for adjusted gross margin is 48% to 50%. We currently expect our gross margin in the second half of 2012 could potentially be above or at the upper end of our guidance range and as a result, our full year gross margin to be at the upper end of our guidance range.
Adjusted operating income was $398 million for the second quarter of 2012, a 4% increase from a very strong Q2 2011 and up 8% from the first quarter of 2012. This increase, which is primarily the result of the favorable gross profit that I just discussed, was realized in spite of R&D expense for the -- was realized in spite of increased levels of spending on R&D and SG&A.
R&D expense for the quarter, on an adjusted basis, was $93 million or approximately 5.5% of total revenues and up approximately 29% from the prior year and 39% on a constant currency basis. This increase was realized mainly as a result of ongoing clinical studies with respect to our respiratory and biologics programs.
At the same time, SG&A, also on an adjusted basis, was $328 million for the quarter or approximately 19.4% of total revenues, and up approximately 9% over the prior year or 13% on a constant currency basis. The increase in SG&A in the current quarter is due in large part to increased sales and marketing in our Specialty franchise, in particular for the EpiPen Auto-Injector, which has resulted in the overall growth of the anaphylaxis market.
For the 6-month period, adjusted R&D expense was $173 million, up 17% over the prior year. As a percentage of revenues, R&D expense to date for 2012 is 5.3%. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues. We expect R&D spending to continue to increase throughout the rest of the year, primarily related to our biologic and respiratory platforms, and we continue to believe that the full year spend will be within our guidance range.
SG&A expense, on an adjusted basis, for the 6 months ended June 30, 2012, was $640 million, an increase of nearly 13% and within our full year guidance range of 18% to 20% of total revenues, albeit at the high end as a result of the increased sales and marketing spend.
Adjusted EBITDA was $448 million and $859 million for the 3 and 6 months ended June 30, 2012, respectively, and remains forecasted to be between $1.75 billion and $1.95 billion for the full year.
I'd like to briefly discuss a few of the one-off items that are being excluded from our adjusted results this quarter. In April, we entered into a new 5-year collective bargaining agreement with our production employees in Morgantown, West Virginia. In conjunction with this new agreement, we incurred approximately $15 million of cost including amounts associated with our planned withdrawal from a multiemployer defined benefit pension plan. Second, we incurred approximately $14 million of restructuring cost principally associated with the planned closure of our manufacturing facility in Napa, California. This amount relates principally to severance and related benefits.
And finally, in accordance with applicable accounting guidance, we incurred a noncash charge of approximately $16 million, which represented an increase to our contingent consideration liability with respect to our acquisition of Pfizer's respiratory platform. Approximately half of this amount relates to the accretion of a liability to its undiscounted value, which would occur each quarter.
Moving on to our consolidated, nonoperating financial metrics. Adjusted interest expense for the second quarter of 2012 was $61 million. As of June 30, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70-30 fixed floating debt portfolio, which we believe is an optimal ratio. During Q2, we entered into forward starting derivative financial instruments to extend to 2016 the period over which we will maintain our 70-30 fixed floating ratio of our debt portfolio, as well as our average effective interest rate.
Adjusted interest expense for the 6-month period was $122 million, and is forecasted to be between $245 million and $265 million for the full year. The effective tax rate in the current quarter was 26% compared to 27% a year ago. Our full year 2012 tax rate range is between 26% and 27%, and we continue to believe that this rate will be sustainable at this level going forward.
Second quarter adjusted net income was $254 million, or $0.60 per share, a 15% increase from our Q2 2011 adjusted diluted EPS of $0.52 per share. For the 6 months, adjusted net income was $478 million or $1.12 per share, a 17% increase over the same prior year period.
As I mentioned previously, our guidance range for diluted EPS is now $2.45 to $2.55 per share. During the quarter, we completed a $500 million share repurchase program under which we repurchased 23.4 million shares at an average cost of $21.36 per share. The impact of this share repurchase program is included in our calculation of adjusted diluted earnings per share on a weighted basis and now to approximately $0.01 for the current quarter. Our revised estimate of diluted shares for the full year is approximately 420 million shares.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis, which takes into account the special items which are outlined in our press release and which I discussed in detail in our first quarter earnings call, was approximately $282 million for the quarter and $349 million for the year-to-date period. In addition, the cash paid to settle previously accrued litigation, which is excluded from adjusted cash from operations, we have also excluded cash received during the quarter with respect to the settlement of a patent litigation matter.
Also during the quarter, Mylan and Sunovion settled outstanding litigation with respect to Sunovion's Xopenex product. As a result of this settlement, Mylan is licensed to continue sales of its concentrate product and will have a loyalty bearing license to sell its non-concentrate  product upon receiving final FDA approval from the U.S. FDA. The settlement also releases Mylan from payment of the $18 million in damages that has been awarded by a jury earlier this year. The net penal impact of these items, as well as a few miscellaneous other litigation matters, was an income of $12.2 million for the quarter, all of which is excluded from our adjusted earnings.
Our GAAP cash flow from operations for the current quarter and year-to-date period was a very strong cash inflow of $302 million and $193 million, respectively, and leaving us with unrestricted cash and marketable securities totaling approximately $347 million at June 30, 2012. We are still forecasting our full year 2012 adjusted operating cash flow to be within our guidance range of $900 million to $1 billion, driven by increased second half earnings, as well as increased cash receipts from accounts receivable related to our significant recent product launches.
Second quarter capital spending was $61 million, bringing the total for the year-to-date to nearly $100 million. And as a result of the timing of planned capital expenditures, we expect full year capital expenditures to be within our guidance range of $300 million to $400 million. In addition to capital expenditures, approximately $70 million was spent during the first half of 2012 to acquire product rights and licenses.
During the current quarter, we borrowed $365 million under our revolving credit facility. This, along with cash on hand and through cash received through our -- from our accounts receivable securitization facility, was used to fund the share repurchase program, which I previously discussed. In July 2012, the size of the accounts receivable securitization facility was increased to $400 million.
Even with the additional borrowings under the revolver and the AR facility, we continue to have a significant financial flexibility. Our leverage ratio at June 30, 2012, as a result of the additional borrowings was 3.09 to 1, which is slightly above our long-term target of 3 to 1. However, we expect to be back below 3 to 1 by December 31, 2012. As such, we will continue to revaluate the uses of free cash flow for transactions based on the parameters, which we've outlined to you in the past.
Additionally, I am pleased that in May, Mylan's credit rating was upgraded by Moody's to Ba1 from Ba2. And following this action, Moody's rating outlook is stable. This change is reflective of Mylan's track record of meeting our prior stated commitments, as well as our solid position within the global generic industry, in particular, our strong geographic diversification and robust product pipeline.
To summarize, our second quarter, much like our first, was strong and in line with what we had anticipated. This positions us well heading into what will be an exciting second half of the year, culminating in what should be our strongest year yet.
That concludes my remarks. I will turn the call over to the operator for Q&A. Beverly?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Your first question comes from the line of David Risinger of Morgan Stanley.",15,"[Operator Instructions] Your first question comes from the line of David Risinger of Morgan Stanley."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","My question is, can you just talk a little bit about that improvement in performance? Obviously, you're going into a little bit easier comps because of the declines in 2011, but if you could speak to how we should think about the prospects for constant cu",80,"My question is, can you just talk a little bit about that improvement in performance? Obviously, you're going into a little bit easier comps because of the declines in 2011, but if you could speak to how we should think about the prospects for constant currency performance in EMEA going forward. And then second, obviously, there was a big hit to prices in Australia, but your Asian business performed well. Could you talk about that outlook on a go-forward basis?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. David, so I'll start with Europe. Look, I think that -- I want to be careful about not talking about this quarter as a trend yet in Europe, but I will say this. We certainly are getting positive indicators. And starting with France, our, as you know",471,"Sure. David, so I'll start with Europe. Look, I think that -- I want to be careful about not talking about this quarter as a trend yet in Europe, but I will say this. We certainly are getting positive indicators. And starting with France, our, as you know, largest market, we continue to see and take initiatives, increased utilization. We see those starting to take hold. We see volumes holding. So that ability of perhaps turning the quarter, maybe throughout the rest of this year, we will see a trend. But what I can tell you, we have our arms around what we can control, our cost of goods structure, our continual repatriation and vertical integration has benefited us. And that said in the past, once that market started to turn around, we -- certainly, we get our disproportionate share because of what we've been doing during these headwinds. Italy and Spain continue to be -- show a lot of growth, especially in volume. So while there continues to be austerity measures and price impact, we see that volume in our product mix and our ability to continue to grow those markets as very promising. So I think when you look overall of where there's still see -- or where we still see opportunity as the utilization being a much better offset the cost containment than just slashing prices. And as -- when you look at some of the other European countries that are much more mature, like the U.K., there is not that opportunity for utilization. They are pretty mature markets, so that to maintain in some of those areas is very different than some of the growth opportunities we see for our strong [indiscernible]. And then let's turn to the Asia Pacific. Yes, Australia continue to see price pressure as one of the most significant to date with the 25%. I will tell you, we continuously have them since 2008 when I believe they took the first big hit on pricing to rightsize that organization to remain very nimble and agile and be able to adapt to the changing environment. We've continued to invest in our R&D and product launches and cost of goods structure, which we'll continue to do, which has helped us hold and offset that price cut. As you mentioned, Japan had a nice increase. And again, we see opportunity. We see utilization for that country at about 24%. As you know the government has talked about getting that up to at least 30% here in the very near term, so again, continuing to capture some of that growth. And as I mentioned, our world driver being our ARV franchise out of our India subsidiary. And that continues to grow nicely, and we continue to be a very competitive market leader around tenders throughout the world."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes of the line of Gary Nachman with Susquehanna Financial.",13,"Your next question comes of the line of Gary Nachman with Susquehanna Financial."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","In terms of the contribution from new products in North America, the $240 million, can you quantify roughly how much of that was Doryx? What were the other big contributors? And those will probably drop off, but should we still see sequential growth in No",56,"In terms of the contribution from new products in North America, the $240 million, can you quantify roughly how much of that was Doryx? What were the other big contributors? And those will probably drop off, but should we still see sequential growth in North America for the rest of the year from other new products?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, I think, Gary, as you know, we don't break out our revenue from products individually. We were very pleased with the launches that we had in the second quarter, and we do have a very strong quarter. We do have a very strong quarter coming up here in",77,"Well, I think, Gary, as you know, we don't break out our revenue from products individually. We were very pleased with the launches that we had in the second quarter, and we do have a very strong quarter. We do have a very strong quarter coming up here in the third quarter for North America. So I think that it will be a very robust year for North America overall, including the second half of the year."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And then maybe for Heather, how is the DTC been going for EpiPen? Have you been able to measure the effect on this and the campaign in terms of drawing in new patients and also growing the market? Just some qualitative metrics around that.",45,"Okay. And then maybe for Heather, how is the DTC been going for EpiPen? Have you been able to measure the effect on this and the campaign in terms of drawing in new patients and also growing the market? Just some qualitative metrics around that."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So we've been very focused. As I mentioned in my remarks, it's actually growing the anaphylaxis market. So really just at the moment with us being the only epinephrine auto-injector on the market at this time, we've really been able to focus on education",172,"So we've been very focused. As I mentioned in my remarks, it's actually growing the anaphylaxis market. So really just at the moment with us being the only epinephrine auto-injector on the market at this time, we've really been able to focus on education around anaphylaxis. So we have seen, as you've seen in these results, we've seen a great response to that. And we obviously look at Q3 to be one of the best ever for EpiPen as we continue to know that it's a very -- it's at the moment still very seasonal with back to school. We see Q3 always historically by being larger, but what we've seen with the script trend and expansion is that peak is starting earlier, lasting longer. So we certainly have seen a benefit and obviously, now with the runway absolutely clear for us through 2015, through our settlement with Teva, I can assure you, we are going to continue as we see those response continue to invest in EpiPen as a franchise."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Frank Pinkerton with SunTrust.",12,"Your next question comes from the line of Frank Pinkerton with SunTrust."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Just first one, can you give us any details on your confidence and the comments you made earlier about the timing for the Copaxone FDA approval?",26,"Just first one, can you give us any details on your confidence and the comments you made earlier about the timing for the Copaxone FDA approval?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Yes, we remain absolutely confident on our regulatory pathway and our ability to receive an approval. As you know, the -- how Hatch-Waxman works, our ability to get an approval prior to the appeals process is not possible. So we are very focused on still",68,"Yes, we remain absolutely confident on our regulatory pathway and our ability to receive an approval. As you know, the -- how Hatch-Waxman works, our ability to get an approval prior to the appeals process is not possible. So we are very focused on still receiving our regulatory approval and absolutely, as I mentioned in my comments, believe that we'll get that prior to the appeals process ending."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay, great. And then maybe a little broader question. In Europe, and I don't want to talk about your business, but can you make comments on other competitors there? What are you seeing out of the regional players, some of the smaller players? Is consolid",64,"Okay, great. And then maybe a little broader question. In Europe, and I don't want to talk about your business, but can you make comments on other competitors there? What are you seeing out of the regional players, some of the smaller players? Is consolidation happening from a standpoint of taking capacity out kind of outside of the top 10 players in that market?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, as we've said before, it's really tough to talk about Europe where it gets one country and one market. I mean, we -- you've got many, many markets, many different regions, many different dynamics. What I would say is as we do participate in many of",191,"Well, as we've said before, it's really tough to talk about Europe where it gets one country and one market. I mean, we -- you've got many, many markets, many different regions, many different dynamics. What I would say is as we do participate in many of those markets throughout Europe, what we have continued to see is, yes, through some of these macroeconomic headwinds, we saw irrational behavior in some countries. We've stated that we always believe that those weren't sustainable business model, that our ability to continue to leverage our global platform very much made us unique throughout the European countries. And so our ability to weather the storm that Europe's been going through and come out on the other side stronger with a much better cost of goods structure could [indiscernible] in position to compete much better than any regional or local player that doesn't have the benefit of the global scale that the Mylan platform have. So I think that's the best way I can describe how we see Mylan fitting in for Europe overall, how Mylan would be very differentiated from a regional or local player."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Two things. First, on gross margin, you talked about how much of this is going to improve as the year progresses, how much of that is just the product mix and good products coming out of the U.S. versus what is more sustainable and I mean, relative to you",115,"Two things. First, on gross margin, you talked about how much of this is going to improve as the year progresses, how much of that is just the product mix and good products coming out of the U.S. versus what is more sustainable and I mean, relative to your comments about taking cost down in Europe, et cetera, et cetera, the gross margin line? And then secondly, are you doing anything in Europe to change the SG&A kind of cost structure because of all this austerity in the difficult markets over there? Because you've really talked about taking cost out of the gross margin line and you haven't talked about SG&A as far as Europe."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So Marc, with respect to the gross margin, certainly a portion of the margin increase in the second half of the year is the seasonality associated with our product mix. Certainly, the Specialty business, including EpiPen, has its strongest quarter of the",178,"So Marc, with respect to the gross margin, certainly a portion of the margin increase in the second half of the year is the seasonality associated with our product mix. Certainly, the Specialty business, including EpiPen, has its strongest quarter of the year in the third quarter, and that it will benefit us. We also have a very strong year for launches in North America, and new product launches, obviously, are beneficial. But aside from North America, as we talked about in the first quarter, we have been seeing through the cost-reduction efforts that we've been taking, whether it be the vertical integration, the repatriation efforts, we have been able to maintain and grow margins in Europe, and we've been able to also -- even with the price cuts that we've seen in Asian countries, been able to weather that with stable margins. So I think that it is a -- the strength of our gross margin is a combination between product mix, new products and then also managing aggressively the cost associated with our existing product portfolio."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Well, I guess, just before you answer the other questions, just on the gross margin. If you didn't have this massive increase in the number of U.S. products, which arguably you're not going to have as much next year versus this year, which is where I'm go",79,"Well, I guess, just before you answer the other questions, just on the gross margin. If you didn't have this massive increase in the number of U.S. products, which arguably you're not going to have as much next year versus this year, which is where I'm going with the question, what is the kind of the core gross margin? I mean, are we -- that 48% kind of becomes like kind of the baseline that we're thinking about now?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I think that we'll certainly provide more detailed guidance with respect to '13 when we get closer to that year. We did talk about that a bit in our Investor Day, and I think we are confident in our 48% to 50% gross margin range that we have as our curren",55,"I think that we'll certainly provide more detailed guidance with respect to '13 when we get closer to that year. We did talk about that a bit in our Investor Day, and I think we are confident in our 48% to 50% gross margin range that we have as our current guidance out there."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","And as far as your question about the rest of European cost, I guess, first I would say that the global scale doesn't just apply to the product side. Our global scale is pulling on sales excellence, marketing excellence, looking at really -- as these mark",125,"And as far as your question about the rest of European cost, I guess, first I would say that the global scale doesn't just apply to the product side. Our global scale is pulling on sales excellence, marketing excellence, looking at really -- as these markets continue to change and adapt, we're able to do so with along with them. So I would say, we have been able to take some restructuring in different countries and adapt in our sales model, and we continue to do so. So we are absolutely looking across the board at where that makes sense. And like I said, at the end of the day, our ability to really pull upon this global scale benefits us across the entire organization."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Have you cut any -- like of the sales force and staff, or how does that work?",17,"Have you cut any -- like of the sales force and staff, or how does that work?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","It depends. I mean, we have countries, take Belgium, who was a total branded generic marketplace, and they have been increasingly switching to an INN substitution. So our ability, obviously, to marry up with the dynamics of that market is important, and w",74,"It depends. I mean, we have countries, take Belgium, who was a total branded generic marketplace, and they have been increasingly switching to an INN substitution. So our ability, obviously, to marry up with the dynamics of that market is important, and we're able to do so. So I would say at the best we can be everything from sales, from marketing to sales reps to how we're selling the market into those countries."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes on the line of Elliot Wilbur of Needham & Company.",13,"Your next question comes on the line of Elliot Wilbur of Needham & Company."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","First question is for Heather. Heather, do you still believe that the generic version of Lidoderm is opportunity for the company in 2013? And if so, could you indicate whether or not you've included it as one of many potential probability adjusted product",49,"First question is for Heather. Heather, do you still believe that the generic version of Lidoderm is opportunity for the company in 2013? And if so, could you indicate whether or not you've included it as one of many potential probability adjusted products in your $2.75 per share guidance?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. I do absolutely believe that Lidoderm could be opportunity for us in the second half of '13. And I guess just to build upon that a little bit, because I know there's been a lot of discussion around Lidoderm, just for your recollection, the citizens",180,"Sure. I do absolutely believe that Lidoderm could be opportunity for us in the second half of '13. And I guess just to build upon that a little bit, because I know there's been a lot of discussion around Lidoderm, just for your recollection, the citizens petition, which has been discussed quite a bit, we filed back in 2006. After that citizens petition was filed, talking about -- Indo [ph] put forward their argument about bioequivalency and how the standards should be changed and what should be required, FDA issued guidance very clearly and have said about what they wanted to see with the Lidoderm patch in the ANDA. So all of that transpired before Watson filed their ANDA in 2009, and absolutely nothing has changed from FDA's perspective on guidance or requirement since that time. So the idea that the citizens petition is holding up the application to manage, it's just not really possible. So again, we look forward to our regulatory approval and still believe that to be a very viable option in the second half of '13."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Elliot, with respect to the second half of your question on whether Lidoderm is in our 2013 numbers or not, I guess what I would say to you is that we risk adjust all of our products and take into consideration that there could be a range of periods in wh",79,"Elliot, with respect to the second half of your question on whether Lidoderm is in our 2013 numbers or not, I guess what I would say to you is that we risk adjust all of our products and take into consideration that there could be a range of periods in when products are introduced and, therefore, without saying specifically whether Lidoderm is in there or not, I would just say that Lidoderm is risk-adjusted into our future business plan."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And I have additional question for probably you John as well. Could you just describe for us what, in terms of management and the Board's perspective on what is the most attractive use of the company's discretionary free cash flow at this point in t",105,"Okay. And I have additional question for probably you John as well. Could you just describe for us what, in terms of management and the Board's perspective on what is the most attractive use of the company's discretionary free cash flow at this point in time. I mean assuming you have a range of options between paying down debt, buying back shares or something more strategic, you kind of have done a little bit of everything over the past couple of years, I'm just kind of wondering what your current thinking is in terms of what's the best use of cash for enhancing shareholder returns?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Look, I'll -- I guess not being a member of the Board of Directors I'm not sure I want to speak on behalf of the Board of Directors, but I think we laid out on Investor Day earlier this year the parameters for how we would evaluate transactions. And I thi",132,"Look, I'll -- I guess not being a member of the Board of Directors I'm not sure I want to speak on behalf of the Board of Directors, but I think we laid out on Investor Day earlier this year the parameters for how we would evaluate transactions. And I think those parameters continue to exist. In May, we believe that executing on a share repurchase program was the best and most appropriate use of the capital we had available to us at that time. And so we execute on that, and we were very pleased with the execution. On a going-forward basis, we'll continue to evaluate opportunities that are available for transactions in the marketplace, again, using the parameters we outlined, and we'll also evaluate the appropriateness of share repurchase program."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","And I would just add, as you might imagine, Robert and the Board are extremely involved at looking at everything and constantly looking at all of our options.",28,"And I would just add, as you might imagine, Robert and the Board are extremely involved at looking at everything and constantly looking at all of our options."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Ronny Gal of Sanford Bernstein.",13,"Your next question comes from the line of Ronny Gal of Sanford Bernstein."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I have two. First, regarding EpiPen, you kind of look at the ACA and its potential implications and you just wonder if EpiPen is not one of the products that is likely to have a disproportionately higher growth from ACA. I was wondering if you guys have d",136,"I have two. First, regarding EpiPen, you kind of look at the ACA and its potential implications and you just wonder if EpiPen is not one of the products that is likely to have a disproportionately higher growth from ACA. I was wondering if you guys have done any work to look at that tailwind that the ACA provide to EpiPen? And second, you kind of mentioned you're building injectable capacity and obviously, this is a good time to bring injectable capacity online. I was wondering if you kind of look at your current build map, when do you think you'll have more capacity, I mean, minimal step-up in capacity around the injectable. I think would you be able to get in the same cycle before some other competitors are able to bring their capacity backup?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Let me start with your second question because I'm not sure I clearly understood your EpiPen question, and so I'll come back to that. But quickly on your ask about our capacity build, as we've announced earlier this year, we are continuing to invest in ou",141,"Let me start with your second question because I'm not sure I clearly understood your EpiPen question, and so I'll come back to that. But quickly on your ask about our capacity build, as we've announced earlier this year, we are continuing to invest in our injectable capacity in Ireland, as well as other areas around the globe. We certainly agree that it's our continual ability to vertically integrate on the injectable front and bring more and more of that into the Mylan global supply chain. It's certainly a benefit to us. So it absolutely is part of our footprint for expansion and capacity building this year as well as into the future. As far as EpiPen, it wasn't clear or you didn't come across clear of what you were asking me. I believe you used some initials of ACA."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I mean the health care reform act, okay, essentially have -- through the expansion of Medicaid and the [indiscernible] changes. A lot more people will be covered and those would be young adults or people that are -- that might have not -- that might be us",72,"I mean the health care reform act, okay, essentially have -- through the expansion of Medicaid and the [indiscernible] changes. A lot more people will be covered and those would be young adults or people that are -- that might have not -- that might be using EpiPen more than the general population. Now I was wondering if you did any announcements toward the effect of the health care reform on EpiPen."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Okay, I think maybe what you're speaking of ACO. But in any event, we absolutely do not. As you may be aware or not aware, most programs allow for a patient to be reimbursed for 2 EpiPens per year. And that's usually a general rule of thumb across all pro",87,"Okay, I think maybe what you're speaking of ACO. But in any event, we absolutely do not. As you may be aware or not aware, most programs allow for a patient to be reimbursed for 2 EpiPens per year. And that's usually a general rule of thumb across all programs whether government or private sector where people are carrying more EpiPens or typically paying out of pocket or get a waiver from their insurance companies. So certainly nothing in the current health care law changes those dynamics."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Ken Cacciatore with Cowen and Company.",14,"Your next question comes from the line of Ken Cacciatore with Cowen and Company."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","My question is looking out to mid-2015. I would think as the management team, you have to look at that EpiPen settlement and clearly have a potential worst-case model or worst-case scenario, although many good things could happen and maybe discount out so",124,"My question is looking out to mid-2015. I would think as the management team, you have to look at that EpiPen settlement and clearly have a potential worst-case model or worst-case scenario, although many good things could happen and maybe discount out some of the other potential positives. So I was wondering, in terms of capital deployment and knowing how long the integration for Merck took, as you're looking at potential acquisitions or other diversification, what should we be thinking in terms of timing? And John, you talked about not wanting to talk about parameters, but maybe you could just walk us through very briefly some of the parameters of assets or that the asset acquisitions that you gave at the analyst meeting?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So Ken, as far as a long-term visibility you're looking for, I think starting what we've been doing since 2008 is continuing to give that long-term visibility. And hopefully, with people have been able to start gaining confidence in our ability to b",379,"Sure. So Ken, as far as a long-term visibility you're looking for, I think starting what we've been doing since 2008 is continuing to give that long-term visibility. And hopefully, with people have been able to start gaining confidence in our ability to be not only laying out guidance and potential targets but our ability to meet or exceed them. So I think as we came out Investor Day with a whole assortment of opportunities that are drivers for 2013 and beyond because, as you mentioned, we need to work today on those things. So whether it's EpiPen, yes, there's a possibility there could be [indiscernible]. While I remain fairly confident that, that's going to be a high hurdle, we have many, many other opportunities. I mean, when we talk about biologics, Advair, Copaxone, all definitely coming after that 2015 time period, not to mention our continuous voluminous amount of launches across the board. That's why today in my remarks, I tried to lay out not only what the platform is generating but with all the different strategic drivers that we discussed that all give benefits. So you don't have to rely on all of them hitting obviously just a couple of them hitting certainly put at great growth to Mylan from this point going forward. And I guess the other thing I'd say on your comment about integration, I could say that our Merck acquisition certainly is in a hemisphere all by itself. When you buy a company 2.5x your size and do a transformational acquisition as we did, certainly that integration, I think took a couple of 3 years that we certainly were able and continue to show every step along the way our ability to realize those synergies. I think when you look at acquisitions outside of that, we've certainly stated we're not doing a large 2.5x our size transformative acquisition. So things like Bioniche respiratory franchise from Pfizer, we've continued to be able to bolt and tuck those in without ever even mentioning integration or missing a beat because I think the platform we have in place today is scalable and sustainable and is able to absorb these kind of acquisitions very, very easily. So there's not a long-term planning period for any of those."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I know never say never, but should we be thinking along the lines of Bioniche going forward, or could we see something more sizable?",24,"I know never say never, but should we be thinking along the lines of Bioniche going forward, or could we see something more sizable?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I mean, I think we've been clear, and I'll let John speak about that. We have a whole range of opportunities and potential from sizing perspective in our continued strengthening our financial flexibility. So all I'm saying is that everything and these typ",55,"I mean, I think we've been clear, and I'll let John speak about that. We have a whole range of opportunities and potential from sizing perspective in our continued strengthening our financial flexibility. So all I'm saying is that everything and these types of acquisitions are certainly nothing compared to what the Merck integration required."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Right. Remember, Ken, that at Investor Day we indicated that we were committed to a long-term debt to EBITDA ratio of 3:1 that we would not go above that which is permitted under credit facility of 4.25:1. And that we would look at the transactions that e",74,"Right. Remember, Ken, that at Investor Day we indicated that we were committed to a long-term debt to EBITDA ratio of 3:1 that we would not go above that which is permitted under credit facility of 4.25:1. And that we would look at the transactions that expanded our portfolio or geographically into areas that we're not in or other shareholder value accretion transactions such as share repurchases that you saw too earlier this year."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes of the line of Shibani Malhotra of RBC.",12,"Your next question comes of the line of Shibani Malhotra of RBC."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I'm just going to follow on from Ken's questions, but just in terms of looking at the Merck portfolio and the acquisitions you've done, Heather, can you just talk us through in terms of the synergies? I mean, should we assume that these have already been",154,"I'm just going to follow on from Ken's questions, but just in terms of looking at the Merck portfolio and the acquisitions you've done, Heather, can you just talk us through in terms of the synergies? I mean, should we assume that these have already been realized, or is there more to go? And then can you talk from the pipeline's standpoint, branded -- sorry, in terms of the filings you were expecting to get approved in Europe and also the kind of new Paragraph IV filings that you are thinking about, how much room is there for new products that we haven't heard of as yet and where we are -- where we are rather, on that? And then just specifically, on the M&A, can you talk about the kind of areas that we're looking at, I mean whether they're branded or generic, and what sort of disease areas you're looking at?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Let me start I guess on the portfolio aspect of your question. Just throughout the rest of this year, we're on track to launch another -- over 300 products throughout the world. We don't speak specifically before launches in Europe as you know. There's so",433,"Let me start I guess on the portfolio aspect of your question. Just throughout the rest of this year, we're on track to launch another -- over 300 products throughout the world. We don't speak specifically before launches in Europe as you know. There's some competitive advantage, and it's not the same system that gives the same visibility, like here in the United States with Paragraph IV. But I can tell you, we've had very successful launches already this year, as I spoke about Torvistart [ph] and Canvistart [ph] and then Ibandronate. And like I said, we continue to have many more. Our total R&D portfolio and filings, we look to be doubling our size by 2015. So I mean, that should give you a sense of the amount of products that we have in the pipeline or already filed with regulatory agencies around the world of what we're going to be launching over the next couple of years. As far as Paragraph IV goes, I mean, certainly, we have been showing, like we did back in Investor Day, the state certain launches that we already know of or our first-to-file, share to file opportunities, 2012 was one of our largest years as far as the states certain so far been, but we continue to already be -- have settlements that go out through '13, '14, '15 of date certain. We continue to get our share of first-to-file opportunities. So I would just say that we continue to maximize and leverage our platform on all of the fronts that we have in the past. Difficult-to-formulate products, the Paragraph IV opportunity and, like I said, just a voluminous amount of dosage forms. And we are investing in everything from injectables, as I mentioned earlier, to our patches, at oral, solid dose soft gels, dermatologicals. So as far as from an M&A, when you think about -- we really have a lot of opportunity to complement this platform across the globe, from our Specialty division to continue to complement our infrastructure and disease state expertise in respiratory and allergy. You look at our Biologics partnerships and our ability to continue to leverage and build upon that, as well as therapeutic categories that we're not in yet. So we see an opportunity to still bid our U.S. generics business with things like whether it would be antibiotics or dermatological things that we're not as large in today. So across the board, I would say, we have many opportunities to continue to fuel the engine that we've put together across all of the fronts I just mentioned."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your final question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your final question comes from the line of Jami Rubin with Goldman Sachs."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","John, just a follow-up on some of the earlier questions regarding uses of cash and share repurchase, can the company expand its share repurchase program without violating your debt covenants? And we're calculating that you have about another $400 million",60,"John, just a follow-up on some of the earlier questions regarding uses of cash and share repurchase, can the company expand its share repurchase program without violating your debt covenants? And we're calculating that you have about another $400 million to $500 million in share repurchase potential that you could do right now, can you confirm that, that is correct?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","There are restrictions and under our bank facilities and borrowing facilities, with respect to our ability to do additional share repurchase programs. At the current time, our Board of Directors has not approved any other share repurchase programs. And qu",59,"There are restrictions and under our bank facilities and borrowing facilities, with respect to our ability to do additional share repurchase programs. At the current time, our Board of Directors has not approved any other share repurchase programs. And quite honestly, I'm not in the position to confirm the $400 million to $500 million capacity at the current time."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","But with the exception of the Board approving a buyback program, do your -- with your covenants, just given your cash flow generation, would your covenants allow you to announce a further share buyback program now?",36,"But with the exception of the Board approving a buyback program, do your -- with your covenants, just given your cash flow generation, would your covenants allow you to announce a further share buyback program now?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I don't think that our covenants would allow us to announce a share repurchase program currently of the size that you were suggesting, no.",25,"I don't think that our covenants would allow us to announce a share repurchase program currently of the size that you were suggesting, no."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And just as a follow-up, EpiPen obviously performed very well this quarter, but we just noticed, in terms of IMS prescription trends during the month of June, demand for Epi dropped pretty considerably compared to the previous months. Just wondering",62,"Okay. And just as a follow-up, EpiPen obviously performed very well this quarter, but we just noticed, in terms of IMS prescription trends during the month of June, demand for Epi dropped pretty considerably compared to the previous months. Just wondering what's going on, what you're seeing, is this just a seasonal adjustment, and how we should think about it going forward?"
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, a couple of things. I think you've heard me say before that I don't believe that EpiPen should be as a seasonal product as it's been historically. But we continue to educate people about obviously some of the unfortunate and unnecessary drugs that h",158,"Well, a couple of things. I think you've heard me say before that I don't believe that EpiPen should be as a seasonal product as it's been historically. But we continue to educate people about obviously some of the unfortunate and unnecessary drugs that have taken place in restaurants and in schools have not been to things like these things that occur more in the springtime. So what I would say as we've seen, as you know, there's been a lot of reports of this allergy season started much earlier this yea since we had such a mild winter. I think that was a contributor to some of the strengths. But I would say, I also put a lot more weight on, like I said, just a pure expansion in education that's taken place in the market. And I continue to see hopefully more and more months becoming drivers short of what it's historically been just in Q3."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So operator, that will conclude our call, and we appreciate very much the support of everybody who participated.",18,"So operator, that will conclude our call, and we appreciate very much the support of everybody who participated."
290203,213782906,331825,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Thank you, everyone, for joining today's conference call. You may now disconnect.",12,"Thank you, everyone, for joining today's conference call. You may now disconnect."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's Second Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. East",78,"Welcome to Mylan's Second Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern Standard Time. The dial-in number is (800) 585-8367 or (404) 537-3406 for international callers, with pin number 94584310. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Beverly. Good morning, everyone. Welcome to Mylan's Second Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive V",490,"Thank you, Beverly. Good morning, everyone. Welcome to Mylan's Second Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making numerous forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often may be identified with the use of words such as may, will, could, should, would, project, believe, anticipate, expect, plan, estimate, guidance, trends, forecast, potential, intend, continue and variations of these words or comparable words.
Our forward-looking statements may today include, among others, statements related to anticipated business levels, trends in some European countries, planned launches of and anticipated exclusivity period for new products, our ability to achieve forecasted full year results while absorbing the impact of negative pricing pressures, expectations for capital expenditures, expectations for R&D, SG&A and other spending.
Our guidance range, future earnings, planned activities, anticipated growth and other expectations and targets for future periods, including our expectations regarding the third and fourth quarters for the 2012 overall. Because these statements are forward looking, they inherently involve risks and uncertainties and, accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the factors set forth under forward-looking statements in our recent earnings release dated July 26, 2012, as well as the risk factors set forth in our report on Form 10-Q for the period ended March 31, 2012, and in our other SEC filings. You can access our Form 10-Q and other SEC filings, including our earnings press release, which we filed on Form 8-K through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures such as adjusted revenue, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with Generally Accepted Accounting Principles or GAAP.
Please refer to today's earnings press release, which is available on our website, as well as on SEC website, as it contains detailed reconciliations of the non-GAAP financial measures we use for our second quarter results prepared in accordance with GAAP.
Before I turn the call over to Heather, let me also remind you that the materials in the call, with the exception of the participant questions, is a property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I will now turn the call over to Heather."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us. I would also like to welcome and recognize Mylan's employees around the world. Because of their dedication and hard work, we once again delivered very strong results. On behalf of",1591,"Thank you, Kris, and good morning, everyone, and thank you for joining us. I would also like to welcome and recognize Mylan's employees around the world. Because of their dedication and hard work, we once again delivered very strong results. On behalf of the Board of Directors and our entire management team, I would like to congratulate them on a job well done.
Mylan had an outstanding second quarter, delivering double-digit top line and bottom line year-over-year growth. Sales were about $1.7 billion, up 12% on a constant currency basis, and our adjusted diluted EPS increased 15% from the same prior year quarter to $0.60 a share. Building on our strong first quarter, this stellar performance supports our confidence that 2012 will be the best year-to-date in Mylan's history, with many more to come.
Among the second quarter's highlights were growth of more than 50% in our Specialty business, double-digit growth in North America and strong performance of our ARV franchise. Our performance this quarter was strong compared to last year's second quarter when we had several very significant product launches. Further, we delivered this growth while continuing to invest in our global platform through increased R&D and sales and marketing programs. In addition, our gross margin was up almost half a percentage point.
We also saw improvement in some European countries. Constant currency third-party net sales in our EMEA region were down about 3% year-over-year, a smaller decline than we've seen in recent quarters. EMEA's top line was essentially flat from Q1 to Q2 of this year. These results are yet another demonstration of our ability to manage our global platform for growth by optimizing new launches and seizing opportunities as we continue to build our base business and effectively manage pricing pressures. It's against this factor of that we look forward to the third quarter, which we project to be by far our strongest of the year, and a fourth quarter that is similar to or slightly higher than the second quarter. We are reaffirming our 2012 adjusted EPS guidance of $2.45 to $2.55 per share, as well as our 2013 target of $2.75.
Earlier this year, when we hosted our Investor Day, we outlined Mylan's strategic growth drivers. I'd like to walk you through several of them now and comment on results achieved or progress made during the second quarter. Our core growth driver is our global operating platform, which we continue to leverage this quarter. In our North America generics business, third-party net sales for the quarter were $845 million, up 13% from the comparable year ago period. More than 70% of these sales come from existing products, with the remainder coming from multiple new launches.
In the U.S., drivers in the quarter included Escitalopram, Doryx and Abacavir, which is enjoying 180 days of exclusivity. We also look forward to important launches throughout the rest of the year, including Modafinil. For our settlement with Teva, we may launch our product on August 10, which is prior to the expiration of the 180-day exclusivity period brand of Teva. We also expect to launch Actos, Actoplus Met and [indiscernible].
In Canada, our robust pipeline has produced 17 new product launches thus far in 2012, an unprecedented number for us, and we expect to sustain a similar level annually through at least 2015. Among our more significant second quarter launches were Crestor and
Tracleer.
In EMEA, constant currency third-party net sales for the quarter totaled $327 million which, as I mentioned earlier, represented a decline of about 3% year-over-year. Nearly 90% of these outcomes from existing products, with the remainder coming from new product introductions throughout the region which included Lipitor, Candesartan, Ibandronate, Lamivudine, which is our first generic ARV launched in Europe.
While existing product volume remained flat year-over-year, pricing was as expected, lower due to government action and ongoing competitive pressure. In this environment, we continue to manage our cost structure aggressively through vertical integration, repatriation of product and other measures taken to manage and reduce cost of goods sold.
In both Italy and Spain, we experienced double-digit constant currency sales growth year-over-year due to higher volumes on existing products and new product launches, which offset pricing impact. In addition to Italy and Spain, we saw some growth in smaller countries. And in Germany, our enhanced cost structure continue to allow us to compete in multiple tenders.
In our Asia-Pacific region, third-party net sales for the quarter totaled nearly $308 million and 9% constant currency increase. The primary driver of this growth was our ARV franchise. In Japan, higher volumes continue to offset price cuts that went into effect on April 1, and of which the market began adjusting during the first quarter.
Our third-party sales in Australia fell slightly as new product revenue and favorable volume and mix nearly offset the impact of price cuts of nearly 25% made in the second quarter by Australia Pharmaceutical Benefits Scheme and most significant agency's history [ph].
As for our Specialty business, our second quarter performance was very strong. Sales rose 51% year-over-year to almost $200 million. Year-over-year sales for the first half of 2012 were up 58%.
Domestic sales of EpiPen Auto-Injector accounted for most of this increase, driven by unprecedented script to expansion and ongoing growth of the anaphylaxis marketplace. Performance sales also grew, and the product continues to do well in all 4 major channels: retail, home health care, hospitals and long-term care. The nebulized LABA market in the U.S. is expected to expand about 15% this year and 10% in 2013. We expect our growth to continue to outpace the market. We also were pleased to announce in May that we had entered into settlement agreements with Sanofi and concerning their Pravana [ph] products.
Moving on to our other strategic growth drivers, we continue to believe we are well positioned to benefit from ongoing measures being taken to boost generic utilization. In the last year, utilization has increased in several European countries such as France, Italy, Spain, Portugal and Belgium, as governments modify reimbursement practices. Recently in France, for instance, when a consumer wants to buy a certain brand of product, he must pay for them out of pocket and then get reimbursed, whereas if he's willing to accept the generic alternative, he will pay nothing.
In addition, Japan continues to represent a significant opportunity. Over the last 12 months, Japan has experienced growth in generic utilization, which now stands at about 24%.
As for our global Institutional business, we continue to invest in research and development and an additional capacity, which will allow us to increase the vertical integration of this business and support the future double-digit sales growth we expect. In addition, year-to-date in the U.S., we have received approvals on 5 injectable products, and we launched several products throughout the rest of the world.
Moving on to our ARV franchise. We continue to strengthen our position as the market leader with our new and innovative dosage forms, and our portfolio now contains 43 products. Currently, approximately 1/3 of all HIV patients being treated in the developing world for the disease rely on a Mylan product.
With respect to geographic expansion, we look forward this summer to launching our commercial business in India. And initially, we'll concentrate on certain therapeutic categories, starting with our ARV portfolio. We also are pleased with progress we are making in our export markets, and we are on track this year to file 150 dossiers in countries around the globe.
Portfolio diversity continues to be an important driver of our business. Year-to-date, we've launched about 300 products, and we're on track to launch approximately 350 more by year end. As we have continued to diversify, today we offer a wide variety of dosage forms, with oral solids making up only about 57% of our portfolio. Examples of other forms include injectables, ophthalmic, patches, soft gel caps, dermatologics, respiratory and liquids.
In neurology, earlier this year, lower courts ruled against us in the U.S. and U.K., respectively on Copaxone, and we intend to appeal those decisions. We remain confident in our application and expect to receive FDA approval before we have the ability to launch our product, given the anticipated length of the appeals process.
Turning to our respiratory franchise. We continue to be on track and expect to launch generic Advair in 2015 in Europe and in 2016 in the U.S. We also continue to invest in internal respiratory capabilities in Ireland. In addition, the development of our COPD combination product remains on track.
As for biogenerics, our product development remains on track, and we look forward to commercializing affordable products globally. 
Finally, earlier this month, we applauded the signing of the Food and Drug Administration Safety and Innovation Act, FDASIA,  which received near-unanimous bipartisan support in Congress. Mylan has long been a passionate leader and an advocate for many pieces of the legislation, which updates the 1938 law governing FDA to help protect the health and safety of consumers by requiring that all facilities that supply product in the U.S., regardless of where they're located, be routinely inspected by the agency and have the one quality standard. Through the landmark Generic Drug User Fee program, the new law also will help expedite approvals of generic drugs by reducing review times of ANDA from 31 months to 10 months over the next 5 years.
I'll now turn the call over to John to discuss this quarter's results in more detail, and I look forward to responding to your questions."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris's comment at the beginning of today'",2098,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris's comment at the beginning of today's call regarding our use of adjusted measures.
I am pleased with our results for the second quarter of 2012, which are in line with our expectations. As you'll recall, in early May, we increased and narrowed our adjusted diluted EPS guidance range for 2012 from $2.30 to $2.50 per share to a range of $2.45 to $2.55 per share. With the exception of our fully diluted share count, which I'll speak about in a few minutes, our other guidance metrics remains unchanged, and I'll walk through each of them today.
Our Q2 results reflect double-digit growth on the top line and bottom line, excluding the effects of foreign currency, and were achieved while continuing to invest in new product development and sales and marketing programs, both of which also grew by double digits.
As Heather discussed previously, our ability to continually introduce new products, in particular this quarter Doryx in the U.S., Lipitor worldwide, has served to mitigate some of the challenges of the macroeconomic environment in Europe, as well as government-mandated price reductions, which took place in Japan and Australia earlier in the year. We continue to manage against these macroeconomic headwinds and remain poised to achieve our forecasted full year result while also fully absorbing their impact.
Getting into the details, let me now walk you through our financial results for the second quarter and first half of 2012. I'll also provide an update on our capital structure and liquidity position. Starting at the top of our income statement, total adjusted revenues for the quarter were approximately $1.7 billion, an increase of 7% over last year's second quarter revenues of approximately $1.6 billion. Year-over-year, third-party net revenue growth on a constant currency basis was approximately 12%. The 5% unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to many of the other functional currencies of our major operations but mainly in Europe and India.
For the first half of 2012, total adjusted revenues were approximately $3.3 billion, an increase of 8% over revenues from the first half of 2011 or 12% on a constant currency basis. As a reminder, our guidance range for total revenues for the full year 2012 is between $6.8 billion and $7.2 billion.
Recognizing current exchange rates and using them to forecast the remainder of the year, we expect to be near the low end of this revenue range as the impact of changes in foreign exchange rates is estimated to have an unfavorable impact approaching $200 million.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 second quarter was a very strong 48.5%, a 30 basis point increase over the same prior year period. This increase was driven by favorable volume and pricing on our EpiPen Auto-Injector and by new product launches, partially offset by lower margins on existing products.
The current quarter also saw margin improvement in Asia Pacific. Sales and gross profit from Mylan Laboratories Limited, our Indian subsidiary, benefited from the effects of a stronger dollar as compared to the rupee, as a significant portion of its sales are denominated in U.S. dollars.
For the 6 months ended June 30, 2012, adjusted gross margins were 48.3% as compared to 47.7% in the prior year. Our guidance range for adjusted gross margin is 48% to 50%. We currently expect our gross margin in the second half of 2012 could potentially be above or at the upper end of our guidance range and as a result, our full year gross margin to be at the upper end of our guidance range.
Adjusted operating income was $398 million for the second quarter of 2012, a 4% increase from a very strong Q2 2011 and up 8% from the first quarter of 2012. This increase, which is primarily the result of the favorable gross profit that I just discussed, was realized in spite of R&D expense for the -- was realized in spite of increased levels of spending on R&D and SG&A.
R&D expense for the quarter, on an adjusted basis, was $93 million or approximately 5.5% of total revenues and up approximately 29% from the prior year and 39% on a constant currency basis. This increase was realized mainly as a result of ongoing clinical studies with respect to our respiratory and biologics programs.
At the same time, SG&A, also on an adjusted basis, was $328 million for the quarter or approximately 19.4% of total revenues, and up approximately 9% over the prior year or 13% on a constant currency basis. The increase in SG&A in the current quarter is due in large part to increased sales and marketing in our Specialty franchise, in particular for the EpiPen Auto-Injector, which has resulted in the overall growth of the anaphylaxis market.
For the 6-month period, adjusted R&D expense was $173 million, up 17% over the prior year. As a percentage of revenues, R&D expense to date for 2012 is 5.3%. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues. We expect R&D spending to continue to increase throughout the rest of the year, primarily related to our biologic and respiratory platforms, and we continue to believe that the full year spend will be within our guidance range.
SG&A expense, on an adjusted basis, for the 6 months ended June 30, 2012, was $640 million, an increase of nearly 13% and within our full year guidance range of 18% to 20% of total revenues, albeit at the high end as a result of the increased sales and marketing spend.
Adjusted EBITDA was $448 million and $859 million for the 3 and 6 months ended June 30, 2012, respectively, and remains forecasted to be between $1.75 billion and $1.95 billion for the full year.
I'd like to briefly discuss a few of the one-off items that are being excluded from our adjusted results this quarter. In April, we entered into a new 5-year collective bargaining agreement with our production employees in Morgantown, West Virginia. In conjunction with this new agreement, we incurred approximately $15 million of cost including amounts associated with our planned withdrawal from a multiemployer defined benefit pension plan. Second, we incurred approximately $14 million of restructuring cost principally associated with the planned closure of our manufacturing facility in Napa, California. This amount relates principally to severance and related benefits.
And finally, in accordance with applicable accounting guidance, we incurred a noncash charge of approximately $16 million, which represented an increase to our contingent consideration liability with respect to our acquisition of Pfizer's respiratory platform. Approximately half of this amount relates to the accretion of a liability to its undiscounted value, which would occur each quarter.
Moving on to our consolidated, nonoperating financial metrics. Adjusted interest expense for the second quarter of 2012 was $61 million. As of June 30, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70-30 fixed floating debt portfolio, which we believe is an optimal ratio. During Q2, we entered into forward starting derivative financial instruments to extend to 2016 the period over which we will maintain our 70-30 fixed floating ratio of our debt portfolio, as well as our average effective interest rate.
Adjusted interest expense for the 6-month period was $122 million, and is forecasted to be between $245 million and $265 million for the full year. The effective tax rate in the current quarter was 26% compared to 27% a year ago. Our full year 2012 tax rate range is between 26% and 27%, and we continue to believe that this rate will be sustainable at this level going forward.
Second quarter adjusted net income was $254 million, or $0.60 per share, a 15% increase from our Q2 2011 adjusted diluted EPS of $0.52 per share. For the 6 months, adjusted net income was $478 million or $1.12 per share, a 17% increase over the same prior year period.
As I mentioned previously, our guidance range for diluted EPS is now $2.45 to $2.55 per share. During the quarter, we completed a $500 million share repurchase program under which we repurchased 23.4 million shares at an average cost of $21.36 per share. The impact of this share repurchase program is included in our calculation of adjusted diluted earnings per share on a weighted basis and now to approximately $0.01 for the current quarter. Our revised estimate of diluted shares for the full year is approximately 420 million shares.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis, which takes into account the special items which are outlined in our press release and which I discussed in detail in our first quarter earnings call, was approximately $282 million for the quarter and $349 million for the year-to-date period. In addition, the cash paid to settle previously accrued litigation, which is excluded from adjusted cash from operations, we have also excluded cash received during the quarter with respect to the settlement of a patent litigation matter.
Also during the quarter, Mylan and Sunovion settled outstanding litigation with respect to Sunovion's Xopenex product. As a result of this settlement, Mylan is licensed to continue sales of its concentrate product and will have a loyalty bearing license to sell its non-concentrate  product upon receiving final FDA approval from the U.S. FDA. The settlement also releases Mylan from payment of the $18 million in damages that has been awarded by a jury earlier this year. The net penal impact of these items, as well as a few miscellaneous other litigation matters, was an income of $12.2 million for the quarter, all of which is excluded from our adjusted earnings.
Our GAAP cash flow from operations for the current quarter and year-to-date period was a very strong cash inflow of $302 million and $193 million, respectively, and leaving us with unrestricted cash and marketable securities totaling approximately $347 million at June 30, 2012. We are still forecasting our full year 2012 adjusted operating cash flow to be within our guidance range of $900 million to $1 billion, driven by increased second half earnings, as well as increased cash receipts from accounts receivable related to our significant recent product launches.
Second quarter capital spending was $61 million, bringing the total for the year-to-date to nearly $100 million. And as a result of the timing of planned capital expenditures, we expect full year capital expenditures to be within our guidance range of $300 million to $400 million. In addition to capital expenditures, approximately $70 million was spent during the first half of 2012 to acquire product rights and licenses.
During the current quarter, we borrowed $365 million under our revolving credit facility. This, along with cash on hand and through cash received through our -- from our accounts receivable securitization facility, was used to fund the share repurchase program, which I previously discussed. In July 2012, the size of the accounts receivable securitization facility was increased to $400 million.
Even with the additional borrowings under the revolver and the AR facility, we continue to have a significant financial flexibility. Our leverage ratio at June 30, 2012, as a result of the additional borrowings was 3.09 to 1, which is slightly above our long-term target of 3 to 1. However, we expect to be back below 3 to 1 by December 31, 2012. As such, we will continue to revaluate the uses of free cash flow for transactions based on the parameters, which we've outlined to you in the past.
Additionally, I am pleased that in May, Mylan's credit rating was upgraded by Moody's to Ba1 from Ba2. And following this action, Moody's rating outlook is stable. This change is reflective of Mylan's track record of meeting our prior stated commitments, as well as our solid position within the global generic industry, in particular, our strong geographic diversification and robust product pipeline.
To summarize, our second quarter, much like our first, was strong and in line with what we had anticipated. This positions us well heading into what will be an exciting second half of the year, culminating in what should be our strongest year yet.
That concludes my remarks. I will turn the call over to the operator for Q&A. Beverly?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Your first question comes from the line of David Risinger of Morgan Stanley.",15,"[Operator Instructions] Your first question comes from the line of David Risinger of Morgan Stanley."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","My question is, can you just talk a little bit about that improvement in performance? Obviously, you're going into a little bit easier comps because of the declines in 2011, but if you could speak to how we should think about the prospects for constant cu",80,"My question is, can you just talk a little bit about that improvement in performance? Obviously, you're going into a little bit easier comps because of the declines in 2011, but if you could speak to how we should think about the prospects for constant currency performance in EMEA going forward. And then second, obviously, there was a big hit to prices in Australia, but your Asian business performed well. Could you talk about that outlook on a go-forward basis?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. David, so I'll start with Europe. Look, I think that -- I want to be careful about not talking about this quarter as a trend yet in Europe, but I will say this. We certainly are getting positive indicators. And starting with France, our, as you know",471,"Sure. David, so I'll start with Europe. Look, I think that -- I want to be careful about not talking about this quarter as a trend yet in Europe, but I will say this. We certainly are getting positive indicators. And starting with France, our, as you know, largest market, we continue to see them take initiatives, increased utilization. We see those starting to take hold. We see volumes holding. So that ability of perhaps turning the quarter, maybe throughout the rest of this year, we will see a trend. But what I can tell you, we have our arms around what we can control, our cost of goods structure, our continual repatriation and vertical integration has benefited us. And that said in the past, once that market started to turn around, we -- certainly, we get our disproportionate share because of what we've been doing during these headwinds. Italy and Spain continue to be -- show a lot of growth, especially in volume. So while there continues to be austerity measures and price impact, we see that volume in our product mix and our ability to continue to grow those markets as very promising. So I think when you look overall of where there's still see -- or where we still see opportunity as the utilization being a much better offset the cost containment than just slashing prices. And as -- when you look at some of the other European countries that are much more mature, like the U.K., there is not that opportunity for utilization. They are pretty mature markets, so thus to maintain in some of those areas is very different than some of the growth opportunities we see for our strong holders. And then let's turn to the Asia Pacific. Yes, Australia continue to see price pressure as one of the most significant to date with the 25%. I will tell you, we continuously have them since 2008 when I believe they took the first big hit on pricing to rightsize that organization to remain very nimble and agile and be able to adapt to the changing environment. We've continued to invest in our R&D and product launches and cost of goods structure, which we'll continue to do, which has helped us hold and offset that price cut. As you mentioned, Japan had a nice increase. And again, we see opportunity. We see utilization for that country at about 24%. As you know the government has talked about getting that up to at least 30% here in the very near term, so again, continuing to capture some of that growth. And as I mentioned, our world driver being our ARV franchise out of our India subsidiary. And that continues to grow nicely, and we continue to be a very competitive market leader around tenders throughout the world."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes of the line of Gary Nachman with Susquehanna Financial.",13,"Your next question comes of the line of Gary Nachman with Susquehanna Financial."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","In terms of the contribution from new products in North America, the $240 million, can you quantify roughly how much of that was Doryx? What were the other big contributors? And those will probably drop off, but should we still see sequential growth in No",56,"In terms of the contribution from new products in North America, the $240 million, can you quantify roughly how much of that was Doryx? What were the other big contributors? And those will probably drop off, but should we still see sequential growth in North America for the rest of the year from other new products?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, I think, Gary, as you know, we don't break out our revenue from products individually. We were very pleased with the launches that we had in the second quarter, and we do have a very strong quarter. We do have a very strong quarter coming up here in",77,"Well, I think, Gary, as you know, we don't break out our revenue from products individually. We were very pleased with the launches that we had in the second quarter, and we do have a very strong quarter. We do have a very strong quarter coming up here in the third quarter for North America. So I think that it will be a very robust year for North America overall, including the second half of the year."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And then maybe for Heather, how is the DTC been going for EpiPen? Have you been able to measure the effect on this and the campaign in terms of drawing in new patients and also growing the market? Just some qualitative metrics around that.",45,"Okay. And then maybe for Heather, how is the DTC been going for EpiPen? Have you been able to measure the effect on this and the campaign in terms of drawing in new patients and also growing the market? Just some qualitative metrics around that."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So we've been very focused. As I mentioned in my remarks, it's actually growing the anaphylaxis market. So really just at the moment with us being the only epinephrine auto-injector on the market at this time, we've really been able to focus on education",172,"So we've been very focused. As I mentioned in my remarks, it's actually growing the anaphylaxis market. So really just at the moment with us being the only epinephrine auto-injector on the market at this time, we've really been able to focus on education around anaphylaxis. So we have seen, as you've seen in these results, we've seen a great response to that. And we obviously look at Q3 to be one of the best ever for EpiPen as we continue to know that it's a very -- it's at the moment still very seasonal with back to school. We see Q3 always historically by being larger, but what we've seen with the script trend and expansion is that peak is starting earlier, lasting longer. So we certainly have seen a benefit and obviously, now with the runway absolutely clear for us through 2015, through our settlement with Teva, I can assure you, we are going to continue as we see those response continue to invest in EpiPen as a franchise."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Frank Pinkerton with SunTrust.",12,"Your next question comes from the line of Frank Pinkerton with SunTrust."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Just first one, can you give us any details on your confidence in the comments you made earlier about the timing for the Copaxone FDA approval?",26,"Just first one, can you give us any details on your confidence in the comments you made earlier about the timing for the Copaxone FDA approval?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Yes, we remain absolutely confident on our regulatory pathway and our ability to receive an approval. As you know, the -- how Hatch-Waxman works, our ability to get an approval prior to the appeals process is not possible. So we are very focused on still",68,"Yes, we remain absolutely confident on our regulatory pathway and our ability to receive an approval. As you know, the -- how Hatch-Waxman works, our ability to get an approval prior to the appeals process is not possible. So we are very focused on still receiving our regulatory approval and absolutely, as I mentioned in my comments, believe that we'll get that prior to the appeals process ending."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay, great. And then maybe a little broader question. In Europe, and I don't want to talk about your business, but can you make comments on other competitors there? What are you seeing out of the regional players, some of the smaller players? Is consolid",64,"Okay, great. And then maybe a little broader question. In Europe, and I don't want to talk about your business, but can you make comments on other competitors there? What are you seeing out of the regional players, some of the smaller players? Is consolidation happening from a standpoint of taking capacity out kind of outside of the top 10 players in that market?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, as we've said before, it's really tough to talk about Europe where it gets one country and one market. I mean, we -- you've got many, many markets, many different regions, many different dynamics. What I would say is as we do participate in many of",191,"Well, as we've said before, it's really tough to talk about Europe where it gets one country and one market. I mean, we -- you've got many, many markets, many different regions, many different dynamics. What I would say is as we do participate in many of those markets throughout Europe, what we have continued to see is, yes, through some of these macroeconomic headwinds, we saw irrational behavior in some countries. We've stated that we always believe that those weren't sustainable business model, that our ability to continue to leverage our global platform very much made us unique throughout the European countries. And so our ability to weather the storm that Europe's been going through, and come out on the other side stronger with a much better cost of goods structure, but as in position to compete much better than any regional or local player that doesn't have the benefit of the global scale that the Mylan platform have. So I think that's the best way I can describe how we see Mylan fitting in for Europe overall, how Mylan would be very differentiated from a regional or local player."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Two things. First, on gross margin, you talked about how much of this is going to improve as the year progresses, how much of that is just the product mix and good products coming out of the U.S. versus what is more sustainable and I mean, relative to you",115,"Two things. First, on gross margin, you talked about how much of this is going to improve as the year progresses, how much of that is just the product mix and good products coming out of the U.S. versus what is more sustainable and I mean, relative to your comments about taking cost down in Europe, et cetera, et cetera, the gross margin line? And then secondly, are you doing anything in Europe to change the SG&A kind of cost structure because of all this austerity in the difficult markets over there? Because you've really talked about taking cost out of the gross margin line and you haven't talked about SG&A as far as Europe."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So Marc, with respect to the gross margin, certainly a portion of the margin increase in the second half of the year is the seasonality associated with our product mix. Certainly, the Specialty business, including EpiPen, has its strongest quarter of the",178,"So Marc, with respect to the gross margin, certainly a portion of the margin increase in the second half of the year is the seasonality associated with our product mix. Certainly, the Specialty business, including EpiPen, has its strongest quarter of the year in the third quarter, and that it will benefit us. We also have a very strong year for launches in North America, and new product launches, obviously, are beneficial. But aside from North America, as we talked about in the first quarter, we have been seeing through the cost-reduction efforts that we've been taking, whether it be the vertical integration, the repatriation efforts, we have been able to maintain and grow margins in Europe, and we've been able to also -- even with the price cuts that we've seen in Asian countries, been able to weather that with stable margins. So I think that it is a -- the strength of our gross margin is a combination between product mix, new products and then also managing aggressively the cost associated with our existing product portfolio."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Well, I guess, just before you answer the other questions, just on the gross margin. If you didn't have this massive increase in the number of U.S. products, which arguably you're not going to have as much next year versus this year, which is where I'm go",79,"Well, I guess, just before you answer the other questions, just on the gross margin. If you didn't have this massive increase in the number of U.S. products, which arguably you're not going to have as much next year versus this year, which is where I'm going with the question, what is the kind of the core gross margin? I mean, are we -- that 48% kind of becomes like kind of the baseline that we're thinking about now?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I think that we'll certainly provide more detailed guidance with respect to '13 when we get closer to that year. We did talk about that a bit in our Investor Day, and I think we are confident in our 48% to 50% gross margin range that we have as our curren",55,"I think that we'll certainly provide more detailed guidance with respect to '13 when we get closer to that year. We did talk about that a bit in our Investor Day, and I think we are confident in our 48% to 50% gross margin range that we have as our current guidance out there."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","And as far as your question about the rest of European cost, I guess, first I would say that the global scale doesn't just apply to the product side. Our global scale is pulling on sales excellence, marketing excellence, looking at really -- as these mark",125,"And as far as your question about the rest of European cost, I guess, first I would say that the global scale doesn't just apply to the product side. Our global scale is pulling on sales excellence, marketing excellence, looking at really -- as these markets continue to change and adapt, we're able to do so with along with them. So I would say, we have been able to take some restructuring in different countries and adapt in our sales model, and we continue to do so. So we are absolutely looking across the board at where that makes sense. And like I said, at the end of the day, our ability to really pull upon this global scale benefits us across the entire organization."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Have you cut any -- like of the sales force and staff, or how does that work?",17,"Have you cut any -- like of the sales force and staff, or how does that work?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","It depends. I mean, we have countries, take Belgium, who was a total branded generic marketplace, and they have been increasingly switching to an INN substitution. So our ability, obviously, to marry up with the dynamics of that market is important, and w",74,"It depends. I mean, we have countries, take Belgium, who was a total branded generic marketplace, and they have been increasingly switching to an INN substitution. So our ability, obviously, to marry up with the dynamics of that market is important, and we're able to do so. So I would say at the best we can be everything from sales, from marketing to sales reps to how we're selling the market into those countries."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes on the line of Elliot Wilbur of Needham & Company.",13,"Your next question comes on the line of Elliot Wilbur of Needham & Company."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","First question is for Heather. Heather, do you still believe that the generic version of Lidoderm is opportunity for the company in 2013? And if so, could you indicate whether or not you've included it as one of many potential probability adjusted product",49,"First question is for Heather. Heather, do you still believe that the generic version of Lidoderm is opportunity for the company in 2013? And if so, could you indicate whether or not you've included it as one of many potential probability adjusted products in your $2.75 per share guidance?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. I do absolutely believe that Lidoderm could be opportunity for us in the second half of '13. And I guess just to build upon that a little bit, because I know there's been a lot of discussion around Lidoderm, just for your recollection, the citizens",180,"Sure. I do absolutely believe that Lidoderm could be opportunity for us in the second half of '13. And I guess just to build upon that a little bit, because I know there's been a lot of discussion around Lidoderm, just for your recollection, the citizens petition, which has been discussed quite a bit, we filed back in 2006. After that citizens petition was filed, talking about -- Indo [ph] put forward their argument about bioequivalency and how the standards should be changed and what should be required, FDA issued guidance very clearly and have said about what they wanted to see with the Lidoderm patch in the ANDA. So all of that transpired before Watson filed their ANDA in 2009, and absolutely nothing has changed from FDA's perspective on guidance or requirement since that time. So the idea that the citizens petition is holding up the application to manage, it's just not really possible. So again, we look forward to our regulatory approval and still believe that to be a very viable option in the second half of '13."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Elliot, with respect to the second half of your question on whether Lidoderm is in our 2013 numbers or not, I guess what I would say to you is that we risk adjust all of our products and take into consideration that there could be a range of periods in wh",79,"Elliot, with respect to the second half of your question on whether Lidoderm is in our 2013 numbers or not, I guess what I would say to you is that we risk adjust all of our products and take into consideration that there could be a range of periods in when products are introduced and, therefore, without saying specifically whether Lidoderm is in there or not, I would just say that Lidoderm is risk-adjusted into our future business plan."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And I have additional question for probably you John as well. Could you just describe for us what, in terms of management and the Board's perspective on what is the most attractive use of the company's discretionary free cash flow at this point in t",105,"Okay. And I have additional question for probably you John as well. Could you just describe for us what, in terms of management and the Board's perspective on what is the most attractive use of the company's discretionary free cash flow at this point in time. I mean assuming you have a range of options between paying down debt, buying back shares or something more strategic, you kind of have done a little bit of everything over the past couple of years, I'm just kind of wondering what your current thinking is in terms of what's the best use of cash for enhancing shareholder returns?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Look, I'll -- I guess not being a member of the Board of Directors I'm not sure I want to speak on behalf of the Board of Directors, but I think we laid out on Investor Day earlier this year the parameters for how we would evaluate transactions. And I thi",132,"Look, I'll -- I guess not being a member of the Board of Directors I'm not sure I want to speak on behalf of the Board of Directors, but I think we laid out on Investor Day earlier this year the parameters for how we would evaluate transactions. And I think those parameters continue to exist. In May, we believe that executing on a share repurchase program was the best and most appropriate use of the capital we had available to us at that time. And so we execute on that, and we were very pleased with the execution. On a going-forward basis, we'll continue to evaluate opportunities that are available for transactions in the marketplace, again, using the parameters we outlined, and we'll also evaluate the appropriateness of share repurchase program."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","And I would just add, as you might imagine, Robert and the Board are extremely involved at looking at everything and constantly looking at all of our options.",28,"And I would just add, as you might imagine, Robert and the Board are extremely involved at looking at everything and constantly looking at all of our options."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Ronny Gal of Sanford Bernstein.",13,"Your next question comes from the line of Ronny Gal of Sanford Bernstein."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I have two. First, regarding EpiPen, you kind of look at the ACA and its potential implications and you just wonder if EpiPen is not one of the products that is likely to have a disproportionately higher growth from ACA. I was wondering if you guys have d",136,"I have two. First, regarding EpiPen, you kind of look at the ACA and its potential implications and you just wonder if EpiPen is not one of the products that is likely to have a disproportionately higher growth from ACA. I was wondering if you guys have done any work to look at that tailwind that the ACA provide to EpiPen? And second, you kind of mentioned you're building injectable capacity and obviously, this is a good time to bring injectable capacity online. I was wondering if you kind of look at your current build map, when do you think you'll have more capacity, I mean, minimal step-up in capacity around the injectable. I think would you be able to get in the same cycle before some other competitors are able to bring their capacity backup?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Let me start with your second question because I'm not sure I clearly understood your EpiPen question, and so I'll come back to that. But quickly on your ask about our capacity build, as we've announced earlier this year, we are continuing to invest in ou",141,"Let me start with your second question because I'm not sure I clearly understood your EpiPen question, and so I'll come back to that. But quickly on your ask about our capacity build, as we've announced earlier this year, we are continuing to invest in our injectable capacity in Ireland, as well as other areas around the globe. We certainly agree that it's our continual ability to vertically integrate on the injectable front and bring more and more of that into the Mylan global supply chain. It's certainly a benefit to us. So it absolutely is part of our footprint for expansion and capacity building this year as well as into the future. As far as EpiPen, it wasn't clear or you didn't come across clear of what you were asking me. I believe you used some initials of ACA."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I mean the health care reform act, okay, essentially have -- through the expansion of Medicaid and the [indiscernible] exchanges. A lot more people will be covered and those would be young adults or people that are -- that might have not -- that might be",72,"I mean the health care reform act, okay, essentially have -- through the expansion of Medicaid and the [indiscernible] exchanges. A lot more people will be covered and those would be young adults or people that are -- that might have not -- that might be using EpiPen more than the general population. Now I was wondering if you did any announcements toward the effect of the health care reform on EpiPen."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Okay, I think maybe what you're speaking of ACO. But in any event, we absolutely do not. As you may be aware or not aware, most programs allow for a patient to be reimbursed for 2 EpiPens per year. And that's usually a general rule of thumb across all pro",87,"Okay, I think maybe what you're speaking of ACO. But in any event, we absolutely do not. As you may be aware or not aware, most programs allow for a patient to be reimbursed for 2 EpiPens per year. And that's usually a general rule of thumb across all programs whether government or private sector where people are carrying more EpiPens or typically paying out of pocket or get a waiver from their insurance companies. So certainly nothing in the current health care law changes those dynamics."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Ken Cacciatore with Cowen and Company.",14,"Your next question comes from the line of Ken Cacciatore with Cowen and Company."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","My question is looking out to mid-2015. I would think as the management team, you have to look at that EpiPen settlement and clearly have a potential worst-case model or worst-case scenario, although many good things could happen and maybe discount out so",124,"My question is looking out to mid-2015. I would think as the management team, you have to look at that EpiPen settlement and clearly have a potential worst-case model or worst-case scenario, although many good things could happen and maybe discount out some of the other potential positives. So I was wondering, in terms of capital deployment and knowing how long the integration for Merck took, as you're looking at potential acquisitions or other diversification, what should we be thinking in terms of timing? And John, you talked about not wanting to talk about parameters, but maybe you could just walk us through very briefly some of the parameters of assets or that the asset acquisitions that you gave at the analyst meeting?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So Ken, as far as a long-term visibility you're looking for, I think starting what we've been doing since 2008 is continuing to give that long-term visibility. And hopefully, with people have been able to start gaining confidence in our ability to b",380,"Sure. So Ken, as far as a long-term visibility you're looking for, I think starting what we've been doing since 2008 is continuing to give that long-term visibility. And hopefully, with people have been able to start gaining confidence in our ability to be not only laying out guidance and potential targets but our ability to meet or exceed them. So I think as we came out Investor Day with a whole assortment of opportunities that are drivers for 2013 and beyond because, as you mentioned, we need to work today on those things. So whether it's EpiPen, yes, there's a possibility there could be an AB-rated. While I remain fairly confident that, that's going to be a high hurdle, we have many, many other opportunities. I mean, when we talk about biologics, Advair, Copaxone, all definitely coming after that 2015 time period, not to mention our continuous voluminous amount of launches across the board. That's why today in my remarks, I tried to lay out not only what the platform is generating but with all the different strategic drivers that we discussed that all give benefits. So you don't have to rely on all of them hitting obviously just a couple of them hitting certainly put at great growth to Mylan from this point going forward. And I guess the other thing I'd say on your comment about integration, I could say that our Merck acquisition certainly is in a hemisphere all by itself. When you buy a company 2.5x your size and do a transformational acquisition as we did, certainly that integration, I think took a couple of 3 years that we certainly were able and continue to show every step along the way our ability to realize those synergies. I think when you look at acquisitions outside of that, we've certainly stated we're not doing a large 2.5x our size transformative acquisition. So things like Bioniche respiratory franchise from Pfizer, we've continued to be able to bolt and tuck those in without ever even mentioning integration or missing a beat because I think the platform we have in place today is scalable and sustainable and is able to absorb these kind of acquisitions very, very easily. So there's not a long-term planning period for any of those."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I know never say never, but should we be thinking along the lines of Bioniche going forward, or could we see something more sizable?",24,"I know never say never, but should we be thinking along the lines of Bioniche going forward, or could we see something more sizable?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I mean, I think we've been clear, and I'll let John speak about that. We have a whole range of opportunities and potential from sizing perspective in our continued strengthening our financial flexibility. So all I'm saying is that everything and these typ",55,"I mean, I think we've been clear, and I'll let John speak about that. We have a whole range of opportunities and potential from sizing perspective in our continued strengthening our financial flexibility. So all I'm saying is that everything and these types of acquisitions are certainly nothing compared to what the Merck integration required."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Right. Remember, Ken, that at Investor Day we indicated that we were committed to a long-term debt to EBITDA ratio of 3:1 that we would not go above that which is permitted under credit facility of 4.25:1. And that we would look at the transactions that e",74,"Right. Remember, Ken, that at Investor Day we indicated that we were committed to a long-term debt to EBITDA ratio of 3:1 that we would not go above that which is permitted under credit facility of 4.25:1. And that we would look at the transactions that expanded our portfolio or geographically into areas that we're not in or other shareholder value accretion transactions such as share repurchases that you saw too earlier this year."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes of the line of Shibani Malhotra of RBC.",12,"Your next question comes of the line of Shibani Malhotra of RBC."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I'm just going to follow on from Ken's questions, but just in terms of looking at the Merck portfolio and the acquisitions you've done, Heather, can you just talk us through in terms of the synergies? I mean, should we assume that these have already been",154,"I'm just going to follow on from Ken's questions, but just in terms of looking at the Merck portfolio and the acquisitions you've done, Heather, can you just talk us through in terms of the synergies? I mean, should we assume that these have already been realized, or is there more to go? And then can you talk from the pipeline's standpoint, branded -- sorry, in terms of the filings you were expecting to get approved in Europe and also the kind of new Paragraph IV filings that you are thinking about, how much room is there for new products that we haven't heard of as yet and where we are -- where we are rather, on that? And then just specifically, on the M&A, can you talk about the kind of areas that we're looking at, I mean whether they're branded or generic, and what sort of disease areas you're looking at?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Let me start I guess on the portfolio aspect of your question. Just throughout the rest of this year, we're on track to launch another -- over 300 products throughout the world. We don't speak specifically before launches in Europe as you know. There's so",431,"Let me start I guess on the portfolio aspect of your question. Just throughout the rest of this year, we're on track to launch another -- over 300 products throughout the world. We don't speak specifically before launches in Europe as you know. There's some competitive advantage, and it's not the same system that gives the same visibility, like here in the United States with Paragraph IV. But I can tell you, we've had very successful launches already this year, as I spoke about Atorvastatin and Candesartan and then Ibandronate. And like I said, we continue to have many more. Our total R&D portfolio and filings, we look to be doubling our size by 2015. So I mean, that should give you a sense of the amount of products that we have in the pipeline or already filed with regulatory agencies around the world of what we're going to be launching over the next couple of years. As far as Paragraph IV goes, I mean, certainly, we have been showing, like we did back in Investor Day, the state certain launches that we already know of or our first-to-file, share to file opportunities, 2012 was one of our largest years as far as the states certain so far been, but we continue to already be -- have settlements that go out through '13, '14, '15 of date certain. We continue to get our share of first-to-file opportunities. So I would just say that we continue to maximize and leverage our platform on all of the fronts that we have in the past. Difficult-to-formulate products, the Paragraph IV opportunity and, like I said, just a voluminous amount of dosage forms. And we are investing in everything from injectables, as I mentioned earlier, to our patches, at oral, solid dose soft gels, dermatologicals. So as far as from an M&A, when you think about -- we really have a lot of opportunity to complement this platform across the globe, from our Specialty division to continue to complement our infrastructure and disease state expertise in respiratory and allergy. You look at our Biologics partnerships and our ability to continue to leverage and build upon that, as well as therapeutic categories that we're not in yet. So we see an opportunity to still bid our U.S. generics business with things like whether it would be antibiotics or dermatological things that we're not as large in today. So across the board, I would say, we have many opportunities to continue to fuel the engine that we've put together across all of the fronts I just mentioned."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your final question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your final question comes from the line of Jami Rubin with Goldman Sachs."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","John, just a follow-up on some of the earlier questions regarding uses of cash and share repurchase, can the company expand its share repurchase program without violating your debt covenants? And we're calculating that you have about another $400 million",60,"John, just a follow-up on some of the earlier questions regarding uses of cash and share repurchase, can the company expand its share repurchase program without violating your debt covenants? And we're calculating that you have about another $400 million to $500 million in share repurchase potential that you could do right now, can you confirm that, that is correct?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","There are restrictions and under our bank facilities and borrowing facilities, with respect to our ability to do additional share repurchase programs. At the current time, our Board of Directors has not approved any other share repurchase programs. And qu",59,"There are restrictions and under our bank facilities and borrowing facilities, with respect to our ability to do additional share repurchase programs. At the current time, our Board of Directors has not approved any other share repurchase programs. And quite honestly, I'm not in the position to confirm the $400 million to $500 million capacity at the current time."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","But with the exception of the Board approving a buyback program, do your -- with your covenants, just given your cash flow generation, would your covenants allow you to announce a further share buyback program now?",36,"But with the exception of the Board approving a buyback program, do your -- with your covenants, just given your cash flow generation, would your covenants allow you to announce a further share buyback program now?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I don't think that our covenants would allow us to announce a share repurchase program currently of the size that you were suggesting, no.",25,"I don't think that our covenants would allow us to announce a share repurchase program currently of the size that you were suggesting, no."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And just as a follow-up, EpiPen obviously performed very well this quarter, but we just noticed, in terms of IMS prescription trends during the month of June, demand for Epi dropped pretty considerably compared to the previous months. Just wondering",62,"Okay. And just as a follow-up, EpiPen obviously performed very well this quarter, but we just noticed, in terms of IMS prescription trends during the month of June, demand for Epi dropped pretty considerably compared to the previous months. Just wondering what's going on, what you're seeing, is this just a seasonal adjustment, and how we should think about it going forward?"
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, a couple of things. I think you've heard me say before that I don't believe that EpiPen should be as a seasonal product as it's been historically. But we continue to educate people about obviously some of the unfortunate and unnecessary dove [ph] th",159,"Well, a couple of things. I think you've heard me say before that I don't believe that EpiPen should be as a seasonal product as it's been historically. But we continue to educate people about obviously some of the unfortunate and unnecessary dove [ph] that have taken place in restaurants and in schools have not been to things like these things that occur more in the springtime. So what I would say as we've seen, as you know, there's been a lot of reports of this allergy season started much earlier this yea since we had such a mild winter. I think that was a contributor to some of the strengths. But I would say, I also put a lot more weight on, like I said, just a pure expansion in education that's taken place in the market. And I continue to see hopefully more and more months becoming drivers short of what it's historically been just in Q3."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So operator, that will conclude our call, and we appreciate very much the support of everybody who participated.",18,"So operator, that will conclude our call, and we appreciate very much the support of everybody who participated."
290203,213782906,331980,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Thank you, everyone, for joining today's conference call. You may now disconnect.",12,"Thank you, everyone, for joining today's conference call. You may now disconnect."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's Second Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. East",78,"Welcome to Mylan's Second Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern Standard Time. The dial-in number is (800) 585-8367 or (404) 537-3406 for international callers, with pin number 94584310. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Beverly. Good morning, everyone. Welcome to Mylan's Second Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive V",490,"Thank you, Beverly. Good morning, everyone. Welcome to Mylan's Second Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making numerous forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often may be identified with the use of words such as may, will, could, should, would, project, believe, anticipate, expect, plan, estimate, guidance, trends, forecast, potential, intend, continue and variations of these words or comparable words.
Our forward-looking statements may today include, among others, statements related to anticipated business levels, trends in some European countries, planned launches of and anticipated exclusivity period for new products, our ability to achieve forecasted full year results while absorbing the impact of negative pricing pressures, expectations for capital expenditures, expectations for R&D, SG&A and other spending.
Our guidance range, future earnings, planned activities, anticipated growth and other expectations and targets for future periods, including our expectations regarding the third and fourth quarters for the 2012 overall. Because these statements are forward looking, they inherently involve risks and uncertainties and, accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the factors set forth under forward-looking statements in our recent earnings release dated July 26, 2012, as well as the risk factors set forth in our report on Form 10-Q for the period ended March 31, 2012, and in our other SEC filings. You can access our Form 10-Q and other SEC filings, including our earnings press release, which we filed on Form 8-K through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures such as adjusted revenue, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with Generally Accepted Accounting Principles or GAAP.
Please refer to today's earnings press release, which is available on our website, as well as on SEC website, as it contains detailed reconciliations of the non-GAAP financial measures we use for our second quarter results prepared in accordance with GAAP.
Before I turn the call over to Heather, let me also remind you that the materials in the call, with the exception of the participant questions, is a property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I will now turn the call over to Heather."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us. I would also like to welcome and recognize Mylan's employees around the world. Because of their dedication and hard work, we once again delivered very strong results. On behalf of",1590,"Thank you, Kris, and good morning, everyone, and thank you for joining us. I would also like to welcome and recognize Mylan's employees around the world. Because of their dedication and hard work, we once again delivered very strong results. On behalf of the Board of Directors and our entire management team, I would like to congratulate them on a job well done.
Mylan had an outstanding second quarter, delivering double-digit top line and bottom line year-over-year growth. Sales were about $1.7 billion, up 12% on a constant currency basis, and our adjusted diluted EPS increased 15% from the same prior year quarter to $0.60 a share. Building on our strong first quarter, this stellar performance supports our confidence that 2012 will be the best year-to-date in Mylan's history, with many more to come.
Among the second quarter's highlights were growth of more than 50% in our Specialty business, double-digit growth in North America and strong performance of our ARV franchise. Our performance this quarter was strong compared to last year's second quarter when we had several very significant product launches. Further, we delivered this growth while continuing to invest in our global platform through increased R&D and sales and marketing programs. In addition, our gross margin was up almost half a percentage point.
We also saw improvement in some European countries. Constant currency third-party net sales in our EMEA region were down about 3% year-over-year, a smaller decline than we've seen in recent quarters. EMEA's top line was essentially flat from Q1 to Q2 of this year. These results are yet another demonstration of our ability to manage our global platform for growth by optimizing new launches and seizing opportunities as we continue to build our base business and effectively manage pricing pressures. It's against this factor of that we look forward to the third quarter, which we project to be by far our strongest of the year, and a fourth quarter that is similar to or slightly higher than the second quarter. We are reaffirming our 2012 adjusted EPS guidance of $2.45 to $2.55 per share, as well as our 2013 target of $2.75.
Earlier this year, when we hosted our Investor Day, we outlined Mylan's strategic growth drivers. I'd like to walk you through several of them now and comment on results achieved or progress made during the second quarter. Our core growth driver is our global operating platform, which we continue to leverage this quarter. In our North America generics business, third-party net sales for the quarter were $845 million, up 13% from the comparable year ago period. More than 70% of these sales come from existing products, with the remainder coming from multiple new launches.
In the U.S., drivers in the quarter included Escitalopram, Doryx and Abacavir, which is enjoying 180 days of exclusivity. We also look forward to important launches throughout the rest of the year, including Modafinil. For our settlement with Teva, we may launch our product on August 10, which is prior to the expiration of the 180-day exclusivity period brand of Teva. We also expect to launch Actos, Actoplus Met and [indiscernible].
In Canada, our robust pipeline has produced 17 new product launches thus far in 2012, an unprecedented number for us, and we expect to sustain a similar level annually through at least 2015. Among our more significant second quarter launches were Crestor and
Tracleer.
In EMEA, constant currency third-party net sales for the quarter totaled $327 million which, as I mentioned earlier, represented a decline of about 3% year-over-year. Nearly 90% of these outcomes from existing products, with the remainder coming from new product introductions throughout the region which included Lipitor, Candesartan, Ibandronate, Lamivudine, which is our first generic ARV launched in Europe.
While existing product volume remained flat year-over-year, pricing was as expected, lower due to government action and ongoing competitive pressure. In this environment, we continue to manage our cost structure aggressively through vertical integration, repatriation of product and other measures taken to manage and reduce cost of goods sold.
In both Italy and Spain, we experienced double-digit constant currency sales growth year-over-year due to higher volumes on existing products and new product launches, which offset pricing impact. In addition to Italy and Spain, we saw some growth in smaller countries. And in Germany, our enhanced cost structure continue to allow us to compete in multiple tenders.
In our Asia-Pacific region, third-party net sales for the quarter totaled nearly $308 million and 9% constant currency increase. The primary driver of this growth was our ARV franchise. In Japan, higher volumes continue to offset price cuts that went into effect on April 1, and of which the market began adjusting during the first quarter.
Our third-party sales in Australia fell slightly as new product revenue and favorable volume and mix nearly offset the impact of price cuts of nearly 25% made in the second quarter by Australia Pharmaceutical Benefits Scheme and most significant agency's history [ph].
As for our Specialty business, our second quarter performance was very strong. Sales rose 51% year-over-year to almost $200 million. Year-over-year sales for the first half of 2012 were up 58%.
Domestic sales of EpiPen Auto-Injector accounted for most of this increase, driven by unprecedented script to expansion and ongoing growth of the anaphylaxis marketplace. Performance sales also grew, and the product continues to do well in all 4 major channels: retail, home health care, hospitals and long-term care. The nebulized LABA market in the U.S. is expected to expand about 15% this year and 10% in 2013. We expect our growth to continue to outpace the market. We also were pleased to announce in May that we had entered into settlement agreements with Sanofi and concerning their Brovana products.
Moving on to our other strategic growth drivers, we continue to believe we are well positioned to benefit from ongoing measures being taken to boost generic utilization. In the last year, utilization has increased in several European countries such as France, Italy, Spain, Portugal and Belgium, as governments modify reimbursement practices. Recently in France, for instance, when a consumer wants to buy a certain brand of product, he must pay for them out of pocket and then get reimbursed, whereas if he's willing to accept the generic alternative, he will pay nothing.
In addition, Japan continues to represent a significant opportunity. Over the last 12 months, Japan has experienced growth in generic utilization, which now stands at about 24%.
As for our global Institutional business, we continue to invest in research and development and an additional capacity, which will allow us to increase the vertical integration of this business and support the future double-digit sales growth we expect. In addition, year-to-date in the U.S., we have received approvals on 5 injectable products, and we launched several products throughout the rest of the world.
Moving on to our ARV franchise. We continue to strengthen our position as the market leader with our new and innovative dosage forms, and our portfolio now contains 43 products. Currently, approximately 1/3 of all HIV patients being treated in the developing world for the disease rely on a Mylan product.
With respect to geographic expansion, we look forward this summer to launching our commercial business in India. And initially, we'll concentrate on certain therapeutic categories, starting with our ARV portfolio. We also are pleased with progress we are making in our export markets, and we are on track this year to file 150 dossiers in countries around the globe.
Portfolio diversity continues to be an important driver of our business. Year-to-date, we've launched about 300 products, and we're on track to launch approximately 350 more by year end. As we have continued to diversify, today we offer a wide variety of dosage forms, with oral solids making up only about 57% of our portfolio. Examples of other forms include injectables, ophthalmic, patches, soft gel caps, dermatologics, respiratory and liquids.
In neurology, earlier this year, lower courts ruled against us in the U.S. and U.K., respectively on Copaxone, and we intend to appeal those decisions. We remain confident in our application and expect to receive FDA approval before we have the ability to launch our product, given the anticipated length of the appeals process.
Turning to our respiratory franchise. We continue to be on track and expect to launch generic Advair in 2015 in Europe and in 2016 in the U.S. We also continue to invest in internal respiratory capabilities in Ireland. In addition, the development of our COPD combination product remains on track.
As for biogenerics, our product development remains on track, and we look forward to commercializing affordable products globally. 
Finally, earlier this month, we applauded the signing of the Food and Drug Administration Safety and Innovation Act, FDASIA,  which received near-unanimous bipartisan support in Congress. Mylan has long been a passionate leader and an advocate for many pieces of the legislation, which updates the 1938 law governing FDA to help protect the health and safety of consumers by requiring that all facilities that supply product in the U.S., regardless of where they're located, be routinely inspected by the agency and have the one quality standard. Through the landmark Generic Drug User Fee program, the new law also will help expedite approvals of generic drugs by reducing review times of ANDA from 31 months to 10 months over the next 5 years.
I'll now turn the call over to John to discuss this quarter's results in more detail, and I look forward to responding to your questions."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris's comment at the beginning of today'",2098,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris's comment at the beginning of today's call regarding our use of adjusted measures.
I am pleased with our results for the second quarter of 2012, which are in line with our expectations. As you'll recall, in early May, we increased and narrowed our adjusted diluted EPS guidance range for 2012 from $2.30 to $2.50 per share to a range of $2.45 to $2.55 per share. With the exception of our fully diluted share count, which I'll speak about in a few minutes, our other guidance metrics remains unchanged, and I'll walk through each of them today.
Our Q2 results reflect double-digit growth on the top line and bottom line, excluding the effects of foreign currency, and were achieved while continuing to invest in new product development and sales and marketing programs, both of which also grew by double digits.
As Heather discussed previously, our ability to continually introduce new products, in particular this quarter Doryx in the U.S., Lipitor worldwide, has served to mitigate some of the challenges of the macroeconomic environment in Europe, as well as government-mandated price reductions, which took place in Japan and Australia earlier in the year. We continue to manage against these macroeconomic headwinds and remain poised to achieve our forecasted full year result while also fully absorbing their impact.
Getting into the details, let me now walk you through our financial results for the second quarter and first half of 2012. I'll also provide an update on our capital structure and liquidity position. Starting at the top of our income statement, total adjusted revenues for the quarter were approximately $1.7 billion, an increase of 7% over last year's second quarter revenues of approximately $1.6 billion. Year-over-year, third-party net revenue growth on a constant currency basis was approximately 12%. The 5% unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to many of the other functional currencies of our major operations but mainly in Europe and India.
For the first half of 2012, total adjusted revenues were approximately $3.3 billion, an increase of 8% over revenues from the first half of 2011 or 12% on a constant currency basis. As a reminder, our guidance range for total revenues for the full year 2012 is between $6.8 billion and $7.2 billion.
Recognizing current exchange rates and using them to forecast the remainder of the year, we expect to be near the low end of this revenue range as the impact of changes in foreign exchange rates is estimated to have an unfavorable impact approaching $200 million.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 second quarter was a very strong 48.5%, a 30 basis point increase over the same prior year period. This increase was driven by favorable volume and pricing on our EpiPen Auto-Injector and by new product launches, partially offset by lower margins on existing products.
The current quarter also saw margin improvement in Asia Pacific. Sales and gross profit from Mylan Laboratories Limited, our Indian subsidiary, benefited from the effects of a stronger dollar as compared to the rupee, as a significant portion of its sales are denominated in U.S. dollars.
For the 6 months ended June 30, 2012, adjusted gross margins were 48.3% as compared to 47.7% in the prior year. Our guidance range for adjusted gross margin is 48% to 50%. We currently expect our gross margin in the second half of 2012 could potentially be above or at the upper end of our guidance range and as a result, our full year gross margin to be at the upper end of our guidance range.
Adjusted operating income was $398 million for the second quarter of 2012, a 4% increase from a very strong Q2 2011 and up 8% from the first quarter of 2012. This increase, which is primarily the result of the favorable gross profit that I just discussed, was realized in spite of R&D expense for the -- was realized in spite of increased levels of spending on R&D and SG&A.
R&D expense for the quarter, on an adjusted basis, was $93 million or approximately 5.5% of total revenues and up approximately 29% from the prior year and 39% on a constant currency basis. This increase was realized mainly as a result of ongoing clinical studies with respect to our respiratory and biologics programs.
At the same time, SG&A, also on an adjusted basis, was $328 million for the quarter or approximately 19.4% of total revenues, and up approximately 9% over the prior year or 13% on a constant currency basis. The increase in SG&A in the current quarter is due in large part to increased sales and marketing in our Specialty franchise, in particular for the EpiPen Auto-Injector, which has resulted in the overall growth of the anaphylaxis market.
For the 6-month period, adjusted R&D expense was $173 million, up 17% over the prior year. As a percentage of revenues, R&D expense to date for 2012 is 5.3%. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues. We expect R&D spending to continue to increase throughout the rest of the year, primarily related to our biologic and respiratory platforms, and we continue to believe that the full year spend will be within our guidance range.
SG&A expense, on an adjusted basis, for the 6 months ended June 30, 2012, was $640 million, an increase of nearly 13% and within our full year guidance range of 18% to 20% of total revenues, albeit at the high end as a result of the increased sales and marketing spend.
Adjusted EBITDA was $448 million and $859 million for the 3 and 6 months ended June 30, 2012, respectively, and remains forecasted to be between $1.75 billion and $1.95 billion for the full year.
I'd like to briefly discuss a few of the one-off items that are being excluded from our adjusted results this quarter. In April, we entered into a new 5-year collective bargaining agreement with our production employees in Morgantown, West Virginia. In conjunction with this new agreement, we incurred approximately $15 million of cost including amounts associated with our planned withdrawal from a multiemployer defined benefit pension plan. Second, we incurred approximately $14 million of restructuring cost principally associated with the planned closure of our manufacturing facility in Napa, California. This amount relates principally to severance and related benefits.
And finally, in accordance with applicable accounting guidance, we incurred a noncash charge of approximately $16 million, which represented an increase to our contingent consideration liability with respect to our acquisition of Pfizer's respiratory platform. Approximately half of this amount relates to the accretion of a liability to its undiscounted value, which would occur each quarter.
Moving on to our consolidated, nonoperating financial metrics. Adjusted interest expense for the second quarter of 2012 was $61 million. As of June 30, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70-30 fixed floating debt portfolio, which we believe is an optimal ratio. During Q2, we entered into forward starting derivative financial instruments to extend to 2016 the period over which we will maintain our 70-30 fixed floating ratio of our debt portfolio, as well as our average effective interest rate.
Adjusted interest expense for the 6-month period was $122 million, and is forecasted to be between $245 million and $265 million for the full year. The effective tax rate in the current quarter was 26% compared to 27% a year ago. Our full year 2012 tax rate range is between 26% and 27%, and we continue to believe that this rate will be sustainable at this level going forward.
Second quarter adjusted net income was $254 million, or $0.60 per share, a 15% increase from our Q2 2011 adjusted diluted EPS of $0.52 per share. For the 6 months, adjusted net income was $478 million or $1.12 per share, a 17% increase over the same prior year period.
As I mentioned previously, our guidance range for diluted EPS is now $2.45 to $2.55 per share. During the quarter, we completed a $500 million share repurchase program under which we repurchased 23.4 million shares at an average cost of $21.36 per share. The impact of this share repurchase program is included in our calculation of adjusted diluted earnings per share on a weighted basis and now to approximately $0.01 for the current quarter. Our revised estimate of diluted shares for the full year is approximately 420 million shares.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis, which takes into account the special items which are outlined in our press release and which I discussed in detail in our first quarter earnings call, was approximately $282 million for the quarter and $349 million for the year-to-date period. In addition, the cash paid to settle previously accrued litigation, which is excluded from adjusted cash from operations, we have also excluded cash received during the quarter with respect to the settlement of a patent litigation matter.
Also during the quarter, Mylan and Sunovion settled outstanding litigation with respect to Sunovion's Xopenex product. As a result of this settlement, Mylan is licensed to continue sales of its concentrate product and will have a loyalty bearing license to sell its non-concentrate  product upon receiving final FDA approval from the U.S. FDA. The settlement also releases Mylan from payment of the $18 million in damages that has been awarded by a jury earlier this year. The net penal impact of these items, as well as a few miscellaneous other litigation matters, was an income of $12.2 million for the quarter, all of which is excluded from our adjusted earnings.
Our GAAP cash flow from operations for the current quarter and year-to-date period was a very strong cash inflow of $302 million and $193 million, respectively, and leaving us with unrestricted cash and marketable securities totaling approximately $347 million at June 30, 2012. We are still forecasting our full year 2012 adjusted operating cash flow to be within our guidance range of $900 million to $1 billion, driven by increased second half earnings, as well as increased cash receipts from accounts receivable related to our significant recent product launches.
Second quarter capital spending was $61 million, bringing the total for the year-to-date to nearly $100 million. And as a result of the timing of planned capital expenditures, we expect full year capital expenditures to be within our guidance range of $300 million to $400 million. In addition to capital expenditures, approximately $70 million was spent during the first half of 2012 to acquire product rights and licenses.
During the current quarter, we borrowed $365 million under our revolving credit facility. This, along with cash on hand and through cash received through our -- from our accounts receivable securitization facility, was used to fund the share repurchase program, which I previously discussed. In July 2012, the size of the accounts receivable securitization facility was increased to $400 million.
Even with the additional borrowings under the revolver and the AR facility, we continue to have a significant financial flexibility. Our leverage ratio at June 30, 2012, as a result of the additional borrowings was 3.09 to 1, which is slightly above our long-term target of 3 to 1. However, we expect to be back below 3 to 1 by December 31, 2012. As such, we will continue to revaluate the uses of free cash flow for transactions based on the parameters, which we've outlined to you in the past.
Additionally, I am pleased that in May, Mylan's credit rating was upgraded by Moody's to Ba1 from Ba2. And following this action, Moody's rating outlook is stable. This change is reflective of Mylan's track record of meeting our prior stated commitments, as well as our solid position within the global generic industry, in particular, our strong geographic diversification and robust product pipeline.
To summarize, our second quarter, much like our first, was strong and in line with what we had anticipated. This positions us well heading into what will be an exciting second half of the year, culminating in what should be our strongest year yet.
That concludes my remarks. I will turn the call over to the operator for Q&A. Beverly?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Your first question comes from the line of David Risinger of Morgan Stanley.",15,"[Operator Instructions] Your first question comes from the line of David Risinger of Morgan Stanley."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","My question is, can you just talk a little bit about that improvement in performance? Obviously, you're going into a little bit easier comps because of the declines in 2011, but if you could speak to how we should think about the prospects for constant cu",80,"My question is, can you just talk a little bit about that improvement in performance? Obviously, you're going into a little bit easier comps because of the declines in 2011, but if you could speak to how we should think about the prospects for constant currency performance in EMEA going forward. And then second, obviously, there was a big hit to prices in Australia, but your Asian business performed well. Could you talk about that outlook on a go-forward basis?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. David, so I'll start with Europe. Look, I think that -- I want to be careful about not talking about this quarter as a trend yet in Europe, but I will say this. We certainly are getting positive indicators. And starting with France, our, as you know",471,"Sure. David, so I'll start with Europe. Look, I think that -- I want to be careful about not talking about this quarter as a trend yet in Europe, but I will say this. We certainly are getting positive indicators. And starting with France, our, as you know, largest market, we continue to see them take initiatives, increased utilization. We see those starting to take hold. We see volumes holding. So that ability of perhaps turning the quarter, maybe throughout the rest of this year, we will see a trend. But what I can tell you, we have our arms around what we can control, our cost of goods structure, our continual repatriation and vertical integration has benefited us. And that said in the past, once that market started to turn around, we -- certainly, we get our disproportionate share because of what we've been doing during these headwinds. Italy and Spain continue to be -- show a lot of growth, especially in volume. So while there continues to be austerity measures and price impact, we see that volume in our product mix and our ability to continue to grow those markets as very promising. So I think when you look overall of where there's still see -- or where we still see opportunity as the utilization being a much better offset the cost containment than just slashing prices. And as -- when you look at some of the other European countries that are much more mature, like the U.K., there is not that opportunity for utilization. They are pretty mature markets, so thus to maintain in some of those areas is very different than some of the growth opportunities we see for our strong holders. And then let's turn to the Asia Pacific. Yes, Australia continue to see price pressure as one of the most significant to date with the 25%. I will tell you, we continuously have them since 2008 when I believe they took the first big hit on pricing to rightsize that organization to remain very nimble and agile and be able to adapt to the changing environment. We've continued to invest in our R&D and product launches and cost of goods structure, which we'll continue to do, which has helped us hold and offset that price cut. As you mentioned, Japan had a nice increase. And again, we see opportunity. We see utilization for that country at about 24%. As you know the government has talked about getting that up to at least 30% here in the very near term, so again, continuing to capture some of that growth. And as I mentioned, our world driver being our ARV franchise out of our India subsidiary. And that continues to grow nicely, and we continue to be a very competitive market leader around tenders throughout the world."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes of the line of Gary Nachman with Susquehanna Financial.",13,"Your next question comes of the line of Gary Nachman with Susquehanna Financial."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","In terms of the contribution from new products in North America, the $240 million, can you quantify roughly how much of that was Doryx? What were the other big contributors? And those will probably drop off, but should we still see sequential growth in No",56,"In terms of the contribution from new products in North America, the $240 million, can you quantify roughly how much of that was Doryx? What were the other big contributors? And those will probably drop off, but should we still see sequential growth in North America for the rest of the year from other new products?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, I think, Gary, as you know, we don't break out our revenue from products individually. We were very pleased with the launches that we had in the second quarter, and we do have a very strong quarter. We do have a very strong quarter coming up here in",77,"Well, I think, Gary, as you know, we don't break out our revenue from products individually. We were very pleased with the launches that we had in the second quarter, and we do have a very strong quarter. We do have a very strong quarter coming up here in the third quarter for North America. So I think that it will be a very robust year for North America overall, including the second half of the year."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And then maybe for Heather, how is the DTC been going for EpiPen? Have you been able to measure the effect on this and the campaign in terms of drawing in new patients and also growing the market? Just some qualitative metrics around that.",45,"Okay. And then maybe for Heather, how is the DTC been going for EpiPen? Have you been able to measure the effect on this and the campaign in terms of drawing in new patients and also growing the market? Just some qualitative metrics around that."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So we've been very focused. As I mentioned in my remarks, it's actually growing the anaphylaxis market. So really just at the moment with us being the only epinephrine auto-injector on the market at this time, we've really been able to focus on education",172,"So we've been very focused. As I mentioned in my remarks, it's actually growing the anaphylaxis market. So really just at the moment with us being the only epinephrine auto-injector on the market at this time, we've really been able to focus on education around anaphylaxis. So we have seen, as you've seen in these results, we've seen a great response to that. And we obviously look at Q3 to be one of the best ever for EpiPen as we continue to know that it's a very -- it's at the moment still very seasonal with back to school. We see Q3 always historically by being larger, but what we've seen with the script trend and expansion is that peak is starting earlier, lasting longer. So we certainly have seen a benefit and obviously, now with the runway absolutely clear for us through 2015, through our settlement with Teva, I can assure you, we are going to continue as we see those response continue to invest in EpiPen as a franchise."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Frank Pinkerton with SunTrust.",12,"Your next question comes from the line of Frank Pinkerton with SunTrust."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Just first one, can you give us any details on your confidence in the comments you made earlier about the timing for the Copaxone FDA approval?",26,"Just first one, can you give us any details on your confidence in the comments you made earlier about the timing for the Copaxone FDA approval?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Yes, we remain absolutely confident on our regulatory pathway and our ability to receive an approval. As you know, the -- how Hatch-Waxman works, our ability to get an approval prior to the appeals process is not possible. So we are very focused on still",68,"Yes, we remain absolutely confident on our regulatory pathway and our ability to receive an approval. As you know, the -- how Hatch-Waxman works, our ability to get an approval prior to the appeals process is not possible. So we are very focused on still receiving our regulatory approval and absolutely, as I mentioned in my comments, believe that we'll get that prior to the appeals process ending."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay, great. And then maybe a little broader question. In Europe, and I don't want to talk about your business, but can you make comments on other competitors there? What are you seeing out of the regional players, some of the smaller players? Is consolid",64,"Okay, great. And then maybe a little broader question. In Europe, and I don't want to talk about your business, but can you make comments on other competitors there? What are you seeing out of the regional players, some of the smaller players? Is consolidation happening from a standpoint of taking capacity out kind of outside of the top 10 players in that market?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, as we've said before, it's really tough to talk about Europe where it gets one country and one market. I mean, we -- you've got many, many markets, many different regions, many different dynamics. What I would say is as we do participate in many of",191,"Well, as we've said before, it's really tough to talk about Europe where it gets one country and one market. I mean, we -- you've got many, many markets, many different regions, many different dynamics. What I would say is as we do participate in many of those markets throughout Europe, what we have continued to see is, yes, through some of these macroeconomic headwinds, we saw irrational behavior in some countries. We've stated that we always believe that those weren't sustainable business model, that our ability to continue to leverage our global platform very much made us unique throughout the European countries. And so our ability to weather the storm that Europe's been going through, and come out on the other side stronger with a much better cost of goods structure, put us in position to compete much better than any regional or local player that doesn't have the benefit of the global scale that the Mylan platform have. So I think that's the best way I can describe how we see Mylan fitting in for Europe overall, how Mylan would be very differentiated from a regional or local player."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Two things. First, on gross margin, you talked about how much of this is going to improve as the year progresses, how much of that is just the product mix and good products coming out of the U.S. versus what is more sustainable and I mean, relative to you",115,"Two things. First, on gross margin, you talked about how much of this is going to improve as the year progresses, how much of that is just the product mix and good products coming out of the U.S. versus what is more sustainable and I mean, relative to your comments about taking cost down in Europe, et cetera, et cetera, the gross margin line? And then secondly, are you doing anything in Europe to change the SG&A kind of cost structure because of all this austerity in the difficult markets over there? Because you've really talked about taking cost out of the gross margin line and you haven't talked about SG&A as far as Europe."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So Marc, with respect to the gross margin, certainly a portion of the margin increase in the second half of the year is the seasonality associated with our product mix. Certainly, the Specialty business, including EpiPen, has its strongest quarter of the",178,"So Marc, with respect to the gross margin, certainly a portion of the margin increase in the second half of the year is the seasonality associated with our product mix. Certainly, the Specialty business, including EpiPen, has its strongest quarter of the year in the third quarter, and that it will benefit us. We also have a very strong year for launches in North America, and new product launches, obviously, are beneficial. But aside from North America, as we talked about in the first quarter, we have been seeing through the cost-reduction efforts that we've been taking, whether it be the vertical integration, the repatriation efforts, we have been able to maintain and grow margins in Europe, and we've been able to also -- even with the price cuts that we've seen in Asian countries, been able to weather that with stable margins. So I think that it is a -- the strength of our gross margin is a combination between product mix, new products and then also managing aggressively the cost associated with our existing product portfolio."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Well, I guess, just before you answer the other questions, just on the gross margin. If you didn't have this massive increase in the number of U.S. products, which arguably you're not going to have as much next year versus this year, which is where I'm go",79,"Well, I guess, just before you answer the other questions, just on the gross margin. If you didn't have this massive increase in the number of U.S. products, which arguably you're not going to have as much next year versus this year, which is where I'm going with the question, what is the kind of the core gross margin? I mean, are we -- that 48% kind of becomes like kind of the baseline that we're thinking about now?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I think that we'll certainly provide more detailed guidance with respect to '13 when we get closer to that year. We did talk about that a bit in our Investor Day, and I think we are confident in our 48% to 50% gross margin range that we have as our curren",55,"I think that we'll certainly provide more detailed guidance with respect to '13 when we get closer to that year. We did talk about that a bit in our Investor Day, and I think we are confident in our 48% to 50% gross margin range that we have as our current guidance out there."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","And as far as your question about the rest of European cost, I guess, first I would say that the global scale doesn't just apply to the product side. Our global scale is pulling on sales excellence, marketing excellence, looking at really -- as these mark",125,"And as far as your question about the rest of European cost, I guess, first I would say that the global scale doesn't just apply to the product side. Our global scale is pulling on sales excellence, marketing excellence, looking at really -- as these markets continue to change and adapt, we're able to do so with along with them. So I would say, we have been able to take some restructuring in different countries and adapt in our sales model, and we continue to do so. So we are absolutely looking across the board at where that makes sense. And like I said, at the end of the day, our ability to really pull upon this global scale benefits us across the entire organization."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Have you cut any -- like of the sales force and staff, or how does that work?",17,"Have you cut any -- like of the sales force and staff, or how does that work?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","It depends. I mean, we have countries, take Belgium, who was a total branded generic marketplace, and they have been increasingly switching to an INN substitution. So our ability, obviously, to marry up with the dynamics of that market is important, and w",74,"It depends. I mean, we have countries, take Belgium, who was a total branded generic marketplace, and they have been increasingly switching to an INN substitution. So our ability, obviously, to marry up with the dynamics of that market is important, and we're able to do so. So I would say at the best we can be everything from sales, from marketing to sales reps to how we're selling the market into those countries."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes on the line of Elliot Wilbur of Needham & Company.",13,"Your next question comes on the line of Elliot Wilbur of Needham & Company."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","First question is for Heather. Heather, do you still believe that the generic version of Lidoderm is opportunity for the company in 2013? And if so, could you indicate whether or not you've included it as one of many potential probability adjusted product",49,"First question is for Heather. Heather, do you still believe that the generic version of Lidoderm is opportunity for the company in 2013? And if so, could you indicate whether or not you've included it as one of many potential probability adjusted products in your $2.75 per share guidance?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. I do absolutely believe that Lidoderm could be opportunity for us in the second half of '13. And I guess just to build upon that a little bit, because I know there's been a lot of discussion around Lidoderm, just for your recollection, the citizens",180,"Sure. I do absolutely believe that Lidoderm could be opportunity for us in the second half of '13. And I guess just to build upon that a little bit, because I know there's been a lot of discussion around Lidoderm, just for your recollection, the citizens petition, which has been discussed quite a bit, we filed back in 2006. After that citizens petition was filed, talking about -- Indo [ph] put forward their argument about bioequivalency and how the standards should be changed and what should be required, FDA issued guidance very clearly and have said about what they wanted to see with the Lidoderm patch in the ANDA. So all of that transpired before Watson filed their ANDA in 2009, and absolutely nothing has changed from FDA's perspective on guidance or requirement since that time. So the idea that the citizens petition is holding up the application to manage, it's just not really possible. So again, we look forward to our regulatory approval and still believe that to be a very viable option in the second half of '13."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Elliot, with respect to the second half of your question on whether Lidoderm is in our 2013 numbers or not, I guess what I would say to you is that we risk adjust all of our products and take into consideration that there could be a range of periods in wh",79,"Elliot, with respect to the second half of your question on whether Lidoderm is in our 2013 numbers or not, I guess what I would say to you is that we risk adjust all of our products and take into consideration that there could be a range of periods in when products are introduced and, therefore, without saying specifically whether Lidoderm is in there or not, I would just say that Lidoderm is risk-adjusted into our future business plan."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And I have additional question for probably you John as well. Could you just describe for us what, in terms of management and the Board's perspective on what is the most attractive use of the company's discretionary free cash flow at this point in t",105,"Okay. And I have additional question for probably you John as well. Could you just describe for us what, in terms of management and the Board's perspective on what is the most attractive use of the company's discretionary free cash flow at this point in time. I mean assuming you have a range of options between paying down debt, buying back shares or something more strategic, you kind of have done a little bit of everything over the past couple of years, I'm just kind of wondering what your current thinking is in terms of what's the best use of cash for enhancing shareholder returns?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Look, I'll -- I guess not being a member of the Board of Directors I'm not sure I want to speak on behalf of the Board of Directors, but I think we laid out on Investor Day earlier this year the parameters for how we would evaluate transactions. And I thi",132,"Look, I'll -- I guess not being a member of the Board of Directors I'm not sure I want to speak on behalf of the Board of Directors, but I think we laid out on Investor Day earlier this year the parameters for how we would evaluate transactions. And I think those parameters continue to exist. In May, we believe that executing on a share repurchase program was the best and most appropriate use of the capital we had available to us at that time. And so we execute on that, and we were very pleased with the execution. On a going-forward basis, we'll continue to evaluate opportunities that are available for transactions in the marketplace, again, using the parameters we outlined, and we'll also evaluate the appropriateness of share repurchase program."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","And I would just add, as you might imagine, Robert and the Board are extremely involved at looking at everything and constantly looking at all of our options.",28,"And I would just add, as you might imagine, Robert and the Board are extremely involved at looking at everything and constantly looking at all of our options."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Ronny Gal of Sanford Bernstein.",13,"Your next question comes from the line of Ronny Gal of Sanford Bernstein."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I have two. First, regarding EpiPen, you kind of look at the ACA and its potential implications and you just wonder if EpiPen is not one of the products that is likely to have a disproportionately higher growth from ACA. I was wondering if you guys have d",136,"I have two. First, regarding EpiPen, you kind of look at the ACA and its potential implications and you just wonder if EpiPen is not one of the products that is likely to have a disproportionately higher growth from ACA. I was wondering if you guys have done any work to look at that tailwind that the ACA provide to EpiPen? And second, you kind of mentioned you're building injectable capacity and obviously, this is a good time to bring injectable capacity online. I was wondering if you kind of look at your current build map, when do you think you'll have more capacity, I mean, minimal step-up in capacity around the injectable. I think would you be able to get in the same cycle before some other competitors are able to bring their capacity backup?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Let me start with your second question because I'm not sure I clearly understood your EpiPen question, and so I'll come back to that. But quickly on your ask about our capacity build, as we've announced earlier this year, we are continuing to invest in ou",141,"Let me start with your second question because I'm not sure I clearly understood your EpiPen question, and so I'll come back to that. But quickly on your ask about our capacity build, as we've announced earlier this year, we are continuing to invest in our injectable capacity in Ireland, as well as other areas around the globe. We certainly agree that it's our continual ability to vertically integrate on the injectable front and bring more and more of that into the Mylan global supply chain. It's certainly a benefit to us. So it absolutely is part of our footprint for expansion and capacity building this year as well as into the future. As far as EpiPen, it wasn't clear or you didn't come across clear of what you were asking me. I believe you used some initials of ACA."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I mean the health care reform act, okay, essentially have -- through the expansion of Medicaid and the [indiscernible] exchanges. A lot more people will be covered and those would be young adults or people that are -- that might have not -- that might be",72,"I mean the health care reform act, okay, essentially have -- through the expansion of Medicaid and the [indiscernible] exchanges. A lot more people will be covered and those would be young adults or people that are -- that might have not -- that might be using EpiPen more than the general population. Now I was wondering if you did any announcements toward the effect of the health care reform on EpiPen."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Okay, I think maybe what you're speaking of ACO. But in any event, we absolutely do not. As you may be aware or not aware, most programs allow for a patient to be reimbursed for 2 EpiPens per year. And that's usually a general rule of thumb across all pro",87,"Okay, I think maybe what you're speaking of ACO. But in any event, we absolutely do not. As you may be aware or not aware, most programs allow for a patient to be reimbursed for 2 EpiPens per year. And that's usually a general rule of thumb across all programs whether government or private sector where people are carrying more EpiPens or typically paying out of pocket or get a waiver from their insurance companies. So certainly nothing in the current health care law changes those dynamics."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes from the line of Ken Cacciatore with Cowen and Company.",14,"Your next question comes from the line of Ken Cacciatore with Cowen and Company."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","My question is looking out to mid-2015. I would think as the management team, you have to look at that EpiPen settlement and clearly have a potential worst-case model or worst-case scenario, although many good things could happen and maybe discount out so",124,"My question is looking out to mid-2015. I would think as the management team, you have to look at that EpiPen settlement and clearly have a potential worst-case model or worst-case scenario, although many good things could happen and maybe discount out some of the other potential positives. So I was wondering, in terms of capital deployment and knowing how long the integration for Merck took, as you're looking at potential acquisitions or other diversification, what should we be thinking in terms of timing? And John, you talked about not wanting to talk about parameters, but maybe you could just walk us through very briefly some of the parameters of assets or that the asset acquisitions that you gave at the analyst meeting?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Sure. So Ken, as far as a long-term visibility you're looking for, I think starting what we've been doing since 2008 is continuing to give that long-term visibility. And hopefully, with people have been able to start gaining confidence in our ability to b",380,"Sure. So Ken, as far as a long-term visibility you're looking for, I think starting what we've been doing since 2008 is continuing to give that long-term visibility. And hopefully, with people have been able to start gaining confidence in our ability to be not only laying out guidance and potential targets but our ability to meet or exceed them. So I think as we came out Investor Day with a whole assortment of opportunities that are drivers for 2013 and beyond because, as you mentioned, we need to work today on those things. So whether it's EpiPen, yes, there's a possibility there could be an AB-rated. While I remain fairly confident that, that's going to be a high hurdle, we have many, many other opportunities. I mean, when we talk about biologics, Advair, Copaxone, all definitely coming after that 2015 time period, not to mention our continuous voluminous amount of launches across the board. That's why today in my remarks, I tried to lay out not only what the platform is generating but with all the different strategic drivers that we discussed that all give benefits. So you don't have to rely on all of them hitting obviously just a couple of them hitting certainly put at great growth to Mylan from this point going forward. And I guess the other thing I'd say on your comment about integration, I could say that our Merck acquisition certainly is in a hemisphere all by itself. When you buy a company 2.5x your size and do a transformational acquisition as we did, certainly that integration, I think took a couple of 3 years that we certainly were able and continue to show every step along the way our ability to realize those synergies. I think when you look at acquisitions outside of that, we've certainly stated we're not doing a large 2.5x our size transformative acquisition. So things like Bioniche respiratory franchise from Pfizer, we've continued to be able to bolt and tuck those in without ever even mentioning integration or missing a beat because I think the platform we have in place today is scalable and sustainable and is able to absorb these kind of acquisitions very, very easily. So there's not a long-term planning period for any of those."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I know never say never, but should we be thinking along the lines of Bioniche going forward, or could we see something more sizable?",24,"I know never say never, but should we be thinking along the lines of Bioniche going forward, or could we see something more sizable?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I mean, I think we've been clear, and I'll let John speak about that. We have a whole range of opportunities and potential from sizing perspective in our continued strengthening our financial flexibility. So all I'm saying is that everything and these typ",55,"I mean, I think we've been clear, and I'll let John speak about that. We have a whole range of opportunities and potential from sizing perspective in our continued strengthening our financial flexibility. So all I'm saying is that everything and these types of acquisitions are certainly nothing compared to what the Merck integration required."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Right. Remember, Ken, that at Investor Day we indicated that we were committed to a long-term debt to EBITDA ratio of 3:1 that we would not go above that which is permitted under credit facility of 4.25:1. And that we would look at the transactions that e",74,"Right. Remember, Ken, that at Investor Day we indicated that we were committed to a long-term debt to EBITDA ratio of 3:1 that we would not go above that which is permitted under credit facility of 4.25:1. And that we would look at the transactions that expanded our portfolio or geographically into areas that we're not in or other shareholder value accretion transactions such as share repurchases that you saw too earlier this year."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your next question comes of the line of Shibani Malhotra of RBC.",12,"Your next question comes of the line of Shibani Malhotra of RBC."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","I'm just going to follow on from Ken's questions, but just in terms of looking at the Merck portfolio and the acquisitions you've done, Heather, can you just talk us through in terms of the synergies? I mean, should we assume that these have already been",154,"I'm just going to follow on from Ken's questions, but just in terms of looking at the Merck portfolio and the acquisitions you've done, Heather, can you just talk us through in terms of the synergies? I mean, should we assume that these have already been realized, or is there more to go? And then can you talk from the pipeline's standpoint, branded -- sorry, in terms of the filings you were expecting to get approved in Europe and also the kind of new Paragraph IV filings that you are thinking about, how much room is there for new products that we haven't heard of as yet and where we are -- where we are rather, on that? And then just specifically, on the M&A, can you talk about the kind of areas that we're looking at, I mean whether they're branded or generic, and what sort of disease areas you're looking at?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Let me start I guess on the portfolio aspect of your question. Just throughout the rest of this year, we're on track to launch another -- over 300 products throughout the world. We don't speak specifically before launches in Europe as you know. There's so",431,"Let me start I guess on the portfolio aspect of your question. Just throughout the rest of this year, we're on track to launch another -- over 300 products throughout the world. We don't speak specifically before launches in Europe as you know. There's some competitive advantage, and it's not the same system that gives the same visibility, like here in the United States with Paragraph IV. But I can tell you, we've had very successful launches already this year, as I spoke about Atorvastatin and Candesartan and then Ibandronate. And like I said, we continue to have many more. Our total R&D portfolio and filings, we look to be doubling our size by 2015. So I mean, that should give you a sense of the amount of products that we have in the pipeline or already filed with regulatory agencies around the world of what we're going to be launching over the next couple of years. As far as Paragraph IV goes, I mean, certainly, we have been showing, like we did back in Investor Day, the state certain launches that we already know of or our first-to-file, share to file opportunities, 2012 was one of our largest years as far as the states certain so far been, but we continue to already be -- have settlements that go out through '13, '14, '15 of date certain. We continue to get our share of first-to-file opportunities. So I would just say that we continue to maximize and leverage our platform on all of the fronts that we have in the past. Difficult-to-formulate products, the Paragraph IV opportunity and, like I said, just a voluminous amount of dosage forms. And we are investing in everything from injectables, as I mentioned earlier, to our patches, at oral, solid dose soft gels, dermatologicals. So as far as from an M&A, when you think about -- we really have a lot of opportunity to complement this platform across the globe, from our Specialty division to continue to complement our infrastructure and disease state expertise in respiratory and allergy. You look at our Biologics partnerships and our ability to continue to leverage and build upon that, as well as therapeutic categories that we're not in yet. So we see an opportunity to still bid our U.S. generics business with things like whether it would be antibiotics or dermatological things that we're not as large in today. So across the board, I would say, we have many opportunities to continue to fuel the engine that we've put together across all of the fronts I just mentioned."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Your final question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your final question comes from the line of Jami Rubin with Goldman Sachs."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","John, just a follow-up on some of the earlier questions regarding uses of cash and share repurchase, can the company expand its share repurchase program without violating your debt covenants? And we're calculating that you have about another $400 million",60,"John, just a follow-up on some of the earlier questions regarding uses of cash and share repurchase, can the company expand its share repurchase program without violating your debt covenants? And we're calculating that you have about another $400 million to $500 million in share repurchase potential that you could do right now, can you confirm that, that is correct?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","There are restrictions and under our bank facilities and borrowing facilities, with respect to our ability to do additional share repurchase programs. At the current time, our Board of Directors has not approved any other share repurchase programs. And qu",59,"There are restrictions and under our bank facilities and borrowing facilities, with respect to our ability to do additional share repurchase programs. At the current time, our Board of Directors has not approved any other share repurchase programs. And quite honestly, I'm not in the position to confirm the $400 million to $500 million capacity at the current time."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","But with the exception of the Board approving a buyback program, do your -- with your covenants, just given your cash flow generation, would your covenants allow you to announce a further share buyback program now?",36,"But with the exception of the Board approving a buyback program, do your -- with your covenants, just given your cash flow generation, would your covenants allow you to announce a further share buyback program now?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","I don't think that our covenants would allow us to announce a share repurchase program currently of the size that you were suggesting, no.",25,"I don't think that our covenants would allow us to announce a share repurchase program currently of the size that you were suggesting, no."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Analysts","Okay. And just as a follow-up, EpiPen obviously performed very well this quarter, but we just noticed, in terms of IMS prescription trends during the month of June, demand for Epi dropped pretty considerably compared to the previous months. Just wondering",62,"Okay. And just as a follow-up, EpiPen obviously performed very well this quarter, but we just noticed, in terms of IMS prescription trends during the month of June, demand for Epi dropped pretty considerably compared to the previous months. Just wondering what's going on, what you're seeing, is this just a seasonal adjustment, and how we should think about it going forward?"
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","Well, a couple of things. I think you've heard me say before that I don't believe that EpiPen should be as a seasonal product as it's been historically. But we continue to educate people about obviously some of the unfortunate and unnecessary deaths that",158,"Well, a couple of things. I think you've heard me say before that I don't believe that EpiPen should be as a seasonal product as it's been historically. But we continue to educate people about obviously some of the unfortunate and unnecessary deaths that have taken place in restaurants and in schools have not been to things like these things that occur more in the springtime. So what I would say as we've seen, as you know, there's been a lot of reports of this allergy season started much earlier this yea since we had such a mild winter. I think that was a contributor to some of the strengths. But I would say, I also put a lot more weight on, like I said, just a pure expansion in education that's taken place in the market. And I continue to see hopefully more and more months becoming drivers short of what it's historically been just in Q3."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Executives","So operator, that will conclude our call, and we appreciate very much the support of everybody who participated.",18,"So operator, that will conclude our call, and we appreciate very much the support of everybody who participated."
290203,213782906,332753,"Mylan, Inc., Q2 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Viatris Inc.","Operator","Thank you, everyone, for joining today's conference call. You may now disconnect.",12,"Thank you, everyone, for joining today's conference call. You may now disconnect."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's Third Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Easte",77,"Welcome to Mylan's Third Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern Time. The dial-in number is (800) 585-8367 or (404) 537-3406 for international callers, with pin number 36921750. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Maria. Good morning, everyone. Welcome to Mylan's Third Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice",488,"Thank you, Maria. Good morning, everyone. Welcome to Mylan's Third Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making numerous forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often may be identified by the use of words such as may, will, could, should, would, project, believe, anticipate, expect, plan, estimate, guidance, trends, forecast, potential, intend, continue and variations of these words or comparable words.
Our forward-looking statements may today including, among others, statements related to anticipated business levels, trends in some European countries, planned launches of and anticipated exclusivity period for new products, our ability to achieve forecasted full year results while absorbing the impact of negative pricing pressures, expectations for capital expenditures, expectations for R&D, SG&A and other spending.
Our guidance range, future earnings, planned activities, anticipated growth and other expectations and targets for future periods, including our expectations regarding the fourth quarter and for 2012 overall. Because these statements are forward looking, they inherently involve risks and uncertainties and, accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the factors set forth under forward-looking statements in our recent earnings press release dated October 25, 2012, as well as the risk factors set forth in our report on Form 10-Q for the period ended June 30, 2012, and in our other SEC filings. You can access our Form 10-Q and other SEC filings, including our earnings press release, which we filed on Form 8-K through the SEC website at www.sec.gov. And we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures such as adjusted revenue, adjusted gross margin and adjusted diluted EPS should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with Generally Accepted Accounting Principles or GAAP.
Please refer to today's earnings press release, which is available on our website, as well as on the SEC website, as it contains detailed reconciliations of the non-GAAP financial measures we use for our third quarter results prepared in accordance with GAAP.
Before I turn the call over to Heather, let me also remind you that materials in the call, with the exception of the participant questions, is a property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'll now turn the call over to Heather."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us today. I'm pleased to announce that Mylan has once again delivered an outstanding quarterly performance marked by double-digit growth on the top and bottom line. Our third quarter",1569,"Thank you, Kris, and good morning, everyone, and thank you for joining us today. I'm pleased to announce that Mylan has once again delivered an outstanding quarterly performance marked by double-digit growth on the top and bottom line. 
Our third quarter constant currency revenues were at 20% year-over-year to $1.8 billion, and our adjusted diluted earnings per share grew 51% to $0.83. I'd like to note that we did more this quarter than we did in all of 2008 with essentially the same assets. This only further highlights the power of our organic growth capabilities. of course, these milestones could only have been achieved through the hardware, dedication and commitment of all of our employees. On behalf of the Board of Directors and our entire management team, I would like to thank all of them.
Now with 3 very successful quarters behind us this year, we are raising our 2012 adjusted EPS guidance range to $2.50 to $2.60 per share. We also are reaffirming our 2013 target of $2.75 per share and our longer-term target of at least $6 per share in 2018. We expect to provide detailed guidance for 2013 in February when we release our fourth quarter and year-end results. We will discuss our longer-term outlook in July during our investor day event, which we will host in New York. 
Our ability to deliver a consistently strong results takes advantage of our opportunities and become ever more efficient, all while mitigating risk and absorbing economic headwinds and price cuts give Mylan a unique profile in this industry. With that said, our expectation of continued growth will come from a combination of things. First, from the continued organic growth of our very strong and powerful existing platform. Second, from against the strategic growth drivers we outlined during our Investor Day. And third, and importantly, from our ability to continue generating significant free cash flow, which allowed us to accelerate our deleveraging and get to a current 2.6:1 debt-to-EBITDA, well below our target. Therefore, we are actively looking at a number of ways to use our increasing financial flexibility to help us accelerate our longer-term target and enhance shareholder value.
Against this backdrop, I'd like to walk you now through Mylan's outstanding third quarter performance, which was characterized by strong double-digit revenue growth in our Specialty, North America and Asia Pacific businesses and a return to growth in Europe. In addition, our gross margin increased nearly 400 basis points year-over-year to 52%.
Starting with North America generics business, we reported third party net revenues of $831 million, a year-over-year increase of 19% at constant currency. Driving the increase where new product launches during the quarter, which contributed to the $258 million and included Valsartan HCT in September with 180 days of exclusively, Modafinil in August and pioglitazone and pioglitazone metformin also in August in bodes 180 days of exclusively. The largest offset lower pricing and volume on existing products. 
As of the end of the third quarter, we had introduced 47 new products this year in the U.S. including 17 that were first-to-file or limited competition. In Canada, as of the end of the third quarter, we had launched a record 22 new products, revenues from which contributed to favorable year-over-year sales growth in that market. 
In addition, revenues from our Institutional business grew by nearly 25% on a constant currency basis during the quarter, with new products and higher volumes responsible for most of the growth. 
In Europe, we reported third party net revenues of $326 million, a year-over-year increase of 6% at constant currency. Many of our European markets realized increased sales, an encouraging sign that the region may finally be turning order. 
In addition, I'd note that as of the second quarter, the latest period for which data are available, generic utilization has risen year-over-year in the 19 European countries where we do business. 
As of the end of the third quarter, Mylan executed 270 country launches in Europe during the year. These launches, along with favorable volumes on existing products, where the primary drivers of our improved performance during the third quarter. The higher product volume included double-digit growth in France, Italy and Spain, which offset some lower pricing resulting from government mandates and competitive conditions. 
France saw the most significant revenue increase in absolute terms, as local currency sales rose 9% compared to last year's third quarter. In addition, to new product launches revenues benefited from the recently signed pharmaceutical convention, which contributed to a 7% point increase in substitution among repertoire listed products from May to August. We also are seeing growth in the French generic market overall in volume and value, and we remain in the market leader. 
We observed similar trends in Italy where new products and higher volumes more than offset the impact of government-mandated price reduction. I'd also note that Italy's government has passed a law requiring general practitioners to prescribe products for patients starting new treatments for chronic and acute conditions. Italy is one of the fastest-growing generic markets in Europe, and we are the country's fastest-growing major player.
In Asia-Pacific, we recorded a third party net revenues of $339 million, a year-over-year constant currency increase of 21%. Our Mylan Lab subsidiary in India, along with Japan and New Zealand, all experienced higher third-party sales. India accounted for the majority of the increase due to significant sales both ARVs and significant growth in API. 
In Australia, where we continue to maintain our leadership position, sales were lower operationally due mainly to steep price cuts made by the government during the year. 
Sales in Japan rose had higher volumes mainly in the distributor channel and new product launches offset NIH pricing cuts that set the factor during the first quarter. In addition, we continue to see increased generic utilization. 
Also during the third quarter, we announced an exclusive long-term strategic collaboration with Pfizer to drive sustained growth for our combined Generics business in Japan. This unique partnership, unprecedented in our industry, leverages the core strength of both organizations and creates a powerful platform that we expect will be a leader in Japan in terms of scale, scope and quality. 
Our Specialty segment, we reported third party net revenues of $294 million, a year-over-year increase of 37%. Sales of EpiPen in the U.S. accounted for most of the increase, with the growth of more than 50% compared to the same period in 2011. Our third quarter is essentially the strongest for sales of this product, and our growth this quarter came off a very strong quarter last year. 
I'd also note that we continue to see our efforts around market expansion pay off to the first 9 months of 2012. The percentage of at-risk individuals in the U.S. who have build a prescription for EpiPen Auto-Injector has risen from 7% to 10%. More importantly, the growth potential for this franchise remains significant.
As I move on now to some of our other drivers of growth through 2018, I'd like to reinforce that each driver and our broad baskets of opportunity is weighted based on it its unique risk reward profile and projected long-term contribution. Our success and our ability to achieve our targets doesn't depend on any 1 driver, and instead, our success is based on the global scale and leverage we have created and our ability to invest and execute on these opportunities. 
With respect to our global Institutional business, we continue to grow and expand our relationships with key customers and invest in the future of this franchise. A few weeks ago, we agreed to purchase an oncology manufacturing facility in India from SMS Pharmaceutical. That facility will produce active pharmaceuticals in finished dosage forms and begin commercial operation as soon as the FDA completes its inspection, which is expected to occur in the next few months. The transaction should close early in the first quarter of 2013.
With respect to geographic expansion, we launched commercial operations in India in August, entering the market with a comprehensive portfolio of ARV products for the treatment of HIV AIDS. We also were selected as a leading supplier of ARV drugs to India's National AIDS Control Organization. 
I'd note that both of these developments also support our ARV growth driver. And in addition, to our expansion in India, we are poised to establish a physical presence shortly in Thailand. 
Portfolio diversity is another important growth driver and we remain excited about the Women's Health Care franchise we are establishing in partnership with Sam Care. During the third quarter we launched 2 oral contraceptives in Germany. We also launched one this week in Canada. And in addition, we have 34 oral contraceptives pending approval with the FDA and expect commercialization to begin in next year's first quarter.
With respect to our Biologics driver, we have continued to advance the development of our 5 lead products. We have held positive meetings with the authorities in the U.S. and Europe to discuss our Biologics program. In addition, we are pleased to report that we initiated our first global Phase III clinical trial on in October. 
Clearly, Mylan continues to operate and grow from a position of great strength and we look forward to leveraging that strength further to deliver even more value to our shareholders. With that, I'll now turn the call over to John, and I look forward to responding to your questions."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris' comment at the beginning of today's",1915,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris' comment at the beginning of today's call regarding our use of adjusted measures.
Let me start by saying, by any measure, the third quarter of 2012 was an exceptional quarter for Mylan. I would like to highlight upfront some of our financial accomplishments. Quarterly revenue of $1.8 billion, the highest amount of revenue in any quarter in our company's history, and revenue grew on a constant currency basis in every region of the world including Europe. Adjusted diluted earnings per share of $0.83, more than we earned in all of 2008, and were achieved while continue to invest in new product development and sales and marketing initiatives. 
Adjusted operating cash flow of $469 million, the most ever for our company in one quarter, and free cash flow of $424 million, which allowed us to repay borrowings during the quarter of $459 million. And to the end of the quarter, and to end the quarter with a growth leverage ratio of 2.7:1, or 2.6:1 when you consider an additional $100 million of borrowings, which we repaid in early October.
On the heels of this strong quarter, we are once again increasing our range of EPS guidance for the full year 2012. We're now projecting adjusted diluted EPS of between $2.50 and $2.60 per share, increased from our previous range of $2.45 to $2.55 per share. We are also revising upward our free cash flow expectations for 2012. We now expect adjusted operating cash flow to be approximately $1 billion in 2012, which is at the very upper end of our 2012 operating cash flow guidance range of $900 million to $1 billion. 
Additionally, as a result of the timing and rationalization of some of our capital programs, our gross capital spending in 2012 is now anticipated to approximate $300 million. The net of these 2 amounts represent our current 2012 free cash flow expectation of approximately $700 million or $100 million higher than the midpoint of our previously communicated expectation.
Our remaining guidance metrics for 2012 remain unchanged, and I'll walk through each of them in a few minutes, and our targets for the 2013 and beyond remain unchanged.
In February, in conjunction with our fourth quarter call, we will provide detailed 2013 financial guidance, which reflects recent developments at our most up-to-date outlook.
So, Mylan has never been better positioned as a company. Today, we possess an unmatched vertically integrated footprint, a broad and growing product portfolio with a robust pipeline of future new product launches and longer-term strategic growth drivers such as our respiratory and Biologics platform. 
Additionally though, Mylan possesses today the financial flexibility to take advantage of shareholder value accretion opportunity. With our current leverage ratio, now meaningfully below our long-term target of 3:1 and our growing EBITDA, today, we have over $4 billion of financial flexibility for earnings accretive transaction. That said, Mylan will do never do a transaction merely for the sake of the transaction or only for financial reasons. Andy transaction must also be the right transaction strategically. Further, we remain committed to our 3:1 long-term growth leverage target. And if we increase our target above this target, we will be committed to deleveraging within an 18-month timeframe.
With that introduction, let me now get into the detailed details and walk you through our financial results for the third quarter and first 9 months of 2012. I will also provide an update on our capital structure and liquidity position. 
Starting at the top of our income statement, total adjusted revenues for the quarter were approximately $1.8 billion, an increase of 14% over last year's third quarter revenues of approximately $1.6 billion. Year-over-year revenue growth on a constant currency basis was approximately 19%. The 5% unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to each of the other functional currencies of our major operations mainly in Europe and India.
Our top line growth was driven by higher volume on a consolidated basis, including significant amount from our 2012 new product launches, as well as favorable sales volume in Europe and Asia-Pacific, which served to more than offset the unfavorable impact of lower pricing throughout the world. In fact, driven by higher volumes and new product introductions, each of the countries in Europe in which we have significant operations, with the exception of Germany, turned in favorable year-over-year constant currency sales growth. 
For the first 9 months of 2012, total adjusted revenues were approximately $5.1 billion, an increase of 10% over revenues from the first 9 months of 2011, or 14% on a constant currency basis. As a reminder, our guidance range for total revenues for the full year of 2012 is between $6.8 billion and $7.2 billion. Recognizing current exchange rates and using them to forecast the remainder of the year, we expect to be near the low end of this guidance range as a result of the unfavorable impact of changes in foreign exchange rates. On a constant currency basis, however, we are projecting to be closer to the midpoint of the range.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 third quarter at 52% was above our guidance range of 48% to 50% and represented an increase over the same prior year period of nearly 400 basis points. This increase was driven by new product launches and favorable volume and pricing on our EpiPen Auto-Injector, partially offset by lower margins on existing products. The current quarter also saw margin improvement from our Indian subsidiary, where sales and gross profit benefited from the effects of a stronger dollar as compared to the rupee as a significant portion of its sale are denominated in U.S. dollars.
For the 9 months ended September 30, 2012, adjusted gross margins were 50% as compared to 48% in the prior year. We currently expect to be at the upper end of our gross margin guidance range for the full year.
Adjusted operating income was $513 million for the third quarter of 2012, a 32% increase from Q3 2011 and up 29% from the second quarter of 2012. The year-over-year increases, which is primarily the result of the favorable gross profit, was realized in spite of increased levels of investment in both R&D and SG&A. 
R&D expense for the quarter, on an adjusted basis, was $104 million or approximately 5.8% of total revenues and up approximately 51% from the prior year. This increase was mainly a result of ongoing spending with respect to our respiratory and Biologics program, including clinical studies. 
At the same time, SG&A, also on an adjusted basis, was $324 million for the quarter or approximately 18% of total revenues and up approximately 5% over the prior year. The increase in SG&A in the current quarter is due in large part to increased selling and marketing in our Specialty franchise. Also contributing to the year-over-year increase were higher payroll and related cost as we continue to build out our infrastructure platform in certain targeted areas.
For the 9-month period, adjusted R&D expense was $277 million, up 28% over the prior year. As a percentage of revenues, R&D expense to date for 2012 is 5.5%. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues, and we continue to believe that the full year spend will be at or slightly below the midpoint of our guidance range.
SG&A expense, on an adjusted basis, for the 9 months ended September 30, 2012, was $964 million, an increase of nearly 10% and within our full year guidance range of 18% to 20% of total revenues. Adjusted EBITDA was $567 million and $1.4 billion for the 3- and 9-month period ended September 30, 2012 period, respectively. We expect to be near the middle to upper end of our guidance range of $1.75 -- or $1.75 billion to $1.95 billion for the full year.
Moving onto our consolidated, nonoperating financial metrics. Adjusted interest expense for the third quarter of 2012 was $61 million. We continue to benefit from low short-term interest rates. As of September 30, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70-30 fix floating debt portfolio, which we believe is an optimal ratio. 
Adjusted interest expense for the 9-month period was $183 million and is forecast to be at the low end of the guidance range of $245 million to $265 million for the full year.
Our adjusted effective tax rate in the current quarter was 26% compared to 27% a year ago. Our full year 2012 tax rate range is between 26% and 27%, and we continue to believe that we will be at the lower end of this range for the calendar year 2012.
Third quarter adjusted net income was $341 million or $0.83 a share, a 51% increase from our Q3 2011 adjusted diluted EPS of $0.55 per share. For the 9 months, adjusted net income was $820 million or $1.94 per share, a 28% increase over the same prior year period. 
As I mentioned previously, our guidance range for adjusted diluted EPS is now $2.50 to $2.60 per share. Our estimate of diluted shares for the full year is approximately 420 million.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis, which takes into account the special items which are outlined in our press release, was approximately $818 million for the year-to-date period and a very strong hundred $469 million for the quarter. Our GAAP cash flow from operations for the current quarter and year-to-date period was a very strong cash inflow of $460 million and $652 million, respectively and left us with unrestricted cash and marketable securities totaling $366 million. As noted earlier, we were forecasting our full year 2012 adjusted operating cash flow to be approximately $1 billion, the high end of our guidance range.
We have been very focused throughout 2012 on operating working capital. On constant currency, net sales growth of 19% in the third quarter and 14% through the first 9 months of 2012, we have been able to limit the growth in our operating working capital to approximately 9%, exclusive of FX impact, as we continue to bring operational efficiencies to our global platform.
Third quarter capital spending was $61 million, bringing the total for the year-to-date period to nearly $160 million. And as a result of the timing of planned expenditures, we expect full year capital expenditures to approximate $300 million.
As mentioned before, these updated estimates yield a current free cash flow estimate of $700 million for the year, which is $100 million stronger than our previously communicated expectation as we continue to generate an increasing amount of cash flows from our global platform.
To summarize, our third quarter exceeded even our high expectations, and as anticipated, positions us to a very strong finish for 2012. Our strong track record for organic growth, coupled with a long-term growth drivers, which Heather discussed, and our significant financial flexibility, all translate into what should be an exciting 2013 and beyond for Mylan. 
That concludes my remarks. I'll turn the call over to the operator for Q&A. Maria?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes of the line of Marc Goodman of UBS.",14,"[Operator Instructions] Our first question comes of the line of Marc Goodman of UBS."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Couple of questions, first on the U.S. business which obviously had a fantastic quarter. There were just a lot of launches and given Diovan and Actavis, actually would've thought revenues would've been even a little higher, so maybe you can comment on som",131,"Couple of questions, first on the U.S. business which obviously had a fantastic quarter. There were just a lot of launches and given Diovan and Actavis, actually would've thought revenues would've been even a little higher, so maybe you can comment on some of the launches there and just the absolute amount way we should be thinking about that? And second, Europe, obviously, great news there, can you talk about profitability and how that has changed throughout the year and what you're doing there to increase profitability? And then third, can you just talk about the about the Institutional business a little bit more? how many new products should we be expecting to launch out of that and helping the business how big a business are you looking to build there?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. Marc, I'll start with a U.S. So, I guess I'd like to first start by saying against our estimates, our U.S. business performed right in line with where we thought it would be. While we absolutely had a significant amount of launches that we forecaste",475,"Sure. Marc, I'll start with a U.S. So, I guess I'd like to first start by saying against our estimates, our U.S. business performed right in line with where we thought it would be. While we absolutely had a significant amount of launches that we forecasted and projected at the beginning of the year, that '12 would be a great year for our U.S. Generics business, I think that if you look at the timing of the launches throughout the quarter, and some of that pull through even from launches we had earlier in the year, so all I can tell you is that absolutely performed in line with where we thought it would. We think it's still showing strength in the base business as well as our continued launches that we have for the remainder of the year. So from our perspective, U.S. business, hitting on all cylinders. Europe profitability, I think as we have talked about in the past that we constantly grew this entire macroeconomic situation throughout Europe has balanced our top and bottom line growth. You heard me quarter after quarter coming in and say we weren't going to chase the bottom, that there's been irrational behavior and that we would continue to hold steady and control what we can control. So in the spirit of time, we've done just that. We continued to increase the profitability around our cost of goods by continuing to vertically integrate and be 100% responsible for our global supply chain. We've continued to make sure that we're structured in the right way with some of the evolving businesses and as they are continuing to change in the different countries. And I think most importantly, and why I wanted to point out in my script, that in all of the countries we're doing business, we see an increase in generic conversion. And I think that should be the brightest spot of all because what it shows is that governments very much are beginning to recognize the long-term sustainability that generic utilization brings versus a onetime price cut. So we've seen additional initiatives in Italy. We've seen additional initiatives in France that are bringing us back up. So from my perspective, we certainly have always maintained the need to balance profitable and revenue I think that our results this quarter are paying off from how we're operating our business in Europe. And lastly, on the Institutional side, in February, we showed our Institutional business being an important strategic growth driver for us. We are continuing to invest in that business, we have numerous launches, we're continuing to very much accelerate our own internal R&D pipeline around this businesses globally. So all I can say is that we certainly are continuing to invest and continue to see this as a very important driver for us in the future."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Next question operator.",3,"Next question operator."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Jami Rubin of Goldman Sachs.",10,"Our next question comes from Jami Rubin of Goldman Sachs."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, both begin generating were the most clear about the company's increased appetite for pursuing an accretive deal given the increased financial flexibility of the balance sheet, and I'm wondering if you could just -- am I reading that right? previo",169,"Heather, both begin generating were the most clear about the company's increased appetite for pursuing an accretive deal given the increased financial flexibility of the balance sheet, and I'm wondering if you could just -- am I reading that right? previous conference calls, we've talked about options on the table to enhance shareholder value, share buybacks, bringing down debt, strategic deals but what I'm hearing from you today is a more outspoken commitment or desire to pursue something strategic. and then secondly, I'm very with the partnership that you signed with Pfizer in Japan and I'm wondering if you could put some numbers around that, what you see in terms of revenue potential over the next 5 years and what that means to your bottom line? And is this the type of partnership that you see could be replicated in other countries such as emerging markets where, again, Pfizer doesn't have the AND capabilities that you have and you don't have the feet on the ground that Pfizer has?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, sure. So, look, to your first question, hopefully you'll see that as our continued commitment to be transparent. When I -- what I spoke of in my opening remarks was a combination, if you'll remember, of us continuing to execute in our existing platf",387,"Okay, sure. So, look, to your first question, hopefully you'll see that as our continued commitment to be transparent. When I -- what I spoke of in my opening remarks was a combination, if you'll remember, of us continuing to execute in our existing platform, continuing to execute against the growth drivers we pointed out. And then obviously, the last point was to looking at ways that we're going to use our increased financial flexibility. And I think, as you have seen, that has been a combination and I think it will continue to be. There's a lot of ways to increase shareholder value and I think what you can rely on is that we're looking at all of them. And we certainly are looking at any and all compelling acquisition that would allow us to continue to deliver or accelerate the that we're already on. And when look at what we have put out there with our own assets at this time, a 15% CAGR in 2018 is an impressive growth target out there. And I think that as this financial flexibility just gives us all that much more ability to accelerate not only that growth, but like I said, in many different ways. As far as Japan goes, I think it's an unprecedented deal in our industry. I think it truly does take the core competencies of both of our organizations and we believe that 1 plus 1 will equal 3 plus. It's about really leveraging the scale and scope and the quality of what we both bring to the table. So while we don't get into putting numbers out there on individual countries, I think you certainly can expect that we believe that this is accretive to our current standalone Generics business, as well as accretive to their standalone Generics business. And that's why the rationale of this deal made all the sense in the world. And I very much believe that it could be a model in other countries where the troops on the ground are important, the brand is important, but having the breadth and the quality of a pipeline is equally as important. And that's where this makes all the sense in the world and very much could make sense in other countries as we move forward. Okay, operator, next question?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question the line of of RBC Capital Markets.",10,"Our next question the line of of RBC Capital Markets."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just going back to question on potential acquisitions and ways to enhance shareholder value, you did mentioned that you aren't going to do anything just for the sake of doing a deal. Can you talk about the kind of things you are looking for and just expan",115,"Just going back to question on potential acquisitions and ways to enhance shareholder value, you did mentioned that you aren't going to do anything just for the sake of doing a deal. Can you talk about the kind of things you are looking for and just expand on what you meant by that. Are you finding valuations to too high or is it what you're looking for at the moment. And then second, a question on fenofibrate, you got the capsules approved a couple of days ago, can you just give us your expectation around the launch of that product including whether or not you have something quantity sufficient quantities for year for the market?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, sure. As far as acquisitions goes, as we've laid out certainly, we don't do an acquisition just to do an acquisition, and I'm not had outgunned ahead to do an acquisition. I think what you hear essays that we continue to now generate significant fre",266,"Okay, sure. As far as acquisitions goes, as we've laid out certainly, we don't do an acquisition just to do an acquisition, and I'm not had outgunned ahead to do an acquisition. I think what you hear essays that we continue to now generate significant free cash flows and have increased flexibility and our looking at all compelling acquisitions. And that could be anything that can be complementary to our current platform. So whether you look at the Specialty side, geography, dosage form, therapeutic category, we have a voluminous number of different ways to continue to accelerate this growth trajectory and we're looking at all of them. As well as in combination to share repurchase programs. I think that the great news is when you look at the kind of cash we have on hand, we have a lot of different ways to get at least to that $6 in 2018 and continuing to show that kind of growth year-over-year that we've I think now, hopefully, have shown that track record of producing year-over-year. So like I said, you're right, we're not just looking at a transaction for transaction's sake, but we certainly are in a position to be looking at all the compelling ones. And as far as your product question, yes, it was a good launch for us. But as you know, we're well beyond any single product launch, especially one of that size. I can tell you, we executed on it. And it's just one of many that we've had this year and we'll have over the next several. Okay, operator, next question."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our next question will come from the line of",11,"[Operator Instructions] Our next question will come from the line of"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","John, a question on the CapEx. In the past, we talked about some leverage in the CapEx as we go from 2012 to 2014. Looking at the guidance for next year versus this year, 7% to 8% growth in earnings at a minimum, how should we think about the CapEx, shoul",74,"John, a question on the CapEx. In the past, we talked about some leverage in the CapEx as we go from 2012 to 2014. Looking at the guidance for next year versus this year, 7% to 8% growth in earnings at a minimum, how should we think about the CapEx, should we grow linearly or should we have a step up in the -- not in the CapEx, in the free cash flow generation?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Ronnie, I think that this -- I think that what you saw happen or what you saw in the results of this quarter was a cash flow generation, the strength of this global platform to generate and throw off cash. And also as you can see, we reduced our expectati",188,"Ronnie, I think that this -- I think that what you saw happen or what you saw in the results of this quarter was a cash flow generation, the strength of this global platform to generate and throw off cash. And also as you can see, we reduced our expectations for capital spending for the year from 350 to 300 the combination of those 2 increasing the free cash flow by $100 million and allowing us to bringing our leverage down to 2.6x after paying $100 million back in the 1st week of October. To be honest with you, I don't really want to give future expectations as to what 2013 or 2014 is going to be, that's not the purpose of the call today. But what I can tell you and it's demonstrated by the working capital efficiency that we've had here in 2013, is that our global operating team are intensely focused on generating cash and then for our ability to put that cash back to work in the business for the benefit of our shareholders. And I think that for today, I'll leave it there."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay next question.",3,"Okay next question."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes of the line of David Risinger of Morgan Stanley.",13,"Our next question comes of the line of David Risinger of Morgan Stanley."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","John, I was hoping that you could just walk us through the financials associated with that partnership with Pfizer and just help us understand how that impacted the revenue in Asia-Pacific and in the quarter, and how will impact things going forward. Just",80,"John, I was hoping that you could just walk us through the financials associated with that partnership with Pfizer and just help us understand how that impacted the revenue in Asia-Pacific and in the quarter, and how will impact things going forward. Just so that we can out there was an incremental positive from that deal in the September quarter that is noticeable on the financials and whether that will continue or whether it's really not noticeable in the financials?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","You won't have to tease it out because although we announced the formation of the partnership, David, the partnership will actually be become -- begin operating here around the end of this year, early next year so that there was no impact of the partnersh",81,"You won't have to tease it out because although we announced the formation of the partnership, David, the partnership will actually be become -- begin operating here around the end of this year, early next year so that there was no impact of the partnership in our third quarter results. What you'll see in our Asia-Pacific results represents the organic growth of our operations in Asia-Pacific and will most likely be that way for Q4 2012 also. Next question, operator."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Greg Gilbert from Merrill Edge.",10,"Our next question comes from Greg Gilbert from Merrill Edge."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, with the third quarter in a row of the group improving growth rates in Europe, are you ready to predict positive growth for that segment going forward? Is a psycho qualitative comments were quite bullish, too. And then, is there any doubt that ex",75,"Heather, with the third quarter in a row of the group improving growth rates in Europe, are you ready to predict positive growth for that segment going forward? Is a psycho qualitative comments were quite bullish, too. And then, is there any doubt that excel generic products just fine in light of some impact issues I think this is obviously important for Mylan and the broader public trust in generics and the trade, et cetera?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. Greg, So look, I think as far as Europe is concerned, we have seen continued improvement and we don't really foresee that stopping. I mean quite honestly, I think when you compare everything, as I said, conversion rates increasing, our leadership po",316,"Sure. Greg, So look, I think as far as Europe is concerned, we have seen continued improvement and we don't really foresee that stopping. I mean quite honestly, I think when you compare everything, as I said, conversion rates increasing, our leadership position in our most important countries I think where we see obviously still competitive pressures but see that volume offsetting that. Those are all the kinds of things that certainly we, from our measurement and what we're looking for, is important. And we start to see all 3 of those things hitting. And like I said, we do foresee that continuing. So that's kind of -- as far as I'm willing to go with my crystal ball, but I can tell you we're excited about the direction Europe's moving and see that continuing. As far as trend, look, I think that it's very important to understand that this is a one-off issue and it really does not speak to the generic industry. I will say it speaks to the pharmaceutical industry overall as you know from time to time as FDA continues to gather data and look at data. There's times where they've taken brand products off the market as well as changing guidelines and changing specs. So this is something that's constantly going on within the FDA in looking and working with companies. I think in this particular instance, it was certainly related to patient safety. FDA made a judgment call our years ago around the 300 milligrams and with the data today that they're looking at has caused them to get to a different place. Certainly, we don't see those events impacting our product and believe this was certainly in relation to just one in particular formulation. So I would tell you that our industry is alive and well and don't really see that's having any impact on that whatsoever. Next question?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Elliot Wilbur of Needham & Company.",10,"Our next question comes from Elliot Wilbur of Needham & Company."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","A question for you, Heather, around your pending application for generic version of Lidoderm management made some very pointed comments about their perceived or their perceptions around your ability to obtain approval for the product on its aqueous nonaqu",165,"A question for you, Heather, around your pending application for generic version of Lidoderm management made some very pointed comments about their perceived or their perceptions around your ability to obtain approval for the product on its aqueous nonaqueous nature the bop possibility of some excipient and in issues I'm assuming that you don't agree with that, but maybe you can sort of comments a little bit on sort of their observations? And then with Watson now having obtained approval, still some ambiguity around the issue of exclusivity, the FDA made it very clear in the approval letter  that Watson didn't obtain approval within 30 months but did not actually make a decision on exclusivity. You said previously that he still fought generic Lidoderm is a possibility terms of your ability to launch in 2013 and I'm just wondering if you still believe that to be the case based on anything new that's happening to the FDA application of them is on the Watson approval?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So I'll start with comment. I guess what I would say, not only do I not agree with them, I have to believe that there credibility should be extremely tarnished at this point. Based at all the exact same things about Watson. Watson was never going to",243,"Sure. So I'll start with comment. I guess what I would say, not only do I not agree with them, I have to believe that there credibility should be extremely tarnished at this point. Based at all the exact same things about Watson. Watson was never going to be able to get an approval. They had all kinds of issues and certainly and was proven to be wrong. I think when you look at trying to stress that based on their experience and expertise in this development, this is not their product, they've been licensed. I think to talk about what kind of science is out there and who has the capability, I can assure you, we are manufacturing and developing our own products and I believe we do have the expertise and the track record with FDA to know and to be able to guide of what we're capable of doing. So that's what I would say about and goats comic and the absolute and so we continue to see this as a possible opportunity in the second half of the year. As you know, FDA historically doesn't make exclusivity decisions until they have to. And we maintain our ability to get this product approved in 2013 and be able to manufacture the quantities needed. And like I said, we still absolutely believe we have the potential for this to be upside second half of '13. So thank you and next question?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Chris Schott of JP Morgan.",10,"Our next question comes from Chris Schott of JP Morgan."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just 2 quick was here. The first was coming back to some of the earlier business development comments. I guess the financial facility are talking about here open up transactions that you might not have been able to pursue in the past i.e. larger transacti",125,"Just 2 quick was here. The first was coming back to some of the earlier business development comments. I guess the financial facility are talking about here open up transactions that you might not have been able to pursue in the past i.e. larger transactions? I was trying to understand here of fiscal of what you're looking at this has changed or comment that the sum of assets you considered before? The second question was on your revivalism see some encouraging macro trends adjusted to talk a little bit more about the competitive dynamics, what you see the market less quarter discuss a bit of a shift focusing more profitability versus sure you're of just wondering how you see the overall competitive environment shaking out?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","So quick on the acquisitions, here's what I say. This, obviously we came out to a commitment with the Street over the last several years that we were going to be deleveraging and executing on the assets that we have. And I think that's what I said this qu",211,"So quick on the acquisitions, here's what I say. This, obviously we came out to a commitment with the Street over the last several years that we were going to be deleveraging and executing on the assets that we have. And I think that's what I said this quarter culminates in that activity. one, showing what this platform can produce, while at the same time accelerating our deleveraging capability. So certainly, what we're in a position now to do is definitely aside from scope and as I said I'll just revert back to say a very compelling -- there's a lot of compelling opportunities out there and we'll look at all of the. And just quickly on the environment in Europe my guess what I would say is we've always stressed the profitability as well as market share, as well as revenue growth and balanced all of that. I can't speak to other companies perhaps being as balanced as their commentary around Europe. But that's why I wanted to stress that I think that's definitely paid off for us, not only to maintain leadership position, but be able to execute what we can and we see that now has especially for our business in Europe turning that corner. Right, next question?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Gary Nachman from Susquehanna Financial Group.",14,"Our next question comes from the line of Gary Nachman from Susquehanna Financial Group."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, on EpiPen, anything you're different differently to prepare Sanofi's launch of next month and do you have a sense of what the pricing dynamics will look like with them in the market? And just what type of growth are you seeing in the market overa",51,"Heather, on EpiPen, anything you're different differently to prepare Sanofi's launch of next month and do you have a sense of what the pricing dynamics will look like with them in the market? And just what type of growth are you seeing in the market overall if you could quantify that?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. The first, like to say that Sanofi has said they're not launching until 2013. But anyway, as far as it relates to look, I think when got a leadership position likely to at 98% of the market, our ability to build that brand equity and make sure that",188,"Sure. The first, like to say that Sanofi has said they're not launching until 2013. But anyway, as far as it relates to look, I think when got a leadership position likely to at 98% of the market, our ability to build that brand equity and make sure that we're continuing to stress and tried and true nature of EpiPen, being around for over 20 years, delivering over  40 million scripts and that is our position in the marketplace. And as we said before, another competitor coming to market in this is this is just shared was voice in increasing that awareness. I think that when you look at what we have been doing to increase that awareness, as I said in my remarks, it's been paying off we've now gone from 7% of the people at-risk to now 10% of the people at-risk with an EpiPen. So obviously, we still see tremendous growth and opportunity for this franchise and the disease state overall. So, look, we're excited about EpiPen, still have a lot that we're executing on we'll be continuing to do so. So operator, next question?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Our next question comes from Michael Faerm of Credit Suisse.",10,"Our next question comes from Michael Faerm of Credit Suisse."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Quick 2 quick questions. One, on the respiratory bye-bye could you just provide an update on status of the COPD candidate, if and when we might see Phase II data? And then a general question on the North America Generics business, what are some of the key",68,"Quick 2 quick questions. One, on the respiratory bye-bye could you just provide an update on status of the COPD candidate, if and when we might see Phase II data? And then a general question on the North America Generics business, what are some of the key drivers now that propel growth next year as you move into a year with fewer launches that you've had this year?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","I'll quickly take the North America question. Look, I think that what we've continued to stress is that we're not about any 1 country, 1 product. It is about literally be able to optimize and leverage our global scale and platform in every country we do b",123,"I'll quickly take the North America question. Look, I think that what we've continued to stress is that we're not about any 1 country, 1 product. It is about literally be able to optimize and leverage our global scale and platform in every country we do business and, the United States not be any different. We have tremendous opportunities from our existing businesses, the largest we did have this year coupled with the largest we have next year, I mean over the last 5 years, we've not had the same number of launches every year, but we've certainly been able to show a trajectory. And like I said, we see that continuing. As far as our respiratory business, Rajiv, you want to?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","I think one is which remains on track and we will kick off our Phase III summer of the and next year 2013. And the second which is also remains on track '15, '16 global launches.",36,"I think one is which remains on track and we will kick off our Phase III summer of the and next year 2013. And the second which is also remains on track '15, '16 global launches."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Operator, next question?",3,"Operator, next question?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question s Ken Cacciatore of Company.",8,"Our next question s Ken Cacciatore of Company."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","I just wanted to go back to potential future acquisitions and strategic development. Is it usually by asset that is available, either brand or generic or do you have something in mind and you focus on that or is that what is ability at that moment in time",48,"I just wanted to go back to potential future acquisitions and strategic development. Is it usually by asset that is available, either brand or generic or do you have something in mind and you focus on that or is that what is ability at that moment in time?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Ken, what I would say is, as I hopefully, everyone has heard me now, loud a clear on this call is we certainly believe that there are many compelling opportunities out there and looking at all of them. And just believe that we've got a lot of ability to b",74,"Ken, what I would say is, as I hopefully, everyone has heard me now, loud a clear on this call is we certainly believe that there are many compelling opportunities out there and looking at all of them. And just believe that we've got a lot of ability to bring in something different complimentary assets to this business and those existing platforms that we have. And I'd say that's what I have to say."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","It may or may not be on the market.",9,"It may or may not be on the market."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","I mean we're looking -- you should know where not would send a sale and we're looking at everything. All right, operator, any more questions?",26,"I mean we're looking -- you should know where not would send a sale and we're looking at everything. All right, operator, any more questions?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from from Buckingham research.",8,"Our next question comes from from Buckingham research."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Personas on a Specialty business. Can you talk a little bit about what pricing was during the quarter? and then just on a settlement with Teva, can you talk about what your ability is to continue to pursue of needed to petition route to make your case wit",91,"Personas on a Specialty business. Can you talk a little bit about what pricing was during the quarter? and then just on a settlement with Teva, can you talk about what your ability is to continue to pursue of needed to petition route to make your case with the FDA on approval? And then for John, maybe for John, can you just talk about in terms of what you're looking at in terms of deals, is there a commitment to not use any type of equity financing or convertible equity financing?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay so quickly on Epi, we certainly have some pricing increases, we have 2 over the years and recently see it as I mentioned, volume increasing even more so than the price. As far as Teva and our settlement, we settled, just to be clear on the IP litigat",101,"Okay so quickly on Epi, we certainly have some pricing increases, we have 2 over the years and recently see it as I mentioned, volume increasing even more so than the price. As far as Teva and our settlement, we settled, just to be clear on the IP litigation, we continue to believe we they have significant hurdles to get an a B-rated product and I can assure you we're continuing -- not only are we continuing to pursue that, but believe that there are, like I said, many hurdles and challenges for them to get than A B-rated product. John?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","In terms of your question about M&A and currency that we would use in any transaction, I think it would be safe to assume that our focus is on use of cash for a transaction has I pointed that out in terms of the amount that we had available something $4 b",78,"In terms of your question about M&A and currency that we would use in any transaction, I think it would be safe to assume that our focus is on use of cash for a transaction has I pointed that out in terms of the amount that we had available something $4 billion or more. And so I think that use of a currency other than cash is not something we are currently focused on. Next question, operator?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Michael Tom of Wells Fargo severities.",11,"Our next question comes from Michael Tom of Wells Fargo severities."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just what question going back to business development and as you look at its how you evaluates different transactions, do you use any internal bar that or internal hurdles that you would compare a potential transaction like the type of accretion you would",57,"Just what question going back to business development and as you look at its how you evaluates different transactions, do you use any internal bar that or internal hurdles that you would compare a potential transaction like the type of accretion you would get from further deleveraging or share repurchases? Any color like that would be appreciated."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Well, Michael, I can assure that we look at many, many, many parameters when looking at the sources and use of capital. And I can tell you that we have been doing that and certainly for any acquisitions, we'll be doing that going forward. Depending on wha",113,"Well, Michael, I can assure that we look at many, many, many parameters when looking at the sources and use of capital. And I can tell you that we have been doing that and certainly for any acquisitions, we'll be doing that going forward. Depending on what part of whether the platform, what kind of a transaction it is, what that contribution means, but is year medium and long-term, all the states aren't taking into consideration as we compare them with other uses of capital. So I would say I would rest assured that we can look at many, many different parameters and have many different things internally that we take into consideration."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","So, operator, we have time for 1 one question.",9,"So, operator, we have time for 1 one question."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our final question comes from the line of Randall Stanicky of Canaccord Genuity.",13,"Our final question comes from the line of Randall Stanicky of Canaccord Genuity."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Of a fairly straightforward 1. Heather or John, can you just identify specifically some of the public U.S. generic opportunities in the next year to obviously is 1 of those. And then Heather, as you look at your U.S. generic base, obviously it expense of",63,"Of a fairly straightforward 1. Heather or John, can you just identify specifically some of the public U.S. generic opportunities in the next year to obviously is 1 of those. And then Heather, as you look at your U.S. generic base, obviously it expense of pipeline, what technologies don't you currently have that you would have an interest in potentially acquiring or developing?"
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives",", as far as detailed opportunities for 2013, I think as we mentioned early, we'll be coming to you with that in February. I mean I think obviously there's already a lot of public is out there around opportunities that we have in 2013, but we certainly we'",179,", as far as detailed opportunities for 2013, I think as we mentioned early, we'll be coming to you with that in February. I mean I think obviously there's already a lot of public is out there around opportunities that we have in 2013, but we certainly we'll be highlighting those more in February. And what was your -- the technology here's what I would say. When you look at our strengths lie extended-release, patch touch technology, I think we can continue to see an injectable space, that can be an area we can further increase therapeutic categories we're in. And so forth. Something dermatologic's topic of what about the luscious, that's an area where essentially to look. Now obviously the, we've already investing in the respiratory. So thing that is not so much a matter areas that we're not in at all but areas again that we can look to accelerate those positions in our positions within the U.S. marketplace. All right, well thank you, everybody, for the call and will look forward to talking to you on February."
290203,222537176,369966,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's Third Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m., East",77,"Welcome to Mylan's Third Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m., Eastern Time. The dial-in number is (800) 585-8367 or (404) 537-3406 for international callers, with pin number 36921750. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Maria. Good morning, everyone. Welcome to Mylan's Third Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice",487,"Thank you, Maria. Good morning, everyone. Welcome to Mylan's Third Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making numerous forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often may be identified by the use of words such as may, will, could, should, would, project, believe, anticipate, expect, plan, estimate, guidance, trends, forecasts, potential, intend, continue and variations of these words or comparable words.
Our forward-looking statements may today, including, among others, statements relating to anticipated business levels; trends in some European countries; planned launches of and anticipated exclusivity period for new products; our ability to achieve forecasted full year results while absorbing the impact of negative pricing pressures; expectations for capital expenditures; expectations for R&D, SG&A and other spending; our guidance range, future earnings, planned activities, anticipated growth and other expectations; and targets for future periods, including our expectations regarding the fourth quarter and for 2012 overall. Because these statements are forward looking, they inherently involve risks and uncertainties, and, accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the factors set forth under Forward-looking Statements in our recent earnings press release dated October 25, 2012, as well as the risk factors set forth in our report on Form 10-Q for the period ended June 30, 2012, and our other SEC filings. You can access our Form 10-Q and other SEC filings, including our earnings press release, which we filed on Form 8-K, through the SEC website at www.sec.gov, and we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures, such as adjusted revenue, adjusted gross margin and adjusted diluted EPS, should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with Generally Accepted Accounting Principles or GAAP.
Please refer to today's earnings press release, which is available on our website as well as on the SEC website, as it contains detailed reconciliations of the non-GAAP financial measures we use to our third quarter results prepared in accordance with GAAP.
Before I turn the call over to Heather, let me also remind you that material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'll now turn the call over to Heather."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us today. I'm pleased to announce that Mylan has once again delivered an outstanding quarterly performance marked by double-digit growth on both the top and bottom lines. Our third q",1569,"Thank you, Kris, and good morning, everyone, and thank you for joining us today. I'm pleased to announce that Mylan has once again delivered an outstanding quarterly performance marked by double-digit growth on both the top and bottom lines. 
Our third quarter constant currency revenues were up 20% year-over-year to $1.8 billion, and our adjusted diluted earnings per share grew 51% to $0.83. I'd like to note that we did more this quarter than we did in all of 2008 with essentially the same assets. This only further highlights the power of our organic growth capabilities. Of course, these milestones could only have been achieved through the hard work, dedication and commitment of all of our employees. On behalf of the Board of Directors and our entire management team, I would like to thank all of them.
Now with 3 very successful quarters behind us this year, we are raising our 2012 adjusted EPS guidance range to $2.50 to $2.60 per share. We also are reaffirming our 2013 target of $2.75 per share and our longer-term target of at least $6 per share in 2018. We expect to provide detailed guidance for 2013 in February when we release our fourth quarter and year-end results. We will discuss our longer-term outlook in July during our Investor Day event, which we will host in New York. 
Our ability to deliver consistently strong results, take swift advantage of our opportunities and become ever more efficient, all while mitigating risk and absorbing economic headwinds and price cuts, give Mylan a unique profile in this industry. With that said, our expectation of continued growth will come from a combination of things: first, from the continued organic growth of our very strong and powerful existing platform; second, from executing against the strategic growth drivers we outlined during our Investor Day; and third, and importantly, from our ability to continue generating significant free cash flows, which allowed us to accelerate our deleveraging and get to our current 2.6:1 debt-to-EBITDA, well below our target. Therefore, we are actively looking at a number of ways to use our increasing financial flexibility to help us accelerate our longer-term targets and enhance shareholder value.
Against this backdrop, I'd like to walk you now through Mylan's outstanding third quarter performance, which was characterized by strong double-digit revenue growth in our Specialty, North America and Asia Pacific businesses and a return to growth in Europe. In addition, our gross margin increased nearly 400 basis points year-over-year to 52%.
Starting with North America generics business, we reported third-party net revenues of $831 million, a year-over-year increase of 19% at constant currency. Driving the increase were new product launches during the quarter, which contributed to $258 million and included Valsartan and HCTZ in September with 180 days of exclusivity, Modafinil in August and pioglitazone and pioglitazone Metformin also in August, and those with 180 days of exclusivity. The launches offset lower pricing and volume on existing products. 
As of the end of the third quarter, we had introduced 47 new products this year in the U.S., including 17 that were first-to-file or limited competition. In Canada, as of the end of the third quarter, we had launched a record 22 new products, revenues from which contributed to favorable year-over-year sales growth in that market. 
In addition, revenues from our Institutional business grew by nearly 25% on a constant currency basis during the quarter with new products and higher volumes responsible for most of the growth. 
In Europe, we reported third-party net revenues of $326 million, a year-over-year increase of 3% at constant currency. Many of our European markets realized increased sales, an encouraging sign that the region may finally be turning a corner. In addition, I'd note that as of the second quarter, the latest period for which data are available, generic utilization has risen year-over-year in the 19 European countries where we do business. As of the end of the third quarter, Mylan executed 270 country product launches in Europe during the year. These launches, along with favorable volumes on existing products, where the primary drivers of our improved performance during the third quarter. The higher product volumes included double-digit growth in France, Italy and Spain, which offset some lower pricing resulting from government mandates and competitive conditions. 
France saw the most significant revenue increase in absolute terms as local currency sales rose 9% compared to last year's third quarter. In addition to new product launches, revenues benefited from the recently signed pharmaceutical convention, which contributed to a 7% point increase in substitution among repertoire-listed products from May to August. We also are seeing growth in the French generics market overall in volume and value, and we remain the market leader. 
We observed similar trends in Italy where new products and higher volumes more than offset the impact of government-mandated price reductions. I'd also note that Italy's government has passed a law requiring general practitioners to prescribe INN products for patients starting new treatments for chronic and acute conditions. Italy is one of the fastest-growing generic markets in Europe, and we are the country's fastest-growing major player.
In Asia Pacific, we reported third-party net revenues of $339 million, a year-over-year constant currency increase of 21%. Our Mylan Lab subsidiary in India, along with Japan and New Zealand, all experienced higher third-party sales. India accounted for the majority of the increase due to significant sales growth of finished-dosage-form ARVs and significant growth in API. 
In Australia, where we continue to maintain our leadership position, sales were lower operationally due mainly to steep price cuts made by the government during the year. 
Sales in Japan rose with higher volumes mainly in the distributor channel, and new product launches offset NIH pricing cuts that took effect during the first quarter. In addition, we continue to see increased generic utilization. 
Also during the third quarter, we announced an exclusive long-term strategic collaboration with Pfizer to drive sustained growth for our combined Generics business in Japan. This unique partnership, unprecedented in our industry, leverages the core strength of both organizations and creates a powerful platform that we expect will be a leader in Japan in terms of scale, scope and quality. 
Our Specialty segment, we reported third-party net revenues of $294 million, a year-over-year increase of 37%. Sales of EPIPEN in the U.S. accounted for most of the increase with a growth of more than 50% compared to the same period in 2011. Our third quarter is essentially the strongest for sales of this product, and our growth this quarter came off a very strong quarter last year. 
I'd also note that we continue to see our efforts around market expansion pay off. Through the first 9 months of 2012, the percentage of at-risk individuals in the U.S. who have billed [ph] their prescription for EPIPEN auto-injector has risen from 7% to 10%. More importantly, the growth potential for this franchise remains significant.
As I move on now to some of our other drivers of growth through 2018, I'd like to reinforce that each driver and our broad basket of opportunities is weighted based on its unique risk-reward profile and projected long-term contribution. Our success and ability to achieve our targets doesn't depend on any one driver, and instead, our success is based on the global scale and leverage we have created and our ability to invest and execute on these opportunities. 
With respect to our global Institutional business, we continue to grow and expand our relationships with key customers and invest in the future of this franchise. A few weeks ago, we agreed to purchase an oncology manufacturing facility in India from SMS Pharmaceuticals. The facility will produce active pharmaceuticals in finished dosage forms and begin commercial operation as soon as the FDA completes its inspection, which is expected to occur in the next few months. The transaction should close early in the first quarter of 2013.
With respect to geographic expansion, we launched commercial operations in India in August, entering the market with a comprehensive portfolio of ARV products for the treatment of HIV/AIDS. We also were selected as a leading supplier of ARV drugs to India's National AIDS Control Organization. I'd note that both of these developments also support our ARV growth driver. And in addition to our expansion in India, we are poised to establish a physical presence shortly in Thailand. 
Portfolio diversity is another important growth driver, and we remain excited about the women's health care Franchise we are establishing in partnership with Famy Care. During the third quarter, we launched 2 oral contraceptives in Germany. We also launched one this week in Canada. And in addition, we have 34 oral contraceptives pending approval with the FDA and expect commercialization to begin in next year's first quarter.
With respect to our biologics driver, we have continued to advance the development of our 5 lead products. We have held positive meetings with the authorities in the U.S. and Europe to discuss our biologics program. In addition, we are pleased to report that we initiated our first global Phase III clinical trial on Herceptin in October. 
Clearly, Mylan continues to operate and grow from a position of great strength, and we look forward to leveraging that strength further to deliver even more value to our shareholders. With that, I'll now turn the call over to John, and I look forward to responding to your questions."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I'll refer you back to Chris' comments at the beginning of to",1918,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I'll refer you back to Chris' comments at the beginning of today's call regarding our use of adjusted measures.
Let me start by saying by any measure, the third quarter of 2012 was an exceptional quarter for Mylan. I would like to highlight upfront some of our financial accomplishments. 
Quarterly revenue of $1.8 billion, the highest amount of revenue in any quarter in our company's history, and revenue grew on a constant currency basis in every region of the world including Europe. 
Adjusted diluted earnings per share of $0.83, more than we earned in all of 2008 and were achieved while continue to invest in new product development and sales and marketing initiatives. 
Adjusted operating cash flow of $469 million, the most ever for our company in one quarter, and free cash flow of $424 million, which allowed us to repay borrowings during the quarter of $459 million. 
And to the end of the quarter -- and to end the quarter with a growth leverage ratio of 2.7:1, or 2.6:1 when you consider an additional $100 million of borrowings, which we repaid in early October.
On the heels of this strong quarter, we are once again increasing our range of EPS guidance for the full year 2012. We're now projecting adjusted diluted EPS of between $2.50 and $2.60 per share, increased from our previous range of $2.45 to $2.55 per share. We are also revising upward our free cash flow expectations for 2012. We now expect adjusted operating cash flow to be approximately $1 billion in 2012, which is at the very upper end of our 2012 operating cash flow guidance range of $900 million to $1 billion. 
Additionally, as a result of the timing and rationalization of some of our capital programs, our gross capital spending in 2012 is now anticipated to approximate $300 million. The net of these 2 amounts represents our current 2012 free cash flow expectation of approximately $700 million, or $100 million higher than the midpoint of our previously communicated expectations.
Our remaining guidance metrics for 2012 remain unchanged, and I'll walk through each of them in a few minutes. And our targets for 2013 and beyond remain unchanged.
In February, in conjunction with our fourth quarter call, we will provide detailed 2013 financial guidance, which reflects recent developments at our most up-to-date outlook.
So Mylan has never been better positioned as a company. Today, we possess an unmatched vertically integrated footprint, a broad and growing product portfolio with a robust pipeline of future new product launches and longer-term strategic growth drivers such as our respiratory and biologics platforms. 
Additionally, though, Mylan possesses today the financial flexibility to take advantage of shareholder value accretion opportunity. With our current leverage ratio now meaningfully below our long-term target of 3:1 and our growing EBITDA, today we have over $4 billion of financial flexibility for earnings accretive transactions. That said, Mylan will do never do a transaction merely for the sake of a transaction or only for financial reasons. Any transaction must also be the right transaction strategically. Further, we remain committed to our 3:1 long-term growth leverage target. And if we increase our leverage above this target, we would be committed to deleveraging within an 18-month time frame.
With that introduction, let me now get into the details and walk you through our financial results for the third quarter and first 9 months of 2012. I will also provide an update on our capital structure and liquidity position. 
Starting at the top of our income statement, total adjusted revenues for the quarter were approximately $1.8 billion, an increase of 14% over last year's third quarter revenues of approximately $1.6 billion. Year-over-year revenue growth on a constant currency basis was approximately 19%. The 5% unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to each of the other functional currencies of our major operations mainly in Europe and India.
Our top line growth was driven by higher volumes on a consolidated basis, including significant amounts from our 2012 new product launches as well as favorable sales volume in Europe and Asia Pacific, which served to more than offset the unfavorable impact of lower pricing throughout the world. In fact, driven by higher volumes and new product introductions, each of the countries in Europe in which we have significant operations, with the exception of Germany, turned in favorable year-over-year constant currency sales growth. 
For the first 9 months of 2012, total adjusted revenues were approximately $5.1 billion, an increase of 10% over revenues from the first 9 months of 2011, or 14% on a constant currency basis. As a reminder, our guidance range for total revenues for the full year 2012 is between $6.8 billion and $7.2 billion. Recognizing current exchange rates and using them to forecast the remainder of the year, we expect to be near the low end of this guidance range as a result of the unfavorable impact of changes in foreign exchange rates. On a constant currency basis, however, we are projecting to be closer to the midpoint of the range.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 third quarter at 52% was above our guidance range of 48% to 50% and represented an increase over the same prior year period of nearly 400 basis points. This increase was driven by new product launches and favorable volumes and pricing on our EPIPEN auto-injector, partially offset by lower margins on existing products. The current quarter also saw margin improvement from our Indian subsidiary, where sales and gross profit benefited from the effects of a stronger dollar as compared to the rupee as a significant portion of its sales are denominated in U.S. dollars.
For the 9 months ended September 30, 2012, adjusted gross margins were 50% as compared to 48% in the prior year. We currently expect to be at the upper end of our gross margin guidance range for the full year.
Adjusted operating income was $513 million for the third quarter of 2012, a 32% increase from Q3 2011 and up 29% from the second quarter of 2012. The year-over-year increases, which is primarily the result of the favorable gross profit, was realized in spite of increased levels of investment in both R&D and SG&A. 
R&D expense for the quarter on an adjusted basis was $104 million, or approximately 5.8% of total revenues, and up approximately 51% from the prior year. This increase was mainly a result of ongoing spending with respect to our respiratory and biologics program, including clinical studies. 
At the same time, SG&A, also on an adjusted basis, was $324 million for the quarter, or approximately 18% of total revenues, and up approximately 5% over the prior year. The increase in SG&A in the current quarter is due in large part to increased selling and marketing in our Specialty franchise. Also contributing to the year-over-year increase were higher payroll and related costs as we continued to build out our infrastructure platform in certain targeted areas.
For the 9-month period, adjusted R&D expense was $277 million, up 28% over the prior year. As a percentage of revenues, R&D expense to date for 2012 is 5.5%. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues, and we continue to believe that the full year spend will be at or slightly below the midpoint of our guidance range.
SG&A expense on an adjusted basis for the 9 months ended September 30, 2012, was $964 million, an increase of nearly 10% and within our full year guidance range of 18% to 20% of total revenues. 
Adjusted EBITDA was $567 million and $1.4 billion for the 3- and 9-month periods ended September 30, 2012, respectively. We expect to be near the middle to upper end of our guidance range of $1.75 -- or $1.75 billion to $1.95 billion for the full year.
Moving on to our consolidated, nonoperating financial metrics. Adjusted interest expense for the third quarter of 2012 was $61 million. We continue to benefit from low short-term interest rates. As of September 30, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70-30 fixed-floating debt portfolio, which we believe is an optimal ratio. 
Adjusted interest expense for the 9-month period was $183 million and is forecasted to be at the low end of the guidance range of $245 million to $265 million for the full year.
Our adjusted effective tax rate in the current quarter was 26% compared to 27% a year ago. Our full year 2012 tax rate range is between 26% and 27%, and we continue to believe that we will be at the lower end of this range for the calendar year 2012.
Third quarter adjusted net income was $341 million, or $0.83 a share, a 51% increase from our Q3 2011 adjusted diluted EPS of $0.55 per share. For the 9 months, adjusted net income was $820 million, or $1.94 per share, a 28% increase over the same prior year period. 
As I mentioned previously, our guidance range for adjusted diluted EPS is now $2.50 to $2.60 per share. Our estimate of diluted shares for the full year is approximately 420 million.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis, which takes into account the special items which are outlined in our press release, was approximately $818 million for the year-to-date period and a very strong $469 million for the quarter. Our GAAP cash flow from operations for the current quarter and year-to-date periods was a very strong cash inflow of $460 million and $652 million, respectively, and left us with unrestricted cash and marketable securities totaling $366 million. As noted earlier, we were forecasting our full year 2012 adjusted operating cash flow to be approximately $1 billion, the high end of our guidance range.
We have been very focused throughout 2012 on operating working capital. On a constant -- on constant currency net sales growth of 19% in the third quarter and 14% through the first 9 months of 2012, we have been able to limit the growth in our operating working capital to approximately 9%, exclusive of FX impacts, as we continue to bring operational efficiencies to our global platform.
Third quarter capital spending was $61 million, bringing the total for the year-to-date period to nearly $160 million. And as a result of the timing of planned expenditures, we expect full year capital expenditures to approximate $300 million.
As I mentioned before, these updated estimates yield a current free cash flow estimate of $700 million for the year, which is $100 million stronger than our previously communicated expectation as we continue to generate an increasing amount of cash flow from our global platform.
To summarize, our third quarter exceeded even our high expectations and, as anticipated, positions us for a very strong finish to 2012. Our strong track record for organic growth, coupled with the long-term growth drivers, which Heather discussed, and our significant financial flexibility all translate into what should be an exciting 2013 and beyond for Mylan. 
That concludes my remarks. I'll turn the call over to the operator for Q&A. Maria?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from the line of Marc Goodman of UBS.",14,"[Operator Instructions] Our first question comes from the line of Marc Goodman of UBS."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Yes, I had a couple of questions. First, on U.S. business, which obviously had a fantastic quarter, there were just a lot of launches. And given Diovan and Actos, I actually would have thought revenues would have been even a little higher. So maybe you ca",133,"Yes, I had a couple of questions. First, on U.S. business, which obviously had a fantastic quarter, there were just a lot of launches. And given Diovan and Actos, I actually would have thought revenues would have been even a little higher. So maybe you can just comment on some of the launches there and just the absolute amount of the way we should be thinking about that. Second, Europe, obviously great news there. Can we talk about profitability and how that's changed throughout the year and what you're doing there to increase profitability? And then third, can you just talk about the Institutional business a little bit more? how many new products should we be expecting to launch out of that? And how big a business are you looking to build there?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So Marc, I'll start with the U.S. So I guess I'd like to first start off by saying against our estimates, our U.S. business performed right in line with where we thought it would be. So while we absolutely had a significant amount of launches that w",478,"Sure. So Marc, I'll start with the U.S. So I guess I'd like to first start off by saying against our estimates, our U.S. business performed right in line with where we thought it would be. So while we absolutely had a significant amount of launches that we forecasted and projected at the beginning of the year, that '12 would be a great year for our U.S. Generics business. I think that if you look at the timing of the launches throughout the quarters, and some of that pulled through even from launches we had earlier in the year, so all I can tell you is that absolutely performed in line with where we thought it would. We think it still is showing strength in the base business as well as our continued launches that we have for the remainder of the year. So from our perspective, U.S. business, hitting on all cylinders. Europe profitability, I think as we have talked about in the past that we constantly, through this entire macroeconomic situation throughout Europe, have balanced our top and bottom line growth. You've heard me quarter after quarter coming and saying we weren't going to chase the bottom, that there's been irrational behavior and that we would continue to hold steady and control what we can control. So in this period of time, we've done just that. We've continued to increase the profitability around our cost of goods by continuing to vertically integrate and be 100% responsible for our global supply chain. We've continued to make sure that we're structured in the right way with some of the evolving businesses and as they are continuing to change in the different countries. And I think most importantly, and why I wanted to point out in my script, that in all the countries we're doing business, we see an increase in generic conversion. And I think that should be the brightest spot of all because what it shows is that governments very much are beginning to recognize the long-term sustainability that generic utilization brings versus a onetime price cut. So we've seen additional initiatives in Italy, we've seen additional initiatives in France that are bringing those back up. So from my perspective, we certainly have always maintained a need to balance profitable and revenues. I think that our results this quarter are paying off from how we're operating our business in Europe. And lastly, on the Institutional side, in February, we showed our Institutional business being an important strategic growth driver for us. We are continuing to invest in that business. We have numerous launches. We're continuing to very much accelerate our own internal R&D pipeline around this businesses globally. So all I can say is that we certainly are continuing to invest and continue to see this as a very important growth driver for us in the future."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Jami Rubin of Goldman Sachs.",10,"Our next question comes from Jami Rubin of Goldman Sachs."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, both you and John, I think, were the most clear about the company's increased appetite for pursuing an accretive deal given the increased financial flexibility of the balance sheet. I'm wondering if you can just -- am I reading that right? In pre",175,"Heather, both you and John, I think, were the most clear about the company's increased appetite for pursuing an accretive deal given the increased financial flexibility of the balance sheet. I'm wondering if you can just -- am I reading that right? In previous conference calls, we've talked about options on the table to enhance shareholder value: share buybacks, bringing down debt, strategic deals. But what I'm hearing from you today is I think a more outspoken commitment or desire to pursue something strategic. And then secondly, I'm very intrigued with the partnership that you signed with Pfizer in Japan, and I'm wondering if you could put some numbers around that, what you see in terms of revenue potential over the next 5 years and what that means to your bottom line. And is this the type of partnership that you see could be replicated in other countries, such as emerging markets where, again, Pfizer doesn't have the AND capabilities that you have and you don't have the feet on the ground that Pfizer has?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, sure. So look, I  think to your first question, hopefully you see that as our continued commitment to be transparent. When I -- what I spoke of in my opening remarks was a combination, if you'll remember. I said of us continuing to execute on our ex",390,"Okay, sure. So look, I  think to your first question, hopefully you see that as our continued commitment to be transparent. When I -- what I spoke of in my opening remarks was a combination, if you'll remember. I said of us continuing to execute on our existing platform, continuing to execute against the growth drivers we pointed out. And then obviously, the last point was to looking at ways that we're going to use our increased financial flexibility. And I think, as you have seen, that has been a combination, and I think it will continue to be. There's a lot of ways to increase shareholder value, and I think what you can rely on is that we're looking at all of them. Now we certainly are looking at any and all compelling acquisitions that would allow us to continue to deliver or accelerate the trajectory that we're already on. I mean, when look at what we have put out there with our own assets at this time, a 15% CAGR in 2018 is an impressive growth target out there. And I think that as -- this financial flexibility just gives us all that much more ability to accelerate not only that growth but, like I said, in many different ways. As far as Japan goes, look, I think it's an unprecedented deal in our industry. I think it truly does take the core competencies of both of our organizations, and we believe that 1 plus 1 will equal 3-plus. It's about really leveraging the scale and scope and the quality of what we both bring to the table. So while we don't get into putting numbers out there around individual countries, I think you certainly can expect that we believe that this is accretive to our current stand-alone Generics business as well as accretive to their stand-alone Generics business, and that's why the rationale of this deal made all the sense in the world. And I very much believe that it could be a model in other countries where the troops on the ground are important, the brand is important, but having the breadth and the quality of a pipeline is equally as important. And that's where this makes all the sense in the world and very much could make sense in other countries as we move forward."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line Shibani Malhotra of RBC Capital Markets.",13,"Our next question comes from the line Shibani Malhotra of RBC Capital Markets."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just going back to Jami's question on potential acquisitions and ways to enhance shareholder value, you did mention that you aren't going to do anything just for the sake of doing a deal. Can you talk about the kind of things you are looking for? And just",121,"Just going back to Jami's question on potential acquisitions and ways to enhance shareholder value, you did mention that you aren't going to do anything just for the sake of doing a deal. Can you talk about the kind of things you are looking for? And just expand on what you meant by that? Are you finding valuations to too high? Or is it -- are you just not finding what you're looking for at the moment? And then second, a question on fenofibrate. You got the capsules approved a couple of days ago. Can you just give us your expectations around the launch of that product, including whether or not you had sufficient sort of quantities for the market?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, sure. Thank you, Shibani. As far as acquisitions go, I think as we've laid out, certainly we don't do any acquisition just to do an acquisition and then not having [ph] gone ahead to do an acquisition. I think what you hear us saying is that we cont",277,"Okay, sure. Thank you, Shibani. As far as acquisitions go, I think as we've laid out, certainly we don't do any acquisition just to do an acquisition and then not having [ph] gone ahead to do an acquisition. I think what you hear us saying is that we continue to now generate significant free cash flows and have increased flexibility and are looking at all compelling acquisitions. And that could be anything that could be complementary to our current platform. So whether you look at the Specialty side, geographies, dosage form, therapeutic categories, I mean, we have a voluminous number of different ways to continue to accelerate this growth trajectory and we're looking at all of them, as well as in combination to share repurchasing programs. I mean, I think that the great news is when you look at the kind of cash we have on hand, we have a lot of different ways to get at least to that $6 in 2018 and continuing to show that kind of growth year-over-year that we've, I think, now, hopefully, have shown that track record of producing year-over-year. So like I said, you're right, we're not just looking at a transaction for transaction's sake, but we certainly are in a position to be looking at all the compelling ones. And as far as your product question, yes, it was a good launch for us. But as you know, we're well beyond any single product launches, especially one of that size. I can tell you we executed on it. And it's just one of many that we've had this year and will have over the next several. Okay, thank you."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our next question will come from the line of Ronny Gal of Sanford Bernstein.",16,"[Operator Instructions] Our next question will come from the line of Ronny Gal of Sanford Bernstein."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","John, question on the CapEx. In the past, you talked about some leverage in the CapEx as we go from 2012 to 2014. Looking at the guidance for next year versus this year, still 7% to 8% growth in earnings at a minimum. How should we think about the CapEx?",80,"John, question on the CapEx. In the past, you talked about some leverage in the CapEx as we go from 2012 to 2014. Looking at the guidance for next year versus this year, still 7% to 8% growth in earnings at a minimum. How should we think about the CapEx? Should we grow linearly? Or should we have a step-up, a further step-up in the -- sorry, not the CapEx, in the cash -- in the free cash flow generation?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","So Ronny, I think that this -- I think that what you saw happen or you saw in the results in this quarter was the cash flow generation, the strength of this global platform to generate and throw off cash. And also, as you could see, we reduced our expecta",190,"So Ronny, I think that this -- I think that what you saw happen or you saw in the results in this quarter was the cash flow generation, the strength of this global platform to generate and throw off cash. And also, as you could see, we reduced our expectations for capital spending for the year from $350 million to $300 million, the combination of those 2 increasing the free cash flow by $100 million and allowing us to bring our leverage down to 2.6x after paying $100 million back in the first week of October. To be honest with you, I don't really want to give future expectations as to what 2013 or 2014 is going to be. That's not the purpose of the call today. But what I can tell you, and it's demonstrated by the working capital efficiency that we've had here in 2013, is that our global operating teams are intensely focused on generating cash and then for our ability to put that cash back to work in the business for the benefit of our shareholders. And I think that for today, I'll leave it there."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, thank you.",3,"Okay, thank you."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes of the line of David Risinger of Morgan Stanley.",13,"Our next question comes of the line of David Risinger of Morgan Stanley."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","John, I was hoping that you could just walk us through the financials associated with that partnership with Pfizer and just help us understand how that impacted the revenue in Asia Pacific in the quarter and how it will impact things going forward just so",83,"John, I was hoping that you could just walk us through the financials associated with that partnership with Pfizer and just help us understand how that impacted the revenue in Asia Pacific in the quarter and how it will impact things going forward just so that we can tease out whether there was an incremental positive from that deal in the September quarter that is noticeable in the financials and whether that will continue or whether it's really not noticeable in the financials."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","You don't -- you won't have to tease it out because although we announced the formation of the partnership, David, the partnership will actually be become -- begin operating here around the end of this year, early next year so that there was no impact of",83,"You don't -- you won't have to tease it out because although we announced the formation of the partnership, David, the partnership will actually be become -- begin operating here around the end of this year, early next year so that there was no impact of the partnership in our third quarter results. What you see in our Asia Pacific results represents the organic growth of our operations in Asia Pacific and will most likely be that way for Q4 2012 also."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Greg Gilbert of Merrill Edge.",10,"Our next question comes from Greg Gilbert of Merrill Edge."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, with the third quarter in a row of improving growth rates in Europe, are you ready to predict positive growth for that segment going forward? It sounds like your qualitative comments are quite bullish, too. And then, is there any doubt that your",77,"Heather, with the third quarter in a row of improving growth rates in Europe, are you ready to predict positive growth for that segment going forward? It sounds like your qualitative comments are quite bullish, too. And then, is there any doubt that your WELLBUTRIN XL generic product is fine in light of Teva impacts, those issues? I think this is obviously important for Mylan and the broader public trust in generics and the trade, et cetera."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. Thanks, Greg. So look, I think as far as Europe is concerned, we have seen continued improvement, and we don't really foresee that stopping. I mean, quite honestly, I think that when you compare everything, as I said, conversion rates increasing our",318,"Sure. Thanks, Greg. So look, I think as far as Europe is concerned, we have seen continued improvement, and we don't really foresee that stopping. I mean, quite honestly, I think that when you compare everything, as I said, conversion rates increasing our leadership position in our most important countries, I think, where we see, obviously, still, say, competitive pressures but see that volume offsetting that, those are all the kind of things that certainly, we, from our measurements and what we're looking for, is important. And we start to see all 3 of those things hitting, and, like I said, we do foresee that continuing. So that's kind of as far as I'm willing to go with my crystal ball. But I can tell you we're excited about the direction Europe's moving and see that continuing. As far as WELLBUTRIN, look, I think that it's very important to understand that this is a one-off issue and it really does not speak to the generic industry. I will say it speaks to the pharmaceutical industry overall. As you know, from time to time, as FDA continues to gather data and look at data, there are times where they've taken brand products off the market as well as changing guidelines and changing specs. So this is something that's constantly going on within the FDA in looking and working with companies. I think in this particular instance, it was certainly related to patient safety. FDA made a judgment call years ago around the 300 milligram. I mean, the data today that they're looking at has caused them to get to a different place. Certainly, we don't see those impacting our product and believe this was certainly in relation to just one in particular formulation. So I would tell you that our industry is alive and well, and I don't really see this having any impact on that whatsoever. Thank you."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Elliot Wilbur of Needham & Company.",10,"Our next question comes from Elliot Wilbur of Needham & Company."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Question for you, Heather, around your pending application for generic version of Lidoderm. Endo management made some very pointed comments about their perceived or their perceptions around your ability to obtain approval for their product based on its no",170,"Question for you, Heather, around your pending application for generic version of Lidoderm. Endo management made some very pointed comments about their perceived or their perceptions around your ability to obtain approval for their product based on its nonaqueous nature and the possibility of some excipient and adhesion issues. I'm assuming that you don't agree with that, but maybe you can just sort of comment a little bit on sort of their observations. And then with Watson now having obtained approval, still some ambiguity around the issue of exclusivity. The FDA made it very clear in the approval letter that Watson did not obtain approval within 30 months but did not actually make a decision on exclusivity. You said previously that you still thought generic Lidoderm was a possibility in terms of your ability to launch in 2013, and I'm just wondering if you still believe that to be the case based on anything new that's happening at the FDA regarding the application and then based on the Watson approval."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So I'll start with Endo's comment. I guess what I would say, not only do I not agree with them, I have to believe that their credibility should be extremely tarnished at this point. I mean, based at all the exact same things about Watson, Watson was",254,"Sure. So I'll start with Endo's comment. I guess what I would say, not only do I not agree with them, I have to believe that their credibility should be extremely tarnished at this point. I mean, based at all the exact same things about Watson, Watson was never going to be able to get their approval. They had all kinds of issues. And certainly, Endo was proven to be wrong. I think when you look at Endo trying to stress that based on their experience and expertise in this development, this is not their product. They didn't license this. So I think as to -- to talk about what kind of science is out there and who has the capability, I can assure you we are manufacturing and developing our own products, and I believe we do have the expertise and the track record with FDA to know and to be able to guide you guys, as we have been, about what we're capable of doing. So I -- that's what I would say about Endo's comments. And we absolutely continue to see this as a possible opportunity in the second half of the year. As you know, FDA historically doesn't make exclusivity decisions until they have to. And so we maintain our ability to get this product approved in 2013 and be able to manufacture the quantities needed. And like I said, we still absolutely believe we have the potential for this to be upside second half of '13. So thank you."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Chris Schott of JP Morgan.",10,"Our next question comes from Chris Schott of JP Morgan."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just 2 quick ones here. The first was coming back to some of the earlier business development comments. I guess that the financial facility you're talking about here open up transactions that you might not have been able to pursue in the past, i.e. larger",151,"Just 2 quick ones here. The first was coming back to some of the earlier business development comments. I guess that the financial facility you're talking about here open up transactions that you might not have been able to pursue in the past, i.e. larger transactions. I was just trying to understand here if the scope of what you're looking at has changed or if this is just trying to come back to some of the assets that you've considered before. And the second question was on your Europe. It seems like we're finally seeing encouraging macro trends. Can you talk a little bit more about the competitive dynamics you're seeing in the market? I think Heather last quarter discussed a bit of a shift, focusing more on profitability versus share in Europe, and I'm just wondering if you're -- how you're seeing the overall competitive environment kind of shaking out."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","So look, quickly on the acquisitions, here's what I say. I mean, Chris, obviously, we came out to a commitment with the Street over the last several years that we were going to be deleveraging and executing on the assets that we had. And I think that, tha",216,"So look, quickly on the acquisitions, here's what I say. I mean, Chris, obviously, we came out to a commitment with the Street over the last several years that we were going to be deleveraging and executing on the assets that we had. And I think that, that's what I think this quarter culminates in that activity, one showing what this platform can produce while, at the same, time accelerating our deleveraging capability. So certainly, what we're in a position now to do is definitely of size and scope. And as I said, I'll just revert back to saying a very compelling -- there's a lot of compelling opportunities out there, and we're looking at all of the. And just quickly on the environment in Europe. I guess what I would say is we've always stressed the profitability as well as market share, as well as revenue growth and balance all of that. I can't speak to other companies perhaps being as balanced as in their commentary around Europe, but that's why I wanted to stress that I think that has definitely paid off for us not only to maintain leadership position but be able to execute and control what we can. And we see that now, especially for our business in Europe, turning that corner."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Gary Nachman of Susquehanna Financial Group.",14,"Our next question comes from the line of Gary Nachman of Susquehanna Financial Group."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, on EPIPEN, anything you're doing differently to prepare for Sanofi's launch of Auvi-Q next month? And do you have a sense of what the pricing dynamics will look like with them in the market? And just what type of growth are you seeing in the mark",53,"Heather, on EPIPEN, anything you're doing differently to prepare for Sanofi's launch of Auvi-Q next month? And do you have a sense of what the pricing dynamics will look like with them in the market? And just what type of growth are you seeing in the market overall, if you could quantify that?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So first, I'd like to say that they -- that Sanofi has said they're not launching until 2013. But anyway, as far as it relates to -- look, I think when you got a leadership position, like we do, at 98% of the market, our ability to build on that bra",200,"Sure. So first, I'd like to say that they -- that Sanofi has said they're not launching until 2013. But anyway, as far as it relates to -- look, I think when you got a leadership position, like we do, at 98% of the market, our ability to build on that brand equity and make sure that we're continuing to stress the tried and true nature of EPIPEN, being around for over 20 years, delivering over 40 million scripts, and that's what -- that is our position in the marketplace. And as we've said before, another competitor coming to market in the sense then as shared voice and increasing that awareness, I think that when you look at the -- what we have been doing to increase that awareness, as I said in my remarks, it's been paying off. We've now gone from where 7% of the people at-risk to now 10% of the people at-risk with an EPIPEN. So obviously, we still see tremendous growth and opportunity for this franchise and the disease state overall. So look, we're excited about EPIPEN, still have a lot. But we're executing on it and will be continuing to do so. Thank you."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Our next question comes from Michael Faerm of Credit Suisse.",10,"Our next question comes from Michael Faerm of Credit Suisse."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Two quick questions, one on the respiratory pipeline. Can you just provide an update on the status of the COPD candidate, if and when we might see Phase II data? And then a general question on the North American Generics business. What are some of the key",68,"Two quick questions, one on the respiratory pipeline. Can you just provide an update on the status of the COPD candidate, if and when we might see Phase II data? And then a general question on the North American Generics business. What are some of the key drivers that will propel growth next year as you move into a year with fewer launches than you've had this year?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Let me -- I'll quickly take the North America question. Look, I think that what we've continued to stress is that we're not about any 1 country, 1 product. It is about literally being able to optimize and leverage the -- our global scale and platform in e",129,"Let me -- I'll quickly take the North America question. Look, I think that what we've continued to stress is that we're not about any 1 country, 1 product. It is about literally being able to optimize and leverage the -- our global scale and platform in every country we do business in, the United States not being any different. We have tremendous opportunities from our existing base business, the launches we did have this year, coupled with the launches we have next year. I mean over the last 5 years, we've not had the same number of launches every year, but we certainly have been able to show a trajectory and, like I said, we see that continuing. As far as our respiratory business, Rajiv, do you want..."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Yes. So regarding respiratory products, I think one is our [indiscernible], which is on the nebulization. See, this remains on track, and we will kick off our Phase III summer -- I mean, next year, I mean, 2013. And the second, which is Advair, is also --",55,"Yes. So regarding respiratory products, I think one is our [indiscernible], which is on the nebulization. See, this remains on track, and we will kick off our Phase III summer -- I mean, next year, I mean, 2013. And the second, which is Advair, is also -- remains on track for '15, '16 global launches."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, thank you.",3,"Okay, thank you."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question s Ken Cacciatore of Cowen and Company.",10,"Our next question s Ken Cacciatore of Cowen and Company."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just want us to go back to potential future acquisitions or strategic developments. Is it usually by asset that is available, either brand or generic? Or do you have a -- do you have something in mind and you focus on that? Or is it kind of what is availa",57,"Just want us to go back to potential future acquisitions or strategic developments. Is it usually by asset that is available, either brand or generic? Or do you have a -- do you have something in mind and you focus on that? Or is it kind of what is available to you at that moment in time?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Ken, what I would say is as I -- hopefully, everyone has heard me now loud and clear on this call is that we certainly believe that there are many compelling opportunities out there and we're looking at all of them. And just believe that we've got a lot o",80,"Ken, what I would say is as I -- hopefully, everyone has heard me now loud and clear on this call is that we certainly believe that there are many compelling opportunities out there and we're looking at all of them. And just believe that we've got a lot of ability to bring in a lot of different complementary assets to this business and in this existing platform that we have. And I'd say that's what I have to say."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","And it may or may not be on the market.",10,"And it may or may not be on the market."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Yes.",1,"Yes."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Yes.",1,"Yes."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","I mean, we're looking -- we're -- you should know we're not standing still and we're looking at everything. All right, operator, thank you.",24,"I mean, we're looking -- we're -- you should know we're not standing still and we're looking at everything. All right, operator, thank you."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from David Buck of Buckingham research.",10,"Our next question comes from David Buck of Buckingham research."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","First one is on the Specialty business. Can you talk a little bit about what pricing was during the quarter? And then just on the settlement with Teva, can you talk about what your ability is to continue to pursue, if needed, the citizen petition route to",93,"First one is on the Specialty business. Can you talk a little bit about what pricing was during the quarter? And then just on the settlement with Teva, can you talk about what your ability is to continue to pursue, if needed, the citizen petition route to make your case with the FDA on approval? And then just maybe for John, can you just talk about in terms of what you're looking at in terms of deals? Is there a commitment to not use any type of equity financing or convertible equity financing?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay. So quickly, listen. On EPI, we certainly had some pricing increases. We had 2 over the year. But, I mean, we certainly see, as I mentioned, volumes increasing even more so than the price. As far as Teva and our settlement, we settled, just to be cle",101,"Okay. So quickly, listen. On EPI, we certainly had some pricing increases. We had 2 over the year. But, I mean, we certainly see, as I mentioned, volumes increasing even more so than the price. As far as Teva and our settlement, we settled, just to be clear, on the IP litigation. We continue to believe they have significant hurdles to get an AB-rated product, and I can assure you we're continuing -- not only are we continuing to pursue that, but believe that there are, like I said, many hurdles and challenges for them to get an AB-rated product. John?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","And in terms of your question about M&A and currency that we would use in any transaction, I think it would be safe to assume that our focus is on use of cash for a transaction, as I pointed that out, in terms of the amount that we had available up to a c",79,"And in terms of your question about M&A and currency that we would use in any transaction, I think it would be safe to assume that our focus is on use of cash for a transaction, as I pointed that out, in terms of the amount that we had available up to a ceiling of $4 billion or more. And so I think that use of a currency other than cash is not something we're currently focused on."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Michael Tong of Wells Fargo severities.",11,"Our next question comes from Michael Tong of Wells Fargo severities."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just one question, going back to business development. And as you look at you evaluate different transactions, do you use any internal bar that -- or internal hurdles that you would compare a potential transaction like the type of accretion you would get",56,"Just one question, going back to business development. And as you look at you evaluate different transactions, do you use any internal bar that -- or internal hurdles that you would compare a potential transaction like the type of accretion you would get from further deleveraging or share repurchases? Any color like that would be appreciated."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Well, Michael, I can assure that we look at many, many, many parameters when looking at the sources and use of capital. And I can tell you that we have been doing that, and certainly, for any acquisitions, we'll be doing that doing forward. Depending on w",114,"Well, Michael, I can assure that we look at many, many, many parameters when looking at the sources and use of capital. And I can tell you that we have been doing that, and certainly, for any acquisitions, we'll be doing that doing forward. Depending on what part of whether the platform, what kind of a transaction it is, what that contribution means, both near, medium and long term, I mean, all these things are taken into consideration as we compare them with other uses of capital. So I would say I would rest assured that we look at many, many different parameters and have many different things internally that we take into consideration."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our final question comes from the line of Randall Stanicky of Canaccord Genuity.",13,"Our final question comes from the line of Randall Stanicky of Canaccord Genuity."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","I have a fairly straightforward one. It can be Heather or John. Can you just identify specifically some of the public U.S. generic opportunities in the next year? So obviously, Lidoderm is one of those. And then, Heather, as you look at your U.S. generic",69,"I have a fairly straightforward one. It can be Heather or John. Can you just identify specifically some of the public U.S. generic opportunities in the next year? So obviously, Lidoderm is one of those. And then, Heather, as you look at your U.S. generic base, obviously you have an expansive pipeline. What technologies don't you currently have that you would have an interest in potentially acquiring or developing?"
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thanks, Randall. As far as for detailed opportunities in 2013, I think, as we mentioned early, we'll be coming to you with that in February. I mean, I think, obviously, there are some very -- there's already a lot of public news out there around the oppor",65,"Thanks, Randall. As far as for detailed opportunities in 2013, I think, as we mentioned early, we'll be coming to you with that in February. I mean, I think, obviously, there are some very -- there's already a lot of public news out there around the opportunities that we have in 2013. But we certainly will be highlighting those more in February. And what was..."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","The technology.",2,"The technology."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Oh, the -- here's what I would say. When you look at where our strengths lie -- so overall [ph] dosage,  extended release, patch technology -- I think we can continue to see in injectable space that, that would be an area that we can continue to further i",132,"Oh, the -- here's what I would say. When you look at where our strengths lie -- so overall [ph] dosage,  extended release, patch technology -- I think we can continue to see in injectable space that, that would be an area that we can continue to further increase therapeutic categories that we're in and so forth. Topical dermatologics, that's an area that we certainly could look and, obviously, where we've already investing in the respiratory. So I would think it's not even so much a matter of areas that we're not in at all but areas, again, that we can look to accelerate those positions and our positions within the U.S. marketplace. All right, well, thank you, everybody, for the call, and we look forward to talking to you in February."
290203,222537176,370276,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's Third Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m., East",77,"Welcome to Mylan's Third Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m., Eastern Time. The dial-in number is (800) 585-8367 or (404) 537-3406 for international callers, with pin number 36921750. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Maria. Good morning, everyone. Welcome to Mylan's Third Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice",488,"Thank you, Maria. Good morning, everyone. Welcome to Mylan's Third Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making numerous forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often may be identified by the use of words such as may, will, could, should, would, project, believe, anticipate, expect, plan, estimate, guidance, trends, forecasts, potential, intend, continue and variations of these words or comparable words.
Our forward-looking statements may today, including, among others, statements relating to anticipated business levels; trends in some European countries; planned launches of and anticipated exclusivity periods for new products; our ability to achieve forecasted full year results while absorbing the impact of negative pricing pressures; expectations for capital expenditures; expectations for R&D, SG&A and other spending; our guidance range, future earnings, planned activities, anticipated growth and other expectations and targets for future periods, including our expectations regarding the fourth quarter and for 2012 overall. Because these statements are forward looking, they inherently involve risks and uncertainties, and, accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the factors set forth under Forward-looking Statements in our recent earnings press release dated October 25, 2012, as well as the risk factors set forth in our report on Form 10-Q for the period ended June 30, 2012, and our other SEC filings. You can access our Form 10-Q and other SEC filings, including our earnings press release, which we filed on Form 8-K, through the SEC website at www.sec.gov, and we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures, such as adjusted revenue, adjusted gross margin and adjusted diluted EPS, should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with Generally Accepted Accounting Principles or GAAP.
Please refer to today's earnings press release, which is available on our website as well as on the SEC website, as it contains detailed reconciliations of the non-GAAP financial measures we use to our third quarter results prepared in accordance with GAAP.
Before I turn the call over to Heather, let me also remind you that the material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'll now turn the call over to Heather."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us today. I'm pleased to announce that Mylan has once again delivered an outstanding quarterly performance marked by double-digit growth on both the top and bottom lines. Our third q",1567,"Thank you, Kris, and good morning, everyone, and thank you for joining us today. I'm pleased to announce that Mylan has once again delivered an outstanding quarterly performance marked by double-digit growth on both the top and bottom lines. 
Our third quarter constant currency revenues rose 20% year-over-year to $1.8 billion, and our adjusted diluted earnings per share grew 51% to $0.83. I'd like to note that we did more this quarter than we did in all of 2008 with essentially the same assets. This only further highlights the power of our organic growth capabilities. Of course, these milestones could only have been achieved through the hard work, dedication and commitment of all of our employees. On behalf of the Board of Directors and our entire management team, I would like to thank all of them.
Now with 3 very successful quarters behind us this year, we are raising our 2012 adjusted EPS guidance range to $2.50 to $2.60 per share. We also are reaffirming our 2013 target of $2.75 per share and our longer-term target of at least $6 per share in 2018. We expect to provide detailed guidance for 2013 in February when we release our fourth quarter and year-end results. We will discuss our longer-term outlook in July during our Investor Day event, which we will host in New York. 
Our ability to deliver consistently strong results, take swift advantage of opportunities and become ever more efficient, all while mitigating risk and absorbing economic headwinds and price cuts, give Mylan a unique profile in this industry. With that said, our expectation of continued growth will come from a combination of things: first, from the continued organic growth of our very strong and powerful existing platform; second, from executing against the strategic growth drivers we outlined during our Investor Day; and third, and importantly, from our ability to continue generating significant free cash flows, which allowed us to accelerate our deleveraging and get to our current 2.6:1 debt-to-EBITDA, well below our target. Therefore, we are actively looking at a number of ways to use our increasing financial flexibility to help us accelerate our longer-term targets and enhance shareholder value.
Against this backdrop, I'd like to walk you now through Mylan's outstanding third quarter performance, which was characterized by strong double-digit revenue growth in our Specialty, North America and Asia Pacific businesses and a return to growth in Europe. In addition, our gross margin increased nearly 400 basis points year-over-year to 52%.
Starting with North America Generics business, we reported third-party net revenues of $831 million, a year-over-year increase of 19% at constant currency. Driving the increase were new product launches during the quarter, which contributed to $258 million and included Valsartan HCTZ in September with 180 days of exclusivity, Modafinil in August and pioglitazone and pioglitazone Metformin also in August, and both with 180 days of exclusivity. The launches offset lower pricing and volume on existing products. 
As of the end of the third quarter, we had introduced 47 new products this year in the U.S., including 17 that were first-to-file or limited competition. In Canada, as of the end of the third quarter, we had launched a record 22 new products, revenue from which contributed to favorable year-over-year sales growth in that market. 
In addition, revenues from our Institutional business grew by nearly 25% on a constant currency basis during the quarter with new products and higher volumes responsible for most of the growth. 
In Europe, we reported third-party net revenues of $326 million, a year-over-year increase of 3% at constant currency. Many of our European markets realized increased sales, an encouraging sign that the region may finally be turning a corner. In addition, I'd note that as of the second quarter, the latest period for which data are available, generic utilization has risen year-over-year in the 19 European countries where we do business. As of the end of the third quarter, Mylan executed 200 country product launches in Europe during the year. These launches, along with favorable volumes on existing products, were the primary drivers of our improved performance during the third quarter. The higher product volumes included double-digit growth in France, Italy and Spain, which offset some lower pricing resulting from government mandates and competitive conditions. 
France saw the most significant revenue increase in absolute terms as local currency sales rose 9% compared to last year's third quarter. In addition to new product launches, revenues benefited from the recently signed pharmaceutical convention, which contributed to a 7% point increase in substitution among repertoire-listed [ph] products from May to August. We also are seeing growth in the French generics market overall in volume and value, and we remain the market leader. 
We observed similar trends in Italy where new products and higher volumes more than offset the impact of government-mandated price reductions. I'd also note that Italy's government has passed a law requiring general practitioners to prescribe INN products for patients starting new treatments for chronic and acute conditions. Italy is one of the fastest-growing generic markets in Europe, and we are the country's fastest-growing major player.
In Asia Pacific, we reported third-party net revenues of $339 million, a year-over-year constant currency increase of 21%. Our Mylan Lab subsidiary in India, along with Japan and New Zealand, all experienced higher third-party sales. India accounted for the majority of the increase due to significant sales growth of finished-dosage-form ARVs and significant growth in API. 
In Australia, where we continue to maintain our leadership position, sales were lower operationally due mainly to steep price cuts made by the government during the year. 
Sales in Japan rose as higher volumes, mainly in the distributor channel, and new product launches offset NIH pricing cuts that took effect during the first quarter. In addition, we continue to see increased generic utilization. 
Also during the third quarter, we announced an exclusive long-term strategic collaboration with Pfizer to drive sustained growth for our combined Generics business in Japan. This unique partnership, unprecedented in our industry, leverages the core strength of both organizations and creates a powerful platform that we expect will be a leader in Japan in terms of scale, scope and quality. 
Our Specialty segment, we reported third-party net revenues of $294 million, a year-over-year increase of 37%. Sales of EPIPEN in the U.S. accounted for most of the increase with a growth of more than 50% compared to the same period in 2011. Our third quarter is essentially the strongest for sales of this product, and our growth this quarter came off a very strong quarter last year. 
I'd also note that we continue to see our efforts around market expansion pay off. Through the first 9 months of 2012, the percentage of at-risk individuals in the U.S. who have filled a prescription for EPIPEN auto-injector has risen from 7% to 10%. More importantly, the growth potential for this franchise remains significant.
As I move on now to some of our other drivers of growth through 2018, I'd like to reinforce that each driver in our broad basket of opportunities is weighted based on its unique risk-reward profile and projected long-term contribution. Our success and ability to achieve our targets doesn't depend on any one driver, and instead, our success is based on the global scale and leverage we have created and our ability to invest and execute on these opportunities. 
With respect to our global Institutional business, we continue to grow and expand our relationships with key customers and invest in the future of this franchise. A few weeks ago, we agreed to purchase an oncology manufacturing facility in India from SMS Pharmaceuticals. The facility will produce active pharmaceuticals and finished dosage forms and begin commercial operation as soon as the FDA completes its inspection, which is expected to occur in the next few months. The transaction should close early in the first quarter of 2013.
With respect to geographic expansion, we launched commercial operations in India in August, entering the market with a comprehensive portfolio of ARV products for the treatment of HIV/AIDS. We also were selected as a leading supplier of ARV drugs to India's National AIDS Control Organization. I'd note that both of these developments also support our ARV growth driver. And in addition to our expansion into India, we are poised to establish a physical presence shortly in Thailand. 
Portfolio diversity is another important growth driver, and we remain excited about the women's health care franchise we are establishing in partnership with Famy Care. During the third quarter, we launched 2 oral contraceptives in Germany. We also launched one this week in Canada. And in addition, we have 34 oral contraceptives pending approval with the FDA and expect commercialization to begin in next year's first quarter.
With respect to our biologics driver, we have continued to advance the development of our 5 lead products. We have held positive meetings with the authorities in the U.S. and Europe to discuss our biologics programs. In addition, we are pleased to report that we initiated our first global Phase III clinical trial on Herceptin in October. 
Clearly, Mylan continues to operate and grow from a position of great strength, and we look forward to leveraging that strength further to deliver even more value to our shareholders. With that, I'll now turn the call over to John, and I will look forward to responding to your questions."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris' comments at the beginning of today'",1918,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris' comments at the beginning of today's call regarding our use of adjusted measures.
Let me start by saying by any measure, the third quarter of 2012 was an exceptional quarter for Mylan. I would like to highlight upfront some of our financial accomplishments. 
Quarterly revenue of $1.8 billion, the highest amount of revenue in any quarter in our company's history, and revenue grew on a constant currency basis in every region of the world including Europe. 
Adjusted diluted earnings per share of $0.83, more than we earned in all of 2008 and were achieved while continuing to invest in new product development and sales and marketing initiatives. 
Adjusted operating cash flow of $469 million, the most ever for our company in one quarter, and free cash flow of $424 million, which allowed us to repay borrowings during the quarter of $459 million. 
And to the end of the quarter -- and to end the quarter with a gross leverage ratio of 2.7:1, or 2.6:1 when you consider an additional $100 million of borrowings, which we repaid in early October.
On the heels of this strong quarter, we are once again increasing our range of EPS guidance for the full year 2012. We're now projecting adjusted diluted EPS of between $2.50 and $2.60 per share, increased from our previous range of $2.45 to $2.55 per share. We are also revising upward our free cash flow expectations for 2012. We now expect adjusted operating cash flow to be approximately $1 billion in 2012, which is at the very upper end of our 2012 operating cash flow guidance range of $900 million to $1 billion. 
Additionally, as a result of the timing and rationalization of some of our capital programs, our gross capital spending in 2012 is now anticipated to approximate $300 million. The net of these 2 amounts represents our current 2012 free cash flow expectation of approximately $700 million, or $100 million higher than the midpoint of our previously communicated expectations.
Our remaining guidance metrics for 2012 remain unchanged, and I'll walk through each of them in a few minutes. And our targets for 2013 and beyond remain unchanged.
In February, in conjunction with our fourth quarter call, we will provide detailed 2013 financial guidance, which reflects recent developments and our most up-to-date outlook.
So Mylan has never been better positioned as a company. Today, we possess an unmatched vertically integrated footprint, a broad and growing product portfolio with a robust pipeline of future new product launches and longer-term strategic growth drivers such as our respiratory and biologics platforms. 
Additionally, though, Mylan possesses today the financial flexibility to take advantage of shareholder value accretion opportunities. With our current leverage ratio now meaningfully below our long-term target of 3:1 and our growing EBITDA, today we have over $4 billion of financial flexibility for earnings accretive transactions. That said, Mylan will never do a transaction merely for the sake of a transaction or only for financial reasons. Any transaction must also be the right transaction strategically. Further, we remain committed to our 3:1 long-term gross leverage target. And if we increase our leverage above this target, we would be committed to deleveraging within an 18-month time frame.
With that introduction, let me now get into the details and walk you through our financial results for the third quarter and first 9 months of 2012. I will also provide an update on our capital structure and liquidity position. 
Starting at the top of our income statement, total adjusted revenues for the quarter were approximately $1.8 billion, an increase of 14% over last year's third quarter revenues of approximately $1.6 billion. Year-over-year revenue growth on a constant currency basis was approximately 19%. The 5% unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to each of the other functional currencies of our major operations mainly in Europe and India.
Our top line growth was driven by higher volumes on a consolidated basis, including significant amounts from our 2012 new product launches as well as favorable sales volumes in Europe and Asia Pacific, which served to more than offset the unfavorable impact of lower pricing throughout the world. In fact, driven by higher volumes and new product introductions, each of the countries in Europe in which we have significant operations, with the exception of Germany, turned in favorable year-over-year constant currency sales growth. 
For the first 9 months of 2012, total adjusted revenues were approximately $5.1 billion, an increase of 10% over revenues from the first 9 months of 2011, or 14% on a constant currency basis. As a reminder, our guidance range for total revenues for the full year 2012 is between $6.8 billion and $7.2 billion. Recognizing current exchange rates and using them to forecast the remainder of the year, we expect to be near the low end of this guidance range as a result of the unfavorable impact of changes in foreign exchange rates. On a constant currency basis, however, we are projecting to be closer to the midpoint of the range.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 third quarter at 52% was above our guidance range of 48% to 50% and represented an increase over the same prior year period of nearly 400 basis points. This increase was driven by new product launches and favorable volume and pricing on our EPIPEN auto-injector, partially offset by lower margin on existing products. The current quarter also saw margin improvement from our Indian subsidiary, where sales and gross profit benefited from the effects of a stronger dollar as compared to the rupee as a significant portion of its sales are denominated in U.S. dollars.
For the 9 months ended September 30, 2012, adjusted gross margins were 50% as compared to 48% in the prior year. We currently expect to be at the upper end of our gross margin guidance range for the full year.
Adjusted operating income was $513 million for the third quarter of 2012, a 32% increase from Q3 2011 and up 29% from the second quarter of 2012. The year-over-year increases, which is primarily the result of the favorable gross profit, was realized in spite of increased levels of investment in both R&D and SG&A. 
R&D expense for the quarter on an adjusted basis was $104 million, or approximately 5.8% of total revenues, and up approximately 51% from the prior year. This increase was mainly a result of ongoing spending with respect to our respiratory and biologics program, including clinical studies. 
At the same time, SG&A, also on an adjusted basis, was $324 million for the quarter, or approximately 18% of total revenues, and up approximately 5% over the prior year. The increase in SG&A in the current quarter is due in large part to increased selling and marketing in our Specialty franchise. Also contributing to the year-over-year increase were higher payroll and related costs as we continue to build out our infrastructure platform in certain targeted areas.
For the 9-month period, adjusted R&D expense was $277 million, up 28% over the prior year. As a percentage of revenues, R&D expense to date for 2012 is 5.5%. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues, and we continue to believe that the full year spend will be at or slightly below the midpoint of our guidance range.
SG&A expense on an adjusted basis for the 9 months ended September 30, 2012, was $964 million, an increase of nearly 10% and within our full year guidance range of 18% to 20% of total revenues. 
Adjusted EBITDA was $567 million and $1.4 billion for the 3- and 9-month periods ended September 30, 2012, respectively. We expect to be near the middle to upper end of our guidance range of $1.75 -- of $1.75 billion to $1.95 billion for the full year.
Moving on to our consolidated, nonoperating financial metrics. Adjusted interest expense for the third quarter of 2012 was $61 million. We continue to benefit from low short-term interest rates. As of September 30, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70-30 fixed-floating debt portfolio, which we believe is an optimal ratio. 
Adjusted interest expense for the 9-month period was $183 million and is forecasted to be at the low end of the guidance range of $245 million to $265 million for the full year.
Our adjusted effective tax rate in the current quarter was 26% compared to 27% a year ago. Our full year 2012 tax rate range is between 26% and 27%, and we continue to believe that we will be at the lower end of this range for the calendar year 2012.
Third quarter adjusted net income was $341 million, or $0.83 a share, a 51% increase from our Q3 2011 adjusted diluted EPS of $0.55 per share. For the 9 months, adjusted net income was $820 million, or $1.94 per share, a 28% increase over the same prior year period. 
As I mentioned previously, our guidance range for adjusted diluted EPS is now $2.50 to $2.60 per share. Our estimate of diluted shares for the full year is approximately 420 million.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis, which takes into account the special items which are outlined in our press release, was approximately $818 million for the year-to-date period and a very strong $469 million for the quarter. Our GAAP cash flow from operations for the current quarter and year-to-date period was a very strong cash inflow of $460 million and $652 million, respectively, and left us with unrestricted cash and marketable securities totaling [ph] $366 million. As noted earlier, we are forecasting our full year 2012 adjusted operating cash flow to be approximately $1 billion, the high end of our guidance range.
We have been very focused throughout 2012 on operating working capital. On a constant -- on constant currency net sales growth of 19% in the third quarter and 14% through the first 9 months of 2012, we have been able to limit the growth in our operating working capital to approximately 9%, exclusive of FX impacts, as we continue to bring operational efficiencies to our global platform.
Third quarter capital spending was $61 million, bringing the total for the year-to-date period to nearly $160 million. And as a result of the timing of planned expenditures, we expect full year capital expenditures to approximate $300 million.
As I mentioned before, these updated estimates yield a current free cash flow estimate of $700 million for the year, which is $100 million stronger than our previously communicated expectation as we continue to generate an increasing amount of cash flow from our global platform.
To summarize, our third quarter exceeded even our high expectations and, as anticipated, positions us for a very strong finish to 2012. Our strong track record for organic growth, coupled with the long-term growth drivers which Heather discussed, and our significant financial flexibility all translate into what should be an exciting 2013 and beyond for Mylan. 
That concludes my remarks. I'll turn the call over to the operator for Q&A. Maria?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from the line of Marc Goodman of UBS.",14,"[Operator Instructions] Our first question comes from the line of Marc Goodman of UBS."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Yes, hi, a couple of questions. First, on the U.S. business, which obviously had a fantastic quarter, there were just a lot of launches. And given Diovan and Actos, I actually would have thought revenues would have been even a little higher. So maybe you",134,"Yes, hi, a couple of questions. First, on the U.S. business, which obviously had a fantastic quarter, there were just a lot of launches. And given Diovan and Actos, I actually would have thought revenues would have been even a little higher. So maybe you can just comment on some of the launches there and just the absolute amount of the way we should be thinking about that. Second, Europe, obviously great news there. Can we talk about profitability and how that has changed throughout the year and what you're doing there to increase profitability? And then third, can you just talk about the Institutional business a little bit more? How many new products should we be expecting to launch out of that? And how big a business are you looking to build there?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So Marc, I'll start with the U.S. So I guess I'd like to first start off by saying against our estimates, our U.S. business performed right in line with where we thought it would be. So while we absolutely had a significant amount of launches that w",477,"Sure. So Marc, I'll start with the U.S. So I guess I'd like to first start off by saying against our estimates, our U.S. business performed right in line with where we thought it would be. So while we absolutely had a significant amount of launches that we forecasted and projected at the beginning of the year, that '12 would be a great year for our U.S. Generics business. I think that if you look at the timing of the launches throughout the quarters, and some of that pull-through even from launches we had earlier in the year, so all I can tell you is that absolutely performed in line with where we thought it would. We think it still is showing strength in the base business as well as our continued launches that we have for the remainder of the year. So from our perspective, U.S. business, hitting on all cylinders. Europe profitability, I think as we have talked about in the past that we constantly, through this entire macroeconomic situation throughout Europe, have balanced our top and bottom line growth. You've heard me quarter after quarter coming and saying we weren't going to chase the bottom, that there's been irrational behavior and that we would continue to hold steady and control what we can control. So in this period of time, we've done just that. We've continued to increase the profitability around our cost of goods by continuing to vertically integrate and be 100% responsible for our global supply chain. We've continued to make sure that we're structured in the right way with some of the evolving businesses and as they are continuing to change in the different countries. And I think most importantly, and why I wanted to point out in my script, that in all the countries we're doing business, we see an increase in generic conversion. And I think that should be the brightest spot of all because what it shows is that governments very much are beginning to recognize the long-term sustainability that generic utilization brings versus a onetime price cut. So we've seen additional initiatives in Italy, we've seen additional initiatives in France that are bringing those back up. So from my perspective, we certainly have always maintained the need to balance profitable and revenues. I think that our results this quarter are paying off from how we're operating our business in Europe. And lastly, on the Institutional side, in February, we showed our Institutional business being an important strategic growth driver for us. We are continuing to invest in that business. We have numerous launches. We're continuing to very much accelerate our own internal R&D pipeline around this businesses globally. So all I can say is that we certainly are continuing to invest and continue to see this as a very important growth driver for us in the future."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Jami Rubin of Goldman Sachs.",10,"Our next question comes from Jami Rubin of Goldman Sachs."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, both you and John, I think, were the most clear about the company's increased appetite for pursuing an accretive deal given the increased financial flexibility of the balance sheet. I'm wondering if you can just -- am I reading that right? In pre",175,"Heather, both you and John, I think, were the most clear about the company's increased appetite for pursuing an accretive deal given the increased financial flexibility of the balance sheet. I'm wondering if you can just -- am I reading that right? In previous conference calls, we've talked about options on the table to enhance shareholder value: share buybacks, bringing down debt, strategic deals. But what I'm hearing from you today is I think a more outspoken commitment or desire to pursue something strategic. And then secondly, I'm very intrigued with the partnership that you signed with Pfizer in Japan, and I'm wondering if you could put some numbers around that, what you see in terms of revenue potential over the next 5 years and what that means to your bottom line? And is this the type of partnership that you see could be replicated in other countries, such as emerging markets where, again, Pfizer doesn't have the AND capabilities that you have and you don't have the feet on the ground that Pfizer has?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, sure. So look, I think to your first question, hopefully you see that as our continued commitment to be transparent. When I -- what I spoke of in my opening remarks was a combination, if you'll remember. I said of us continuing to execute on our exi",391,"Okay, sure. So look, I think to your first question, hopefully you see that as our continued commitment to be transparent. When I -- what I spoke of in my opening remarks was a combination, if you'll remember. I said of us continuing to execute on our existing platform, continuing to execute against the growth drivers we pointed out. And then obviously, the last point was to looking at ways that we're going to use our increased financial flexibility. And I think, as you have seen, that has been a combination, and I think it will continue to be. There's a lot of ways to increase shareholder value, and I think what you can rely on is that we're looking at all of them. And we certainly are looking at any and all compelling acquisitions that would allow us to continue to deliver or accelerate the trajectory that we're already on. I mean, when you look at what we have put out there with our own assets at this time, a 15% CAGR in 2018 is an impressive growth target out there. And I think that as -- this financial flexibility just gives us all that much more ability to accelerate not only that growth but, like I said, in many different ways. As far as Japan goes, look, I think it's an unprecedented deal in our industry. I think it truly does take the core competencies of both of our organizations, and we believe that 1 plus 1 will equal 3-plus. It's about really leveraging the scale and scope and the quality of what we both bring to the table. So while we don't get into putting numbers out there around individual countries, I think you certainly can expect that we believe that this is accretive to our current stand-alone Generics business as well as accretive to their stand-alone Generics business, and that's why the rationale of this deal made all the sense in the world. And I very much believe that it could be a model in other countries where the troops on the ground are important, the brand is important, but having the breadth and the quality of a pipeline is equally as important. And that's where this makes all the sense in the world and very much could make sense in other countries as we move forward."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line Shibani Malhotra of RBC Capital Markets.",13,"Our next question comes from the line Shibani Malhotra of RBC Capital Markets."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just going back to Jami's question on potential acquisitions and ways to enhance shareholder value, you did mention that you aren't going to do anything just for the sake of doing a deal. Can you talk about the kind of things you are looking for? And just",120,"Just going back to Jami's question on potential acquisitions and ways to enhance shareholder value, you did mention that you aren't going to do anything just for the sake of doing a deal. Can you talk about the kind of things you are looking for? And just expand on what you meant by that? Are you finding valuations too high? Or is it -- are you just not finding what you're looking for at the moment? And then second, a question on fenofibrate. You got the capsules approved a couple of days ago. Can you just give us your expectations around the launch of that product, including whether or not you had sufficient sort of quantities for the market?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, sure. Thank you, Shibani. As far as acquisitions go, I think as we've laid out, certainly we don't do any acquisition just to do an acquisition and have not had a gun to our head to do an acquisition. I think what you hear us saying is that we conti",280,"Okay, sure. Thank you, Shibani. As far as acquisitions go, I think as we've laid out, certainly we don't do any acquisition just to do an acquisition and have not had a gun to our head to do an acquisition. I think what you hear us saying is that we continue to now generate significant free cash flows and have increased flexibility and are looking at all compelling acquisitions. And that could be anything that to be complementary to our current platform. So whether you look at the Specialty side, geographies, dosage form, therapeutic categories -- I mean, we have a voluminous number of different ways to continue to accelerate this growth trajectory and we're looking at all of them, as well as in combination to share repurchasing programs. I mean, I think that the great news is when you look at the kind of cash we have on hand, we have a lot of different ways to get at least to that $6 in 2018 and continuing to show that kind of growth year-over-year that we've, I think, now, hopefully, have shown that track record of producing year-over-year. So like I said, you're right, we're not just looking at a transaction for transaction's sake, but we certainly are in a position to be looking at all the compelling ones. And as far as your product question, yes, it was a good launch for us. But as you know, we're well beyond any single product launches, especially one of that size. I can tell you we executed on it. And it's just one of many that we've had this year and will have over the next several. Okay, thank you."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our next question will come from the line of Ronny Gal of Sanford Bernstein.",16,"[Operator Instructions] Our next question will come from the line of Ronny Gal of Sanford Bernstein."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","John, question on the CapEx. In the past, you talked about some leverage in the CapEx as we go from 2012 to 2014. Looking at the guidance for next year versus this year, still 7% to 8% growth in earnings at a minimum. How should we think about the CapEx?",80,"John, question on the CapEx. In the past, you talked about some leverage in the CapEx as we go from 2012 to 2014. Looking at the guidance for next year versus this year, still 7% to 8% growth in earnings at a minimum. How should we think about the CapEx? Should we grow linearly? Or should we have a step-up, a further step-up in the -- sorry, not the CapEx, in the cash -- in the free cash flow generation?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","So Ronny, I think that this -- I think that what you saw happen or you saw the results in this quarter was the cash flow generation, the strength of this global platform to generate and throw off cash. And also, as you could see, we reduced our expectatio",189,"So Ronny, I think that this -- I think that what you saw happen or you saw the results in this quarter was the cash flow generation, the strength of this global platform to generate and throw off cash. And also, as you could see, we reduced our expectations for capital spending for the year from $350 million to $300 million, the combination of those 2 increasing the free cash flow by $100 million and allowing us to bring our leverage down to 2.6x after paying $100 million back in the first week of October. To be honest with you, I don't really want to give future expectations as to what 2013 or 2014 is going to be. That's not the purpose of the call today. But what I can tell you, and it's demonstrated by the working capital efficiency that we've had here in 2013, is that our global operating teams are intensely focused on generating cash and then for our ability to put that cash back to work in the business for the benefit of our shareholders. And I think that for today, I'll leave it there."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes of the line of David Risinger of Morgan Stanley.",13,"Our next question comes of the line of David Risinger of Morgan Stanley."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","John, I was hoping that you could just walk us through the financials associated with that partnership with Pfizer and just help us understand how that impacted the revenue in Asia Pacific in the quarter and how it will impact things going forward just so",83,"John, I was hoping that you could just walk us through the financials associated with that partnership with Pfizer and just help us understand how that impacted the revenue in Asia Pacific in the quarter and how it will impact things going forward just so that we can tease out whether there was an incremental positive from that deal in the September quarter that is noticeable in the financials and whether that will continue or whether it's really not noticeable in the financials."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","You don't -- you won't have to tease it out because although we announced the formation of the partnership, David, the partnership will actually be become -- begin operating here around the end of this year, early next year so that there was no impact of",83,"You don't -- you won't have to tease it out because although we announced the formation of the partnership, David, the partnership will actually be become -- begin operating here around the end of this year, early next year so that there was no impact of the partnership in our third quarter results. What you see in our Asia Pacific results represents the organic growth of our operations in Asia Pacific and will most likely be that way for Q4 2012 also."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Greg Gilbert of Merrill Lynch.",10,"Our next question comes from Greg Gilbert of Merrill Lynch."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, with the third quarter in a row of improving growth rates in Europe, are you ready to predict positive growth for that segment going forward? It sounds like your qualitative comments are quite bullish, too. And then, is there any doubt that your",76,"Heather, with the third quarter in a row of improving growth rates in Europe, are you ready to predict positive growth for that segment going forward? It sounds like your qualitative comments are quite bullish, too. And then, is there any doubt that your WELLBUTRIN XL generic product is fine in light of Teva Impax's issues? I think this is obviously important for Mylan and the broader public trust in generics and the trade, et cetera."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. Thanks, Greg. So look, I think as far as Europe is concerned, we have seen continued improvement, and we don't really foresee that stopping. I mean, quite honestly, I think that when you compare everything, as I said, conversion rates increasing, ou",323,"Sure. Thanks, Greg. So look, I think as far as Europe is concerned, we have seen continued improvement, and we don't really foresee that stopping. I mean, quite honestly, I think that when you compare everything, as I said, conversion rates increasing, our leadership position in our most important countries, I think, where we see -- obviously still see competitive pressures -- but see that volume offsetting that. Those are all the kind of things that certainly, we, from our measurements and what we're looking for, is important. And we start to see all 3 of those things hitting, and, like I said, we do foresee that continuing. So that's kind of is as far as I'm willing to go with my crystal ball. But I can tell you we're excited about the direction Europe is moving and see that continuing. As far as WELLBUTRIN, look, I think that it's very important to understand that this is a one-off issue and it really does not speak to the generic industry. I will say it speaks to the pharmaceutical industry overall. As you know, from time to time, as FDA continues to gather data and look at data, there are times where they've taken brand products off the market as well as changing guidelines and changing specs. So this is something that's constantly going on within the FDA in looking and working with companies. I think in this particular instance, it was certainly related to patient safety. FDA made a judgment call years ago around the 300 milligram. And when -- the data today that they're looking at has caused them to get to a different place. Certainly, we don't see this impacting our product and believe this was certainly in relation to just one in particular formulation. So I would tell you that our industry is alive and well, and I don't really see this having any impact on that whatsoever. Thank you."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Elliot Wilbur of Needham & Company.",10,"Our next question comes from Elliot Wilbur of Needham & Company."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Question for you, Heather, around your pending application for generic version of Lidoderm. Endo management made some very pointed comments about their perceived or their perceptions around your ability to obtain approval for their product based on its no",172,"Question for you, Heather, around your pending application for generic version of Lidoderm. Endo management made some very pointed comments about their perceived or their perceptions around your ability to obtain approval for their product based on its nonaqueous nature and the possibility of some excipient and adhesion issues. I'm assuming that you don't agree with that, but maybe you can just sort of comment a little bit on sort of their observations. And then with Watson now having obtained approval, still some ambiguity around the issue of exclusivity. The FDA made it very clear in the approval letter that Watson did not obtain approval within 30 months but did not actually make a decision on exclusivity. You said previously that you still thought generic Lidoderm was a possibility in terms of your ability to launch in 2013, and I'm just wondering if you still believe that to be the case based on anything new that's happening at the FDA with regard to the application and then based on the Watson approval."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So I'll start with Endo's comments. I guess what I would say, not only do I not agree with them, I have to believe that their credibility should be extremely tarnished at this point. I mean, they said all the exact same things about Watson -- Watson",252,"Sure. So I'll start with Endo's comments. I guess what I would say, not only do I not agree with them, I have to believe that their credibility should be extremely tarnished at this point. I mean, they said all the exact same things about Watson -- Watson was never going to be able to get their approval. They had all kinds of issues. And certainly, Endo was proven to be wrong. I think when you look at Endo trying to stress that based on their experience and expertise in this development, this is not their product. They have end-licensed  it. So I think to talk about what kind of science is out there and who has the capability, I can assure you we are manufacturing and developing our own product, and I believe we do have the expertise and the track record with FDA to know and to be able to guide you guys, as we have been, about what we're capable of doing. So I -- that's what I would say about Endo's comments. And we absolutely continue to see this as a possible opportunity in the second half of the year. As you know, FDA historically doesn't make exclusivity decisions until they have to. And so we maintain our ability to get this product approved in 2013 and be able to manufacture the quantities needed. And like I said, we still absolutely believe we have the potential for this to be upside second half of '13. So thank you."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Chris Schott of JP Morgan.",10,"Our next question comes from Chris Schott of JP Morgan."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just 2 quick ones here. The first was coming back to some of the earlier business development comments. I guess does the financial flexibility you're talking about here open up transactions that you might not have been able to pursue in the past, i.e. lar",150,"Just 2 quick ones here. The first was coming back to some of the earlier business development comments. I guess does the financial flexibility you're talking about here open up transactions that you might not have been able to pursue in the past, i.e. larger transactions? I was just trying to understand here if the scope of what you're looking at has changed or if this is just kind of coming back to some of the assets that you've considered before? The second question was on your Europe. It seems like we're finally seeing encouraging macro trends. Can you talk a little bit more about the competitive dynamics you're seeing in the market? I think Teva last quarter discussed a bit of a shift, focusing more on profitability versus share in Europe, and I'm just wondering if you're -- how you're seeing the overall competitive environment kind of shaking out."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","So look, quickly on the acquisition, here's what I would say. I mean, Chris, obviously, we came out to a commitment with the Street over the last several years that we were going to be deleveraging and executing on the assets that we had. And I think that",217,"So look, quickly on the acquisition, here's what I would say. I mean, Chris, obviously, we came out to a commitment with the Street over the last several years that we were going to be deleveraging and executing on the assets that we had. And I think that, that's what I think this quarter culminates in that activity, one showing what this platform can produce while at the same time accelerating our deleveraging capability. So certainly, what we're in a position now to do is definitely of size and scope. And as I said, I'll just revert back to saying a very compelling -- there's a lot of compelling opportunities out there, and we're looking at all of them. And just quickly on the environment in Europe. I guess what I would say is we've always stressed the profitability as well as market share, as well as revenue growth and balanced all of that. I can't speak to other companies perhaps being as balanced as in their commentary around Europe, but that's why I wanted to stress that I think that has definitely paid off for us not only to maintain leadership position but be able to execute and control what we can. And we see that now, especially for our business in Europe, turning that corner."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Gary Nachman of Susquehanna Financial Group.",14,"Our next question comes from the line of Gary Nachman of Susquehanna Financial Group."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, on EPIPEN, anything you're doing differently to prepare for Sanofi's launch of Auvi-Q next month? And do you have a sense of what the pricing dynamics will look like with them in the market? And just what type of growth are you seeing in the mark",53,"Heather, on EPIPEN, anything you're doing differently to prepare for Sanofi's launch of Auvi-Q next month? And do you have a sense of what the pricing dynamics will look like with them in the market? And just what type of growth are you seeing in the market overall, if you could quantify that?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So first, I'd like to say that they -- that Sanofi has said they're not launching until 2013. But anyway, as far as it relates to -- look, I think when you have got a leadership position, like we do, at 98% of the market, our ability to build on tha",201,"Sure. So first, I'd like to say that they -- that Sanofi has said they're not launching until 2013. But anyway, as far as it relates to -- look, I think when you have got a leadership position, like we do, at 98% of the market, our ability to build on that brand equity and make sure that we're continuing to stress the tried and true nature of EPIPEN, being around for over 20 years, delivering over 40 million scripts, and that's what -- that is our position in the marketplace. And as we've said before, another competitor coming to market in a sense then is just shared voice and increasing that awareness. I think that when you look at the -- what we have been doing to increase that awareness, as I said in my remarks, it's been paying off. We've now gone from where 7% of the people at-risk to now 10% of the people at-risk with an EPIPEN. So obviously, we still see tremendous growth and opportunity for this franchise and the disease state overall. So look, we're excited about EPIPEN, still have a lot that we're executing on and will be continuing to do so. Thank you."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Our next question comes from Michael Faerm of Credit Suisse.",10,"Our next question comes from Michael Faerm of Credit Suisse."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Two quick questions, one on the respiratory pipeline. Can you just provide an update on the status of the COPD candidate, if and when we might see Phase II data? And then a general question on the North American Generics business. What are some of the key",68,"Two quick questions, one on the respiratory pipeline. Can you just provide an update on the status of the COPD candidate, if and when we might see Phase II data? And then a general question on the North American Generics business. What are some of the key drivers that will propel growth next year as you move into a year with fewer launches than you've had this year?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Let me -- I'll quickly take the North America question. Look, I think that what we've continued to stress is that we're not about any 1 country, 1 product. It is about literally being able to optimize and leverage the -- our global scale and platform in e",129,"Let me -- I'll quickly take the North America question. Look, I think that what we've continued to stress is that we're not about any 1 country, 1 product. It is about literally being able to optimize and leverage the -- our global scale and platform in every country we do business in, the United States not being any different. We have tremendous opportunities from our existing base business, the launches we did have this year, coupled with the launches we have next year. I mean over the last 5 years, we've not had the same number of launches every year, but we certainly have been able to show a trajectory and, like I said, we see that continuing. As for our respiratory business, Rajiv, do you want to..."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Yes. So regarding respiratory products, I think one is our COMBO, which is on the nebulization stage, which remains on track, and we will kick off our Phase III somewhere in the early next year, early 2013. And the second product, which is Advair, is also",55,"Yes. So regarding respiratory products, I think one is our COMBO, which is on the nebulization stage, which remains on track, and we will kick off our Phase III somewhere in the early next year, early 2013. And the second product, which is Advair, is also -- remains on track for '15, '16 global launches."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Ken Cacciatore of Cowen and Company.",11,"Our next question comes from Ken Cacciatore of Cowen and Company."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just wanted to go back to potential future acquisitions or strategic developments. Is it usually by asset that is available, either brand or generic? Or do you have a -- do you have something in mind and you focus on that? Or is it kind of what is availab",56,"Just wanted to go back to potential future acquisitions or strategic developments. Is it usually by asset that is available, either brand or generic? Or do you have a -- do you have something in mind and you focus on that? Or is it kind of what is available to you at that moment in time?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Ken, what I would say is as I -- hopefully, everyone has heard me now loud and clear on this call is that we certainly believe that there are many compelling opportunities out there and we're looking at all of them. And just believe that we've got a lot o",79,"Ken, what I would say is as I -- hopefully, everyone has heard me now loud and clear on this call is that we certainly believe that there are many compelling opportunities out there and we're looking at all of them. And just believe that we've got a lot of ability to bring in a lot of different complementary assets to this business in this existing platform that we have. And I'd say that's what I have to say."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","And it may or may not be on the market.",10,"And it may or may not be on the market."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Yes.",1,"Yes."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Yes.",1,"Yes."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","I mean, we're looking -- we're -- you should know we're not standing still and we're looking at everything. All right, Operator, thank you. Any more questions?",27,"I mean, we're looking -- we're -- you should know we're not standing still and we're looking at everything. All right, Operator, thank you. Any more questions?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from David Buck of Buckingham Research.",10,"Our next question comes from David Buck of Buckingham Research."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","First one is on the Specialty business. Can you talk a little bit about what pricing was during the quarter? And then just on the settlement with Teva, can you talk about what your ability is to continue to pursue, if needed, the citizen [ph] petition rou",94,"First one is on the Specialty business. Can you talk a little bit about what pricing was during the quarter? And then just on the settlement with Teva, can you talk about what your ability is to continue to pursue, if needed, the citizen [ph] petition route to make your case with the FDA on approval? And then just maybe for John, can you just talk about in terms of what you're looking at in terms of deals? Is there a commitment to not use any type of equity financing or convertible equity financing?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay. So quickly, listen. On EPI, we certainly had some pricing increases. We had 2 over the year. But, I mean, we certainly see, as I mentioned, volume increasing even more so than the price. As far as Teva and our settlement, we settled, just to be clea",101,"Okay. So quickly, listen. On EPI, we certainly had some pricing increases. We had 2 over the year. But, I mean, we certainly see, as I mentioned, volume increasing even more so than the price. As far as Teva and our settlement, we settled, just to be clear, on the IP litigation. We continue to believe they have significant hurdles to get an AB-rated product, and I can assure you we're continuing -- not only are we continuing to pursue that, but believe that there are, like I said, many hurdles and challenges for them to get an AB-rated product. John?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","And in terms of your question about M&A and currency that we would use in any transaction, I think it would be safe to assume that our focus is on use of cash for a transaction, as I pointed that out, in terms of the amount that we had available up to a c",79,"And in terms of your question about M&A and currency that we would use in any transaction, I think it would be safe to assume that our focus is on use of cash for a transaction, as I pointed that out, in terms of the amount that we had available up to a ceiling of $4 billion or more. And so I think that use of a currency other than cash is not something we're currently focused on."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Michael Tong of Wells Fargo Securities.",11,"Our next question comes from Michael Tong of Wells Fargo Securities."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just one question, going back to business development. And as you look at how you evaluate different transactions, do you use any internal bar that -- or internal hurdles that you would compare a potential transaction like the type of accretion you would",57,"Just one question, going back to business development. And as you look at how you evaluate different transactions, do you use any internal bar that -- or internal hurdles that you would compare a potential transaction like the type of accretion you would get from further deleveraging or share repurchases? Any color like that would be appreciated."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Well, Michael, I can assure you, we look at many, many, many parameters when looking at the sources and use of capital. And I can tell you that we have been doing that, and certainly, for any acquisitions, we'll be doing that going forward. Depending on w",114,"Well, Michael, I can assure you, we look at many, many, many parameters when looking at the sources and use of capital. And I can tell you that we have been doing that, and certainly, for any acquisitions, we'll be doing that going forward. Depending on what part of whether the platform, what kind of a transaction it is, what that contribution means, both near, medium and long term, I mean, all these things are taken into consideration as we compare them with other uses of capital. So I would say I would rest assured that we look at many, many different parameters and have many different things internally that we take into consideration."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our final question comes from the line of Randall Stanicky of Canaccord Genuity.",13,"Our final question comes from the line of Randall Stanicky of Canaccord Genuity."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","I have a fairly straightforward one. It can be Heather or John. Can you just identify specifically some of the public U.S. generic opportunities in the next year? So obviously, Lidoderm is one of those. And then, Heather, as you look at your U.S. generic",69,"I have a fairly straightforward one. It can be Heather or John. Can you just identify specifically some of the public U.S. generic opportunities in the next year? So obviously, Lidoderm is one of those. And then, Heather, as you look at your U.S. generic base, obviously you have an expansive pipeline. What technologies don't you currently have that you would have an interest in potentially acquiring or developing?"
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thanks, Randall. As far as for detailed opportunities in 2013, I think, as we mentioned earlier, we'll be coming to you with that in February. I mean, I think, obviously, there are some very -- there's already a lot of public news out there around the opp",65,"Thanks, Randall. As far as for detailed opportunities in 2013, I think, as we mentioned earlier, we'll be coming to you with that in February. I mean, I think, obviously, there are some very -- there's already a lot of public news out there around the opportunities that we have in 2013. But we certainly will be highlighting those more in February. And what was..."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","The technology.",2,"The technology."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Oh, the -- here's what I would say. When you look at where our strengths lie -- solid oral dosage,  extended release, patch technology -- I think we can continue to see an injectable space, that, that would be an area that we can continue to further incre",131,"Oh, the -- here's what I would say. When you look at where our strengths lie -- solid oral dosage,  extended release, patch technology -- I think we can continue to see an injectable space, that, that would be an area that we can continue to further increase therapeutic categories that we're in and so forth. Topicals, dermatologics, that's an area that we certainly could look and, obviously, where we've already investing in the respiratory. So I would think it's not even so much a matter of areas that we're not in at all but areas, again, that we can look to accelerate those positions and our positions within the U.S. marketplace. All right, well, thank you, everybody, for the call, and we look forward to talking to you in February."
290203,222537176,370442,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Welcome to Mylan's Third Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m., East",77,"Welcome to Mylan's Third Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m., Eastern Time. The dial-in number is (800) 585-8367 or (404) 537-3406 for international callers, with pin number 36921750. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Maria. Good morning, everyone. Welcome to Mylan's Third Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice",488,"Thank you, Maria. Good morning, everyone. Welcome to Mylan's Third Quarter 2012 Earnings Call. Joining me for today's call are Mylan's Chief Executive Officer, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.
During today's call, including the Q&A, we will be making numerous forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often may be identified by the use of words such as may, will, could, should, would, project, believe, anticipate, expect, plan, estimate, guidance, trends, forecasts, potential, intend, continue and variations of these words or comparable words.
Our forward-looking statements may today, including, among others, statements relating to anticipated business levels; trends in some European countries; planned launches of and anticipated exclusivity periods for new products; our ability to achieve forecasted full year results while absorbing the impact of negative pricing pressures; expectations for capital expenditures; expectations for R&D, SG&A and other spending; our guidance range, future earnings, planned activities, anticipated growth and other expectations and targets for future periods, including our expectations regarding the fourth quarter and for 2012 overall. Because these statements are forward looking, they inherently involve risks and uncertainties, and, accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the factors set forth under Forward-looking Statements in our recent earnings press release dated October 25, 2012, as well as the risk factors set forth in our report on Form 10-Q for the period ended June 30, 2012, and our other SEC filings. You can access our Form 10-Q and other SEC filings, including our earnings press release, which we filed on Form 8-K, through the SEC website at www.sec.gov, and we strongly encourage you to do so.
In addition, during this call, we will be referring to certain actual and projected financial metrics of Mylan on an adjusted basis, which are non-GAAP financial measures. It should be noted that non-GAAP measures, such as adjusted revenue, adjusted gross margin and adjusted diluted EPS, should be used only as a supplement to, not as a substitute for, or as a superior measure to measures of financial performance prepared in accordance with Generally Accepted Accounting Principles or GAAP.
Please refer to today's earnings press release, which is available on our website as well as on the SEC website, as it contains detailed reconciliations of the non-GAAP financial measures we use to our third quarter results prepared in accordance with GAAP.
Before I turn the call over to Heather, let me also remind you that the material in the call, with the exception of the participant questions, is the property of Mylan and cannot be recorded or rebroadcast without Mylan's expressed written permission.
With that, I'll now turn the call over to Heather."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Kris, and good morning, everyone, and thank you for joining us today. I'm pleased to announce that Mylan has once again delivered an outstanding quarterly performance marked by double-digit growth on both the top and bottom lines. Our third q",1566,"Thank you, Kris, and good morning, everyone, and thank you for joining us today. I'm pleased to announce that Mylan has once again delivered an outstanding quarterly performance marked by double-digit growth on both the top and bottom lines. 
Our third quarter constant currency revenues rose 20% year-over-year to $1.8 billion, and our adjusted diluted earnings per share grew 51% to $0.83. I'd like to note that we did more this quarter than we did in all of 2008 with essentially the same assets. This only further highlights the power of our organic growth capabilities. Of course, these milestones could only have been achieved through the hard work, dedication and commitment of all of our employees. On behalf of the Board of Directors and our entire management team, I would like to thank all of them.
Now with 3 very successful quarters behind us this year, we are raising our 2012 adjusted EPS guidance range to $2.50 to $2.60 per share. We also are reaffirming our 2013 target of $2.75 per share and our longer-term target of at least $6 per share in 2018. We expect to provide detailed guidance for 2013 in February when we release our fourth quarter and year-end results. We will discuss our longer-term outlook in July during our Investor Day event, which we will host in New York. 
Our ability to deliver consistently strong results, take swift advantage of opportunities and become ever more efficient, all while mitigating risk and absorbing economic headwinds and price cuts, give Mylan a unique profile in this industry. With that said, our expectation of continued growth will come from a combination of things: first, from the continued organic growth of our very strong and powerful existing platform; second, from executing against the strategic growth drivers we outlined during our Investor Day; and third, and importantly, from our ability to continue generating significant free cash flows, which allowed us to accelerate our deleveraging and get to our current 2.6:1 debt-to-EBITDA, well below our target. Therefore, we are actively looking at a number of ways to use our increasing financial flexibility to help us accelerate our longer-term targets and enhance shareholder value.
Against this backdrop, I'd like to walk you now through Mylan's outstanding third quarter performance, which was characterized by strong double-digit revenue growth in our Specialty, North America and Asia Pacific businesses and a return to growth in Europe. In addition, our gross margin increased nearly 400 basis points year-over-year to 52%.
Starting with North America Generics business, we reported third-party net revenues of $831 million, a year-over-year increase of 19% at constant currency. Driving the increase were new product launches during the quarter, which contributed to $258 million and included Valsartan HCTZ in September with 180 days of exclusivity, Modafinil in August and pioglitazone and pioglitazone Metformin also in August, and both with 180 days of exclusivity. The launches offset lower pricing and volume on existing products. 
As of the end of the third quarter, we had introduced 47 new products this year in the U.S., including 17 that were first-to-file or limited competition. In Canada, as of the end of the third quarter, we had launched a record 22 new products, revenue from which contributed to favorable year-over-year sales growth in that market. 
In addition, revenues from our Institutional business grew by nearly 25% on a constant currency basis during the quarter with new products and higher volumes responsible for most of the growth. 
In Europe, we reported third-party net revenues of $326 million, a year-over-year increase of 3% at constant currency. Many of our European markets realized increased sales, an encouraging sign that the region may finally be turning a corner. In addition, I'd note that as of the second quarter, the latest period for which data are available, generic utilization has risen year-over-year in the 19 European countries where we do business. As of the end of the third quarter, Mylan executed 200 country product launches in Europe during the year. These launches, along with favorable volumes on existing products, were the primary drivers of our improved performance during the third quarter. The higher product volumes included double-digit growth in France, Italy and Spain, which offset some lower pricing resulting from government mandates and competitive conditions. 
France saw the most significant revenue increase in absolute terms as local currency sales rose 9% compared to last year's third quarter. In addition to new product launches, revenues benefited from the recently signed pharmaceutical convention, which contributed to a 7% point increase in substitution among repertoire-listed products from May to August. We also are seeing growth in the French generics market overall in volume and value, and we remain the market leader. 
We observed similar trends in Italy where new products and higher volumes more than offset the impact of government-mandated price reductions. I'd also note that Italy's government has passed a law requiring general practitioners to prescribe INN products for patients starting new treatments for chronic and acute conditions. Italy is one of the fastest-growing generic markets in Europe, and we are the country's fastest-growing major player.
In Asia Pacific, we reported third-party net revenues of $339 million, a year-over-year constant currency increase of 21%. Our Mylan Lab subsidiary in India, along with Japan and New Zealand, all experienced higher third-party sales. India accounted for the majority of the increase due to significant sales growth of finished-dosage-form ARVs and significant growth in API. 
In Australia, where we continue to maintain our leadership position, sales were lower operationally due mainly to steep price cuts made by the government during the year. 
Sales in Japan rose as higher volumes, mainly in the distributor channel, and new product launches offset NIH pricing cuts that took effect during the first quarter. In addition, we continue to see increased generic utilization. 
Also during the third quarter, we announced an exclusive long-term strategic collaboration with Pfizer to drive sustained growth for our combined Generics business in Japan. This unique partnership, unprecedented in our industry, leverages the core strength of both organizations and creates a powerful platform that we expect will be a leader in Japan in terms of scale, scope and quality. 
Our Specialty segment, we reported third-party net revenues of $294 million, a year-over-year increase of 37%. Sales of EPIPEN in the U.S. accounted for most of the increase with a growth of more than 50% compared to the same period in 2011. Our third quarter is essentially the strongest for sales of this product, and our growth this quarter came off a very strong quarter last year. 
I'd also note that we continue to see our efforts around market expansion pay off. Through the first 9 months of 2012, the percentage of at-risk individuals in the U.S. who have filled a prescription for EPIPEN auto-injector has risen from 7% to 10%. More importantly, the growth potential for this franchise remains significant.
As I move on now to some of our other drivers of growth through 2018, I'd like to reinforce that each driver in our broad basket of opportunities is weighted based on its unique risk-reward profile and projected long-term contribution. Our success and ability to achieve our targets doesn't depend on any one driver, and instead, our success is based on the global scale and leverage we have created and our ability to invest and execute on these opportunities. 
With respect to our global Institutional business, we continue to grow and expand our relationships with key customers and invest in the future of this franchise. A few weeks ago, we agreed to purchase an oncology manufacturing facility in India from SMS Pharmaceuticals. The facility will produce active pharmaceuticals and finished dosage forms and begin commercial operation as soon as the FDA completes its inspection, which is expected to occur in the next few months. The transaction should close early in the first quarter of 2013.
With respect to geographic expansion, we launched commercial operations in India in August, entering the market with a comprehensive portfolio of ARV products for the treatment of HIV/AIDS. We also were selected as a leading supplier of ARV drugs to India's National AIDS Control Organization. I'd note that both of these developments also support our ARV growth driver. And in addition to our expansion into India, we are poised to establish a physical presence shortly in Thailand. 
Portfolio diversity is another important growth driver, and we remain excited about the women's health care franchise we are establishing in partnership with Famy Care. During the third quarter, we launched 2 oral contraceptives in Germany. We also launched one this week in Canada. And in addition, we have 34 oral contraceptives pending approval with the FDA and expect commercialization to begin in next year's first quarter.
With respect to our biologics driver, we have continued to advance the development of our 5 lead products. We have held positive meetings with the authorities in the U.S. and Europe to discuss our biologics programs. In addition, we are pleased to report that we initiated our first global Phase III clinical trial on Herceptin in October. 
Clearly, Mylan continues to operate and grow from a position of great strength, and we look forward to leveraging that strength further to deliver even more value to our shareholders. With that, I'll now turn the call over to John, and I will look forward to responding to your questions."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris' comments at the beginning of today'",1917,"Thank you, Heather, and good morning, everyone. This morning, I'm going to be referring to financial metrics that have been prepared on an adjusted basis. These are non-GAAP financial measures. I refer you back to Kris' comments at the beginning of today's call regarding our use of adjusted measures.
Let me start by saying by any measure, the third quarter of 2012 was an exceptional quarter for Mylan. I would like to highlight upfront some of our financial accomplishments. 
Quarterly revenue of $1.8 billion, the highest amount of revenue in any quarter in our company's history, and revenue grew on a constant currency basis in every region of the world including Europe. 
Adjusted diluted earnings per share of $0.83, more than we earned in all of 2008 and were achieved while continuing to invest in new product development and sales and marketing initiatives. 
Adjusted operating cash flow of $469 million, the most ever for our company in one quarter, and free cash flow of $424 million, which allowed us to repay borrowings during the quarter of $459 million. 
And to the end of the quarter -- and to end the quarter with a gross leverage ratio of 2.7:1, or 2.6:1 when you consider an additional $100 million of borrowings, which we repaid in early October.
On the heels of this strong quarter, we are once again increasing our range of EPS guidance for the full year 2012. We're now projecting adjusted diluted EPS of between $2.50 and $2.60 per share, increased from our previous range of $2.45 to $2.55 per share. We are also revising upward our free cash flow expectations for 2012. We now expect adjusted operating cash flow to be approximately $1 billion in 2012, which is at the very upper end of our 2012 operating cash flow guidance range of $900 million to $1 billion. 
Additionally, as a result of the timing and rationalization of some of our capital programs, our gross capital spending in 2012 is now anticipated to approximate $300 million. The net of these 2 amounts represents our current 2012 free cash flow expectation of approximately $700 million, or $100 million higher than the midpoint of our previously communicated expectations.
Our remaining guidance metrics for 2012 remain unchanged, and I'll walk through each of them in a few minutes. And our targets for 2013 and beyond remain unchanged.
In February, in conjunction with our fourth quarter call, we will provide detailed 2013 financial guidance, which reflects recent developments and our most up-to-date outlook.
So Mylan has never been better positioned as a company. Today, we possess an unmatched vertically integrated footprint, a broad and growing product portfolio with a robust pipeline of future new product launches and longer-term strategic growth drivers such as our respiratory and biologics platforms. 
Additionally, though, Mylan possesses today the financial flexibility to take advantage of shareholder value accretion opportunities. With our current leverage ratio now meaningfully below our long-term target of 3:1 and our growing EBITDA, today we have over $4 billion of financial flexibility for earnings accretive transactions. That said, Mylan will never do a transaction merely for the sake of a transaction or only for financial reasons. Any transaction must also be the right transaction strategically. Further, we remain committed to our 3:1 long-term gross leverage target. And if we increase our leverage above this target, we would be committed to deleveraging within an 18-month time frame.
With that introduction, let me now get into the details and walk you through our financial results for the third quarter and first 9 months of 2012. I will also provide an update on our capital structure and liquidity position. 
Starting at the top of our income statement, total adjusted revenues for the quarter were approximately $1.8 billion, an increase of 14% over last year's third quarter revenues of approximately $1.6 billion. Year-over-year revenue growth on a constant currency basis was approximately 19%. The 5% unfavorable effect of foreign currency translation primarily reflects a stronger U.S. dollar in comparison to each of the other functional currencies of our major operations mainly in Europe and India.
Our top line growth was driven by higher volumes on a consolidated basis, including significant amounts from our 2012 new product launches as well as favorable sales volumes in Europe and Asia Pacific, which served to more than offset the unfavorable impact of lower pricing throughout the world. In fact, driven by higher volumes and new product introductions, each of the countries in Europe in which we have significant operations, with the exception of Germany, turned in favorable year-over-year constant currency sales growth. 
For the first 9 months of 2012, total adjusted revenues were approximately $5.1 billion, an increase of 10% over revenues from the first 9 months of 2011, or 14% on a constant currency basis. As a reminder, our guidance range for total revenues for the full year 2012 is between $6.8 billion and $7.2 billion. Recognizing current exchange rates and using them to forecast the remainder of the year, we expect to be near the low end of this guidance range as a result of the unfavorable impact of changes in foreign exchange rates. On a constant currency basis, however, we are projecting to be closer to the midpoint of the range.
Looking at our operating profitability measures. Adjusted gross margin for the 2012 third quarter at 52% was above our guidance range of 48% to 50% and represented an increase over the same prior year period of nearly 400 basis points. This increase was driven by new product launches and favorable volume and pricing on our EPIPEN auto-injector, partially offset by lower margin on existing products. The current quarter also saw margin improvement from our Indian subsidiary, where sales and gross profit benefited from the effects of a stronger dollar as compared to the rupee as a significant portion of its sales are denominated in U.S. dollars.
For the 9 months ended September 30, 2012, adjusted gross margins were 50% as compared to 48% in the prior year. We currently expect to be at the upper end of our gross margin guidance range for the full year.
Adjusted operating income was $513 million for the third quarter of 2012, a 32% increase from Q3 2011 and up 29% from the second quarter of 2012. The year-over-year increases, which is primarily the result of the favorable gross profit, was realized in spite of increased levels of investment in both R&D and SG&A. 
R&D expense for the quarter on an adjusted basis was $104 million, or approximately 5.8% of total revenues, and up approximately 51% from the prior year. This increase was mainly a result of ongoing spending with respect to our respiratory and biologics program, including clinical studies. 
At the same time, SG&A, also on an adjusted basis, was $324 million for the quarter, or approximately 18% of total revenues, and up approximately 5% over the prior year. The increase in SG&A in the current quarter is due in large part to increased selling and marketing in our Specialty franchise. Also contributing to the year-over-year increase were higher payroll and related costs as we continue to build out our infrastructure platform in certain targeted areas.
For the 9-month period, adjusted R&D expense was $277 million, up 28% over the prior year. As a percentage of revenues, R&D expense to date for 2012 is 5.5%. Our guidance range for R&D expense for the full year is between 5.5% and 6.5% of total revenues, and we continue to believe that the full year spend will be at or slightly below the midpoint of our guidance range.
SG&A expense on an adjusted basis for the 9 months ended September 30, 2012, was $964 million, an increase of nearly 10% and within our full year guidance range of 18% to 20% of total revenues. 
Adjusted EBITDA was $567 million and $1.4 billion for the 3- and 9-month periods ended September 30, 2012, respectively. We expect to be near the middle to upper end of our guidance range of $1.75 -- of $1.75 billion to $1.95 billion for the full year.
Moving on to our consolidated, nonoperating financial metrics. Adjusted interest expense for the third quarter of 2012 was $61 million. We continue to benefit from low short-term interest rates. As of September 30, 2012, the average rate on all of our outstanding borrowings was approximately 5%. We continue to use interest rate swaps in order to target a long-term 70-30 fixed-floating debt portfolio, which we believe is an optimal ratio. 
Adjusted interest expense for the 9-month period was $183 million and is forecasted to be at the low end of the guidance range of $245 million to $265 million for the full year.
Our adjusted effective tax rate in the current quarter was 26% compared to 27% a year ago. Our full year 2012 tax rate range is between 26% and 27%, and we continue to believe that we will be at the lower end of this range for the calendar year 2012.
Third quarter adjusted net income was $341 million, or $0.83 a share, a 51% increase from our Q3 2011 adjusted diluted EPS of $0.55 per share. For the 9 months, adjusted net income was $820 million, or $1.94 per share, a 28% increase over the same prior year period. 
As I mentioned previously, our guidance range for adjusted diluted EPS is now $2.50 to $2.60 per share. Our estimate of diluted shares for the full year is approximately 420 million.
Turning to our cash flow metrics. Cash flow from operations on an adjusted basis, which takes into account the special items which are outlined in our press release, was approximately $818 million for the year-to-date period and a very strong $469 million for the quarter. Our GAAP cash flow from operations for the current quarter and year-to-date period was a very strong cash inflow of $460 million and $652 million, respectively, and left us with unrestricted cash and marketable securities totaling $366 million. As noted earlier, we are forecasting our full year 2012 adjusted operating cash flow to be approximately $1 billion, the high end of our guidance range.
We have been very focused throughout 2012 on operating working capital. On a constant -- on constant currency net sales growth of 19% in the third quarter and 14% through the first 9 months of 2012, we have been able to limit the growth in our operating working capital to approximately 9%, exclusive of FX impacts, as we continue to bring operational efficiencies to our global platform.
Third quarter capital spending was $61 million, bringing the total for the year-to-date period to nearly $160 million. And as a result of the timing of planned expenditures, we expect full year capital expenditures to approximate $300 million.
As I mentioned before, these updated estimates yield a current free cash flow estimate of $700 million for the year, which is $100 million stronger than our previously communicated expectation as we continue to generate an increasing amount of cash flow from our global platform.
To summarize, our third quarter exceeded even our high expectations and, as anticipated, positions us for a very strong finish to 2012. Our strong track record for organic growth, coupled with the long-term growth drivers which Heather discussed, and our significant financial flexibility all translate into what should be an exciting 2013 and beyond for Mylan. 
That concludes my remarks. I'll turn the call over to the operator for Q&A. Maria?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our first question comes from the line of Marc Goodman of UBS.",14,"[Operator Instructions] Our first question comes from the line of Marc Goodman of UBS."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Yes, hi, a couple of questions. First, on the U.S. business, which obviously had a fantastic quarter, there were just a lot of launches. And given Diovan and Actos, I actually would have thought revenues would have been even a little higher. So maybe you",134,"Yes, hi, a couple of questions. First, on the U.S. business, which obviously had a fantastic quarter, there were just a lot of launches. And given Diovan and Actos, I actually would have thought revenues would have been even a little higher. So maybe you can just comment on some of the launches there and just the absolute amount of the way we should be thinking about that. Second, Europe, obviously great news there. Can we talk about profitability and how that has changed throughout the year and what you're doing there to increase profitability? And then third, can you just talk about the Institutional business a little bit more? How many new products should we be expecting to launch out of that? And how big a business are you looking to build there?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So Marc, I'll start with the U.S. So I guess I'd like to first start off by saying against our estimates, our U.S. business performed right in line with where we thought it would be. So while we absolutely had a significant amount of launches that w",477,"Sure. So Marc, I'll start with the U.S. So I guess I'd like to first start off by saying against our estimates, our U.S. business performed right in line with where we thought it would be. So while we absolutely had a significant amount of launches that we forecasted and projected at the beginning of the year, that '12 would be a great year for our U.S. Generics business. I think that if you look at the timing of the launches throughout the quarters, and some of that pull-through even from launches we had earlier in the year, so all I can tell you is that absolutely performed in line with where we thought it would. We think it still is showing strength in the base business as well as our continued launches that we have for the remainder of the year. So from our perspective, U.S. business, hitting on all cylinders. Europe profitability, I think as we have talked about in the past that we constantly, through this entire macroeconomic situation throughout Europe, have balanced our top and bottom line growth. You've heard me quarter after quarter coming and saying we weren't going to chase the bottom, that there's been irrational behavior and that we would continue to hold steady and control what we can control. So in this period of time, we've done just that. We've continued to increase the profitability around our cost of goods by continuing to vertically integrate and be 100% responsible for our global supply chain. We've continued to make sure that we're structured in the right way with some of the evolving businesses and as they are continuing to change in the different countries. And I think most importantly, and why I wanted to point out in my script, that in all the countries we're doing business, we see an increase in generic conversion. And I think that should be the brightest spot of all because what it shows is that governments very much are beginning to recognize the long-term sustainability that generic utilization brings versus a onetime price cut. So we've seen additional initiatives in Italy, we've seen additional initiatives in France that are bringing those back up. So from my perspective, we certainly have always maintained the need to balance profitable and revenues. I think that our results this quarter are paying off from how we're operating our business in Europe. And lastly, on the Institutional side, in February, we showed our Institutional business being an important strategic growth driver for us. We are continuing to invest in that business. We have numerous launches. We're continuing to very much accelerate our own internal R&D pipeline around this businesses globally. So all I can say is that we certainly are continuing to invest and continue to see this as a very important growth driver for us in the future."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Jami Rubin of Goldman Sachs.",10,"Our next question comes from Jami Rubin of Goldman Sachs."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, both you and John, I think, were the most clear about the company's increased appetite for pursuing an accretive deal given the increased financial flexibility of the balance sheet. I'm wondering if you can just -- am I reading that right? In pre",175,"Heather, both you and John, I think, were the most clear about the company's increased appetite for pursuing an accretive deal given the increased financial flexibility of the balance sheet. I'm wondering if you can just -- am I reading that right? In previous conference calls, we've talked about options on the table to enhance shareholder value: share buybacks, bringing down debt, strategic deals. But what I'm hearing from you today is I think a more outspoken commitment or desire to pursue something strategic. And then secondly, I'm very intrigued with the partnership that you signed with Pfizer in Japan, and I'm wondering if you could put some numbers around that, what you see in terms of revenue potential over the next 5 years and what that means to your bottom line? And is this the type of partnership that you see could be replicated in other countries, such as emerging markets where, again, Pfizer doesn't have the AND capabilities that you have and you don't have the feet on the ground that Pfizer has?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, sure. So look, I think to your first question, hopefully you see that as our continued commitment to be transparent. When I -- what I spoke of in my opening remarks was a combination, if you'll remember. I said of us continuing to execute on our exi",391,"Okay, sure. So look, I think to your first question, hopefully you see that as our continued commitment to be transparent. When I -- what I spoke of in my opening remarks was a combination, if you'll remember. I said of us continuing to execute on our existing platform, continuing to execute against the growth drivers we pointed out. And then obviously, the last point was to looking at ways that we're going to use our increased financial flexibility. And I think, as you have seen, that has been a combination, and I think it will continue to be. There's a lot of ways to increase shareholder value, and I think what you can rely on is that we're looking at all of them. And we certainly are looking at any and all compelling acquisitions that would allow us to continue to deliver or accelerate the trajectory that we're already on. I mean, when you look at what we have put out there with our own assets at this time, a 15% CAGR in 2018 is an impressive growth target out there. And I think that as -- this financial flexibility just gives us all that much more ability to accelerate not only that growth but, like I said, in many different ways. As far as Japan goes, look, I think it's an unprecedented deal in our industry. I think it truly does take the core competencies of both of our organizations, and we believe that 1 plus 1 will equal 3-plus. It's about really leveraging the scale and scope and the quality of what we both bring to the table. So while we don't get into putting numbers out there around individual countries, I think you certainly can expect that we believe that this is accretive to our current stand-alone Generics business as well as accretive to their stand-alone Generics business, and that's why the rationale of this deal made all the sense in the world. And I very much believe that it could be a model in other countries where the troops on the ground are important, the brand is important, but having the breadth and the quality of a pipeline is equally as important. And that's where this makes all the sense in the world and very much could make sense in other countries as we move forward."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line Shibani Malhotra of RBC Capital Markets.",13,"Our next question comes from the line Shibani Malhotra of RBC Capital Markets."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just going back to Jami's question on potential acquisitions and ways to enhance shareholder value, you did mention that you aren't going to do anything just for the sake of doing a deal. Can you talk about the kind of things you are looking for? And just",120,"Just going back to Jami's question on potential acquisitions and ways to enhance shareholder value, you did mention that you aren't going to do anything just for the sake of doing a deal. Can you talk about the kind of things you are looking for? And just expand on what you meant by that? Are you finding valuations too high? Or is it -- are you just not finding what you're looking for at the moment? And then second, a question on fenofibrate. You got the capsules approved a couple of days ago. Can you just give us your expectations around the launch of that product, including whether or not you had sufficient sort of quantities for the market?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, sure. Thank you, Shibani. As far as acquisitions go, I think as we've laid out, certainly we don't do any acquisition just to do an acquisition and have not had a gun to our head to do an acquisition. I think what you hear us saying is that we conti",280,"Okay, sure. Thank you, Shibani. As far as acquisitions go, I think as we've laid out, certainly we don't do any acquisition just to do an acquisition and have not had a gun to our head to do an acquisition. I think what you hear us saying is that we continue to now generate significant free cash flows and have increased flexibility and are looking at all compelling acquisitions. And that could be anything that to be complementary to our current platform. So whether you look at the Specialty side, geographies, dosage form, therapeutic categories -- I mean, we have a voluminous number of different ways to continue to accelerate this growth trajectory and we're looking at all of them, as well as in combination to share repurchasing programs. I mean, I think that the great news is when you look at the kind of cash we have on hand, we have a lot of different ways to get at least to that $6 in 2018 and continuing to show that kind of growth year-over-year that we've, I think, now, hopefully, have shown that track record of producing year-over-year. So like I said, you're right, we're not just looking at a transaction for transaction's sake, but we certainly are in a position to be looking at all the compelling ones. And as far as your product question, yes, it was a good launch for us. But as you know, we're well beyond any single product launches, especially one of that size. I can tell you we executed on it. And it's just one of many that we've had this year and will have over the next several. Okay, thank you."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","[Operator Instructions] Our next question will come from the line of Ronny Gal of Sanford Bernstein.",16,"[Operator Instructions] Our next question will come from the line of Ronny Gal of Sanford Bernstein."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","John, question on the CapEx. In the past, you talked about some leverage in the CapEx as we go from 2012 to 2014. Looking at the guidance for next year versus this year, still 7% to 8% growth in earnings at a minimum. How should we think about the CapEx?",80,"John, question on the CapEx. In the past, you talked about some leverage in the CapEx as we go from 2012 to 2014. Looking at the guidance for next year versus this year, still 7% to 8% growth in earnings at a minimum. How should we think about the CapEx? Should we grow linearly? Or should we have a step-up, a further step-up in the -- sorry, not the CapEx, in the cash -- in the free cash flow generation?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","So Ronny, I think that this -- I think that what you saw happen or you saw the results in this quarter was the cash flow generation, the strength of this global platform to generate and throw off cash. And also, as you could see, we reduced our expectatio",189,"So Ronny, I think that this -- I think that what you saw happen or you saw the results in this quarter was the cash flow generation, the strength of this global platform to generate and throw off cash. And also, as you could see, we reduced our expectations for capital spending for the year from $350 million to $300 million, the combination of those 2 increasing the free cash flow by $100 million and allowing us to bring our leverage down to 2.6x after paying $100 million back in the first week of October. To be honest with you, I don't really want to give future expectations as to what 2013 or 2014 is going to be. That's not the purpose of the call today. But what I can tell you, and it's demonstrated by the working capital efficiency that we've had here in 2013, is that our global operating teams are intensely focused on generating cash and then for our ability to put that cash back to work in the business for the benefit of our shareholders. And I think that for today, I'll leave it there."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay, thank you.",3,"Okay, thank you."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes of the line of David Risinger of Morgan Stanley.",13,"Our next question comes of the line of David Risinger of Morgan Stanley."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","John, I was hoping that you could just walk us through the financials associated with that partnership with Pfizer and just help us understand how that impacted the revenue in Asia Pacific in the quarter and how it will impact things going forward just so",83,"John, I was hoping that you could just walk us through the financials associated with that partnership with Pfizer and just help us understand how that impacted the revenue in Asia Pacific in the quarter and how it will impact things going forward just so that we can tease out whether there was an incremental positive from that deal in the September quarter that is noticeable in the financials and whether that will continue or whether it's really not noticeable in the financials."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","You don't -- you won't have to tease it out because although we announced the formation of the partnership, David, the partnership will actually be become -- begin operating here around the end of this year, early next year so that there was no impact of",83,"You don't -- you won't have to tease it out because although we announced the formation of the partnership, David, the partnership will actually be become -- begin operating here around the end of this year, early next year so that there was no impact of the partnership in our third quarter results. What you see in our Asia Pacific results represents the organic growth of our operations in Asia Pacific and will most likely be that way for Q4 2012 also."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Greg Gilbert of Merrill Lynch.",10,"Our next question comes from Greg Gilbert of Merrill Lynch."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, with the third quarter in a row of improving growth rates in Europe, are you ready to predict positive growth for that segment going forward? It sounds like your qualitative comments are quite bullish, too. And then, is there any doubt that your",76,"Heather, with the third quarter in a row of improving growth rates in Europe, are you ready to predict positive growth for that segment going forward? It sounds like your qualitative comments are quite bullish, too. And then, is there any doubt that your WELLBUTRIN XL generic product is fine in light of Teva Impax's issues? I think this is obviously important for Mylan and the broader public trust in generics and the trade, et cetera."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. Thanks, Greg. So look, I think as far as Europe is concerned, we have seen continued improvement, and we don't really foresee that stopping. I mean, quite honestly, I think that when you compare everything, as I said, conversion rates increasing, ou",323,"Sure. Thanks, Greg. So look, I think as far as Europe is concerned, we have seen continued improvement, and we don't really foresee that stopping. I mean, quite honestly, I think that when you compare everything, as I said, conversion rates increasing, our leadership position in our most important countries, I think, where we see -- obviously still see competitive pressures -- but see that volume offsetting that. Those are all the kind of things that certainly, we, from our measurements and what we're looking for, is important. And we start to see all 3 of those things hitting, and, like I said, we do foresee that continuing. So that's kind of is as far as I'm willing to go with my crystal ball. But I can tell you we're excited about the direction Europe is moving and see that continuing. As far as WELLBUTRIN, look, I think that it's very important to understand that this is a one-off issue and it really does not speak to the generic industry. I will say it speaks to the pharmaceutical industry overall. As you know, from time to time, as FDA continues to gather data and look at data, there are times where they've taken brand products off the market as well as changing guidelines and changing specs. So this is something that's constantly going on within the FDA in looking and working with companies. I think in this particular instance, it was certainly related to patient safety. FDA made a judgment call years ago around the 300 milligram. And when -- the data today that they're looking at has caused them to get to a different place. Certainly, we don't see this impacting our product and believe this was certainly in relation to just one in particular formulation. So I would tell you that our industry is alive and well, and I don't really see this having any impact on that whatsoever. Thank you."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Elliot Wilbur of Needham & Company.",10,"Our next question comes from Elliot Wilbur of Needham & Company."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Question for you, Heather, around your pending application for generic version of Lidoderm. Endo management made some very pointed comments about their perceived or their perceptions around your ability to obtain approval for their product based on its no",172,"Question for you, Heather, around your pending application for generic version of Lidoderm. Endo management made some very pointed comments about their perceived or their perceptions around your ability to obtain approval for their product based on its nonaqueous nature and the possibility of some excipient and adhesion issues. I'm assuming that you don't agree with that, but maybe you can just sort of comment a little bit on sort of their observations. And then with Watson now having obtained approval, still some ambiguity around the issue of exclusivity. The FDA made it very clear in the approval letter that Watson did not obtain approval within 30 months but did not actually make a decision on exclusivity. You said previously that you still thought generic Lidoderm was a possibility in terms of your ability to launch in 2013, and I'm just wondering if you still believe that to be the case based on anything new that's happening at the FDA with regard to the application and then based on the Watson approval."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So I'll start with Endo's comments. I guess what I would say, not only do I not agree with them, I have to believe that their credibility should be extremely tarnished at this point. I mean, they said all the exact same things about Watson -- Watson",252,"Sure. So I'll start with Endo's comments. I guess what I would say, not only do I not agree with them, I have to believe that their credibility should be extremely tarnished at this point. I mean, they said all the exact same things about Watson -- Watson was never going to be able to get their approval. They had all kinds of issues. And certainly, Endo was proven to be wrong. I think when you look at Endo trying to stress that based on their experience and expertise in this development, this is not their product. They have end-licensed it. So I think to talk about what kind of science is out there and who has the capability, I can assure you we are manufacturing and developing our own product, and I believe we do have the expertise and the track record with FDA to know and to be able to guide you guys, as we have been, about what we're capable of doing. So I -- that's what I would say about Endo's comments. And we absolutely continue to see this as a possible opportunity in the second half of the year. As you know, FDA historically doesn't make exclusivity decisions until they have to. And so we maintain our ability to get this product approved in 2013 and be able to manufacture the quantities needed. And like I said, we still absolutely believe we have the potential for this to be upside second half of '13. So thank you."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Chris Schott of JPMorgan.",9,"Our next question comes from Chris Schott of JPMorgan."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just 2 quick ones here. The first was coming back to some of the earlier business development comments. I guess does the financial flexibility you're talking about here open up transactions that you might not have been able to pursue in the past, i.e. lar",150,"Just 2 quick ones here. The first was coming back to some of the earlier business development comments. I guess does the financial flexibility you're talking about here open up transactions that you might not have been able to pursue in the past, i.e. larger transactions? I was just trying to understand here if the scope of what you're looking at has changed or if this is just kind of coming back to some of the assets that you've considered before? The second question was on your Europe. It seems like we're finally seeing encouraging macro trends. Can you talk a little bit more about the competitive dynamics you're seeing in the market? I think Teva last quarter discussed a bit of a shift, focusing more on profitability versus share in Europe, and I'm just wondering if you're -- how you're seeing the overall competitive environment kind of shaking out."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","So look, quickly on the acquisition, here's what I would say. I mean, Chris, obviously, we came out to a commitment with the Street over the last several years that we were going to be deleveraging and executing on the assets that we had. And I think that",217,"So look, quickly on the acquisition, here's what I would say. I mean, Chris, obviously, we came out to a commitment with the Street over the last several years that we were going to be deleveraging and executing on the assets that we had. And I think that, that's what I think this quarter culminates in that activity, one showing what this platform can produce while at the same time accelerating our deleveraging capability. So certainly, what we're in a position now to do is definitely of size and scope. And as I said, I'll just revert back to saying a very compelling -- there's a lot of compelling opportunities out there, and we're looking at all of them. And just quickly on the environment in Europe. I guess what I would say is we've always stressed the profitability as well as market share, as well as revenue growth and balanced all of that. I can't speak to other companies perhaps being as balanced as in their commentary around Europe, but that's why I wanted to stress that I think that has definitely paid off for us not only to maintain leadership position but be able to execute and control what we can. And we see that now, especially for our business in Europe, turning that corner."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from the line of Gary Nachman of Susquehanna Financial Group.",14,"Our next question comes from the line of Gary Nachman of Susquehanna Financial Group."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Heather, on EPIPEN, anything you're doing differently to prepare for Sanofi's launch of Auvi-Q next month? And do you have a sense of what the pricing dynamics will look like with them in the market? And just what type of growth are you seeing in the mark",53,"Heather, on EPIPEN, anything you're doing differently to prepare for Sanofi's launch of Auvi-Q next month? And do you have a sense of what the pricing dynamics will look like with them in the market? And just what type of growth are you seeing in the market overall, if you could quantify that?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Sure. So first, I'd like to say that they -- that Sanofi has said they're not launching until 2013. But anyway, as far as it relates to -- look, I think when you have got a leadership position, like we do, at 98% of the market, our ability to build on tha",201,"Sure. So first, I'd like to say that they -- that Sanofi has said they're not launching until 2013. But anyway, as far as it relates to -- look, I think when you have got a leadership position, like we do, at 98% of the market, our ability to build on that brand equity and make sure that we're continuing to stress the tried and true nature of EPIPEN, being around for over 20 years, delivering over 40 million scripts, and that's what -- that is our position in the marketplace. And as we've said before, another competitor coming to market in a sense then is just shared voice and increasing that awareness. I think that when you look at the -- what we have been doing to increase that awareness, as I said in my remarks, it's been paying off. We've now gone from where 7% of the people at-risk to now 10% of the people at-risk with an EPIPEN. So obviously, we still see tremendous growth and opportunity for this franchise and the disease state overall. So look, we're excited about EPIPEN, still have a lot that we're executing on and will be continuing to do so. Thank you."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Michael Faerm of Credit Suisse.",10,"Our next question comes from Michael Faerm of Credit Suisse."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Two quick questions, one on the respiratory pipeline. Can you just provide an update on the status of the COPD candidate, if and when we might see Phase II data? And then a general question on the North American Generics business. What are some of the key",68,"Two quick questions, one on the respiratory pipeline. Can you just provide an update on the status of the COPD candidate, if and when we might see Phase II data? And then a general question on the North American Generics business. What are some of the key drivers that will propel growth next year as you move into a year with fewer launches than you've had this year?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Let me -- I'll quickly take the North America question. Look, I think that what we've continued to stress is that we're not about any 1 country, 1 product. It is about literally being able to optimize and leverage the -- our global scale and platform in e",129,"Let me -- I'll quickly take the North America question. Look, I think that what we've continued to stress is that we're not about any 1 country, 1 product. It is about literally being able to optimize and leverage the -- our global scale and platform in every country we do business in, the United States not being any different. We have tremendous opportunities from our existing base business, the launches we did have this year, coupled with the launches we have next year. I mean over the last 5 years, we've not had the same number of launches every year, but we certainly have been able to show a trajectory and, like I said, we see that continuing. As for our respiratory business, Rajiv, do you want to..."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Yes. So regarding respiratory products, I think one is our COMBO, which is on the nebulization stage, which remains on track, and we will kick off our Phase III somewhere in the early next year, early 2013. And the second product, which is Advair, is also",55,"Yes. So regarding respiratory products, I think one is our COMBO, which is on the nebulization stage, which remains on track, and we will kick off our Phase III somewhere in the early next year, early 2013. And the second product, which is Advair, is also -- remains on track for '15, '16 global launches."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Ken Cacciatore of Cowen and Company.",11,"Our next question comes from Ken Cacciatore of Cowen and Company."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just wanted to go back to potential future acquisitions or strategic developments. Is it usually by asset that is available, either brand or generic? Or do you have a -- do you have something in mind and you focus on that? Or is it kind of what is availab",56,"Just wanted to go back to potential future acquisitions or strategic developments. Is it usually by asset that is available, either brand or generic? Or do you have a -- do you have something in mind and you focus on that? Or is it kind of what is available to you at that moment in time?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Ken, what I would say is as I -- hopefully, everyone has heard me now loud and clear on this call is that we certainly believe that there are many compelling opportunities out there and we're looking at all of them. And just believe that we've got a lot o",79,"Ken, what I would say is as I -- hopefully, everyone has heard me now loud and clear on this call is that we certainly believe that there are many compelling opportunities out there and we're looking at all of them. And just believe that we've got a lot of ability to bring in a lot of different complementary assets to this business in this existing platform that we have. And I'd say that's what I have to say."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","And it may or may not be on the market.",10,"And it may or may not be on the market."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Yes.",1,"Yes."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Yes.",1,"Yes."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","I mean, we're looking -- we're -- you should know we're not standing still and we're looking at everything. All right, Operator, thank you. Any more questions?",27,"I mean, we're looking -- we're -- you should know we're not standing still and we're looking at everything. All right, Operator, thank you. Any more questions?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from David Buck of Buckingham Research.",10,"Our next question comes from David Buck of Buckingham Research."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","First one is on the Specialty business. Can you talk a little bit about what pricing was during the quarter? And then just on the settlement with Teva, can you talk about what your ability is to continue to pursue, if needed, the citizen [ph] petition rou",94,"First one is on the Specialty business. Can you talk a little bit about what pricing was during the quarter? And then just on the settlement with Teva, can you talk about what your ability is to continue to pursue, if needed, the citizen [ph] petition route to make your case with the FDA on approval? And then just maybe for John, can you just talk about in terms of what you're looking at in terms of deals? Is there a commitment to not use any type of equity financing or convertible equity financing?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Okay. So quickly, listen. On EPI, we certainly had some pricing increases. We had 2 over the year. But, I mean, we certainly see, as I mentioned, volume increasing even more so than the price. As far as Teva and our settlement, we settled, just to be clea",101,"Okay. So quickly, listen. On EPI, we certainly had some pricing increases. We had 2 over the year. But, I mean, we certainly see, as I mentioned, volume increasing even more so than the price. As far as Teva and our settlement, we settled, just to be clear, on the IP litigation. We continue to believe they have significant hurdles to get an AB-rated product, and I can assure you we're continuing -- not only are we continuing to pursue that, but believe that there are, like I said, many hurdles and challenges for them to get an AB-rated product. John?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","And in terms of your question about M&A and currency that we would use in any transaction, I think it would be safe to assume that our focus is on use of cash for a transaction, as I pointed that out, in terms of the amount that we had available up to a c",79,"And in terms of your question about M&A and currency that we would use in any transaction, I think it would be safe to assume that our focus is on use of cash for a transaction, as I pointed that out, in terms of the amount that we had available up to a ceiling of $4 billion or more. And so I think that use of a currency other than cash is not something we're currently focused on."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our next question comes from Michael Tong of Wells Fargo Securities.",11,"Our next question comes from Michael Tong of Wells Fargo Securities."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","Just one question, going back to business development. And as you look at how you evaluate different transactions, do you use any internal bar that -- or internal hurdles that you would compare a potential transaction like the type of accretion you would",57,"Just one question, going back to business development. And as you look at how you evaluate different transactions, do you use any internal bar that -- or internal hurdles that you would compare a potential transaction like the type of accretion you would get from further deleveraging or share repurchases? Any color like that would be appreciated."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Well, Michael, I can assure you, we look at many, many, many parameters when looking at the sources and use of capital. And I can tell you that we have been doing that, and certainly, for any acquisitions, we'll be doing that going forward. Depending on w",114,"Well, Michael, I can assure you, we look at many, many, many parameters when looking at the sources and use of capital. And I can tell you that we have been doing that, and certainly, for any acquisitions, we'll be doing that going forward. Depending on what part of whether the platform, what kind of a transaction it is, what that contribution means, both near, medium and long term, I mean, all these things are taken into consideration as we compare them with other uses of capital. So I would say I would rest assured that we look at many, many different parameters and have many different things internally that we take into consideration."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Our final question comes from the line of Randall Stanicky of Canaccord Genuity.",13,"Our final question comes from the line of Randall Stanicky of Canaccord Genuity."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Analysts","I have a fairly straightforward one. It can be Heather or John. Can you just identify specifically some of the public U.S. generic opportunities in the next year? So obviously, Lidoderm is one of those. And then, Heather, as you look at your U.S. generic",69,"I have a fairly straightforward one. It can be Heather or John. Can you just identify specifically some of the public U.S. generic opportunities in the next year? So obviously, Lidoderm is one of those. And then, Heather, as you look at your U.S. generic base, obviously you have an expansive pipeline. What technologies don't you currently have that you would have an interest in potentially acquiring or developing?"
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Thanks, Randall. As far as for detailed opportunities in 2013, I think, as we mentioned earlier, we'll be coming to you with that in February. I mean, I think, obviously, there are some very -- there's already a lot of public news out there around the opp",65,"Thanks, Randall. As far as for detailed opportunities in 2013, I think, as we mentioned earlier, we'll be coming to you with that in February. I mean, I think, obviously, there are some very -- there's already a lot of public news out there around the opportunities that we have in 2013. But we certainly will be highlighting those more in February. And what was..."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","The technology.",2,"The technology."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Executives","Oh, the -- here's what I would say. When you look at where our strengths lie -- solid oral dosage, extended release, patch technology -- I think we can continue to see an injectable space, that, that would be an area that we can continue to further increa",131,"Oh, the -- here's what I would say. When you look at where our strengths lie -- solid oral dosage, extended release, patch technology -- I think we can continue to see an injectable space, that, that would be an area that we can continue to further increase therapeutic categories that we're in and so forth. Topicals, dermatologics, that's an area that we certainly could look and, obviously, where we've already investing in the respiratory. So I would think it's not even so much a matter of areas that we're not in at all but areas, again, that we can look to accelerate those positions and our positions within the U.S. marketplace. All right, well, thank you, everybody, for the call, and we look forward to talking to you in February."
290203,222537176,371102,"Mylan, Inc., Q3 2012 Earnings Call, Oct 25, 2012",2012-10-25,"Earnings Calls","Viatris Inc.","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
